0001140361-13-031299.txt : 20130809 0001140361-13-031299.hdr.sgml : 20130809 20130809071708 ACCESSION NUMBER: 0001140361-13-031299 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20130630 FILED AS OF DATE: 20130809 DATE AS OF CHANGE: 20130809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34236 FILM NUMBER: 131024421 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 5165937000 MAIL ADDRESS: STREET 1: 35 WILBUR STREET CITY: LYNBROOK STATE: NY ZIP: 11563 10-Q 1 form10q.htm BIOSPECIFICS TECHNOLOGIES CORP 10-Q 6-30-2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________________to __________________

001-34236

(Commission file number)

BIOSPECIFICS TECHNOLOGIES CORP.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		11-3054851
(State or Other Jurisdiction		(I.R.S. Employer
of Incorporation or Organization)		Identification No.)

35 Wilbur Street Lynbrook, NY 11563

(Address of Principal Executive Offices) (Zip Code)

516.593.7000

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o	Accelerated filer x
Non-accelerated filer o (Do not check if a smaller reporting company)	Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

Indicate the number of shares outstanding of the issuer's classes of common stock, as of the latest practicable date:

Class of Stock	Outstanding August 7, 2013
Common Stock ($.001 par value)	6,339,815

BIOSPECIFICS TECHNOLOGIES CORP.

TABLE OF CONTENTS

		Page
	PART I – FINANCIAL INFORMATION
ITEM 1.	Consolidated Financial Statements	4
	Consolidated Balance Sheet as of June 30, 2013 and December 31, 2012	4
	Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2013 and 2012	5
	Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2013 and 2012	6
	Notes to Consolidated Financial Statements	7
ITEM 2.	Management’s Discussion and Analysis	13
ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	22
ITEM 4.	Controls and Procedures	22

	PART II – OTHER INFORMATION
ITEM 1.	Legal Proceedings	22
ITEM 1A.	Risk Factors	22
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22
ITEM 3.	Defaults Upon Senior Securities	23
ITEM 4.	Reserved	23
ITEM 5.	Other Information	23
ITEM 6.	Exhibits	23

Table of Contents

Introductory Comments – Terminology

Throughout this quarterly report on Form 10-Q (this “Report”), the terms “BioSpecifics,” “Company,” “we,” “our,” and “us” refer to BioSpecifics Technologies Corp. and its subsidiary, Advance Biofactures Corp. (“ABC-NY”).

Introductory Comments – Forward-Looking Statements – Bingham to Update

This Report includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, expected revenue growth, and the assumptions underlying or relating to such statements, are “forward-looking statements”. The forward-looking statements include statements concerning, among other things, the timing of reporting top-line data from BioSpecifics’ phase II clinical trial of XIAFLEX for the treatment of human lipoma and its placebo controlled randomized study to evaluate the efficacy of XIAFLEX for the treatment of canine lipoma; and the timing for receiving the final earn-out payments under BioSpecifics’ agreement with DFB Biotech, Inc. and its affiliates. In some cases, these statements can be identified by forward-looking words such as “believe,” “expect,” “anticipate,” “plan,” “estimate,” “likely,” “may,” “will,” “could,” “continue,” “project,” “predict,” “goal,” the negative or plural of these words, and other similar expressions. These forward-looking statements are predictions based on BioSpecifics’ current expectations and its projections about future events. There are a number of important factors that could cause BioSpecifics’ actual results to differ materially from those indicated by such forward-looking statements, including the timing of regulatory filings and action; the ability of BioSpecifics’ partner, Auxilium Pharmaceuticals, Inc., and its partners, Swedish Orphan Biovitrum AB, Asahi Kasei Pharma Corporation and Actelion Pharmaceuticals Ltd., to achieve their objectives for XIAFLEX in their applicable territories; the market for XIAFLEX in, and initiation and outcome of clinical trials for, additional indications including frozen shoulder, cellulite, human lipoma and canine lipoma, all of which will determine the amount of milestone, royalty and sublicense income BioSpecifics may receive; the potential of XIAFLEX to be used in additional indications; the timing of results of any clinical trials; the receipt of any applicable milestone payments from Auxilium Pharmaceuticals, Inc.; whether royalty payments BioSpecifics is entitled to receive will exceed set-offs; and other risk factors identified in BioSpecifics’ Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Report on Form 10-Q for the first quarter of 2013 and its Current Reports on Form 8-K filed with the Securities and Exchange Commission. All forward-looking statements included in this Report are made as of the date hereof, and BioSpecifics assumes no obligation to update these forward-looking statements.

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1:

Consolidated Financial Statements

BioSpecifics Technologies Corp.

Consolidated Balance Sheets

	June 30,			December 31,
	2013			2012
	(unaudited)			(audited)
Assets
Current assets:
Cash and cash equivalents	$	4,017,531		$	3,383,737
Short-term investments		7,966,964			5,120,000
Accounts receivable, net		3,903,942			5,082,360
Income tax receivable		51,070			51,070
Deferred tax assets		79,482			88,910
Prepaid expenses and other current assets		411,110			149,724
Total current assets		16,430,099			13,875,801

Deferred royalty buy-down		2,750,000			2,750,000
Deferred tax assets - long term		1,492,509			1,484,141
Patent costs, net		248,160			280,322

Total assets		20,920,768			18,390,264

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses		660,560			512,866
Deferred tax liability		382,704			-
Deferred revenue		78,328			133,524
Accrued liabilities of discontinued operations		78,138			78,138
Total current liabilities		1,199,730			724,528

Long-term deferred revenue		172,825			207,390

Stockholders' equity:
Series A Preferred stock, $.50 par value, 700,000 shares authorized; none outstanding		-			-
Common stock, $.001 par value; 10,000,000 shares authorized ; 6,625,168 shares issued at June 30, 2013 and December 31, 2012, respectively		6,625			6,625
Additional paid-in capital		20,794,154			20,688,706
Retained earnings (deficit)		2,070,441			(310,829	)
Treasury stock, 285,352 and 260,632 shares at cost at June 30, 2013 and December 31, 2012, respectively		(3,323,007	)		(2,926,156	)
Total stockholders' equity		19,548,213			17,458,346

Total liabilities and stockholders’ equity	$	20,920,768		$	18,390,264

See accompanying notes to consolidated financial statements

Table of Contents

BioSpecifics Technologies Corp.

Consolidated Statements of Operations

(unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Revenues:
Net sales	$	27,500		$	1,246		$	29,743		$	8,750
Royalties		3,197,603			2,491,313			6,630,503			4,391,282
Licensing revenues		44,880			109,275			589,761			788,550
Total Revenues		3,269,983			2,601,834			7,250,007			5,188,582

Costs and expenses:
Research and development		470,044			404,346			764,918			653,898
General and administrative		1,236,254			1,149,926			2,854,736			2,238,648
Total Cost and Expenses		1,706,298			1,554,272			3,619,654			2,892,546

Operating income		1,563,685			1,047,562			3,630,353			2,296,036

Other income (expense):
Interest income		6,510			9,771			12,376			19,264
		6,510			9,771			12,376			19,264

Income before expense for income tax		1,570,195			1,057,333			3,642,729			2,315,300
Income tax benefit (expense)		(542,009	)		(390,651	)		(1,261,459	)		(906,228	)

Net income	$	1,028,186		$	666,682		$	2,381,270		$	1,409,072

Basic net income per share	$	0.16		$	0.11		$	0.37		$	0.22
Diluted net income per share	$	0.15		$	0.10		$	0.34		$	0.20

Shares used in computation of basic net income per share		6,345,277			6,343,356			6,351,083			6,339,930
Shares used in computation of diluted net income per share		6,968,057			6,971,687			6,966,045			6,984,258

Consolidated Statements of Comprehensive Income

(unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Net income	$	1,028,186	$	666,682	$	2,381,270	$	1,409,072
Other comprehensive income (loss)		-		-		-		-
Comprehensive income	$	1,028,186	$	666,682	$	2,381,270	$	1,409,072

See accompanying notes to consolidated financial statements

Table of Contents

BioSpecifics Technologies Corp.

Consolidated Statements of Cash Flows

(unaudited)

	Six Months Ended June 30,
Cash flows from operating activities:	2013			2012
Net income	$	2,381,270		$	1,409,072
Adjustments to reconcile net income to net cash provided
By operating activities:
Depreciation and amortization		32,162			29,019
Stock-based compensation expense		105,449			175,685
Deferred tax assets		1,060			416,055
Changes in operating assets and liabilities:
Accounts receivable		1,178,418			416,072
Prepaid expenses and other current assets		(261,387	)		72,403
Accounts payable and accrued expenses		147,694			(5,033	)
Accrued taxes payable		382,704			102,471
Deferred revenue		(89,761	)		(218,550	)
Net cash provided by operating activities		3,877,609			2,397,194

Cash flows from investing activities:
Maturity of marketable investments		4,430,000			2,000,000
Purchases of marketable investments		(7,276,964	)		(2,000,000	)
Payment for royalty buy down		-			(1,500,000	)
Net cash used in investing activities		(2,846,964	)		(1,500,000	)

Cash flows from financing activities:
Proceeds from stock option exercises		-			78,000
Payments for repurchase of common stock		(396,851	)		(485,904	)
Excess tax benefits from share-based payment arrangements		-			102,052
Net cash used in in financing activities		(396,851	)		(305,852	)

Increase in cash and cash equivalents		633,794			591,342
Cash and cash equivalents at beginning of year		3,383,737			3,196,831
Cash and cash equivalents at end of period	$	4,017,531		$	3,788,173

Supplemental disclosures of cash flow information:
Cash paid during the year for:
Interest	$	-		$	-
Taxes	$	888,500		$	92,000

Supplemental disclosures of non-cash transactions:

Under our agreement with Auxilium certain patent costs paid by Auxilium on behalf of the Company are creditable against future royalties. For the six month period ended June 30, 2013, we accrued approximately $30,000 related to certain patent costs of which we amortized approximately $16,100 in the 2013 period. For the six months ended June 30, 2012, we accrued approximately $64,000 related to these costs of which approximately $29,000 was amortized in the 2012 period.

See accompanying notes to consolidated financial statements

Table of Contents

BIOSPECIFICS TECHNOLOGIES CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2013

(Unaudited)

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

We are a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. We have a development and license agreement with Auxilium Pharmaceuticals, Inc. (“Auxilium”) for injectable collagenase (which Auxilium has named XIAFLEX^® (collagenase clostridium histolyticum)) for clinical indications in Dupuytren’s contracture, Peyronie’s disease, frozen shoulder (adhesive capsulitis) and cellulite (edematous fibrosclerotic panniculopathy) (the “Auxilium Agreement”). Auxilium has an option to acquire additional indications that we may pursue, including human and canine lipoma. Auxilium is currently selling XIAFLEX in the U.S. for the treatment of Dupuytren’s contracture. In addition, Auxilium has an agreement with Asahi Kasei Pharma Corporation (“Asahi”) pursuant to which Asahi has the right to commercialize XIAFLEX for the treatment of Dupuytren’s contracture and Peyronie’s disease in Japan. Auxilium also has an agreement with Actelion Pharmaceuticals Ltd. (“Actelion”) pursuant to which Actelion has the right to commercialize XIAFLEX for the treatment of Dupuytren’s contracture and Peyronie’s disease in Canada, Australia, Brazil and Mexico. Auxilium has been granted a Notice of Compliance (approval) by Health Canada for XIAFLEX for the treatment of Dupuytren’s contracture in adults with a palpable cord in Canada. In July 2013 Auxilium entered into a long-term collaboration with Swedish Orphan Biovitrum AB (“Sobi”) for the development, supply and commercialization of XIAPEX^® (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture. In addition, work is on-going to file for approval of XIAPEX for the treatment of Peyronie's disease in the EU.

Pursuant to a March 2006 agreement (the “DFB Agreement”) between the Company and DFB Biotech, Inc. (“DFB”), we continue to receive earn-out payments based on the sales of Santyl. Our right to receive earn-out payments with respect to the marketed topical product sold to DFB expires in August 2013, and we expect to receive our final earn-out payment for Santyl by the end of the year.

Operational Highlights

On July 23, 2013 we presented a poster titled “Biomechanical Evaluation of Human Uterine Fibroids after Exposure to Purified Clostridial Collagenase” at the Society for the Study of Reproduction 46^th Annual Meeting in Montreal, Quebec, Canada. The poster provided data which showed that highly purified collagenase can reduce the stiffness of human uterine fibroid tissue in laboratory experiments. Increased tissue rigidity has been implicated as a cause of the morbidity associated with uterine fibroids. The results of this ex vivo study show that treatment of fibroids with determined doses of purified collagenase caused a statistically significant decrease in the stiffness of the tissue. This hypothesis was tested in fibroid tissue obtained after hysterectomy or myomectomy surgery from patients. Tissues were injected with collagenase and compared to control-injected tissue.

On July 16, 2013, Auxilium announced that it has entered into a long-term collaboration with Sobi for the development, supply and commercialization of XIAPEX (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture. In addition, Auxilium stated that work is on-going to file for approval of XIAPEX for the treatment of Peyronie's disease in the EU. Under the terms of the collaboration agreement, Sobi will receive exclusive rights to commercialize XIAPEX for Dupuytren’s contracture and Peyronie’s disease, subject to applicable regulatory approvals, in 28 EU member countries, Switzerland, Norway, Iceland, 18 Central Eastern Europe/Commonwealth of Independent countries, including Russia and Turkey, and 22 Middle Eastern & North African countries. Since 2011, XIAPEX has been approved for the treatment of Dupuytren's contracture in 28 EU member countries, Switzerland, and Norway. Sobi, via its Partner Products business unit, will be primarily responsible for the applicable regulatory, clinical and commercialization activities for XIAPEX in Dupuytren's contracture and Peyronie's disease in these countries.

In April 2013, we completed enrollment in our placebo-controlled, randomized Phase II trial, Chien-804, to evaluate the efficacy of XIAFLEX for the treatment of subcutaneous benign lipomas in 32 canines randomized 1:1 XIAFLEX to placebo. The lipoma volume will be measured at baseline, 1 month and 3 months with the primary efficacy endpoint being the relative change in lipoma volume from baseline to 3 months, as determined by CT scan.

Table of Contents

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements are unaudited, but include all adjustments (consisting only of normal, recurring adjustments) which we consider necessary for a fair presentation of our financial position at such dates and the operating results and cash flows for those periods. Although we believe that the disclosures in our financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) has been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for quarterly reporting.

The information included in this Report should be read in conjunction with our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC.

Principles of Consolidation

The audited consolidated financial statements include the accounts of the Company and its subsidiary, Advance Biofactures Corp. (“ABC-NY”).

Critical Accounting Policies, Estimates and Assumptions

The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of management’s estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Cash, Cash Equivalents and Short-term Investments

Cash, cash equivalents and short-term investments are stated at market value. Cash equivalents include only securities having a maturity of three months or less at the time of purchase. The Company limits its credit risk associated with cash, cash equivalents and short-term investments by placing its investments with banks it believes are highly creditworthy and with highly rated money market funds, U.S. government securities, or short-term commercial paper.

Fair Value Measurements

Management believes that the carrying amounts of the Company’s financial instruments, including cash, cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of those instruments.

Concentration of Credit Risk and Major Customers

The Company maintains bank account balances, which, at times, may exceed insured limits. The Company has not experienced any losses with these accounts and believes that it is not exposed to any significant credit risk on cash.

The Company maintains its investment in FDIC insured certificates of deposits with several banks.

At June 30, 2013, the accounts receivable balance of $3.9 million was primarily from two customers, comprised of $2.5 million (64% of total) from DFB and $1.4 million (36% of total) from Auxilium.

The Company has been dependent in each year on two customers who generate almost all its revenues. In the quarter ended June 30, 2013, the licensing and royalty revenues from Auxilium were $4.7 million (65% of total) and royalty revenues from DFB were $2.5 million (35% of total).

Revenue Recognition

We currently recognize revenues resulting from product sales, the licensing and sublicensing of the use of our technology and from services we sometimes perform in connection with the licensed technology under the guidance of Accounting Standards Codification 605, Revenue Recognition (“ASC 605”).

Table of Contents

If we determine that separate elements exist in a revenue arrangement under ASC 605, we recognize revenue for delivered elements only when the fair values of undelivered elements are known, when the associated earnings process is complete, when payment is reasonably assured and, to the extent the milestone amount relates to our performance obligation, when our customer confirms that we have met the requirements under the terms of the agreement.

Revenues, and their respective treatment for financial reporting purposes, are as follows:

Product Sales

We recognize revenue from product sales when there is persuasive evidence that an arrangement exists, title passes, the price is fixed or determinable and collectability is reasonably assured. No right of return exists for our products except in the case of damaged goods. To date, we have not experienced any significant returns of our products.

Net sales include the sales of the collagenase for laboratory use that are recognized at the time the product is shipped to customers for laboratory use.

Royalty/Mark-Up on Cost of Goods Sold / Earn-Out Revenue

For those arrangements for which royalty, mark-up on cost of goods sold or earn-out payment information becomes available and collectability is reasonably assured, we recognize revenue during the applicable period earned. For interim quarterly reporting purposes, when collectability is reasonably assured but a reasonable estimate of royalty, mark-up on cost of goods sold or earn-out payment revenues cannot be made, the royalty, mark-up on cost of goods sold or earn-out payment revenues are generally recognized in the quarter that the applicable licensee provides the written report and related information to us.

Under the Auxilium Agreement, we do not participate in the selling, marketing or manufacturing of products for which we receive royalties and a mark-up of the cost of goods sold revenues. The royalty and mark-up on cost of goods sold revenues will generally be recognized in the quarter that Auxilium provides the written reports and related information to us, that is, royalty and mark-up on cost of goods sold revenues are generally recognized one quarter following the quarter in which the underlying sales by Auxilium occurred. The royalties payable by Auxilium to us are subject to set-off for certain patent costs.

Licensing Revenue

We include revenue recognized from upfront licensing, sublicensing and milestone payments in “License Revenues” in our consolidated statements of operations in this Report.

Upfront License and Sublicensing Fees

We generally recognize revenue from upfront licensing and sublicensing fees when the agreement is signed, we have completed the earnings process and we have no ongoing performance obligation with respect to the arrangement. Nonrefundable upfront technology license for product candidates for which we are providing continuing services related to product development are deferred and recognized as revenue over the development period.

Milestones

Milestones, in the form of additional license fees, typically represent nonrefundable payments to be received in conjunction with the achievement of a specific event identified in the contract, such as completion of specified development activities and/or regulatory submissions and/or approvals. We believe that a milestone represents the culmination of a distinct earnings process when it is not associated with ongoing research, development or other performance on our part. We recognize such milestones as revenue when they become due and collection is reasonably assured. When a milestone does not represent the culmination of a distinct earnings process, we recognize revenue in a manner similar to that of an upfront license fee.

Table of Contents

The timing and amount of revenue that we recognize from licenses of technology, either from upfront fees or milestones where we are providing continuing services related to product development, is primarily dependent upon our estimates of the development period. We define the development period as the point from which research activities commence up to regulatory approval of either our, or our partners’ submission assuming no further research is necessary. As product candidates move through the development process, it is necessary to revise these estimates to consider changes to the product development cycle, such as changes in the clinical development plan, regulatory requirements, or various other factors, many of which may be outside of our control. Should the U.S. Food and Drug Administration or other regulatory agencies require additional data or information, we would adjust our development period estimates accordingly. The impact on revenue of changes in our estimates and the timing thereof is recognized prospectively over the remaining estimated product development period.

Treasury Stock

The Company accounts for treasury stock under the cost method and includes treasury stock as a component of stockholders’ equity.

Receivables, Deferred Revenue and Allowance for Doubtful Accounts

Trade accounts receivable are stated at the amount the Company expects to collect. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. We consider the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. Our accounts receivable balance is typically due from our two large pharmaceutical customers. These companies have historically paid timely and have been financially stable organizations. Due to the nature of the accounts receivable balance, we believe the risk of doubtful accounts is minimal. If the financial condition of our customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. We provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after we have used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable.

At June 30, 2013, the accounts receivable balance of $3.9 million was primarily from two customers, comprised of $2.5 million from DFB and $1.4 million from Auxilium.

Deferred revenue of $0.5 million consists of licensing fees related to the cash payments received under the Auxilium Agreement in prior years and amortized over the expected development period of certain indications for XIAFLEX.

We recorded no material bad debt expense in each of the last three years. The allowance for doubtful accounts balance was approximately $30,000 at June 30, 2013 and 2012.

Reimbursable Third Party Development Costs

We accrue patent expenses for research and development that are reimbursable by us under the Auxilium Agreement. We capitalize certain patent costs related to estimated third party development costs that are reimbursable under the Auxilium Agreement. As of June 30, 2013 our net reimbursable third party patent costs accrual was approximately $30,000.

Royalty Buy-Down

On March 31, 2012, we entered into an amendment to our existing agreement with Dr. Martin K. Gelbard, dated August 27, 2008, related to our future royalty obligations for Peyronie’s disease. The amendment enables us to buy down a portion of our future royalty obligations in exchange for an initial cash payment of $1.5 million and five additional cash payments payable upon the occurrence of a milestone event.

As of June 30, 2013, we have capitalized $2.75 million related to this agreement which will be amortized over approximately five years beginning on the date of the first commercial sale of XIAFLEX for the treatment of Peyronie’s disease, which represents the period estimated to be benefited using the straight-line method. In accordance with Accounting Standards Codification 350, Intangibles, Goodwill and Other, the Company amortizes intangible assets with finite lives in a manner that reflects the pattern in which the economic benefits of the assets are consumed or otherwise used up. If that pattern cannot be reliably determined, the assets are amortized using the straight-line method.

Table of Contents

Research and Development Expenses

Research and development (“R&D”) expenses include, but are not limited to, internal costs, such as salaries and benefits, costs of materials, lab expense, facility costs and overhead. R&D expenses also consist of third party costs, such as medical professional fees, product costs used in clinical trials, consulting fees and costs associated with clinical study arrangements. We may fund R&D at medical research institutions under agreements that are generally cancelable. All of these costs are charged to R&D as incurred, which may be measured by percentage of completion, contract milestones, patient enrollment, or the passage of time.

Clinical Trial Expenses

Our cost accruals for clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with various clinical trial centers and clinical research organizations. In the normal course of business we contract with third parties to perform various clinical trial activities in the ongoing development of potential drugs. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, the completion of portions of the clinical trial, or similar conditions. The objective of our accrual policy is to match the recording of expenses in our financial statements to the actual cost of services received and efforts expended. As such, expenses related to each patient enrolled in a clinical trial are recognized ratably beginning upon entry into the trial and over the course of the patient’s continued participation in the trial. In the event of early termination of a clinical trial, we accrue an amount based on our estimate of the remaining non-cancelable obligations associated with the winding down of the clinical trial. Our estimates and assumptions could differ significantly from the amounts that may actually be incurred.

Stock-Based Compensation

The Company has two stock-based compensation plans in effect. Accounting Standards Codification 718, Compensation - Stock Compensation (“ASC 718”), requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based awards including stock options and common stock issued to our employees and directors under our stock plans. It requires companies to estimate the fair value of share-based awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service periods in our consolidated statements of operations.

Under the ASC 718, we estimate the fair value of our employee stock awards at the date of grant using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions. The most significant of these assumptions are our estimates of the expected volatility of the market price of our stock and the expected term of an award. When establishing an estimate of the expected term of an award, we consider the vesting period for the award, our recent historical experience of employee stock option exercises (including forfeitures) and the expected volatility. When there is uncertainty in the factors used to determine the expected term of an award, we use the simplified method. As required under the accounting rules, we review our valuation assumptions at each grant date and, as a result, our valuation assumptions used to value employee stock-based awards granted in future periods may change. We granted to one of our consultants 15,000 stock options, valued at approximately $79,000, during the three month period ended June 30, 2013. We used the Black-Scholes valuation model to estimate the value of options using 37% volatility, a risk free rate of 0.68% and average exercise period of five years.

Further, ASC 718 requires that employee stock-based compensation costs be recognized over the requisite service period, or the vesting period, in a manner similar to all other forms of compensation paid to employees. The allocation of employee stock-based compensation costs to each operating expense line are estimated based on specific employee headcount information at each grant date and estimated stock option forfeiture rates and revised, if necessary, in future periods if actual employee headcount information or forfeitures differ materially from those estimates. As a result, the amount of employee stock-based compensation costs we recognize in each operating expense category in future periods may differ significantly from what we have recorded in the current period.

Table of Contents

Stock-based compensation expense recognized under ASC 718 was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Research and development	$	79,049	$	122,679	$	92,249	$	144,817
General and administrative		-		13,200		13,200		30,868
Total stock-based compensation expense	$	79,049	$	135,879	$	105,449	$	175,685

Stock Option Activity

A summary of our stock option activity during the six months ended June 30, 2013 is presented below:

	Total Number		Weighted-Average
Options	of Shares		Exercise Price
Outstanding as of December 31, 2012		1,182,000	$	8.90
Granted		15,000		15.85
Forfeited		-		-
Exercised		-		-
Expired		-		-
Outstanding as of June 30, 2013		1,197,000	$	8.99

Exercisable as of June 30, 2013		1,177,000	$	8.64

During the six months ended June 30, 2013 and 2012, zero and $78,000, respectively, were received from stock options exercised by option holders.

The aggregate intrinsic value of options outstanding and exercisable as of June 30, 2013 was approximately $8.2 million. Aggregate intrinsic value represents the total pre-tax intrinsic value based on the closing price of our common stock of $15.60 on June 28, 2013, which would have been received by the option holders had all option holders exercised their options as of that date. We have no unrecognized compensation cost related to stock options outstanding as of June 30, 2013.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, less accumulated depreciation. Machinery and equipment, furniture and fixtures, and autos are depreciated on the straight-line basis over their estimated useful lives of 5 to 10 years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the remaining life of the lease.

Provision for Income Taxes

Deferred tax assets and liabilities are recognized based on the expected future tax consequences, using current tax rates, of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

We use the asset and liability method of accounting for income taxes, as set forth in Accounting Standards Codification 740-10-25-2. Under this method, deferred income taxes, when required, are provided on the basis of the difference between the financial reporting and income tax basis of assets and liabilities at the statutory rates enacted for future periods. In accordance with Accounting Standards Codification 740-10-45-25, Income Statement Classification of Interest and Penalties, we classify interest associated with income taxes under interest expense and tax penalties under other.

Table of Contents

3. NET INCOME (LOSS) PER SHARE

In accordance with Accounting Standards Codification 260, Earnings Per Share, basic net income (loss) per share amount is computed using the weighted-average number of shares of common stock outstanding during the periods presented, while diluted net income (loss) per share is computed using the sum of the weighted-average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of diluted earnings per share result from the assumed exercise of stock options using the converted method.

The following table summarizes the number of common equivalent shares that were included for the calculation of diluted net income purposes from continuing operations reported in the consolidated statement of operations.

	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Stock options		622,780		628,331		614,962		644,328

4. COMPREHENSIVE INCOME (LOSS)

For the three and six months ended June 30, 2013 and 2012, we had no components of other comprehensive income or loss other than net income itself.

5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consisted of the following:

	June 30,		December 31,
	2013		2012
Trade accounts payable and accrued expenses	$	365,054	$	$ 304,635
Accrued legal and other professional fees		129,822		61,147
Accrued payroll and related costs		165,684		147,084

Total	$	660,560	$	512,866

6. PATENT COSTS

We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 2 to 14 years, and review for impairment on a quarterly basis and when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.

As of June 30, 2013, the Company’s capitalized costs related to certain patent costs paid by Auxilium on behalf of the Company, which are reimbursable to Auxilium under the Auxilium Agreement. These patent costs are creditable against future royalty revenues. For each period presented below net patent costs consisted of:

	June 30,			December 31,
	2013			2012
Patents	$	472,375		$	472,375
Accumulated Amortization		(224,215	)		(192,053	)
	$	248,160		$	280,322

The amortization expense for patents for the six months ended June 30, 2013 was approximately $32,000. In the comparable period of 2012, the amortization expense for patents was approximately $29,000. The estimated aggregate amortization expense for each of the next five years is approximately as follows:

2014	$	53,000
2015		25,000
2016		20,000
2017		20,000
2018		20,000

Table of Contents

7. PROVISION FOR INCOME TAXES

In determining our provision for income taxes, we consider all available information, including operating results, ongoing tax planning, and forecasts of future taxable income. The significant components of the Company's deferred tax assets pursuant to Accounting Standards Codification 740-10-50 consist of stock-based compensation and deferred revenues. For the six month period ended June 30, 2013, the provision for income taxes was $1.3 million. For the six month period ended June 30, 2013, the valuation allowance with respect to the Company’s net deferred tax assets remained unchanged. As of June 30, 2013, our remaining deferred tax assets were approximately $1.5 million.

For the six month period ended June 30, 2012 our provision for income taxes was $0.9 million, primarily a non-cash charge. For the six month period ended June 30, 2012, the valuation allowance with respect to the company’s net deferred tax assets remained unchanged. Our remaining deferred tax assets decreased by $0.4 million to approximately $2.6 million, primarily because we used our Orphan Drug Tax Credit to reduce our taxes payable, during six months ended June 30, 2012.

8. RELATED PARTY TRANSACTIONS

Our corporate headquarters are currently located at 35 Wilbur St., Lynbrook, NY 11563. As previously reported, our previous lease for our headquarters terminated on June 30, 2010. Our subsidiary, ABC-NY (together with the Company, the “Tenant”) and Wilbur St. Corp. (the “Landlord”) were parties to a lease agreement initially dated as of January 30, 1998 and modified as of June 24, 2009 (the “Lease Agreement”), pursuant to which the Landlord leased to the Tenant the premises located at 35 Wilbur Street, Lynbrook, NY 11563 (the “Premises”) until June 30, 2010 and for a monthly rental price of $11,250 plus utilities and real estate taxes. Following the expiration of the Lease Agreement, the Tenant continued to lease the Premises from the Landlord on a month-to-month basis. We notified the Landlord of our termination of the Lease Agreement effective March 31, 2011, but continue to hold over in the Premises.

9. SUBSEQUENT EVENTS

We have evaluated subsequent events for recognition or disclosure through the time of filing these consolidated financial statements on Form 10-Q with the SEC on August 9, 2013.

Item 2:

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the consolidated financial statements and the related notes thereto included elsewhere in this Report and is qualified by reference to them.

Overview

Table of Contents

Operational Highlights

On July 23, 2013 we, presented a poster titled “Biomechanical Evaluation of Human Uterine Fibroids after Exposure to Purified Clostridial Collagenase” at the Society for the Study of Reproduction 46^th Annual Meeting in Montreal, Quebec, Canada. The poster provided data which showed that highly purified collagenase can reduce the stiffness of human uterine fibroid tissue in laboratory experiments. Increased tissue rigidity has been implicated as a cause of the morbidity associated with uterine fibroids. The results of this ex vivo study show that treatment of fibroids with determined doses of purified collagenase caused a statistically significant decrease in the stiffness of the tissue. This hypothesis was tested in fibroid tissue obtained after hysterectomy or myomectomy surgery from patients. Tissues were injected with collagenase and compared to control-injected tissue.

On July 16, 2013, Auxilium announced that it has entered into a long-term collaboration with Sobi for the development, supply and commercialization of XIAPEX (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture. In addition, work is on-going to file for approval of XIAPEX for the treatment of Peyronie's disease in the EU. Under the terms of the collaboration agreement, Sobi will receive exclusive rights to commercialize XIAPEX for Dupuytren’s contracture and Peyronie’s disease, subject to applicable regulatory approvals, in 28 EU member countries, Switzerland, Norway, Iceland, 18 Central Eastern Europe/Commonwealth of Independent countries, including Russia and Turkey, and 22 Middle Eastern & North African countries. Since 2011, XIAPEX has been approved for the treatment of Dupuytren's contracture in 28 EU member countries, Switzerland, and Norway. Sobi, via its Partner Products business unit, will be primarily responsible for the applicable regulatory, clinical and commercialization activities for XIAPEX in Dupuytren's contracture and Peyronie's disease in these countries.

Outlook

Currently, we generate revenue from two primary sources: in connection with the DFB Agreement and in connection with the Auxilium Agreement. Under the DFB Agreement, our right to receive earn-out payments with respect to the marketed topical product sold to DFB expires in August 2013, and we expect to receive our final earn-out payment for Santyl by the end of the year. Under the Auxilium Agreement, we receive license, sublicense income, royalties, milestones and mark-up on cost of goods sold payments related to the sale and approval of XIAFLEX as described above.

Significant Risks

We are dependent to a significant extent on third parties, and our principal licensee, Auxilium, may not be able to continue successfully commercializing XIAFLEX for Dupuytren’s contracture, successfully develop XIAFLEX for additional indications, obtain required regulatory approvals, manufacture XIAFLEX at an acceptable cost, in a timely manner and with appropriate quality, or successfully market products or maintain desired margins for products sold, and as a result we may not achieve sustained profitable operations.

Critical Accounting Policies, Estimates and Assumptions

The preparation of unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on historical experience and on various other assumptions that we believe are reasonable under the circumstances. The information at June 30, 2013 and for the three and six months ended June 30, 2013 and 2012 is unaudited but includes all adjustments (consisting only of normal recurring adjustments) which, in the opinion of management, are necessary to state fairly the financial information set forth herein. The December 31, 2012 balance sheet amounts and disclosures included herein have been derived from the Company’s December 31, 2012 audited consolidated financial statements. The interim results are not necessarily indicative of results to be expected for the full fiscal year. These unaudited consolidated financial statements should be read in conjunction with the unaudited consolidated financial statements for the period ended March 31, 2013 included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 10, 2013 and the audited consolidated financial statements for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2013. While our significant accounting policies are described in more detail in the notes to our unaudited consolidated financial statements, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our unaudited consolidated financial statements. Actual results have differed in the past, and may differ in the future, from our estimates and could impact our earnings in any period during which an adjustment is made.

Table of Contents

Revenue Recognition. We recognize revenues from product sales when there is persuasive evidence that an arrangement exists, title passes, the price is fixed and determinable, and payment is reasonably assured. We currently recognize revenues resulting from the licensing, sublicensing and use of our technology and from services we sometimes perform in connection with the licensed technology.

We enter into product development licenses and collaboration agreements that may contain multiple elements, such as upfront license and sublicense fees, milestones related to the achievement of particular stages in product development and royalties. As a result, significant contract interpretation is sometimes required to determine the appropriate accounting, including whether the deliverables specified in a multiple-element arrangement should be treated as separate units of accounting for revenue recognition purposes, and if so, how the aggregate contract value should be allocated among the deliverable elements and when to recognize revenue for each element.

We recognize revenue for delivered elements only when the fair values of undelivered elements are known, when the associated earnings process is complete and, to the extent the milestone amount relates to our performance obligation, when our licensee confirms that we have met the requirements under the terms of the agreement, and when payment is reasonably assured. Changes in the allocation of the contract value between various deliverable elements might impact the timing of revenue recognition, but in any event, would not change the total revenue recognized on the contract. For example, nonrefundable upfront product license fees for product candidates for which we are providing continuing services related to product development are deferred and recognized as revenue over the development period.

Milestones, in the form of additional license fees, typically represent nonrefundable payments to be received in conjunction with the achievement of a specific event identified in a contract, such as completion of specified clinical development activities and/or regulatory submissions and/or approvals. We believe that a milestone represents the culmination of a distinct earnings process when it is not associated with ongoing research, development or other performance on our part. We recognize such milestones as revenue when they become due and payment is reasonably assured. When a milestone does not represent the culmination of a distinct earnings process, we recognize revenue in a manner similar to that of an upfront product license fee.

Royalty/ Mark-up on Cost of Goods Sold / Earn-Out Revenue

Under the Auxilium Agreement, we do not participate in the selling, marketing or manufacturing of products for which we receive royalties and a mark-up on the cost of goods sold revenues. The royalty and mark-up on cost of goods sold revenues will generally be recognized in the quarter that Auxilium provides the written reports and related information to us, that is, royalty and mark-up on cost of goods sold revenues are generally recognized one quarter following the quarter in which the underlying sales by Auxilium occurred. The royalties payable by Auxilium to us are subject to set-off for certain patent costs.

Under the DFB Agreement, pursuant to which we sold our topical collagenase business to DFB, we have the right to receive earn-out payments in the future based on sales of certain products. Generally, under the DFB Agreement we would receive payments and a report within ninety (90) days from the end of each calendar year after DFB has sold the royalty-bearing product. Currently, DFB is providing us earn-out reports on a quarterly basis. We expect to receive the final earn-out payment under the DFB Agreement at the end of 2013.

Table of Contents

Reimbursable Third Party Development Costs. We accrue patent expenses for research and development that are reimbursable by us under the Auxilium Agreement. We capitalize certain patent costs related to estimated third party development costs that are reimbursable under the Auxilium Agreement. As of June 30, 2013 our net reimbursable third party patent costs accrual was approximately $30,000.

Receivables and Deferred Revenue. Accounts receivable as of June 30, 2013 is approximately $3.9 million, which consists of approximately $2.5 million due from DFB in accordance with the earn-out under the DFB Agreement and approximately $1.4 million in royalties and mark-up on costs of goods sold due from Auxilium in accordance with the terms of the Auxilium Agreement. Deferred revenue of $0.5 million consists of licensing fees related to the cash payments received under the Auxilium Agreement in prior years and amortized over the expected development period of certain indications for XIAFLEX.

Royalty Buy-Down. On March 31, 2012, we entered into an amendment to our existing agreement with Dr. Martin K. Gelbard, dated August 27, 2008, related to our future royalty obligations for Peyronie’s disease. The amendment enables us to buy down a portion of our future royalty obligations in exchange for an initial cash payment of $1.5 million and five additional cash payments payable upon the occurrence of a milestone event.

Stock Based Compensation. Under ASC 718, we estimate the fair value of our employee stock awards at the date of grant using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions. The most significant assumptions are our estimates of the expected volatility of the market price of our stock and the expected term of an award. Expected volatility is based on the historical volatility of our common stock. When establishing an estimate of the expected term of an award, we consider the vesting period for the award, our historical experience of employee stock option exercises (including forfeitures) and the expected volatility. As required under the accounting rules, we review our valuation assumptions at each grant date and, as a result, we are likely to change our valuation assumptions used to value future employee stock-based awards granted, to the extent any such awards are granted.

RESULTS OF OPERATIONS

THREE MONTHS ENDED JUNE 30, 2013 AND 2012

Revenues

Product Revenues, net

Product revenues include the sales of the collagenase for laboratory use recognized at the time it is shipped to customers. We had a small amount of revenue from the sale of collagenase for laboratory use. For the three months ended June 30, 2013 and 2012 product revenues were $27,500 and $1,246, respectively. This increase was primarily related to the amount of material required to perform testing and additional research by our customers.

Royalties

Royalties consist of royalties and the mark-up on cost of goods sold under the Auxilium Agreement and earn-out revenues associated with the DFB Agreement. Total royalty, mark-up on cost of goods sold and earn-out revenues for the three month period ended June 30, 2013 were $3.2 million as compared to $2.5 million in the 2012 period, an increase of $0.7 million or 28%. Royalty and the mark-up on cost of goods sold revenues recognized under the Auxilium Agreement were $1.7 million for the 2013 period compared to $1.5 million in the 2012 period. The increase of $0.2 million was due to increased net sales of XIAFLEX during 2013 reported to us by Auxilium.

Table of Contents

We receive earn-out revenues from DFB under the earn-out payment provision of the DFB Agreement after certain net sales levels are achieved. Revenues recognized under the DFB Agreement were $1.5 million for the three months ended June 30, 2013 as compared to $0.9 million in the 2012 period. The increase of $0.6 million was due to increased net sales of Santyl during 2013 reported to us by DFB. DFB’s Santyl assets were purchased by Smith & Nephew plc at the end of the fourth quarter of 2012.

Licensing Revenue

Under current accounting guidance, nonrefundable upfront license fees for product candidates for which we are providing continuing services related to product development are deferred and recognized as revenue over the development period. The remaining balance will be recognized over the respective development periods or when we determine that we have no ongoing performance obligations.

Research and Development Activities and Expenses

Research and development expenses include, but are not limited to, internal costs, such as salaries and benefits, costs of materials, lab expense, facility costs and overhead. Research and development expenses also consist of third party costs, such as medical professional fees, product costs used in clinical trials, consulting fees and costs associated with clinical study arrangements. Research and development expenses were $470,044 and $404,346, respectively, for the three months ended June 30, 2013 and 2012, representing an increase in 2013 of $65,698, or 16%. This increase in research and development expenses was primarily due to expenses related to our clinical development and research programs partially offset by lower stock based compensation expense.

We are currently working to develop XIAFLEX for the treatment of human and canine lipoma. We have initiated a placebo controlled randomized study to evaluate the efficacy of XIAFLEX for the treatment of subcutaneous benign lipomas in canines. The study will consist of 32 canines randomized at 1:1 XIAFLEX or placebo. The treatment is a single injection of XIAFLEX or placebo. The primary efficacy endpoint will be the relative change in lipoma volume from baseline to 3 months, as determined by CT scan. We have completed enrollment for this study, and top-line data is expected in the second half of 2013.

Also, we have initiated a 14-patient, single center dose escalation, phase II clinical trial of XIAFLEX for the treatment of human lipomas. The study is a single injection, open-label trial, and XIAFLEX is being administered in four ascending doses (0.058 mg to 0.44 mg). The primary efficacy endpoint will be a change in the visible surface area of the target lipoma, as determined at six months post-injection. We have completed enrollment for this study, and top-line data is expected in the second half of 2013.

The following table summarizes our research and development expenses related to our clinical development programs.

	Three Months Ended June 30, 2013		Three Months Ended June 30, 2012
Program
Canine Lipoma	$	180,646	$	127,510
Human Lipoma	$	39,184	$	74,155

Successful development of drugs is inherently difficult and uncertain. Our business requires investments in research and development over many years, often for drug candidates that may fail during the research and development process. Even if the Company is able to successfully complete the development of our drug candidates, our long-term prospects depend upon our ability and the ability of our partners, particularly with respect to XIAFLEX, to continue to successfully commercialize these drug candidates.

Table of Contents

There is significant uncertainty regarding our ability to successfully develop drug candidates in other indications. These risks include the uncertainty of:

the nature, timing and estimated costs of the efforts necessary to complete the development of our drug candidate projects;

the anticipated completion dates for our drug candidate projects;

the scope, rate of progress and cost of our clinical trials that we are currently running or may commence in the future with respect to our drug candidate projects;

the scope, rate of progress of our preclinical studies and other research and development activities related to our drug candidate projects;

clinical trial results for our drug candidate projects;

the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights relating to our drug candidate projects;

the terms and timing of any strategic alliance, licensing and other arrangements that we have or may establish in the future relating to our drug candidate projects;

the cost and timing of regulatory approvals with respect to our drug candidate projects; and

the cost of establishing clinical supplies for our drug candidate projects.

Our current resources and liquidity are sufficient to advance our significant current research and development projects and, Auxilium will have the option to exclusively license the canine and human lipoma indications upon completion of the appropriate opt-in study.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and other related costs for personnel, consultant costs, legal fees, investor relations, professional fees and overhead costs. General and administrative expenses were $1.2 million and $1.1 million for the three months ended June 30, 2013 and 2012, respectively, an increase of approximately $0.1 million, or 8%, from 2012. The increase in general and administrative expenses was due to increased professional fees, investor relations and consulting services.

Other Income and expense

Other income for the three months ended June 30, 2013 was $6,510 compared to $9,771 in the 2012 period. Other income in both periods consisted of interest earned on our investments.

Provision for Income Taxes

Our deferred tax liabilities, deferred tax assets and related valuation allowances are impacted by events and transactions arising in the ordinary course of business, research and development activities, vesting of nonqualified options, deferred revenues and other items. Deferred tax assets are affected by the valuation allowance which is dependent upon several factors, including estimates of the realization of deferred income tax assets, and the impact of estimated future taxable income. Significant judgment is required to determine the estimated amount of valuation allowance to record. Changes in the estimate of the valuation allowance could materially increase or decrease our provision for income taxes in future periods.

For the three month period ended June 30, 2013 our provision for income taxes was $0.5 million. The provision for income taxes for the three month period ended June 30, 2013 is based on an estimated effective tax rate derived from an estimate of consolidated earnings before taxes, adjusted for nondeductible expenses and other permanent differences for fiscal year 2013. For the three month period ended June 30, 2013, the valuation allowance with respect to our net deferred tax assets remained unchanged. As of June 30, 2013, our remaining deferred tax assets were approximately $1.5 million.

For the three month period ended June 30, 2012 our provision for income taxes was $0.4 million, primarily a non-cash charge. Our income tax expense for the three month period ended June 30, 2012 is based on an estimated effective tax rate derived from an estimate of consolidated earnings before taxes, adjusted for nondeductible expenses and other permanent differences for fiscal year 2012. For the three month period ended June 30, 2012, the valuation allowance with respect to our net deferred tax assets remained unchanged. As of June 30, 2012, our remaining deferred tax assets decreased by $0.4 million to approximately $2.6 million.

Table of Contents

Net Income

For the three months ended June 30, 2013 we recorded net income of $1.0 million, or $0.16 per basic common share and $0.15 per diluted common share, compared to a net income of $0.7 million, or $0.11 per basic and $0.10 per diluted common share, for the same period in 2012.

SIX MONTHS ENDED JUNE 30, 2013 AND 2012

Revenues

Product Revenues, net

Product revenues include the sales of the collagenase for laboratory use recognized at the time it is shipped to customers. We had a small amount of revenue from the sale of collagenase for laboratory use. For the six months ended June 30, 2013 and 2012 product revenues were $29,743 and $8,750, respectively. This increase was primarily related to the amount of material required to perform testing and additional research by our customers.

Royalties

Royalties consist of royalties and the mark-up on cost of goods sold under the Auxilium Agreement and earn-out revenues associated with the DFB Agreement. Total royalty, mark-up on cost of goods sold and earn-out revenues for the six month period ended June 30, 2013 were $6.6 million as compared to $4.4 million in the 2012 period, an increase of $2.2 million or 51%. Royalty and the mark-up on cost of goods sold revenues recognized under the Auxilium Agreement were $4.1 million for the 2013 period compared to $3.1 million in the 2012 period. The increase of $1.0 million was due to increased net sales of XIAFLEX during 2013 reported to us by Auxilium.

We receive earn-out revenues from DFB under the earn-out payment provision of the DFB Agreement after certain net sales levels are achieved. Revenues recognized under the DFB Agreement were $2.5 million for the six months ended June 30, 2013 as compared to $1.3 in the 2012 period. The increase of $1.2 million was due to increased net sales of Santyl during 2013 reported to us by DFB. DFB’s Santyl assets were purchased by Smith & Nephew plc at the end of the fourth quarter of 2012.

Licensing Revenue

Licensing revenue consists of licensing fees, sublicensing fees and milestones. Certain licensing fees recognized are related to the cash payments received under the Auxilium Agreement in prior years and amortized over the expected development period. For the six months ended June 30, 2013, we recognized total licensing revenue of approximately $0.6 million as compared to $0.8 million in the 2012 period. In the 2013 period, licensing fees recognized of $0.5 million were related to the exercise by Auxilium of its exclusive option to expand the field of its license for injectable collagenase to include the potential treatment of adult patients with edematous fibrosclerotic panniculopathy, commonly known as cellulite. License fees recognized related to development were $88,761 as compared to $218,550 in the comparable period of 2012. Sublicensing fees recognized in 2013 were zero and $570,000 in the comparable period of 2012. In the 2012 period, sublicensing fees recognized were related to the $10.0 million paid to Auxilium by Actelion for the rights to develop and commercialize XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease in Canada, Australia, Brazil and Mexico.

Research and Development Activities and Expenses

Research and development expenses include, but are not limited to, internal costs, such as salaries and benefits, costs of materials, lab expense, facility costs and overhead. Research and development expenses also consist of third party costs, such as medical professional fees, product costs used in clinical trials, consulting fees and costs associated with clinical study arrangements. Research and development expenses were $764,918 and $653,898, respectively, for the six months ended June 30, 2013 and 2012, representing an increase in 2013 of $111,020, or 17%. This increase in research and development expenses was primarily due to expenses related to our clinical development and research programs partially offset by lower stock based compensation expense.

Table of Contents

The following table summarizes our research and development expenses related to our clinical development programs.

	Six Months Ended June 30, 2013		Six Months Ended June 30, 2012		Accumulated Expenses Since January 1, 2010
Program
Canine Lipoma	$	270,717	$	209,801	$	1,243,705
Human Lipoma	$	83,021	$	102,433	$	487,890

There is significant uncertainty regarding our ability to successfully develop drug candidates in other indications. These risks include the uncertainty of:

the nature, timing and estimated costs of the efforts necessary to complete the development of our drug candidate projects;

the anticipated completion dates for our drug candidate projects;

the scope, rate of progress and cost of our clinical trials that we are currently running or may commence in the future with respect to our drug candidate projects;

the scope, rate of progress of our preclinical studies and other research and development activities related to our drug candidate projects;

clinical trial results for our drug candidate projects;

the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights relating to our drug candidate projects;

the terms and timing of any strategic alliance, licensing and other arrangements that we have or may establish in the future relating to our drug candidate projects;

the cost and timing of regulatory approvals with respect to our drug candidate projects; and

the cost of establishing clinical supplies for our drug candidate projects.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and other related costs for personnel, consultant costs, legal fees, investor relations, professional fees and overhead costs. General and administrative expenses were $2.9 million and $2.2 million for the six months ended June 30, 2013 and 2012, respectively, an increase of approximately $0.7 million, or 28%, from 2012. The increase in general and administrative expenses was due to increased third party licensing and royalty fees, investor relations, legal fees, consulting services and professional fees.

Table of Contents

Other Income and expense

Other income for the six months ended June 30, 2013 was $12,376 compared to $19,264 in the 2012 period. Other income in both periods consisted of interest earned on our investments.

Provision for Income Taxes

For the six month period ended June 30, 2013 our provision for income taxes was $1.3 million. The provision for income taxes for the six month period ended June 30, 2013 is based on an estimated effective tax rate derived from an estimate of consolidated earnings before taxes, adjusted for nondeductible expenses and other permanent differences for fiscal year 2013. For the six month period ended June 30, 2013, the valuation allowance with respect to our net deferred tax assets remained unchanged. As of June 30, 2013, our remaining deferred tax assets were approximately $1.5 million.

Our provision for income taxes was $0.9 million for the six month period ended June 30, 2012, We paid $0.1 million of cash and applied $0.2 million of its tax refunds receivable to reduce its income taxes payable. We also used $0.4 million, of tax assets (primarily Orphan Tax Credit) and availed itself of $0.1 million tax deductible expense related to exercise of stock options to further reduce its tax liability. Our income tax expense for the six month period ended June 30, 2012 is based on an estimated effective tax rate derived from an estimate of consolidated earnings before taxes, adjusted for nondeductible expenses and other permanent differences for fiscal year 2012. For the six month period ended June 30, 2012, the valuation allowance with respect to our net deferred tax assets remained unchanged. As of June 30, 2012, our remaining deferred tax assets decreased by $0.4 million to approximately $2.6 million.

Net Income

For the six months ended June 30, 2013 we recorded net income of $2.4 million, or $0.37 per basic common share and $0.34 per diluted common share, compared to a net income of $1.4 million, or $0.22 per basic and $0.20 per diluted common share, for the same period in 2012.

Liquidity and Capital Resources

To date, we have financed our operations primarily through product sales, debt instruments, licensing revenues and royalties under agreements with third parties and sales of our common stock. At June 30, 2013 and December 31, 2012, we had cash and cash equivalents and investments in the aggregate of approximately $12.0 million and $8.5 million, respectively.

Net cash provided by operating activities for the six months ended June 30, 2013 was $3.9 million as compared to $2.4 million for the same period in 2012. Cash provided by operations in the 2013 period resulted primarily from our operating income for the period, a payment of earn-out royalties due under the DFB Agreement on an annual basis and licensing fees, milestones, royalties and mark-up on cost goods sold revenues under the Auxilium Agreement. Cash provided by operations in the 2012 period resulted primarily from our operating income for the period, a payment of earn-out royalties due under the DFB Agreement on an annual basis and sublicensing fees, royalties and mark-up on cost goods sold revenues under the Auxilium Agreement.

Net cash used in investing activities for the six months ended June 30, 2013 was $2.8 million as compared to $1.5 million for the 2012 period. The net cash used in investing activities in the 2013 reflects the maturing of $4.4 million and reinvestment of $ 7.3 million in marketable securities. The net cash used in investing activities in the 2012 reflects the maturing and reinvestment of $2.0 million in marketable securities and a one-time cash payment related to our future royalty obligations for Peyronie's disease of $1.5 million.

Table of Contents

Net cash used in financing activities for the six months ended June 30, 2013 was $0.4 million as compared $0.3 million in the compared period of 2012. In the 2013 period, net cash used in financing activities was mainly due to the repurchase of our common stock under our stock repurchase program. In 2012, net cash used in financing activities was mainly due to the repurchase of our common stock under our stock repurchase program during the period partially offset by excess tax benefits related to share-based payments and proceeds received from stock option exercises.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.

Item 3:

Quantitative and Qualitative Disclosures About Market Risk.

We do not use derivative financial instruments or derivative commodity instruments for trading purposes. Our financial instruments consist of cash, cash equivalents, short-term investments, trade accounts receivable, accounts payable and long-term obligations. We consider investments that, when purchased, have a remaining maturity of 90 days or less to be cash equivalents.

Our investment portfolio is subject to interest rate risk, although limited given the nature of the investments, and will fall in value in the event market interest rates increase. All our cash and cash equivalents and short-term investments at June 30, 2013, amounting to approximately $11.9 million, were maintained in bank demand accounts, money market accounts, and certificates of deposit. We do not hedge our interest rate risks, as we believe reasonably possible near-term changes in interest rates would not materially affect our results of operations, financial position or cash flows.

We are subject to market risks in the normal course of our business, including changes in interest rates. There have been no significant changes in our exposure to market risks since December 31, 2012.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company, under the supervision and with the participation of Thomas L. Wegman, the Company’s President, Principal Executive Officer and Principal Financial Officer, evaluated the effectiveness of its disclosure controls and procedures as of the end of the period covered by this Report. Based on that evaluation, management has concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Company’s management to allow timely decisions regarding required disclosure. Because of the inherent limitations in all control systems, any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Furthermore, our controls and procedures can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control, and misstatements due to error or fraud may occur and not be detected on a timely basis.

Changes in Internal Controls

There were no changes in our internal controls over financial reporting during the six month period ended June 30, 2013 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II: OTHER INFORMATION

Item 1.

Legal Proceedings

None.

Item 1A.

Risk Factors

There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K filed with the SEC on March 15, 2013.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

During the six month period ended June 30, 2013, we did not issue any unregistered shares of securities.

Table of Contents

Issuer Purchases of Equity Securities (1)

Period	Total Number of Shares Purchased (2)		Average Price Paid Per Share (3)		Total Number of Shares Purchased as Part of Publicly Announced Plan		Maximum Number (or Dollar Value) of Shares that may yet be Purchased under the Plan
							$	1,672,146
January 1, 2013 – January 31, 2013		6,271	$	15.15		135,636	$	1,577,114
February 1, 2013 – February 28, 2013		3,615	$	15.83		139,251	$	1,519,874
March 1, 2013 – March 31, 2013		3,206	$	16.74		142,457	$	1,466,196
April 1, 2013 – April 30, 2013		4,081	$	17.08		146,538	$	1,396,488
May 1, 2013 – May 31, 2013		4,320	$	15.94		150,858	$	1,327,616
June 1, 2013 – June 30, 2013		3,227	$	16.21		154,085	$	1,275,294

(1)

On June 4, 2010, we announced that our board of directors authorized a stock repurchase program under Rule 10b-18 of the Exchange Act of up to $2.0 million of our outstanding common stock over a period of 12 months. On June 20, 2011, we announced that our Board of Directors had reauthorized this stock repurchase program. On November 15, 2012, we announced that our Board of Directors had reauthorized this stock repurchase program.

(2)

The purchases were made in open-market transactions.

(3)

Includes commissions paid, if any, related to the stock repurchase transactions.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

None.

Item 6.

Exhibits

	3.1	Registrant’s Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 10-KSB filed with the Commission on March 2, 2007)
	3.2	Registrant’s Amended and Restated By-laws (incorporated by reference to Exhibit 3.2 of the Registrant’s Form 10-KSB filed with the Commission on March 2, 2007)
	31*	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule13a-14(a)/15d-14(a).
	32*	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002.

* filed herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

	BIOSPECIFICS TECHNOLOGIES CORP.
	(Registrant)
Date: August 9, 2013	/s/ Thomas L. Wegman
	Thomas L. Wegman
	President, Principal Executive Officer and Principal Financial Officer

EX-32 2 ex32.htm EXHIBIT 32

Exhibit 32

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULES 13a-14(b) AND 15d-14(b) OF

THE SECURITIES EXCHANGE ACT OF 1934 AND

18 U.S.C. SECTION 1350

The undersigned, Thomas L. Wegman, the President, Principal Executive Officer and Principal Financial Officer of BioSpecifics Technologies Corp. (the “Company”), DOES HEREBY CERTIFY that:

1.	The Company’s report on Form 10-Q for the quarterly period ended March 31, 2013 (the “Report”), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

IN WITNESS WHEREOF, the undersigned has executed this certification this 9th day of August, 2013.

/s/ Thomas L. Wegman

Thomas L. Wegman

President, Principal Executive Officer and Principal Financial Officer

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange of 1934, as amended (the “Exchange Act”) or otherwise subject to liability pursuant to that section. Such certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-31 3 ex31.htm EXHIBIT 31

Exhibit 31

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULES 13a-14(a) AND 15d-14(a) OF

THE SECURITIES EXCHANGE ACT OF 1934

I, Thomas L. Wegman, certify that:

1.	I have reviewed this report on Form 10-Q for the quarterly period ended June 30, 2013 of BioSpecifics Technologies Corp.;

2.	Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and to the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: August 9, 2013

/s/ Thomas L. Wegman

Thomas L. Wegman

President, Principal Executive Officer and Principal Financial Officer

EX-101.INS 4 bstc-20130630.xml XBRL INSTANCE DOCUMENT 0000875622 2013-01-01 2013-06-30 0000875622 2013-08-07 0000875622 2012-12-31 0000875622 2012-06-30 0000875622 2013-06-30 0000875622 2011-12-31 0000875622 bstc:DfbBiotechIncMember 2013-06-30 0000875622 bstc:AuxiliumMember 2013-06-30 0000875622 us-gaap:PatentsMember 2012-12-31 0000875622 us-gaap:PatentsMember 2013-06-30 0000875622 2013-04-01 2013-06-30 0000875622 2012-04-01 2012-06-30 0000875622 2012-01-01 2012-06-30 0000875622 bstc:AuxiliumMember 2013-04-01 2013-06-30 0000875622 bstc:DfbBiotechIncMember 2013-04-01 2013-06-30 0000875622 2012-01-01 2012-03-31 0000875622 us-gaap:PatentsMember 2013-01-01 2013-06-30 0000875622 us-gaap:PatentsMember 2012-01-01 2012-06-30 0000875622 us-gaap:SegmentGeographicalGroupsOfCountriesGroupTwoMember 2013-06-30 0000875622 us-gaap:SegmentGeographicalGroupsOfCountriesGroupOneMember 2013-06-30 0000875622 us-gaap:MaximumMember 2013-01-01 2013-06-30 0000875622 us-gaap:MinimumMember 2013-01-01 2013-06-30 0000875622 bstc:DfbBiotechIncMember us-gaap:AccountsReceivableMember 2013-01-01 2013-06-30 0000875622 bstc:LicensingConsultingAndRoyaltyRevenueMember bstc:DfbBiotechIncMember 2013-04-01 2013-06-30 0000875622 bstc:AuxiliumMember us-gaap:AccountsReceivableMember 2013-01-01 2013-06-30 0000875622 bstc:LicensingConsultingAndRoyaltyRevenueMember bstc:AuxiliumMember 2013-04-01 2013-06-30 0000875622 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-06-30 0000875622 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-06-30 0000875622 us-gaap:ResearchAndDevelopmentExpenseMember 2013-04-01 2013-06-30 0000875622 us-gaap:GeneralAndAdministrativeExpenseMember 2013-04-01 2013-06-30 0000875622 us-gaap:GeneralAndAdministrativeExpenseMember 2012-04-01 2012-06-30 0000875622 us-gaap:ResearchAndDevelopmentExpenseMember 2012-04-01 2012-06-30 0000875622 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-06-30 0000875622 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-06-30 0000875622 2013-06-28 0000875622 us-gaap:MaximumMember us-gaap:PatentsMember 2013-01-01 2013-06-30 0000875622 us-gaap:PatentsMember us-gaap:MinimumMember 2013-01-01 2013-06-30 0000875622 us-gaap:AffiliatedEntityMember 2013-01-01 2013-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure bstc:Customer bstc:Quarter bstc:Payment false --12-31 2013-06-30 No No Yes Accelerated Filer BIOSPECIFICS TECHNOLOGIES CORP 0000875622 6339815 2013 Q2 10-Q

512866

660560

5082360

3903942

2500000

1400000

61147

129822

20688706

20794154

13200

92249

79049

105449

13200

135879

122679

30868

144817

175685

30000

16100

32000

29000

13875801

16430099

18390264

20920768

3383737

3788173

4017531

3196831

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Cash, Cash Equivalents and Short-term Investments</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cash, cash equivalents and short-term investments are stated at market value. Cash equivalents include only securities having a maturity of three months or less at the time of purchase. The Company limits its credit risk associated with cash, cash equivalents and short-term investments by placing its investments with banks it believes are highly creditworthy and with highly rated money market funds, U.S. government securities, or short-term commercial paper.</div></div>

633794

591342

6625

6625168

0.001

10000000

1028186

666682

1409072

2381270

0.64

0.35

0.36

0.65

1706298

1554272

2892546

3619654

2750000

500000

1500000

2600000

88910

79482

172825

207390

133524

78328

1484141

1492509

382704

32162

29019

78138

0.15

0.10

0.34

0.20

0.16

0.11

0.22

0.37

147084

165684

102052

P14Y

P2Y

20000

224215

192053

472375

53000

20000

25000

1236254

1149926

2854736

2238648

1570195

1057333

3642729

2315300

542009

390651

906228

1261459

51070

888500

92000

-1060

-416055

382704

102471

-89761

-218550

-1178418

-416072

147694

-5033

261387

-72403

622780

628331

614962

644328

280322

248160

6510

9771

12376

19264

2011-03-31

724528

1199730

18390264

20920768

44880

109275

788550

589761

-2846964

-1500000

-396851

-305852

1028186

666682

1409072

2381270

3877609

2397194

9771

6510

19264

12376

1563685

1047562

2296036

3630353

11250

396851

485904

7276964

2000000

700000

0.50

149724

411110

4430000

2000000

78000

P5Y

P10Y

470044

404346

653898

764918

-310829

2070441

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Revenue Recognition</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We currently recognize revenues resulting from product sales, the licensing and sublicensing of the use of our technology and from services we sometimes perform in connection with the licensed technology under the guidance of Accounting Standards Codification 605, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenue Recognition</font> (“ASC 605”).</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">If we determine that separate elements exist in a revenue arrangement under ASC 605, we recognize revenue for delivered elements only when the fair values of undelivered elements are known, when the associated earnings process is complete, when payment is reasonably assured and, to the extent the milestone amount relates to our performance obligation, when our customer confirms that we have met the requirements under the terms of the agreement.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenues, and their respective treatment for financial reporting purposes, are as follows:</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Product Sales</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We recognize revenue from product sales when there is persuasive evidence that an arrangement exists, title passes, the price is fixed or determinable and collectability is reasonably assured. No right of return exists for our products except in the case of damaged goods. To date, we have not experienced any significant returns of our products.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Net sales include the sales of the collagenase for laboratory use that are recognized at the time the product is shipped to customers for laboratory use.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Royalty/Mark-Up on Cost of Goods Sold / Earn-Out Revenue</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">For those arrangements for which royalty, mark-up on cost of goods sold or earn-out payment information becomes available and collectability is reasonably assured, we recognize revenue during the applicable period earned. For interim quarterly reporting purposes, when collectability is reasonably assured but a reasonable estimate of royalty, mark-up on cost of goods sold or earn-out payment revenues cannot be made, the royalty, mark-up on cost of goods sold or earn-out payment revenues are generally recognized in the quarter that the applicable licensee provides the written report and related information to us.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Under the Auxilium Agreement, we do not participate in the selling, marketing or manufacturing of products for which we receive royalties and a mark-up of the cost of goods sold revenues. The royalty and mark-up on cost of goods sold revenues will generally be recognized in the quarter that Auxilium provides the written reports and related information to us, that is, royalty and mark-up on cost of goods sold revenues are generally recognized one quarter following the quarter in which the underlying sales by Auxilium occurred.<font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </font>The royalties payable by Auxilium to us are subject to set-off for certain patent costs.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Under the DFB Agreement, pursuant to which we sold our topical collagenase business to DFB, we have the right to receive earn-out payments in the future based on sales of certain products.  Generally, under the DFB Agreement we would receive payments and a report within ninety (90) days from the end of each calendar year after DFB has sold the royalty-bearing product.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Licensing Revenue</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We include revenue recognized from upfront licensing, sublicensing and milestone payments in “License Revenues” in our consolidated statements of operations in this Report.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Upfront License and Sublicensing Fees</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We generally recognize revenue from upfront licensing and sublicensing fees when the agreement is signed, we have completed the earnings process and we have no ongoing performance obligation with respect to the arrangement. Nonrefundable upfront technology license for product candidates for which we are providing continuing services related to product development are deferred and recognized as revenue over the development period.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Milestones</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Milestones, in the form of additional license fees, typically represent nonrefundable payments to be received in conjunction with the achievement of a specific event identified in the contract, such as completion of specified development activities and/or regulatory submissions and/or approvals. We believe that a milestone represents the culmination of a distinct earnings process when it is not associated with ongoing research, development or other performance on our part. We recognize such milestones as revenue when they become due and collection is reasonably assured. When a milestone does not represent the culmination of a distinct earnings process, we recognize revenue in a manner similar to that of an upfront license fee.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The timing and amount of revenue that we recognize from licenses of technology, either from upfront fees or milestones where we are providing continuing services related to product development, is primarily dependent upon our estimates of the development period. We define the development period as the point from which research activities commence up to regulatory approval of either our, or our partners’ submission assuming no further research is necessary. As product candidates move through the development process, it is necessary to revise these estimates to consider changes to the product development cycle, such as changes in the clinical development plan, regulatory requirements, or various other factors, many of which may be outside of our control. Should the U.S. Food and Drug Administration or other regulatory agencies require additional data or information, we would adjust our development period estimates accordingly. The impact on revenue of changes in our estimates and the timing thereof is recognized prospectively over the remaining estimated product development period.</div></div>

4700000

3197603

2500000

2491313

4391282

6630503

8200000

P5Y

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The estimated aggregate amortization expense for each of the next five years is approximately as follows:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 60%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="background-color: #cceeff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2014</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">53,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2015</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">25,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2016</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">20,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2017</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">20,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2018</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">20,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr></table></div>

27500

1246

29743

8750

3269983

2601834

7250007

5188582

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">A summary of our stock option activity during the six months ended June 30, 2013 is presented below:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="width: 73.32%; vertical-align: top;"><div> </div></td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Total Number</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" style="white-space: nowrap; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Weighted-Average</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;">Options</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">of Shares</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Exercise Price</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding as of December 31, 2012</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,182,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">8.90</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Granted</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">15,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">15.85</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Forfeited</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Exercised</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expired</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Outstanding as of </font>June 30, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">1,197,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">8.99</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Exercisable as of </font>June 30, 2013</td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">1,177,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">8.64</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"></td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Accounts payable and accrued expenses consisted of the following:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="width: 66%; vertical-align: top;"><div> </div></td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30<font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: top;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Trade accounts payable and accrued expenses</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">365,054</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$ 304,635</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accrued legal and other professional fees</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">129,822</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">61,147</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accrued payroll and related costs</div></td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">165,684</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">147,084</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.2pt; font-size: 10pt; font-weight: bold;">Total</div></td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">660,560</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><strong>$</strong></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><strong>512,866</strong></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">For each period presented below net patent costs consisted of:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="width: 56%; vertical-align: top;"><div> </div></td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30<font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 56%; vertical-align: top;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 56%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Patents</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">472,375</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">472,375</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 56%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accumulated Amortization</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(224,215</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(192,053</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 56%; vertical-align: top;"><div> </div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">248,160</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">280,322</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The following table summarizes the number of common equivalent shares that were included for the calculation of diluted net income purposes from continuing operations reported in the consolidated statement of operations.</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Six Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;">Stock options</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">622,780</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">628,331</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">614,962</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">644,328</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>Stock-based compensation expense recognized under ASC 718 was as follows:</div><div> </div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Six Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Research and development</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">79,049</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">122,679</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">92,249</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">144,817</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">General and administrative</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">13,200</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">13,200</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">30,868</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.2pt; font-size: 10pt; font-weight: bold;">Total stock-based compensation expense</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">79,049</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">135,879</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">105,449</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">175,685</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr></table></div>

105449

175685

15000

15.60

15.85

0.0068

0.37

8.64

1177000

8.90

8.99

1182000

1197000

5120000

7966964

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Basis of Presentation</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The accompanying consolidated financial statements are unaudited, but include all adjustments (consisting only of normal, recurring adjustments) which we consider necessary for a fair presentation of our financial position at such dates and the operating results and cash flows for those periods. Although we believe that the disclosures in our financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) has been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for quarterly reporting.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The information included in this Report should be read in conjunction with our </font>Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and our <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC.</font></div><div><br /></div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Principles of Consolidation</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The audited consolidated financial statements include the accounts of the Company and its subsidiary, Advance Biofactures Corp. (“ABC-NY”).</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Critical Accounting Policies, Estimates and Assumptions</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of management’s estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Cash, Cash Equivalents and Short-term Investments</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cash, cash equivalents and short-term investments are stated at market value. Cash equivalents include only securities having a maturity of three months or less at the time of purchase. The Company limits its credit risk associated with cash, cash equivalents and short-term investments by placing its investments with banks it believes are highly creditworthy and with highly rated money market funds, U.S. government securities, or short-term commercial paper.</div><div><br /></div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value Measurements</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Management believes that the carrying amounts of the Company’s financial instruments, including cash, cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of those instruments.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Concentration of Credit Risk and Major Customers</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company maintains bank account balances, which, at times, may exceed insured limits. The Company has not experienced any losses with these accounts and believes that it is not exposed to any significant credit risk on cash.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company maintains its investment in FDIC insured certificates of deposits with several banks.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">At June 30, 2013, the accounts receivable balance of $3.9 million was primarily from two customers, comprised of $2.5 million (64% of total) from DFB and $1.4 million (36% of total) from Auxilium.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company has been dependent in each year on two customers who generate almost all its revenues. In the quarter ended June 30, 2013, the licensing and royalty revenues from Auxilium were $4.7 million (65% of total) and royalty revenues from DFB were $2.5 million (35% of total).</div><div><br /></div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Revenue Recognition</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We currently recognize revenues resulting from product sales, the licensing and sublicensing of the use of our technology and from services we sometimes perform in connection with the licensed technology under the guidance of Accounting Standards Codification 605, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenue Recognition</font> (“ASC 605”).</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">If we determine that separate elements exist in a revenue arrangement under ASC 605, we recognize revenue for delivered elements only when the fair values of undelivered elements are known, when the associated earnings process is complete, when payment is reasonably assured and, to the extent the milestone amount relates to our performance obligation, when our customer confirms that we have met the requirements under the terms of the agreement.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenues, and their respective treatment for financial reporting purposes, are as follows:</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Product Sales</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We recognize revenue from product sales when there is persuasive evidence that an arrangement exists, title passes, the price is fixed or determinable and collectability is reasonably assured. No right of return exists for our products except in the case of damaged goods. To date, we have not experienced any significant returns of our products.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Net sales include the sales of the collagenase for laboratory use that are recognized at the time the product is shipped to customers for laboratory use.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Royalty/Mark-Up on Cost of Goods Sold / Earn-Out Revenue</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">For those arrangements for which royalty, mark-up on cost of goods sold or earn-out payment information becomes available and collectability is reasonably assured, we recognize revenue during the applicable period earned. For interim quarterly reporting purposes, when collectability is reasonably assured but a reasonable estimate of royalty, mark-up on cost of goods sold or earn-out payment revenues cannot be made, the royalty, mark-up on cost of goods sold or earn-out payment revenues are generally recognized in the quarter that the applicable licensee provides the written report and related information to us.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Under the Auxilium Agreement, we do not participate in the selling, marketing or manufacturing of products for which we receive royalties and a mark-up of the cost of goods sold revenues. The royalty and mark-up on cost of goods sold revenues will generally be recognized in the quarter that Auxilium provides the written reports and related information to us, that is, royalty and mark-up on cost of goods sold revenues are generally recognized one quarter following the quarter in which the underlying sales by Auxilium occurred.<font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </font>The royalties payable by Auxilium to us are subject to set-off for certain patent costs.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Under the DFB Agreement, pursuant to which we sold our topical collagenase business to DFB, we have the right to receive earn-out payments in the future based on sales of certain products.  Generally, under the DFB Agreement we would receive payments and a report within ninety (90) days from the end of each calendar year after DFB has sold the royalty-bearing product.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Licensing Revenue</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We include revenue recognized from upfront licensing, sublicensing and milestone payments in “License Revenues” in our consolidated statements of operations in this Report.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Upfront License and Sublicensing Fees</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We generally recognize revenue from upfront licensing and sublicensing fees when the agreement is signed, we have completed the earnings process and we have no ongoing performance obligation with respect to the arrangement. Nonrefundable upfront technology license for product candidates for which we are providing continuing services related to product development are deferred and recognized as revenue over the development period.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Milestones</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Milestones, in the form of additional license fees, typically represent nonrefundable payments to be received in conjunction with the achievement of a specific event identified in the contract, such as completion of specified development activities and/or regulatory submissions and/or approvals. We believe that a milestone represents the culmination of a distinct earnings process when it is not associated with ongoing research, development or other performance on our part. We recognize such milestones as revenue when they become due and collection is reasonably assured. When a milestone does not represent the culmination of a distinct earnings process, we recognize revenue in a manner similar to that of an upfront license fee.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The timing and amount of revenue that we recognize from licenses of technology, either from upfront fees or milestones where we are providing continuing services related to product development, is primarily dependent upon our estimates of the development period. We define the development period as the point from which research activities commence up to regulatory approval of either our, or our partners’ submission assuming no further research is necessary. As product candidates move through the development process, it is necessary to revise these estimates to consider changes to the product development cycle, such as changes in the clinical development plan, regulatory requirements, or various other factors, many of which may be outside of our control. Should the U.S. Food and Drug Administration or other regulatory agencies require additional data or information, we would adjust our development period estimates accordingly. The impact on revenue of changes in our estimates and the timing thereof is recognized prospectively over the remaining estimated product development period.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Treasury Stock</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company accounts for treasury stock under the cost method and includes treasury stock as a component of stockholders’ equity.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Receivables, Deferred Revenue</font> and Allowance for Doubtful Accounts</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Trade accounts receivable are stated at the amount the Company expects to collect. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. We consider the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms.  Our accounts receivable balance is typically due from our two large pharmaceutical customers.  These companies have historically paid timely and have been financially stable organizations.  Due to the nature of the accounts receivable balance, we believe the risk of doubtful accounts is minimal.  If the financial condition of our customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required.  We provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after we have used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">At June 30, 2013, the accounts receivable balance of $3.9 million was primarily from two customers, comprised of $2.5 million from DFB and $1.4 million from Auxilium.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Deferred revenue of $0.5 million consists of <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">licensing fees related to the cash payments received under the Auxilium Agreement in prior years and amortized over the expected development period of certain indications for XIAFLEX.</font></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We recorded no material bad debt expense in each of the last three years.  The allowance for doubtful accounts balance was approximately $30,000 at June 30, 2013 and 2012.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Reimbursable Third Party Development Costs</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We accrue patent expenses for research and development that are reimbursable by us under the Auxilium Agreement.  We capitalize certain patent costs related to estimated third party development costs that are reimbursable under the Auxilium Agreement. As of <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">June 30, 2013</font> our net reimbursable third party patent costs accrual was approximately $30,000.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Royalty Buy-Down</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On March 31, 2012, we entered into an amendment to our existing agreement with Dr. Martin K. Gelbard, dated August 27, 2008, related to our future royalty obligations for Peyronie’s disease. The amendment enables us to buy down a portion of our future royalty obligations in exchange for an initial cash payment of $1.5 million and five additional cash payments payable upon the occurrence of a milestone event.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">As of June 30, 2013, we have capitalized $2.75 million related to this agreement which will be amortized over approximately five years beginning on the date of the first commercial sale of XIAFLEX for the treatment of Peyronie’s disease, which represents the period estimated to be benefited using the straight-line method. In accordance with Accounting Standards Codification 350,<font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> Intangibles, Goodwill and Other</font>, the Company amortizes intangible assets with finite lives in a manner that reflects the pattern in which the economic benefits of the assets are consumed or otherwise used up. If that pattern cannot be reliably determined, the assets are amortized using the straight-line method.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Research and Development Expenses</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Research and development </font>(“R&D”) <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">expenses </font>include, but are not limited to, internal costs, such as salaries and benefits, costs of materials, lab expense, facility costs and overhead. R&D expenses also consist of third party costs, such as medical professional fees, product costs used in clinical trials, consulting fees and costs associated with clinical study arrangements. We may fund R&D at medical research institutions under agreements that are generally cancelable. All of these costs are charged to R&D as incurred, which may be measured by percentage of completion, contract milestones, patient enrollment, or the passage of time.</div><div><br /></div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Clinical Trial Expenses</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Our cost accruals for clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with various clinical trial centers and clinical research organizations. In the normal course of business we contract with third parties to perform various clinical trial activities in the ongoing development of potential drugs. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, the completion of portions of the clinical trial, or similar conditions. The objective of our accrual policy is to match the recording of expenses in our financial statements to the actual cost of services received and efforts expended. As such, expenses related to each patient enrolled in a clinical trial are recognized ratably beginning upon entry into the trial and over the course of the patient’s continued participation in the trial. In the event of early termination of a clinical trial, we accrue an amount based on our estimate of the remaining non-cancelable obligations associated with the winding down of the clinical trial. Our estimates and assumptions could differ significantly from the amounts that may actually be incurred.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Stock-Based Compensation</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company has two stock-based compensation plans in effect. Accounting Standards Codification 718, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Compensation - Stock Compensation </font>(“ASC 718”), requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based awards including stock options and common stock issued to our employees and directors under our stock plans. It requires companies to estimate the fair value of share-based awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service periods in our consolidated statements of operations.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Under the ASC 718, we estimate the fair value of our employee stock awards at the date of grant using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions. The most significant of these assumptions are our estimates of the expected volatility of the market price of our stock and the expected term of an award. When establishing an estimate of the expected term of an award, we consider the vesting period for the award, our recent historical experience of employee stock option exercises (including forfeitures) and the expected volatility. <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">When there is uncertainty in the factors used to determine the expected term of an award, we use the simplified method. </font>As required under the accounting rules, we review our valuation assumptions at each grant date and, as a result, our valuation assumptions used to value employee stock-based awards granted in future periods may change. We granted to one of our consultants 15,000 stock options, valued at approximately $79,000, during the three month period ended June 30, 2013. We used the Black-Scholes valuation model to estimate the value of options using 37% volatility, a risk free rate of 0.68% and average exercise period of five years.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Further, ASC 718 requires that employee stock-based compensation costs be recognized over the requisite service period, or the vesting period, in a manner similar to all other forms of compensation paid to employees. The allocation of employee stock-based compensation costs to each operating expense line are estimated based on specific employee headcount information at each grant date and estimated stock option forfeiture rates and revised, if necessary, in future periods if actual employee headcount information or forfeitures differ materially from those estimates. As a result, the amount of employee stock-based compensation costs we recognize in each operating expense category in future periods may differ significantly from what we have recorded in the current period.</div><div><br /></div><div>Stock-based compensation expense recognized under ASC 718 was as follows:</div><div> </div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Six Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Research and development</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">79,049</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">122,679</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">92,249</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">144,817</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">General and administrative</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">13,200</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">13,200</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">30,868</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.2pt; font-size: 10pt; font-weight: bold;">Total stock-based compensation expense</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">79,049</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">135,879</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">105,449</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">175,685</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr></table><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stock Option Activity</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">A summary of our stock option activity during the six months ended June 30, 2013 is presented below:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="width: 73.32%; vertical-align: top;"><div> </div></td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Total Number</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" style="white-space: nowrap; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Weighted-Average</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;">Options</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">of Shares</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Exercise Price</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding as of December 31, 2012</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,182,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">8.90</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Granted</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">15,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">15.85</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Forfeited</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Exercised</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expired</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Outstanding as of </font>June 30, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">1,197,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">8.99</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Exercisable as of </font>June 30, 2013</td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">1,177,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">8.64</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"></td></tr></table><div> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">During the six months ended June 30, 2013 and 2012, zero and $78,000, respectively, were received from stock options exercised by option holders.</div><div style="text-align: left;"><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The aggregate intrinsic value of options outstanding and exercisable as of June 30, 2013 was approximately $8.2 million. Aggregate intrinsic value represents the total pre-tax intrinsic value based on the closing price of our common stock of $15.60 on June 28, 2013, which would have been received by the option holders had all option holders exercised their options as of that date. We have no unrecognized compensation cost related to stock options outstanding as of June 30, 2013.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Property, Plant and Equipment</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Property, plant and equipment are stated at cost, less accumulated depreciation. Machinery and equipment, furniture and fixtures, and autos are depreciated on the straight-line basis over their estimated useful lives of 5 to 10 years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the remaining life of the lease.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Provision for Income Taxes</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Deferred tax assets and liabilities are recognized based on the expected future tax consequences, using current tax rates, of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We use the asset and liability method of accounting for income taxes, as set forth in Accounting Standards Codification 740-10-25-2. Under this method, deferred income taxes, when required, are provided on the basis of the difference between the financial reporting and income tax basis of assets and liabilities at the statutory rates enacted for future periods. </font>In accordance with Accounting Standards Codification 740-10-45-25, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Income Statement Classification of Interest and Penalties</font>, we classify interest associated with income taxes under interest expense and tax penalties under other.</div></div>

79000

17458346

19548213

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">9. SUBSEQUENT EVENTS</div><div style="text-align: justify;"><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We have evaluated subsequent events for recognition or disclosure through the time of filing these consolidated financial statements on Form 10-Q with the SEC on August 9, 2013.</div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Receivables, Deferred Revenue</font> and Allowance for Doubtful Accounts</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Trade accounts receivable are stated at the amount the Company expects to collect. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. We consider the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms.  Our accounts receivable balance is typically due from our two large pharmaceutical customers.  These companies have historically paid timely and have been financially stable organizations.  Due to the nature of the accounts receivable balance, we believe the risk of doubtful accounts is minimal.  If the financial condition of our customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required.  We provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after we have used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">At June 30, 2013, the accounts receivable balance of $3.9 million was primarily from two customers, comprised of $2.5 million from DFB and $1.4 million from Auxilium.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Deferred revenue of $0.5 million consists of <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">licensing fees related to the cash payments received under the Auxilium Agreement in prior years and amortized over the expected development period of certain indications for XIAFLEX.</font></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We recorded no material bad debt expense in each of the last three years.  The allowance for doubtful accounts balance was approximately $30,000 at June 30, 2013 and 2012.</div></div>

3323007

2926156

260632

285352

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Critical Accounting Policies, Estimates and Assumptions</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of management’s estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div></div>

6345277

6343356

6351083

6339930

6968057

6971687

6984258

6966045

5 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Clinical Trial Expenses</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Our cost accruals for clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with various clinical trial centers and clinical research organizations. In the normal course of business we contract with third parties to perform various clinical trial activities in the ongoing development of potential drugs. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, the completion of portions of the clinical trial, or similar conditions. The objective of our accrual policy is to match the recording of expenses in our financial statements to the actual cost of services received and efforts expended. As such, expenses related to each patient enrolled in a clinical trial are recognized ratably beginning upon entry into the trial and over the course of the patient’s continued participation in the trial. In the event of early termination of a clinical trial, we accrue an amount based on our estimate of the remaining non-cancelable obligations associated with the winding down of the clinical trial. Our estimates and assumptions could differ significantly from the amounts that may actually be incurred.</div></div> 30000 64000 P3Y 1 P90D <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Royalty Buy-Down</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On March 31, 2012, we entered into an amendment to our existing agreement with Dr. Martin K. Gelbard, dated August 27, 2008, related to our future royalty obligations for Peyronie’s disease. The amendment enables us to buy down a portion of our future royalty obligations in exchange for an initial cash payment of $1.5 million and five additional cash payments payable upon the occurrence of a milestone event.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">As of June 30, 2013, we have capitalized $2.75 million related to this agreement which will be amortized over approximately five years beginning on the date of the first commercial sale of XIAFLEX for the treatment of Peyronie’s disease, which represents the period estimated to be benefited using the straight-line method. In accordance with Accounting Standards Codification 350,<font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> Intangibles, Goodwill and Other</font>, the Company amortizes intangible assets with finite lives in a manner that reflects the pattern in which the economic benefits of the assets are consumed or otherwise used up. If that pattern cannot be reliably determined, the assets are amortized using the straight-line method.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Reimbursable Third Party Development Costs</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We accrue patent expenses for research and development that are reimbursable by us under the Auxilium Agreement.  We capitalize certain patent costs related to estimated third party development costs that are reimbursable under the Auxilium Agreement. As of <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">June 30, 2013</font> our net reimbursable third party patent costs accrual was approximately $30,000.</div></div> 2 P5Y 1500000 1500000 0 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Treasury Stock</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company accounts for treasury stock under the cost method and includes treasury stock as a component of stockholders’ equity.</div></div> 304635 365054 30000 P3M P1M 22 18 28 EX-101.SCH 5 bstc-20130630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - Consolidated Statements of Comprehensive Income (unaudited) link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 040100 - Statement - Consolidated Statements of Cash Flows (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - NET INCOME (LOSS) PER SHARE link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - PATENT COSTS link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - PROVISION FOR INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 070200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 080200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - PATENT COSTS (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - NET INCOME (LOSS) PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - PATENT COSTS (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - PROVISION FOR INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 bstc-20130630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 bstc-20130630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 bstc-20130630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] Accounts payable and accrued expenses Total Accounts Payable and Accrued Liabilities, Current ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts payable and accrued expenses [Abstract] Accounts Payable and Accrued Liabilities, Current [Abstract] Accounts receivable, net Accounts receivable Accounts Receivable [Member] Accrued legal and other professional fees Additional paid-in capital Adjustments to reconcile net income to net cash provided By operating activities: ABC-NY [Member] Affiliated Entity [Member] Stock-based compensation expense Allocated Share-based Compensation Expense Allowance for doubtful accounts Patent amortization expenses Amortization expense for patents Current assets: Assets Assets [Abstract] Total current assets Assets, Current Total assets Assets Basis of Presentation Cash and cash equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of year Cash, Cash Equivalents and Short-term Investments Increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Common stock, $.001 par value; 10,000,000 shares authorized ; 6,625,168 shares issued at June 30, 2013 and December 31, 2012, respectively Common Stock, Value, Issued Common stock, issued (in shares) Common stock, par value (in dollars per share) Common stock, authorized (in shares) COMPREHENSIVE INCOME (LOSS) [Abstract] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent COMPREHENSIVE INCOME (LOSS) Concentration Risk [Line Items] Concentration Risk Benchmark [Domain] Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration of Credit Risk and Major Customers Concentration risk percentage (in hundredths) Principles of Consolidation Costs and expenses: Total Cost and Expenses Costs and Expenses Deferred royalty buy-down Deferred revenue Deferred Revenue Deferred tax assets Deferred Tax Assets, Net Deferred tax assets Long-term deferred revenue Deferred revenue Deferred Revenue, Current Deferred tax assets - long term Deferred tax liability Depreciation and amortization Accrued liabilities of discontinued operations Diluted net income per share (in dollars per share) Basic net income per share (in dollars per share) NET INCOME (LOSS) PER SHARE Earnings Per Share [Text Block] NET INCOME (LOSS) PER SHARE [Abstract] Accrued payroll and related costs Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Unrecognized compensation cost related to non-vested stock options outstanding Excess tax benefits from share-based payment arrangements Excess Tax Benefit (Tax Deficiency) from Share-based Compensation, Financing Activities Fair Value Measurements Estimated useful lives Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Assets, Major Class Name [Domain] 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Five Finite-Lived Intangible Assets [Line Items] 2016 Estimated amortization expense [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Patent Costs [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Patents 2014 2017 2015 Finite-Lived Intangible Assets, Amortization Expense, Year Two General and administrative General and Administrative [Member] PATENT COSTS [Abstract] Income before expense for income tax Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Consolidated Statements of Operations (unaudited) [Abstract] PROVISION FOR INCOME TAXES Income Tax Disclosure [Text Block] PROVISION FOR INCOME TAXES [Abstract] Net income tax expense (benefit) Income tax benefit (expense) Income Tax Expense (Benefit) Income tax receivable Provision for Income Taxes Taxes Deferred tax assets Decrease in deferred tax assets Increase (Decrease) in Deferred Income Taxes Accrued taxes payable Deferred revenue Increase (Decrease) in Deferred Revenue Accounts receivable Increase (Decrease) in Accounts Receivable Accounts payable and accrued expenses Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Changes in operating assets and liabilities: Stock options (in shares) PATENT COSTS Intangible Assets Disclosure [Text Block] Patent costs, net Net patent costs Interest Interest income Investment Income, Interest Termination of Lease Agreement Total current liabilities Liabilities, Current Current liabilities: Liabilities and Stockholders' Equity Total liabilities and stockholders' equity Liabilities and Equity Licensing revenues Major Customers [Axis] Maximum [Member] Minimum [Member] Name of Major Customer [Domain] Cash flows from financing activities: Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from investing activities: Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Net income Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Supplemental disclosures of non-cash transactions: Total other income Nonoperating Income (Expense) Other income (expense): Operating income Operating Income (Loss) Monthly rental price ORGANIZATION AND DESCRIPTION OF BUSINESS [Abstract] ORGANIZATION AND DESCRIPTION OF BUSINESS Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Other comprehensive income (loss) Patents [Member] ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract] Payments for repurchase of common stock Payments for Repurchase of Common Stock Purchases of marketable investments Payments to Acquire Marketable Securities Series A Preferred stock, $.50 par value, 700,000 shares authorized; none outstanding Series A Preferred stock, authorized (in shares) Series A Preferred stock, par value (in dollars per share) Series A Preferred stock, outstanding (in shares) Prepaid expenses and other current assets Maturity of marketable investments Proceeds from stock option exercises Estimated useful life of property, plant and equipment Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Property, Plant and Equipment Property, Plant and Equipment [Line Items] Range [Axis] Range [Domain] RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Related Party Transaction [Line Items] Related Party [Domain] RELATED PARTY TRANSACTIONS [Abstract] Related Party [Axis] Research and development Research and Development [Member] Research and Development Expenses Retained earnings (deficit) Retained Earnings (Accumulated Deficit) Revenue Recognition Royalties Royalty revenue Aggregate intrinsic value of options outstanding and exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Average exercise period EX-101.PRE 9 bstc-20130630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R8.xml IDEA: ORGANIZATION AND DESCRIPTION OF BUSINESS 2.4.0.8060100 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESStruefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0ORGANIZATION AND DESCRIPTION OF BUSINESS [Abstract]2false 2us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">1. ORGANIZATION AND DESCRIPTION OF BUSINESS</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We are a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. We have a development and license agreement with Auxilium Pharmaceuticals, Inc. (“Auxilium”) for injectable collagenase (which Auxilium has named XIAFLEX<sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">®</sup> (collagenase clostridium histolyticum)) for clinical indications in Dupuytren’s contracture, Peyronie’s disease, frozen shoulder (<font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">adhesive capsulitis</font>) and cellulite (<font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">edematous fibrosclerotic panniculopathy</font>) (the “Auxilium Agreement”). Auxilium has an option to acquire additional indications that we may pursue, including human and canine lipoma. Auxilium is currently selling XIAFLEX in the U.S. for the treatment of Dupuytren’s contracture. In addition, Auxilium has an agreement with Asahi Kasei Pharma Corporation (“Asahi”) pursuant to which Asahi has the right to commercialize XIAFLEX for the treatment of Dupuytren’s contracture and Peyronie’s disease in Japan. Auxilium also has an agreement with Actelion Pharmaceuticals Ltd. (“Actelion”) pursuant to which Actelion has the right to commercialize XIAFLEX for the treatment of Dupuytren’s contracture and Peyronie’s disease in Canada, Australia, Brazil and Mexico. Auxilium has been granted a Notice of Compliance (approval) by Health Canada for XIAFLEX for the treatment of Dupuytren’s contracture in adults with a palpable cord in Canada. In July 2013 Auxilium entered into a long-term collaboration with Swedish Orphan Biovitrum AB (“Sobi”) for the development, supply and commercialization of XIAPEX<sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">®</sup> (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture.  In addition, work is on-going to file for approval of XIAPEX for the treatment of Peyronie's disease in the EU.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Pursuant to a March 2006 agreement (the “DFB Agreement”) between the Company and DFB Biotech, Inc. (“DFB”), we continue to receive earn-out payments based on the sales of Santyl.  Our right to receive earn-out payments with respect to the marketed topical product sold to DFB expires in August 2013, and we expect to receive our final earn-out payment for Santyl by the end of the year.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Operational Highlights</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On July 23, 2013 we presented a poster titled “Biomechanical Evaluation of Human Uterine Fibroids after Exposure to Purified Clostridial Collagenase” at the Society for the Study of Reproduction 46<sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">th</sup> Annual Meeting in Montreal, Quebec, Canada.  The poster provided data which showed that highly purified collagenase can reduce the stiffness of human uterine fibroid tissue in laboratory experiments. Increased tissue rigidity has been implicated as a cause of the morbidity associated with uterine fibroids. The results of this <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">ex vivo</font> study show that treatment of fibroids with determined doses of purified collagenase caused a statistically significant decrease in the stiffness of the tissue. This hypothesis was tested in fibroid tissue obtained after hysterectomy or myomectomy surgery from patients. Tissues were injected with collagenase and compared to control-injected tissue.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On July 16, 2013, Auxilium announced that it has entered into a long-term collaboration with Sobi for the development, supply and commercialization of XIAPEX (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture.  In addition, Auxilium stated that work is on-going to file for approval of XIAPEX for the treatment of Peyronie's disease in the EU. Under the terms of the collaboration agreement, Sobi will receive exclusive rights to commercialize XIAPEX for Dupuytren’s contracture and Peyronie’s disease, subject to applicable regulatory approvals, in 28 EU member countries, Switzerland, Norway, Iceland, 18 Central Eastern Europe/Commonwealth of Independent countries, including Russia and Turkey, and 22 Middle Eastern & North African countries.  Since 2011, XIAPEX has been approved for the treatment of Dupuytren's contracture in 28 EU member countries, Switzerland, and Norway.  Sobi, via its Partner Products business unit, will be primarily responsible for the applicable regulatory, clinical and commercialization activities for XIAPEX in Dupuytren's contracture and Peyronie's disease in these countries.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In April 2013, we completed enrollment in our placebo-controlled, randomized Phase II trial, Chien-804, to evaluate the efficacy of XIAFLEX for the treatment of subcutaneous benign lipomas in 32 canines randomized 1:1 XIAFLEX to placebo. The lipoma volume will be measured at baseline, 1 month and 3 months with the primary efficacy endpoint being the relative change in lipoma volume from baseline to 3 months, as determined by CT scan.</div></div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 46R -Paragraph 4, 14, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2134480 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number FAS140-4/FIN46(R)-8 -Paragraph 8, C1, C7 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2122150 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -SubTopic 15 -URI http://asc.fasb.org/subtopic&trid=2122524 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2197480 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 2-6 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 235 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2209116 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 94-6 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0ORGANIZATION AND DESCRIPTION OF BUSINESSfalseORGANIZATION AND DESCRIPTION OF BUSINESSUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/OrganizationAndDescriptionOfBusiness12 XML 11 R6.xml IDEA: Consolidated Statements of Cash Flows (unaudited) 2.4.0.8040000 - Statement - Consolidated Statements of Cash Flows (unaudited)truefalsefalse1false USDfalsefalse$c20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$c20120101to20120630http://www.sec.gov/CIK0000875622duration2012-01-01T00:00:002012-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 2us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Cash flows from operating activities:2false 3us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse23812702381270USD$falsetruefalse2truefalsefalse14090721409072USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Net income3true 3us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Adjustments to reconcile net income to net cash provided By operating activities:4false 4us-gaap_DepreciationDepletionAndAmortizationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse3216232162falsefalsefalse2truefalsefalse2901929019falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Depreciation and amortization5false 4us-gaap_ShareBasedCompensationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse105449105449falsefalsefalse2truefalsefalse175685175685falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Stock-based compensation expense6false 4us-gaap_IncreaseDecreaseInDeferredIncomeTaxesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse10601060falsefalsefalse2truefalsefalse416055416055falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Deferred tax assets7true 3us-gaap_IncreaseDecreaseInOperatingAssetsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Changes in operating assets and liabilities:8false 4us-gaap_IncreaseDecreaseInAccountsReceivableus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse11784181178418falsefalsefalse2truefalsefalse416072416072falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Accounts receivable9false 4us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-261387-261387falsefalsefalse2truefalsefalse7240372403falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Prepaid expenses and other current assets10false 4us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse147694147694falsefalsefalse2truefalsefalse-5033-5033falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Accounts payable and accrued expenses11false 4us-gaap_IncreaseDecreaseInAccruedTaxesPayableus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse382704382704falsefalsefalse2truefalsefalse102471102471falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.No definition available.false2Accrued taxes payable12false 4us-gaap_IncreaseDecreaseInDeferredRevenueus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-89761-89761falsefalsefalse2truefalsefalse-218550-218550falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Deferred revenue13false 3us-gaap_NetCashProvidedByUsedInOperatingActivitiesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse38776093877609falsefalsefalse2truefalsefalse23971942397194falsefalsefalsexbrli:monetaryItemTypemonetaryThe net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585 true2Net cash provided by operating activities14true 2us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Cash flows from investing activities:15false 3us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecuritiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse44300004430000falsefalsefalse2truefalsefalse20000002000000falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 16 -Subparagraph b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 16 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585 false2Maturity of marketable investments16false 3us-gaap_PaymentsToAcquireMarketableSecuritiesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-7276964-7276964falsefalsefalse2truefalsefalse-2000000-2000000falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562 false2Purchases of marketable investments17false 3bstc_PaymentForRoyaltyBuyDownbstc_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse00falsefalsefalse2truefalsefalse-1500000-1500000falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow from initial payment related to the purchase of royalty interests.No definition available.false2Payment for royalty buy down18false 3us-gaap_NetCashProvidedByUsedInInvestingActivitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-2846964-2846964falsefalsefalse2truefalsefalse-1500000-1500000falsefalsefalsexbrli:monetaryItemTypemonetaryThe net cash inflow or outflow from investing activity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true2Net cash used in investing activities19true 2us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Cash flows from financing activities:20false 3us-gaap_ProceedsFromStockOptionsExercisedus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse00falsefalsefalse2truefalsefalse7800078000falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (j) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph i -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Proceeds from stock option exercises21false 3us-gaap_PaymentsForRepurchaseOfCommonStockus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-396851-396851falsefalsefalse2truefalsefalse-485904-485904falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow to reacquire common stock during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Payments for repurchase of common stock22false 3us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00falsefalsefalse2truefalsefalse102052102052falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of excess tax benefit (tax deficiency) that arises when compensation cost from non-qualified share-based compensation recognized on the entity's tax return exceeds (is less than) compensation cost from equity-based compensation recognized in financial statements. Excess tax benefit (tax deficiency) increases (decreases) net cash provided by financing activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11374-113907 false2Excess tax benefits from share-based payment arrangements23false 3us-gaap_NetCashProvidedByUsedInFinancingActivitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-396851-396851falsefalsefalse2truefalsefalse-305852-305852falsefalsefalsexbrli:monetaryItemTypemonetaryThe net cash inflow or outflow from financing activity for the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true2Net cash used in financing activities24false 2us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse633794633794falsefalsefalse2truefalsefalse591342591342falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true2Increase in cash and cash equivalents25false 2us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse33837373383737falsefalsefalse2truefalsefalse31968313196831falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Cash and cash equivalents at beginning of year26false 2us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse40175314017531falsefalsefalse2truefalsefalse37881733788173falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Cash and cash equivalents at end of period27true 3bstc_CashPaidDuringYearForAbstractbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Cash paid during the year for:28false 4us-gaap_InterestPaidus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse00falsefalsefalse2truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of cash paid for interest during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 29 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585 false2Interest29false 4us-gaap_IncomeTaxesPaidus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse888500888500USD$falsetruefalse2truefalsefalse9200092000USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 29 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 27 -Subparagraph f -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585 false2TaxesfalseConsolidated Statements of Cash Flows (unaudited) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited229 XML 12 R17.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2013

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Basis of Presentation

Principles of Consolidation

The audited consolidated financial statements include the accounts of the Company and its subsidiary, Advance Biofactures Corp. (“ABC-NY”).

Critical Accounting Policies, Estimates and Assumptions

Cash, Cash Equivalents and Short-term Investments

Fair Value Measurements

Concentration of Credit Risk and Major Customers

The Company maintains its investment in FDIC insured certificates of deposits with several banks.

At June 30, 2013, the accounts receivable balance of $3.9 million was primarily from two customers, comprised of $2.5 million (64% of total) from DFB and $1.4 million (36% of total) from Auxilium.

Revenue Recognition

Revenues, and their respective treatment for financial reporting purposes, are as follows:

Product Sales

Net sales include the sales of the collagenase for laboratory use that are recognized at the time the product is shipped to customers for laboratory use.

Royalty/Mark-Up on Cost of Goods Sold / Earn-Out Revenue

Licensing Revenue

We include revenue recognized from upfront licensing, sublicensing and milestone payments in “License Revenues” in our consolidated statements of operations in this Report.

Upfront License and Sublicensing Fees

Milestones

Treasury Stock

The Company accounts for treasury stock under the cost method and includes treasury stock as a component of stockholders’ equity.

Receivables, Deferred Revenue and Allowance for Doubtful Accounts

At June 30, 2013, the accounts receivable balance of $3.9 million was primarily from two customers, comprised of $2.5 million from DFB and $1.4 million from Auxilium.

We recorded no material bad debt expense in each of the last three years. The allowance for doubtful accounts balance was approximately $30,000 at June 30, 2013 and 2012.

Reimbursable Third Party Development Costs

Royalty Buy-Down

Research and Development Expenses

Clinical Trial Expenses

Stock-Based Compensation

Stock-based compensation expense recognized under ASC 718 was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Research and development	$	79,049	$	122,679	$	92,249	$	144,817
General and administrative		-		13,200		13,200		30,868
Total stock-based compensation expense	$	79,049	$	135,879	$	105,449	$	175,685

Stock Option Activity

A summary of our stock option activity during the six months ended June 30, 2013 is presented below:

	Total Number		Weighted-Average
Options	of Shares		Exercise Price
Outstanding as of December 31, 2012		1,182,000	$	8.90
Granted		15,000		15.85
Forfeited		-		-
Exercised		-		-
Expired		-		-
Outstanding as of June 30, 2013		1,197,000	$	8.99

Exercisable as of June 30, 2013		1,177,000	$	8.64

During the six months ended June 30, 2013 and 2012, zero and $78,000, respectively, were received from stock options exercised by option holders.

Property, Plant and Equipment

Provision for Income Taxes

XML 13 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenues:
Net sales	$ 27,500	$ 1,246	$ 29,743	$ 8,750
Royalties	3,197,603	2,491,313	6,630,503	4,391,282
Licensing revenues	44,880	109,275	589,761	788,550
Total Revenues	3,269,983	2,601,834	7,250,007	5,188,582
Costs and expenses:
Research and development	470,044	404,346	764,918	653,898
General and administrative	1,236,254	1,149,926	2,854,736	2,238,648
Total Cost and Expenses	1,706,298	1,554,272	3,619,654	2,892,546
Operating income	1,563,685	1,047,562	3,630,353	2,296,036
Other income (expense):
Interest income	6,510	9,771	12,376	19,264
Total other income	6,510	9,771	12,376	19,264
Income before expense for income tax	1,570,195	1,057,333	3,642,729	2,315,300
Income tax benefit (expense)	(542,009)	(390,651)	(1,261,459)	(906,228)
Net income	$ 1,028,186	$ 666,682	$ 2,381,270	$ 1,409,072
Basic net income per share (in dollars per share)	$ 0.16	$ 0.11	$ 0.37	$ 0.22
Diluted net income per share (in dollars per share)	$ 0.15	$ 0.10	$ 0.34	$ 0.20
Shares used in computation of basic net income per share (in shares)	6,345,277	6,343,356	6,351,083	6,339,930
Shares used in computation of diluted net income per share (in shares)	6,968,057	6,971,687	6,966,045	6,984,258

XML 14 R10.htm IDEA: XBRL DOCUMENT

NET INCOME (LOSS) PER SHARE

6 Months Ended

Jun. 30, 2013

NET INCOME (LOSS) PER SHARE [Abstract]

NET INCOME (LOSS) PER SHARE

3. NET INCOME (LOSS) PER SHARE

	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Stock options		622,780		628,331		614,962		644,328

- Definition

The entire disclosure for earnings per share.

+ References+ Details

XML 15 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 16 R24.htm IDEA: XBRL DOCUMENT

NET INCOME (LOSS) PER SHARE (Details)	3 Months Ended		6 Months Ended
NET INCOME (LOSS) PER SHARE (Details)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Number of common equivalent shares included for the calculation of diluted net income [Abstract]
Stock options (in shares)	622,780	628,331	614,962	644,328

XML 17 R18.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2013

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Stock-Based Compensation Expense

Stock-based compensation expense recognized under ASC 718 was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Research and development	$	79,049	$	122,679	$	92,249	$	144,817
General and administrative		-		13,200		13,200		30,868
Total stock-based compensation expense	$	79,049	$	135,879	$	105,449	$	175,685

Summary of Stock Option Activity

A summary of our stock option activity during the six months ended June 30, 2013 is presented below:

	Total Number		Weighted-Average
Options	of Shares		Exercise Price
Outstanding as of December 31, 2012		1,182,000	$	8.90
Granted		15,000		15.85
Forfeited		-		-
Exercised		-		-
Expired		-		-
Outstanding as of June 30, 2013		1,197,000	$	8.99

Exercisable as of June 30, 2013		1,177,000	$	8.64

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References+ Details

XML 18 R25.xml IDEA: ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) 2.4.0.8090500 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)truefalsefalse1false USDfalsefalse$c20130630http://www.sec.gov/CIK0000875622instant2013-06-30T00:00:000001-01-01T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$c20121231http://www.sec.gov/CIK0000875622instant2012-12-31T00:00:000001-01-01T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 2us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Accounts payable and accrued expenses [Abstract]2false 3bstc_TradeAccountsPayableAndAccruedExpensesbstc_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse365054365054USD$falsetruefalse2truefalsefalse304635304635USD$falsetruefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business and pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).No definition available.false2Trade accounts payable and accrued expenses3false 3us-gaap_AccruedProfessionalFeesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse129822129822falsefalsefalse2truefalsefalse6114761147falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 7 -Chapter 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6911-107765 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 8 -Chapter 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Accrued legal and other professional fees4false 3us-gaap_EmployeeRelatedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse165684165684falsefalsefalse2truefalsefalse147084147084falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Accrued payroll and related costs5false 3us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse660560660560USD$falsetruefalse2truefalsefalse512866512866USD$falsetruefalsexbrli:monetaryItemTypemonetarySum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Article 5 true2TotalfalseACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/AccountsPayableAndAccruedExpensesDetails25 ZIP 19 0001140361-13-031299-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-13-031299-xbrl.zip M4$L#!!0````(`"LZ"4,F)6ZC%80``+7M!``1`!P`8G-T8RTR,#$S,#8S,"YX M;6Q55`D``\+/!%+"SP12=7@+``$$)0X```0Y`0``[#UK<^)(DM\OXOY#K;=W MMSL"L"1`@'NZ-S"F>WS3;7MLS]Q.3%QLR%(!FA82JY)L,[_^,JLDH1<@GA9N M.B9BL)25E>_*>J5^^.?SV"*/U&6F8W\XD6O2":&V[ABF/?QPXK.JQG33//GG MQ__^KQ_^4JU^IC9U-8\:Y&%*+DRF6P[S74KN',OW``,C-[?7GRZ_](E24VJ` MC?2B;='6=6CZKD:YE$0[.B$L9 M=1^I4:M6L??G!]%DY'F3L]/3IZ>G&CZI.>[P5)&D^JEI,T^S M=7H2P%NF_6T!.+Y^T%@$_IR!?ZIS:."@<\K?1J#,S`,$M/+IO[Y^N=-'=*Q5 MT_1@]\:L89P:]52\#$%-YC04N;6(60$1-;`?*?.2N!G5:T/G\52\@V:R4I7D M:ET.&X&>AYHVB5H--/;`>PA>Y#0QJ)G?";S(Z\%SY_+0.86W(:#MC_,!#<\] M]:83>@H0U#7UJ(%C%VCCV-54.]WQ;<^=YC,1O,QA1/==%QQD7KO@;4Y#6S-U MEM^*O\(FN26I<"Z"(."HY-R`_H46>,^\HM'1#N86>HMP\GS!Q/+'0<_FSD MTL&'$Z2B&G96>V;&"3D5B'A@`,W:'GWVB&E\.-$YG"S)GA.1QV$C:&I[IC<- MGD5/30.?#TSJ$DX837`3BJEW^=/)1PG^M5M-55%^.$TW#KLZS>DKZ&D"1ND8 MZ?Y!/JYW`9'V(Y*-6I#D$,OL7:H1M8U8$[5:EV8=&[$&X=-8U^&C0':+Q=F6 M6@_OVI_.&[/9YX#60KK/IOLWQ>#AW/3\:@^NK3U MKW3\0-T7$-ML2*+#,8UXCEX80,;SQ#)UTQ,T$L,$.#&?"/+'LRQW)Q]Q&#_+ MX?&'TURT,W).\^@IJ[7/U6[7?S8MTQ^_4L4FV7M=.N4C_K\_F;;IT2\F3%$O M;<`]-!\LVF6,>NQ\*N1B:4PH^P:2+]MCAZWK%1@^^1@V2G#^`F:PPT1'N/;1 M#`[!#'8:X1L'/[ULE&=ZJ43B/)R)1$*P4CE M1$??W8=?\*N!SV^O6Q2 MQA_2K]FR. M#WUJ&;$STWB"KV.&LL@"8.A^E180Y^MH`1D+Z#FV#HRY&AZSO#79M_/I.;7U MT5ASOXEE)YT?6F.W5*?FHP8)G1#:<3VB\'K$*OTNT\?,LN?"K:QNWSE2SO.DM?:2V_WV8_7+SXTY07%[;](WC&F%Y0OUQ M-^(8X+^;`/\ZC/TP8_MQ7W!)6,?+0(9OT>M!?SRQG"FE=]1]!"7>C327GFN, M&CUG/`&!<\5W+-Z7TQ;3`W%Y2P+ MC*!KC&$ZQ;@)/=+^,R(]]&6C'4MO%LX+B?$8V_=OW[>44R7K+B#$HVUG\I:C;1]M^_7D)7NV[6->\OKSDA+9=^H`\=&^C_:]^;F3 M4IWHWK-]'W.35YR;E,VVY6/L/D#K+G7L+M&9P;W;]S%VO^[872+;AMFDTCZ( M"P[I4WQ*>Q^G^-8^97X\_[?^=M6!GG0OVVKH#BSY-9QCW+UU;>I7QU.5B\_5 M4@NK6=X`4=-[5X-40>=E+#$7F+T19PL&`],R\5F?2^*P+;OYR;UBR2EKW2.J88543\&A&$JRD)4X;LX>L0U#[--D6G+X;[ M+]5J%Z`-;$$^6=J0%_Z%%P8USZ(W^(($3GF+Y4!S2WP.-(N!+C(MHYYZO%(K M]&,R7;/(;S#!(WW;(!@4XOT&<`(,H?HB<"PGH1I6'EJ$)J+GPM%]SKB8D>;2 M$L((D,*$Q(/?7#01(2*VD_^EEE7]9CM/-KD#K3DV-<@E8SYUXQ0)8(3]"4%# M2`&XG+(K1U"T$$V:LE\=RX=DRYV"[BSJLBP]$80`6)6.5/-T_Z'EB-4"TQX2 MO-+FY]`10$:``FXY.;]A5%N&)DT6)Y;T0)5#QYUFB>'OP]?+:>`5N8-:W[QI MG*($KC0AMW3(U_]`1%?:F&8IF0'@^^6DG%]>W]WT>Y>?+GMWY+[?^_'J^LOU MY\O^'>E=W][$Z4IBSBB.'ZJTR*5MT&?R$\T14@#"(0!@.6WQ?&TNF@PASGCL M@%]YCOZM0OAR%2/7OH=K#UAX/8-C\!`]97IR:13L.4BQ2)6-4"L5<0H*HN804 M`560F)^5/%)B*++$W$\GN0$;GR_O4):J/R>[Q':SL3$X9DY@4,5#Y@1T@X7S M71]<](NI/4!R[IF45<((%5*2/J<>M,?%>M$ZUC@,;FEB19'CA$TI*9MJRDI; M57\X7:.[\K_'Z/L]AS"YSS_]9A>88*$7$\R^WQ M[Y;W'O)CPKRI!5/6`'0S/R3GA%9FGCO3_X^]-ZG,&+W5/!$ M\2,29^3!L0S1=[-&NKW>]2]7]W?DIOM;]_Q+GW2O+O#A[2_]"]+_UTW_ZJY_ MAS2>`I$Q>L.?#RXY#7^G0';*$J<_,IM)S&RTP&RHV(O@48W!$`B/G`'Q1A1P M69;S!#'\;`W&/-$1L@,V`D9,W1,0J6M0%]V!0(I@331#?"PD^)M--#W\.Q#* MDVEXHS/2D?Z6EL7:5N2YT2^#/`84/C@>3)/2W:HJ=/M((76"\!WJQG,F"9/D M/[7QY/U?957*R.'4,PIW)R_L+=E%`JWNH.P`+P2=.5TLXR+/"H7:=N=7_^/; ME-0EI``A\J/%FC9?X5+"5WG6F10?3!Q<_(2)^/]<$<9%8]$!\+6IWH[F$#>' M"ZJ+1<>Z7"FCPDYCD:-`#`FB6U4\/B/*Y#DB8%^!91$-NS0O$>BC;O\J\7_8 M/6&.91K+F7\)`\3\94>&MQ-%')6^':4K!Z/T%4/0@Z9_&[J0^QE5T)_C@E)T MG=+!8+5`-)]#_L2T<9_IC%1;-242]`J:&FONT+2KB/&,Q'&DQ_1[5S,H)J[+ ML]FUHF6O/P;'SSD7#`_QWF2!BN^5ETJ%E\`'2\$%8`],MU['$:..*DWY$Q]L/VQICUA3F#MQL^4I&2?+Y MU0@M=2XJPVQ+;>]JME4>VSH:_M'PDX;?:%6D5V/X^YZ7'5/*4J:4"^@H8]IW MM):CM1PG"4LF";*:/TN8M[-V[WB:M:O)0:-L.1(01`S'?[#HCI*D[:8>\Y2V MWHKWBC(I:SXV3RBJ*E6:JK2G%.WE3/OH=_DFQCS7L8,B.W*2N5 MMJHN9>)@;#DV%)_R(Z?17X&?KG;@.N>P<_;PM1L5:Z\0F\X]1SZKZ7Y%O4T. MQTMMI9YW[TCU3L-95O47GPZ)\%W'\BEK9/?Q17AN2?9B[-1 M]"L?\[FM-D\^*DWNQ]MB-ZR$OF,^4\7N%[,H-]9DL=@.90Z'V/`F!O>);G2[ M1)7E1BM!_H(.]LY``9^2E4Y;45;G`$*Q)^B<:*8!DP&B:Q,3DO(,R1'D#0!> MVCT!MHZP%4EMMUM2_#)//O(=DEE`I(K4ZC3D9F,%,D41*+`(?L>M^H!5HDB\ M3!0)RCI5@Y)FXG9.HJC9?+\.L>=7H`HP+[MX4Y:B=XNMN:XDHDDASM=10UA[ MB^LA5GWKX)50I#+;0A5T%*71>5TJ*&'1]84J:'6D_:A@)P(N"6_[#+2EK'R^ M4`U[";([":%+!A"IV7AM]E72RN/E&,AW(N)EO#7;K52:8^B[D<' M^_3S4E:I7KRD([75]NMRA1*64E[L"HU&6VX=4JR55XBUK:;:;F[$W)-FZUBP MP.6+Z=[`MZ)K8GD<(,2?\TL>\=<;+*W+]7:KV<9JJKDHMT-' M(6]O0-CJ=(K1D=_]6ORWZQU)41OI?M?KL-"Z=4>16HET+-DA#)QHHBQ]RYAG= MP+1A=#9A]L*`#3KFL0WR)C`CS3<@%!D5\N![Q+1UR\?K\WB%PT`*!>C;H.X3 M(G9L:XI2L1T7+*Z"VY/@0/@FUN(=>1J9D*0_45$RRJ`NL2$18`P+:V+RHI&! M9N).V4RVB-7QW1BU$X?Q_1:B>83Y@`_983SUQ^)3S@0K2&+7@,6W//%&U]B( M#"`A8;PC;^1`\BDJ+[,:Z5KPP!]RTAZH94*J#2"`'Q$:T=8^`UFDB$F)3C/H M?WPLD.HY9*Q]HQR!:0]0+)SF@#6*)R4\,C:9134\]U`A.G4]#?#'H84X0;2! M#@PD(+=SP#L!`C@`JMPU>$;X9'HC\DOMKD:&8CH'N.`UG2`%VLR+)Z`KW9Q8 MP.);<62BK2C2>][R<[=[$SV3W[\C(XV!E*B-6C1P:#0(B-09FQYBG?@N\[$0 M)X@`N7=]*]".2X>^Q1EC8:6P.[0347D.(?K/^@@+RO-JE2;?H21O$2Y&TUV_ MEZ`&U?D?44X8F'/#@J6ULCHE=K3UHE7W*3.+VXLW@H@EYI6$@9E;!F@/!*7Q MMZ##/WR;%V(7UH+VS043EL#Z.1)N@`0@(:4?$ZP=&7@3#55`J(W=?N6S\;I< M(3@0B$WP`._6>>_:M@_.D"7NIXBX*98,%93%:T4A<0KXDP7/.>_<)/N]6H+_ MS.&]S`&AS*@XJ_B,82>*/Q`;8-)CT9Q9&0+")!__UY]!=;V>YKH8NG_5+#]G M4K8\T:C7V_56/;8"4*BGO3%08%;9:K?E5KVD#!3(OTFK6Y9(R(!0R.C3[[:TZ,I2+>MX*!A) M&S=GA,T8,6>,\$2+ISX&IH!CS?U&/3QHZM.:$$@<3YB]\@R5S=*-D?;(TU-H M[^&SJ4A)7$K)&,@<,W90CC[_B&!\T^QOV&^:M0CPC M,!?@5Y#R!(A'4]X);Q*\%'76@5DZ#84X\&T#U"421N>1NC9?19^)K8)2B5$* MCPGRM/S`:0BOOU@9#B;%8U? M.RM2526V;Y#&N!.J"E7Z7H4J)J@R.3GD+>3RXN,T65-(5]D7'!2A,%/#'RB4 MXXM(:[\%8A)NH*]E4=]9L#1^0Q0T< M:8%AS3K8&^$%'&)MPB''W!XICCP.Y$%OOSB,O:M`LN=A3G2O/5=(U_-< M\\$7]=L]AX`NG/;_[%_=7?Y:Y]<7L'??6#N^NXN M+T1DT#G>]_O%C09,`>=+KZQSX$_!.J68?_+9H/D&WVK2$XYH"D?$J3.X8@#BC30;+ZF% M;V$>2ZU!D:GB$N..10-;YY^_"G>,>F(.?LOGX#:N1_\!-$5WV;)>%&N/C41[ MWOP[OIT<=F+Q(O; MGYQ9W,L%LS,HW^<-A,A`7'C.EJ]VE9;QKD<2$;7"@[J6O;,;FAXR^J9>ZQ#H MU^([`-O:TBXJW)Q,>6WBBU9M3VK=KX&U_$Q.HI M[T1CO`6-%O=&KC5F@'4U`QA>["VM;--NQS>@P4@H+U2#YD0U?21V^H#'A-3` MOYU@`]S#FK&Q3\?!RI/-$^HN1YO7F@4G3NXS1E`>92!B(:/M*%8 M+ACYM@'M("%Y-_]N?70]/7:0=-YIN0Q9-U&'\M(CCYG&Y]-S"+\C7,<6%]4S M!TT%&6M=WF_$DWH%UR_B![<6,;*F@+]$%@;M\!`+_NR"H=P&AG(K#&4FW*+E M#E:4>F,UJ4=TS\@&J@.B`YJWJH=ZH:LF,>VEQBS); M]6JR5U MXTYJB1.(W?->]>JW^(&_8AG/7$./!2WFA:<.\Z\G<`CP]/#]ANO3+4E5.HGM MJ"3Z;5*VVI759K.A)!=@=TG9"DO#2KNC-!OJ?BA;:5VWKLH=M=DH0-D%'5`7 M9[AADO_@3ZN&\Y0)SR&@8&6="CJM9G)[)X%QVP056?Q>D:!@+%T^WHR MS6N?J9L2[0'16NX-F0RJS6KHM=L=>1&A.07,MDQDH;(IC?CF8!$BOSCV4!SA M,J)P$'C?8E^[@J1T@^M6+:4=/^,R%_E."2U4C:Q5[\SW_1Q"TU%L[IVU%*J- M+M'5FTIC+I%S#7-+%!:QS'9=::].X,QS2)588`$$+:"(%VVF=;G1;L@->;$K M+=+]3@@OXE<-2)2DSF:$6T'0G2Z@-Q:8-S#<_(B:Q;U3.HMD>6VE)>4XV#)B M)R[%4[_\DAI^8S9VYS9+\PP8?EN4%XJPC?@]W0U35456$Z/#\@[WR,IJ\X&. M)'?69"4JRSE3'-]G,AF29-KX+K@["-/'#&\FFSA,LSZ[CC^YY%->TQY>Q!I? MAVVSQ8'7<9%66Z['(^B9 MA:<30Y0KK0_4,VM_8M2WR8-`N*E/J/,YX!WLF_Y5O4$N'?VK69!2,OI7]>-64?K#MWC'1E2[ M(K_CJC'AR\:9):@TLK+NI.S\P%B]1J[Z]\ESEN2F?TON?NS>]E_FBOW+[I]< M9DLPQ`JFW'F01VNN@;L=QO^W]Z;-C2-7HNCW&W'_`VZ_]IOJ")#-G53WC"-8 M*E5/S715R265VWZ.&Q,@D!3A!@$:BU3L7__.DIE(D*!(2EQ`B8ZPK9(`Y,F3 M)\^^<,83ZL6M7L,NS?&DGW^RL*6X[^X(0FN9V`O)G[8U6KS-;S"G[0?C4H,E M@$ET?D(I222M,HKJ8N"'R41X-0?SMNZ$%694=`_*)M2T%T"L1RV))NJ^-0C8$K@J/":?\P+-O4>_8;UE0JEC$G,S;JF1 M[Q`X$,Y$P>I.D4XBK]))7>,(^\01Z)1-`=O$]+<_*#VRY$26$4Q9E)0HI=M> MJ,8/KA.XLN>(B6]32F4Q)EW*E"MI25!+&VT'R:8BYBD:05$="J6<:/W24W#. M")`3GWSJ?_BL^_?/=?\VG?U)W?TN=9/U`V%+-Y)C#S_O;S3Z_ M,7TZ3U*8CCX`>F<#E'9O'UL&CB3XA-)<6"WV\TS M*9Y)\>BDV.S8%[U]Z31G4CR3XN:DV.G8[=;@]$C14+)_I!C38O!I=8[$M5FWUTCMVG*.3O#A\P MD>$6.U&8?\?RKD]1^G>1YE/NR*[Y+`%X`L(:R[C:*XQY7M`WG%!"95)O12C& M?FJ]P7^\@Q]=[/DSERU45DW(LZWW7#>+9>YNZM_3L2XAGI:!#\M%WL,GRW>F MOY9_['D)XB9JGP/%::-LNYZ%C5:CV]HUWM[C\!ON'OQ1.-@7J;0?/CY&3QD/ M<97S:R[J7X&\JJ:^?'1"YX[S1HKMP#AMA07M%PWB[K5V7\$L0F9ZF$-$"(1*F:D& MY,3MAKU,J&E`QJ(A-MX7O#6_VM;7 M1.#8S%_]L:A]=&`39OWQNM%_JV?W\6?QJ_N;X_@_7W!H$OU>0B[KF_]\W>S\ MW<#9!E`^!5U+V/D([TX?J=^N#KH84(VNUEZP!9>J4`,E>P38UM^Q6]E[>&=S M!"7FE^2'\#/XE:?-!2Q48C]M88T&6+/W_+UP.M(Q-D,K;WZHKIM-,]:WS0\^ M@UTDQC?7E`#N?*NX=(X^`7GA#*FKTW MA6\EU'MN63N13V*E=>$Y^>%G]LEJM7LML[/2FM4.`/]VW;2:G8N+5J]*\&\W ML6#0[?3;E8)_NQX!K?:@UQEL#W]AB`3[IR[S3G(2(RC6`^=N'6^H:U_ M]0T^&\5@<>,PXP^IF&(_I2C$O:"?&;_Q`7-_P-!>Q`=_"==%OU&^:+[F6UJ2 MGZ,%"\O1:L6UU%+/O(O=?J-Y8- M$B_.Y["/^[`-CV\W4:<]RCE0($./A'^T1EROEC]?5=_\WLO$^W7K^LOGOWZX M^?#YD_7^\Q=5,'X[_-O5356=]!]PQ``ZJ_V02D+!5)G%T;U/@^FQQE06D:9\ MUQZX--3W1$SC!9Q[QP_(6V[,9C==\[)<%'[B15P,^PT'OX:XL$TZ M%=*OZR0<#1AGY#R'I^3W$0YRF^]\2-!"6H$Y%GTO<^P+8T\*$X>,$,B_)7D_ M0*/IVBR+DPQ?3*,-:N[[G4:MV:AU&WQL"9;P%O;(<7,9H"S$VO%`%AL2)G5+ M#7+2XYMD`?OJ81*KZ8F&@7S?K+?5Z(>ZE1_%]@MA*$;"C@77>6\"(+V9<%,5 MH2F+,6&]=!FZ8X'S7;"Z/G0GZ%3W3!B'=&@+H.`=XM>HTK_DHU3);422@CEB M00_`J&PQ^Q9'TEK#2OCH&_E@&-N8"N-08@?%\P#I\9UX(EVTMJ,+=V=T\7DM M"7AR/+"'XZ\!#_GL&AR-5"2-5KU7AJ41\,HLP18/W(`!$?XYGN$HLG=Q=D=B M7(ZV@F_"#QF.XX&'^`!DF--6O2B6YK$5,+E!O/(Q7:!,Q5"V\!N94;#4+D=_ M4#ZI,BV>9?!U.ZU&8TF_75IDKP!O91FU+QJ];O/8`&^AN@*\+;,EZC$`WLKF M:;9ZS4YW>YK`ZYQG$*P$51@#3)Z2"-AM-OI+AL#"=_^QG(J$ M`./#N;Y"S:)(URO?4]T:EFH9/B4,!3X.3;S#&8$IC3TL5RHL?VP7L:&:-QEF MEK@'VPL^;+++?2']2+:A$6CC?FUO+EC&HL_@N_`$42S_)E*SO9QN-+72H>NKL.(F<.\G M->QO#6T4T$[='A*PPXDM=8]CBK%P?P/JF+G,1:![#6M::U!P/0<+L*0=?XBG:\!"@%@J[)@=*/SF'%"M7DB2")L\`](( M"P5#*2/*T,_*3$1F4NA!40O)!VD@\3;:^JIDPLINU,E,073=_TVY&N2$N8KU.1MPBL+[?8W6O(0 MN]BV-J#3;SYU%^LH[4OY\)/5![YZ1M(VEV=PT>\]NJ=5PY$.MI_M+DRK.>AV M-V('&VZH9##H1K2W,,/SN3RNV1]TFH,UQ+>PYK&VMCV+,X?4;;6SX2;E"YMO M2EY:3"G99-#!-MZ63K]WL8X%KH6A$OO>[GB[C87\AN=L>P4A7X,RC]K0E:$E M?D:-4.;YK4>$_(+B#?)#``Q]AK_RS/2K7K,]Z#^&B4U@J"@FMB.)?JO3>)0F MML)$H;$.M:3G]L%E7E0N)Z*"T6D44B%?,DS3V!]E5#]]&^7%?4"0^/`PCC'0 MP3-1M_+!-Q?VW6NU^H-%T?0L>"J!@T?=^LLX&+3;B_K&Z>/@44ZPA(-FYZ*W M*/!.'P>/\H`E''0Z[=:B.K,;'"QE>6^>U5-,K3XG]_S>; MV\JF\_PFU/PR=%_KX]>^WG2";D5*HK<"'RMRT5]M8<(P[K@6^*%V']Z30U+X ML24`Q*G#,P:H)I)>M2VD.?*&8L9>"Z/,S8XU%TZU:#2W]`QB.)"1F#C!>"$#B091(!8I8.-/1UF*%93@%HF4J&W??S34K[8D^8AG,P`!+ELM[=!!\J2Q+IM^SP^TA4H M7^UY;5"?TD?S0)W7]T+O]J,4NZ-&3\\]MS,YF.0`UB#5;5KMYKZ:\3\+LSML MNG\HQK)MH]]=D=?V39>K0(`5ZK?]'/9Q/O03;;.]@H-0.F;G7[+;O>[>[KEY\:S9W(^D_.A MIE:5@#>F_YRF2%O5,VEWVOYZA.V#/:U5!3E(T"L>%]WPK,RJC=6^[^69KY7K??Z@QL./<#,9`CT6I%P#A? MF9=Q908-N]TZE/MUK[2Z+&115GC MA38UREAH"-$&E:S16*ZFTTTL*+]%931$8]D+8R];33?9:LD>6A>\!T15GE_D MW-W%X@YS>U9^DY(U9*)*B#EL8^P+3EE'LM[66,9!-&,Y;G+L5(W>@5,UUE_H MSN!9#J'=<+I&LW/`N,5S9.L+%IRG(16[;>08E7+O'B(RN6#Z5N36KG&G/7E[ M1[FU!X3A6_2J=W<->KYT@?>>!_XI#K=99>CURO-0.$S]+K++T.++W6#87>H.)Q89P35P/96!^TKGSRDTBO MOLF&V+]$D4+?JF7S1+[:G.@*\6W8@;O=[1T?P-AW`+EJ]SA8`W]*$ M"=TJ\5=JV*+KA&O#\=@/N`'B59ABU\U5/)G>O/HV\WGHR3MXI[EVCNX7KHB^ M=N)T?AL[8>*X/#%E;OZ%F'$."0.BYN;"MYJU1KMFMNPH@T7OV&C:8UN7W*YV M:3/Y,_*)IZ@%_5:G:W:06/[JKH':A**;%Q?]=F-;J*@/P-6_,L#\(W`-0X_Z M>TRBP!-QPL\_!77-0?NB4:#D=:OL&^B-YD)>M!K]7OF)KP/:%6'"TUBXJGX9 M8)%V.AT!H,""12^O4.HMAPU=M$R)YSN$ZPM6&I_4.S7MS^PMA)- MW86^B*O``B7.NL2)'=>J&?%H;KWYFE#_XA\LEA`(]1!X[SW1ZB+<\`G\@OK` MVSF^_2'4K^9O/K.'8&O0Z5V8MW[SE2NRW^W:C#6[C>(LV=WO]SVWDW[*?O6K M.SO?]D5O8([,V'SABFQWN^-M-[J#;NO9V^6NTR6[R$?//7/69J,U:`YZ!4#S M;S\;EJV$0`_^,VCM#Y1M=.E.XZ+0]W.WL&S7F[$]:+;ZC4U@>>1V?-9#W[:^ M'?K573&#]J#?[YD#?S9?N"+;W8J86NV+?O-BO6A[=+M1F(_M4[,Y9>O)I?YY MYL/\[$YF3!Z2]4!_7H*81LTN@ONY^)4= M2+QNKPVJ2`YJR0K[`')+>ZC3[YIM.`\&Y%8SSR]Z#7-F^X&`W')XWWB7#]7;.$(TY\F+Q288V$JJ?ZC'_K3;/J%OKMV1SMPCJUQ M!+5,JW93L/.SC.^<4.:!VS@6FBHH\Q&EU]RO3[L6W^NY-GI6R\9]3\VU"BL- M0\]SB1-/'5=D%'=6XT%!Y;N/@GO2_>14K7L11#/N M;3H&HH0__%.XJ9P($`3.G0@=6;TPS8+4G]$\8T_.#DKJ%JPZ<>YQ6?-C/&_) MY?;EREN-:A'::ORL'M6_:O[\@YQ?50KE&V[ZJ5>8 M.(D5.E/8[]\^#-__>O4W/(LDFZFSP):QM8FDA68!K0EP@0";5"W%[O'\%@/X M_0X?.7P;?VN],:'"JY7&OD<0^4D:!7/X8C;]@??B`A1T2`9::0A'-LOF*;#8 M8L]4`#$&-@=WU;:NQ3R.0E\4GO#\!/F3C:UM_Q#8/#K*T*$*F"TKHMG'Q"G' MFX@$2UM<9Y9DZ-TMSI+Z@>@#BT[PC^*`D`E/3)TTRA)K[(_B"-B>B",X#6N& MP[S=#.C722?S!6C?X%TIHN MP`^"NO[2M&QA#B2?9+!11AWP^A#;(,]@[\9Z?J+&"X)T3@"_^)JD?77GO]9O MZKJ`"^C+2=7U7TMQ=0OGGDG0[:5M+E[TQ)GXUG\#+?KRKH,,C''*(6&C<-'Q MT<(M-V>%RUM-G\.E$'#*-Z(^P=%T*F*49]@X6NWU:?N3X\]67RK$X7\Y0"L& MSH%U1:LPX*:"!B,OL#KKU]1;X'3RR74X4!\\/AHNG=#Q'"0"[,`-JI5MO8V= M/_R`WOXHOOENM'`31CC`[P[T-"J7LS[AQ1,($39MAB_@*+TW5`1W[P0_H*/B M/X43`!YY+=K-,W?F(_V"'),-Q1VX]\%,RI'8R_=%E/Y?&=PB*F34VZ#.A20_ M\3);013>U>`W4Q9#(T7;]/&;!P'XFJC!UF_]Z-Y/8^0:;PMG?Q.-_"4)MR"= M@:MELQE6!89>X:RU\@B(N:Z:@%MS2O^VP%SR;+@"FWF(XM^1LT5A[2Y"A@:H M!V6>E1)%+CD*RA=5Y/QO!2+&QZZ^5K:;^K7!`!SKHQ,#"V@U&CV#SRR*IG?O MWY9+I<($3=DEG:@)WP#:3(4[*5'!X*_F5W@*9(1C+C/!L]EQG).PA!.'M2C# MAN-S-EP*XV`3)Q#4&OX&MC,/E@;.*S:V^G-E4^^G3OR[X'[Q,U*A@!:\S,4! ML@$UD<>]"V_6ILK[DVSIG'$:/!$A1$6KP#Y$XT]3?T M5$4OUO'NC91VK`RM,H.DC4N*R7_"'P-\H+(CFS\K'MU6!>?":((/S!WX$G;X M]],`_FU0-=#[5."0!J*:JWS^,1SE?Y*6]15>1!7K/:J)O@?2?8R?`H.?;7&@ M%[B=_ACG(U\J_@??NLSYHG%OU+S9F\CU13K7+.HFS;PY+OI%2-)%(#J]G;/Q M=%)@W\,PS`#8CT*0JPFN!KIT<(:R;?TE$R/AVEH0%N8@*)3JL;V>DSI2.0%# MXP'O(NJP$Z0=TF$9105QX>`08-BLD#-X_?$X%`FQ!U9Q,XG\,2,?#C`!51C! ME#(6)_;BQ8U]8@XHK7GLE'X6.`H<"*!:*QX^ZA@NE^K#<0(8.#I9WMUI%(_X M^<6!M@NP)%SV#T1&6@2]#K+I<`;,-^O>OX\*!@HLBF2$^)=S14S)IP!7(U12 MRF?#HXL2YLDK3BE+Z!+AC&00ZDA;:%0`<='HX!#G@,OQ95*2%DZ2)#"=!6(, M4#29SW#`+TY,P9X*J:!!%/#JPBE'(YS[@4O3C9O,D>"`14?3.8Y6F<[QZM*_ MX"+>":`$FN$"=IO/M'!+WX%5!"E\_^2I[+1[5$'4^T9259O>O]:H!Y_# M2X!&3?5%=&I5S6:D4B:Z5G,P=YP\):0!):66G(+N^78;GM[HGU+=`1P@/T3; M)Q9WV+`4N:K"3(*.!ZLU@(U:4Y[A0",>8\J_O`$B^4/$`2QH@QT7/SAST!U= MP;]H#JQ+@5"!:'7P]H;6519',_$CCP5[8*N.YHY[8B:H,ZOY^=SE\25+$M^A MC=UFH.S-66]KM:R/ON6CP$J&@,I`,M$'[D,4D%TA0I`(`1T^[`@-@UG@N&(4U:2T`+V29HEY MT93&6%U/M]FK`G76S MU`D%NBU'(@0<2,\?&37MEG0')B8@S9^:^JNPL@2;E1=^V;J/@FPJ-#E-X>`R ME`_`/-%V0Z43[C+W=Z)S;JM>3R0B$$XFP7F^%[C+,^"V.*^,>"ZI2D![Y`RF MH6BDQ14`(/&M5D1@U3HV*FJ&P@(FU^6MER&3FZPW06FL%E^X-)_/0ZJ?1/IY?.M\>UZLW@Q2;K#8@;>R542_ZEMY M6FE4!;?RU#JSK;9RK;PWR-C`QLUBEQ@D^WSAEEN4\;^X(?7:^RC.7_H\YE=X M/.KSDAT6DFS7KW>$'6U%:YU!]Z+1>=Z.<#2B#$]]),<:*0\WP@7SL"PO4+UX M&\G7\K?REYYW4/U6OYCMOM&:Q]K:=EE!C87$]NVV=B-0J;*&F$3"`[9!4X)C MM:WOZ]T&6,,Q%K%C_+#?H`)X.438EC:HOGKVEG*8'YOP7/RV'*>^$4U?M`\/C?@XP4:DO*]NW)KJU:JSA9+3N]@6S2N_K;T^-EX]0DW:PTM&E\_WC8VN%=/V`8\ M1X.99:M;+BJ-6(N59;@\S;H$?'Q19E&"84;*)7=6>$95<;-ST6]U"OM8M\QQ M]K))'6H3_M-XVEX^.BFJ#>1AF.9JCZ\KWDLV$;E">,E[,,EOG`"_KS[R>;Q[ M]:[3:2\R\2W7/^I>GZGO/7FOZDWVG!#'4"EFXAOZ\Y(2C=9<#=_X3"\D5_*% MW34B6;O2@?>Q927SZC-Z="]7N@]XEHAQ%EB!/R:K<(:.[SB=V^B#DYFQ`O1[ M"J?49.;XRE3Y:_GV-;X+%'*EWOQ*J_R*BZS-DD>W&R7!R]548XCK[M\+6UVW MTK,WZWP[Y&9Y-;W99N.)N[W6F[K6F]+/;[R'ZRCPW?FKS:]_%(E5#0U6B64$8.H`YP%] M5/$)_@:LN($C?],;I>^KK/VA.-K<,NN"-BVF6557=*Z3^7E0M[Y<_3J\O7IG M70^_W/[=NOTR_'0SO,0BF-K60GKHK0B=A;Q09#'Y3BE%O[Z45OHK/!5$L5=XDQ)L9K`%5(XYIX2V MF&>G8BM!G_*&/)5X!;?_OYPPPZ@A;K%Y<3$@$*:1QTE(\AG$0:N#.&A<+(-3 M;,)5S%!=3IO'M]4.&$9/I9`R0F0P4TQ1Y5Q%!;!86D8(2]!=RP\5D)6%J1\4 MCY9Y/::C<,!SH:(2T?!]LVFWT/D9``%EJ=FU";/UD/%2/-GY5LQP>$^38U0( M5NA&7XKY+B#0-G&ATGL)1WRB^%>U*];6"RC%Q`'>0BV-:APP)E%$Y6%AE/+) M%M\9TS5(B]W52F##X+)P*8+,&=#MIBUS-T99#BT"2_*+A)3,TE$P;R!FMN#Y MAJ1)!(&$YV%D22W+$WX.I->[_*F=%.YW^HU&IV-NXY&E]@SX5H'>3J/3[O2J M`O@6)F*OVQY<#*H!^';!M%[GHOD\P(WG+/G@DH7^Z&=99WMM2M-:'%95<2I- M:W[N1U==A>),.+,(Y8O.[GM7D*E[`4][?@O@<$JB8)F#2B-(-3!GICZ7GV#. M(N8A4JTU-2E.,MQA@I4O3JQD]DB$8NSCG^DI=E9B@CDE7`;.2/F=P2)T7)3V M<_DDN:%!LJ':""IXCA##4XV%B"[F`2:I3$P'.3LC*V@!J*GP5+W,&$PYKO<8 M"T2-*J'A93-N%)2G#:825EP'Z\%!P\#W9#HA0;J00*]?Y2QU)X[112/S]G_C M6M=Q!J^;FP+52\$8*W+Q0R#M-&-++J/<6ZUIRM)9/)@[P'%,.J>+%84!.E'K MUC`(I'Y!;#21MJT[<>([UG0*RV-F'9D%H,2S#HE@FEERHSD&SES4U^Y(59-9 M@Y21K#(D+2!%4-&BD##+&>I&4J&M+.09($U^!@SI3:SB#;BLP<)E1OV5$Z,9 MGEAOAH:+XAV0I.NG2\$E]9IZRWA'OO*4X$RMW6P,6A?F3M8M8EV2KX";)EB]1G?%?-A]U%^M(D1=BU6HZK^Y M1/`*S2&.H\<=ETP_C)$Z="8WR^I$X+#?5%@BD")@.5@]_#Z`'KS]5[ MAF8CE`":880PH?&]JFQ`OJ%JAGV\ADX"*M:(IOK*)'NL!I$^*,"[D#XHK2^@ MUQWHGK/GV;U&SD2^5WP[X*[>R>92M"(^X,+!P2U$?V_E5[@)3FE[Q^669%D23*'DN(%EB"'KN0G MV'[%X!;$3%#(8?$W*=A*Y+%SU<<60-_0X1YKSD0I(VS)!`$UF&(3K/0*UZU/ MD6Q<`!2?J1(N\XY4P>MC[LHHL+BB-SDMKZM M:&-RF;.@:DYLV6`6X/*BB1+/:K7*WE=L1LMG*LWI8F$73QI-!TS"KZS1.16 MGJ8<3]76H^(ASY>I!TXMF?BSF2SOE8PQ*?GLJ7=M^!+-G2"=_XA90[6O,_3' M7T;L!,"A1(EU@X[Q'\ELJGW.4DLRSJK2R7LRBZ.D(/_YX-@8CWG#-J5ZU3+: ML2MW3)>).X#`\TLM//R0!"BICB.!E2L@[.\=/]CJ\J]0/[PL5C$7H_X2+W#$ M.@.RC??4P`Z]/E-+1@!UT+`HE(CS;0(.>Z7R/P@=D2?>]'1L:4O"Q9KRE#P@ M#KK!2(G8P7>+'AOC5DM6*1$D^QH4\2JM"*&Z47!+K(?83T&?D@B5H3)V$)AG M#RPAJRZGS$O+EWO-$>UY$4D'BKZZ_@Q/6G5AX+9OMDR#)$LNAG^$V9AJ=J5I MIT53?JN8I*DPG8]6N2V=_(05EUXZ976BLC\&DP9'=A^E#DT)5(>:D$(K*,& MC9E'CC]Y_/QMV2`!?G@"Q"MI%_5W!>JX$(E5OX7]Y*%ITK^#.3[#LG`TSS<7 MN>R'K._:V;VA2T,9MOFI(E7`/:8K:$)*&.6LJ+S+0"+26C0>0)X/9'3H(I&=J$P]1M?OJ7+\K=/!;W?I*$O\XHP0Q MW5=+ZTT:KTK_,Q(!?E'T:1MF7F%'",T#M@C5$.B%^>Y+1HK.&U@$*\WAFKRY M:/P`VNK<2`>0K;"$`R@!%`ATUE!ZF>SD@JMBFP5NSI4SB=H(GB'!Q_"?NC:6 M3SFJN)KUF]!ZN%)@#"9&YYK-X/_"-'<3VD4?(7%+[;,P*=;,UI&-@)6Y;C;& MDFT57%VA3S4PNOLU6C:J)9F\"*``?2&*/!4Z878B$:EP@8B[,3'Y7E3:4B^1 MMMD[SYI)`,SY!8_Y=ZQ MTM:!AF&!AGP8"XQ!DDQ3.S%\TZJ5-4HQ'2#%*BB/G',%%0H%(&LDJ@++#S.2 M[C-67W-9---9U,J[Y+IL:)W4S/NH0:57)_Z,1 MQ%6R&(,;V#$][^.L:83"Z.E\)CNFQ4*V),3:9(/,9D9Q^DAKWIX,F?PS"Q=B M)I@Z+C@OFU:VD)[1$V0A0<`MPBY*G&BGW$PR"IW'_?,8-366X0^(8A:&T0(( MB._'*#;;0\%]GOJ4,*#_JCM&431_)`*$4CIJ#-F@THRZ_R!.QB5_M85N\5>(/LY0.Z.`&=LS1"5!ZT-^^; M8EQSZ38`8[_@+\"=K'`4_H:OFLCP(L&;R8EC.Z2L\#]0[`3VB.VC$A_6([J[U]DTT2MKS(D=0R6G9+2%'+F,2A4VR9%,8D[BC?V56D#8EO")R@JB MD.0=VMXY/3V0&WL'4L(F7[CN`):W43&:/J1DD6HS[& M6[CW.?TY$09"4YEGA?84=[5*E%Y1)M#=N1L(@PG+-Q275OE1!:`")[1-#)H! M.\+;/1P\5A4P=T/73A0GZ/0)J0:VD+2$U>0`K(H3R-YE=>N&1D,0%#05X'T4 ML<;Q+L[NK*$'2/>QP(@9DN*DYKF"6NCZ1*Q+#227&+M2*1:E_/-"R6RQ?5+=O`L>-?T<6I>]'N-]A;`&,W.L6?P M'K'Z;CR2"\$Z&Z&VM3CJ=L>HW2H]O]6Y:+:;VZ!V6V"VZ6[5OFBVS)&G.R>Z M+=+H>_!$=P.BHWX9-?;683D6J`W,2(=&E'HTM\SG9`\H:_C@Q&`-RVISVY+U MYF@W8(_^-/9!^K@6-4=9W"M]CSYGKFHL^G:>/R(7I/6*M>VXEEZ)%FING26) M5#UH+5#U_N#3J!\""\=T6M5%0++HG6'JO>/'M.00-1,%UHS:1M^*>%J&J87< MS$+M_?X`R:G1G0@O"X2<,^>GHO8KF9N`0UB%6L=R%Q';>L^.YB'7_3+1J@J4 M?]R2\?I(\:Q:*1KS.K1,O@HOPDN8*\@%Z/-5S7'=O0F2:Q;.W1TH5AC'P!B]]53`C1H-*=G?Z'-D?#XGF8F[IXQ`]1(QO"]=/*3U6O\:1%)3SZ+--8_>9BU!R?Q']^-HA1DK5YV MY+B_WX%Z'WHUL,:C^"?K_W%=(<;P70E19_"GDAD)>LK-OO.':16@VLZ2EIAZ MN]A>\]'=%4WM359+@Z]MVX;.QP^OL$P M>HB=V7]\Q___W>'.NT$Z<^_7M44BKU7*Q3W=;V.+;U:C;/TJLSUZI^EUTN37@>^7F?I M]CKNU9\@?B+Z5SG*I1\,EGA7U: M_6[!H5RRP([`VBIDTFR9_8SV"-56X8K61;_3/A"RM@CI#/K=38]0_MZ&>[S4 M+LE\\=ETU6[U+BX&*Y"U*XBVB\+U0+ZT._N%:,N)+!BE[.\;1UM04K\WCFW$8ZV'-5.]!:`'WPW=9*K>]3^XU^(SP5TJ_BR6UKV!)KJO%O M0?OGN1!6:_;-HA*8GRW)K?0C\"<-XJ:,8O5>Z3<^)8O^9-7Z]=;L"<8P\/T[ M/ZSA%P$FXQL;G*D4F4\SFY^%O'WRO/605?%^H2Y$S<$WE"3%GVP\]'A'&[]7?"Y<'ELKEVZ^S4?&%. MS:;='+1.T*_YLJEM#P?]DK.B!O6+4Z/?G4>53TW8_!([Z-$Y!Z%?6!"Z>8HI M5&=2.TU2JP_6Y&!6CM)>O9'Q/HK'PM\AYS\YY>ZEFA*U$U/!SE1VIK*SHK]W MAJ^'(I]5_1>F?QWP*IZU_#.5G0B5'2;N^_(,@RN<1OI$*?%$%!T^D%@%/6\[ M*%^Z)KBSX'05#_)D`#W?BZK=BR-3_6LVFU:V8`_V,-=T.>A/Z%?]W0NYN#N1 MS9T59+-O%;_\=@,TEA=EHT!LR(2J!68EU?95]-NTFQ?]/4:'JD)I+\"8/`Q! M[#,GH8+T/ZA?7+QP8W8'5NGAW?7'<](?US5?$<_Y^9A?X3$?5+\_J$)M-*+< M3*$^FA)=:=7YK#"3PMP_.87Y4&KR63E^8*E[: MJ'?HNCB6(L&^T'H\*?PRSH1G_>KS2%!LO[]Y5][/8_51^.Q+'LOIOPN(<$"]-E_UT]UO'I->J2JKE(Z[N3*UGO]<[UZGNLK9/J MXUXT5[N@J.Z)&9]`-?P)D8-9H%?%`]O2S'NLJ/-0C.5`AOQA*>M,X:^>PK\'ZZMC]]H'+#S<%6WM/.9R4I)0 M.<@"<><$)`#E!.`X&@N:*`J_'I>,6]^?W_587.*P8#S+#;WOZ]QL7=B#UKZT MV=/!_9D4CTZ*O:;=[*R9RE!%2MR%C^>%65U*UH"Y%43?78.H/XN.[MW69J M[BQQ^;CZV"JD]'H-N]L[=N9R)6R35WGODC2.PKO\>N3_/HD;DH/;;;;L0:^W M=A,G0\M/2F#>/CVX-'69)PO6:+2@E<\6M'BXX%8)RX\,*7Q%>LY)7FP$:,J"KQ\6O22)\XZ^_85GY%O5.O(?FRTV_9[?X) MIEZ>R?E,SB^(G/<4S5D(-IV42!NZ;C;-.,5K.(T`Z#^HQG]WVOY1@I<[RFZI M&J"53@1]TVIU[%9S7WQA7\2U!TS\<+X]502TVK>G>=&R&]V#VO^G=WN>*<$W MC%$=RSOVC!!:%7H,G^:LV$.&:_>Z_59G8#=/(75AE[[%\Y4Y7YEG7)E!PV[O MK8SNH+3ZI/2(C9,12K,B?B-?-AJ.`*YS)ZQ/&87/X$_4.&Z[Q`CU-?DQ_I9L M0?>:4B-NS7YL%N!K%RT^,'*QT]X?I#A(6+*!3P;384UR^)9A(WBQG$T M)63[88;01#,X&^K[9\5B%L7XGA_R5^&7J'*3)R%)X?^F"`XLD+]47[QH!^\N M=^@\CLMG$ES9Q1PXW\[$^9N*&6'.34OB9_O,LFB(I>F0LDU56>9 M+_/TJY)E[4)TC2P`$KXHD#3_-8OIATI0-U@JQ*.6:K M9?<'^XIIG#/GSJ2X!2D.[':[>2;%,RD>G12;'?NB=\#NCV=2/)/B"E+L=.QV M:W!ZI/BD>.D6,-8U5TQ?4EGT-@%6M;A,VG?U+!B//IG^_^^?1?Y]U_ MM8%(`N>+2(03NQ,:@^&)>Q%$,\QI?N4!R-WZ%5]#OX3^A=WH7)R>B_1,S6=J M+AL]UK)[_3,Y[VPRQ0LK#CR-RK^+EMVJ&$]^5CWJF8)?&P4W.QU[T#S@X+U= MEZGNL0732=D9OXA0Q'*VJ^--_=!/4BR8O!>[<\F>0'>6E*(.TW^N["W^%)U2/O M+]9)7:Q^U^X-#C7ZH'J-9'=<6Y@73ZXQ(9>J'4L77ENJ:&6ASW_]VFBTOK,\ MX?I3)TBP7N_/P#2!9QJ[+EUCWR"W-,BM#4#N=X$:-P;Y?12/A8^-6]_X(5S& M('#B!$?S1C'3GA';5^3M_/\F6MGCK\;/CBQ]YE[N,@%LU@D'T(F M@(72VJMO(G;]1%S'6":[U?FU%Y#16(>'_0&N,?P+K*#PRQUZMT?J&M!H"0W5 M+W&4)-OAK;E(1%U@SUO@;GOX\CN#+UJ$LE*TK**"7FOPR-FW<`_UWN(>5I_, M`2B_B(4]$3UO?#T#V`O<&K-7WV9^?#C,TG+<9_JT>,J6@!OXY=\>$,.\X,GA M=PNP-7:_^,GOUA@+KGTL"A%):L$A;2B]-^"*[QT__JL39-AN/YLRI+CF>UCR M@USQ"RRX'1X[)AX_?'H/F*PW&KW!#MCXI@";]U^XR%KO(^PV'_CI?/\H5(O^ M5:_Y3"2V$(7M_IX06`YN42Z6M`>QC.6LT;S01D0N:=&:MB4O@6U),D>-WEX> MW:`NP2-"^!FRWUA[2YZQ5M`-ZKW.[I24#0$ME7%[TNM*Q,/S]+H=ZG0EL.V? M=KGKSAY)5(XQV8`8EU3F9K^_4Z5Y":H5-MN>:*_$W*D,[97`MA?:^YRE2>J$ MZ(`Y.-\TUMZ*;[::K79S'=^\V.%A;`CH^8"V$6P7:YU.)WA`^^'>QA(KN'?) ME5CFWH/63KGW$E0O%[T;"<>+W0K'1]!+/MBW2^C=#"_\^6'H?0BQ(X!_+ZX# M)TRNH\!WYR]U]MBCO;=+4+D8ZMA@E-?!QJI$M!F>*TXP M$^,QV&%U:^BZ48;CSNZL&R0M(+8$/N?Y8U\V8^PW![:%N\'5"V=,/_]D^2GL MR]W1;@J\H69Q(_3"+PG)^"X^_H:C.H-6J_&S;'>H?]/\^0?;BG%27"S'R,D. MB:K'9%FPPK:R!)'A6&.P7FOW:+Y:C,BI2"<1\"$<*^=2,\I8\!SY-+*<(&"= M5&+=>2!,\BPZ_&!BMG2GTB-XD3V=<0G M^"TZSKKU(:$;U%CCH458GA3:X$?TH'`XQ'(Y4E]#57Q*F#MEDV^B><+8@1.$;M^6%:F<+%L1)`$C$8 MGI<(GT@*CUH8'*%-R#TFBIQ$B8M-_FGJQ+^+U)J1^BF1(/<>>L674Q%/\1&@ M:L)+W?IM(D)<#>Q./YE(BM<87EQ\\7TZ#Z0Q7QT44C1^A>E03Z*43R-H0.NH MVTQ\@#'&@#5]/O9%R.`OG!^?!3PC7;MH!"O6,LX-PQ^6-YMCJE[.QI]+GH0[ M6!)';R*+DF0`)R,G98X=R;T2ONZ>0`3B/5Z/520M?"KQ`1]`,YH/UXN"8)@H MDE3=;PG?N72+LP`W\H#(AX(UA]E^@OM02#M`XWPZZ*X!5&WF2`V\G MP,7L1UY7V^3K6#S'(L.]DZ$XP-,XP_/3?&OJ@-XU0;40:%/H!U$\A)JZD>(` M%HQ36;LB9S>+HFV*^WV->;Z-A6UX6J[N?4K/5*7:V5&0K ML+^EI3I+6JCQ$3B\PR5^D:.#6,62`,KYD\84+M[N_\D@4AMQK$,1L;Q^C7IO M\">P@R&R#VO%'O&Q.0LCE'F\:>>>$=S$^W<"OW<"OW<"OW<=_K< M"OW<"KW*)'ENA?Y$-OXR&^*>VR&_YM,_J7;(Y],_W_WSZ;_.NW]NA7YNA7YN M'GUNA7ZFYC,UGUNAGQM)OZ!&TN=6Z&<*/FT*/K="/[="WR'*CMZ!^=PJ^MP* M_4S?%0"TTO1]*NVBJT/DYX[1I](Q^E1H^]P*O9)05I>PSZW0M^MA5SGSY=P* M_=RFN7+M+H^`E',K]/,=.]^QYU;HYU;HYXOU$B[6*VB% MOJOZV7VT#.$>(=S#QAIBWP$_G9=`MY,-/!?8H95D4["OY\46!;+^U)'0FW79 MB?^-J[*3LGIL++F?Q2(15!\^$D'TL+*J\9&]Y8&I3T[\5-3P%@#:>)_5K,M3 M#>]JLN-=%4]NV_SRM>[PQ[+@-V44%4@+676FL@7<+K6O#9&W3YYWFG6O(+JI MD=Z:T]CP8CTE'K67\SI3ST&HI]B@]9"1L8,R[+4FR@DQ9>;`>?=-["$"3."= M<`4U!VTW21M?4^#U@O-WGP=#)+']W2]^&QQ['Q^ M8O3[?&&SD/)Q:L)&3NG:E4#9<[)2%1*F3B,=BOLT'NXV[CM+[4QJ%2:U^MZB M$A7)L7MY1H:>OZ.NAIF=5_X7I7P>\BF?9*4>"***EIX5RDH7[HFN+/@=!4/\F0`/=^+JMV+ M(U/]:S:;5N55((3XIYU2RW+0G]"/S^*?"[FX.Y'-J_*[CU-NOG7%0K7`K*3: MOK*.P&Y>]/<8':H*I;T`8_(P!+'/G(0*TC_._W[AQNP.K-+#N^N/YZ0_KFN^ M(I[S\S&_PF,^J'Y_4(5:QCMXCMXF"O71E.A*J\YGA9D4YO[)*9XC&-G!7P;X_GX!;F<.M9U9XUFJM2[PDQN,,!RWZ8`I(3WT4:+$[\CDQW&LYA7M(&BH=`\WJ+ MH\L']98%T`;PO;HU7+EH+&19?,+3S:F0&7Y52YUO2P_KL=(TICB(:"[Y#,NS M\EGKTRF.G>9S'5O?-[OU7@-?(8!;`P88B&'BNQ/K(]`S3=`RVDM%?$4S@:GE..PI:16XP?R%>"I6WCH0_X, M;"M$POXBQO_QG8L7MMEJ-[\#//C\NZ^-1NL[RQ,N4%"08/."/W>;+=2"3-"7 M/[P/V-J-7KOQ.&S]BU[OHM?9%#9?C^"VABY-&L<#).SZ<)'_<0O+6V\#..G_ MNP1Q_F[^JGH3WZ/72O;0;#332._FSX]*P">W@=@WWUHYIZUNW7S]^''XY>_6 MY_?6S8=?/GUX_^%R^.G6&EY>?O[ZZ?;#IU^LZ\^_?KC\<'5S:&:[TE([FE!= M!1'P`9^XR#5S8>(%)8IK$*L=^Z(2N3TU-X1=\LX'5 MP35V,@]SM6UKE*7`'-P@\P0Q0F(VP!^D=T1 M:",1^`)D#HDA_*#G)R@Z,_@^;S[-Z`34RC/P$(#2Q>&[,P"`'L`CCSUX1H"B MFTZLK_6;NG7'$SG@6_!G,4,(G)RQ@DX`GYP%L,4W?.D&K5;C9WKSE^'P6O^N M^?,/()(3EOYPBAXVO045`X3XU$_QJ[,L3C+DVX`"W'V*Y3'] M\0;I!$Y3/G'US9TXX9VP0-(";A+$P1M\SH#IYNJR``T>)^`\!D$&FP,T@%B! M+94IH)6XE'OQ/MTND)E)+^D$.-87PHN53$B!&Z$>Z=!?X0S_F84NO474@O1= M<%W]12-7?@2>?`\KP?*UO\C;)-012)/C(PV9E.7C;'.H[^Y\[\,PS.`R+`/W MWQJXN7`49$NU[7"?`O@][9U(\NJR7MC_[@B)[=)]B:;K_`[#[;K4K+Y<0!T> MOB-;R"0,6:YM(`>5T$NE",WPEY)I7;)`):KVX==)-@)AYH,0LZVA=T^,]ZT? MC1TW):%Q&<6S>H&O#M]>UC[]W61C5617JP[R$CFV"_@JTXJ<".]2$P>)3*QR;T`<^A`P7V]KE8A:%)?#6?V4^GCQ22Y:0L0WP.'?T MLCKV9O]G,(4+V')R;+'^X8S'PF4UQ)DR$;*$4ZQ=;*+3A5Y1#0350Z#6`_0) M3RHUR271X/FP9,S>'M:2-(@G1:.@[]D6_J]U!8=Q[P0:%8;=:YB>%=R;L1%2 M7\7"1I)2`Y[T4#I]#S7DJ1/_+E+V!]49(>9W%)\C!3[)M;&)'!?KT]&]B$->Z`WM*T2%L_'+FS-E%S!PZSH2G!HD4_,-L%K-/U\N$ M,JV,14.\IH*WADS;`/^DV'9$WM1<$E\RM_A"W")$P^*?<,4N`8X(;E9E"=+D M?5.PZM&R3X@9J<.'?P2H*2;2M6X3(^4O3YTYD($K2,CCY?,D`RTR5;3#T8N` M%!/[`CX&5(3,-DJ0?I1%DQ@:+**P>$,`N;[^3)2P"QV_DA@N6)-GH\<=R+^* M5/4(ZHO"`76G]^\^7&KTHO.%-INR]>0)\C)))";BGJ:9DC"I[,:':3&T81>- MEYP!*=*C>$^[?J'"3A25FL7`<6(`1*J`#Y'EJMMF4^`EIL@-OMNJ=_6[;WJ= M/Q'[P8#4#_SRN_=O.;[8K'?R!]N]I0>'V3<_\+-I97&[>.W(_05$(J@N`,E) M..Z$_0P8;C.Q!O<[DNZW%+VH4XQ7H3/5IU.Y%V&&VOB'L,2/4G*@8&>!?%"! MQCB:.T$ZU]\IXI-#N-]WZGWCG+HF^E=_`P^/7R\<<]M\_63TF2^\->L+QQ#/ M/A%>_C?0CK(X!A(FUZF,K^:$P*8ATAJ1!.@C7@;F:`):3U)&C4DVRG\AU2QI M_Z+[+Q7N)(R"Z(ZU;_ON,M]3_,UP4=Q@&-B)/73(>,SL\:.]1M@F MNKE$\-;YB0[@LSXNF7X8(W5X`C5=/Y2AF80]-L(2@?1SB&]^0KS8410,QEZ, M\022^4P@$J>8W;),\>0P]D`_`GF/JKCZ,EG'#Q/!+#I7QDE7P.\NO8%6YN]A M]!#:^7N&M0MR(@2:1'$;80`,=3"4K0'L4;X!M@&K*G@-G20*073/R4,4DY[G MVN#4DHD_F[%) MG*OSRY_=&\(.=-V_L`'PXT)?SU!;C5OM%6$)674[Y5:MDVA4P5.H8T9X7 MD70`%3KU77_&F<;,3@58^IB0Q$$/LN1B#%]F'-"6IIT63?FM>M#9XO)H55J/ MDY^PXM)+IYP[0FYSTJ"W'Z<.30D/?A`8I#`2ZZA!8^:1XT\>/W];^E#AAR=` MO))V47]7H+)&J;B"^BWLAW%.%C8>=D`A#I:%HWF^N<@E"]^K[SKW9D.7AC)L M\U-%JE"!#Q-2PBA'+[/1/RGL'<'B:2T:CXG*5(8<4BLZI0&UIW`#T9%F7#XS M/T[?&V9TZ"*)9I1:8>HQHRP!JS84=(31<%J`@T`OSW9>,%)TWL`B8O0*NR9N+ MQ@^@K`93F(D^$]= M&_M5>]`JKF;])K0>KA08@XG1N68S^#^@$>T5M(L^0N*6VF=A4JSA!F.$"(6. MQ/"'J83<0A*,D?I")3HBEDFGQ63(4Z$39B<2D0H7E,AB8O*]J+2E7B+GBC;[ M$J4L.Y3'PK#F<_<2&6H`M=2JB3,J7QHSBB5O&^5ZY+5%47@7$0,I]8ZQVUGZ MA93/S3`LT)`/8X')(233U$X,W[34-$F**?/2Q:(D3ETOJ%`H`%DCD1G[H()E M)-N5I]RH=5(?\P"5030C=.`'/#$6L?03%FQ='7&R,'^%\]N-=]G4.*F;\5&Q MC\J2?PZAK64Q!C>`.6$E-M(82'Q-(X(<37/2`]BPXYH!H%23S#2S!#(8&76: M93G='`B>8-B?CAE7MI">T1-D(4'`+<)()OR[D%F8QJ#SVUQFX6@7M[_8Q2KO']TEL!]EGG]^J^4YG+O!`F5^Q6J+QQ#-BS4/;I9@`XW M!8J#51IP4>`J+%UVXAAYFL-BSIFZ_/AUS%JW"[M!1QSZ#HN\@84.&D\$=,[2 M"%$:Z,2\;XIQS:7;@!)Y#'\!I>V7.PI_PU=-9'B1X,WDQ+$=4E;X'RAV`GL$ M7@TL%=9S8F9X#M-,N,"FB5I?94CJECV&2D[):`LYB`W]@ZDA,T#ME6N1Y[*D,TD=>>9R=)H+Y$32/P@ M:C@F5_8$7@#RJ<(52WEWT@,G;YO)+BA;$N\7F,YDT&BVH7@$V0>,*0"1LBW5 M10PQ&RQ/Y3,X#6=5<]XS&$$QO:[71ZZ@:M#JUC`ID\_3B#A23"5B2QM5-TJR M&%W01ENX]\GK+,P\:G(GJP(X+GA*E%Y1)M#=N8M9@YH)RS<4EP[\D$S&`E"! M$]HF!LV`'>'M'@X^`GN;N1NZ=J*84L]"2O7E4\)$-)`M6$/M>T;-.,B%**AC M)G4F;3'*B7T?1:QQO(NS.VOH`=*!`:ED/L5)S7,%M9#J>25XICP$U#L6N3JU MT\7.;4TN*R1P2JC.R*JG6C@X_&#.GB5_.H.](@O7BM#81&F1]%51H;SJ%$6" MYXE/:Z4*SBQOFY#K58!ML*KQ-?4]K_1X5^M<%>2B^TV'N8TIV7ANW6`-?R5` MJH"Z<(8_C5*03>1>EB9XLOH$=*$BA`\'"HHM^+WLT MF*P4[V8Z/Q$"W7]-^H[]J#(3025GPH/OE/%F^G]T@A!55:%/F%11)(5W439* MQYFNQRHSA%Y9^;[D)HY7G@!;+)')JZL*Y7T8.7=3*:U)12=]1^448PHG'P)? M2$^=0N&:YJQ?9F4OI-1Q?;@*SJ%HP1(9'6M69>12/GK:ZB-0M!+!)J4*%$AA MSA:'RDU0$82%<&!NQKEY[H_:P4]&.A!E@->H5H:)B#L M4:IKDU.];:LL0PN$9AA-82T_]."/J"7![SV9@6.(8;VPBOA1:I'IF?Z1@DXRT`O$\5K$]`5*'I87>6PMJSAQ9^,UF(, M.^O[AH$\V3Y&]TK=N5*U$#DP'"(RB6Z2.U&U^S1[)'/"HB`IL#X*2R;*\Q.G M'+57AA\K#@MN46F9&N%6$($R!YU5A;]]&+[_]>IO:YM/O'C*D1[5V*,N.5B! M#`]3^16B=)2J$DE==B,%94`*"=4HT_DL2'&#FY;K:XI#E#3G`_:"[66==$4S MQ==VPU?7V?C3419SX\/;B1][UK43@Q;PSK@*F%M8V6#-;T)6XJHT$UV/.XX, MMR$>O'F]C<12`P,C3`]]E*4L*#FN,Z/@V!^B--O%Y&&Y#I02GF>$YX+?D%XI MA^QQF(;[8\K+C;"U98OJ9BC2(J#FY@JHH%,"KK#RME8Q-6A-!J[U-IO7WD4/ ME>TH]SDLMG9JD06"#=80&HGOXCI^#_YD M_7?=^D4$(R?V;(O3.(;9';IX6WU*G)FRLJR^W M7S4R-C3G\U#'[N<8*NAM8,8:-,0Y$YCX.1*+FEB1)Q"*66L;B3L_#+EK(4=S M9)XS6\)QDII].S!+#O\HM3-+M13+BX.P&>0CM&;KB%O)E82 MT%$AQ7_&2$J!^]O%UEKR+/%>J6]@'$^HDOPQ7BY,X;YG?Y$.6TMK?1RP[VY" M``9*MB]?T\Q1TH MUJ<(OBY9].S%C^?4NN:@SYJEU"P-SG>,$*/;1PI\Q:XB_T M,_[W7:%]YE[`TSIS`1P9B>*NLG@'\+I08Q-B?S97M9``C*CV3D6\@0<[L2HF M4!?6EGH@]59C"Q%^%S@CI;';Z`AG'Z34&$,6#1/A`/\T$&+TW`F22#DFF"/D MVN<"4,`8R&D,4F8L*-$`_L')6SJ%@)8EAH$N;16H3R6LQ%]D+$#(W4E(%_MB MJ5>3-//FA:HF&9.84W.JPJ:P^9>$,<]V"(&TTXQ5%K8!M#@U3(4\6]-%Z4*U M3=@E-Y!<,A$*4&23Y+PD`598GJKTJ/;`+J833+FC%#6-!S&(#7^<.X[#Z_PR M6V>?&>DO&'-(?5;8XB@(.)%%"F0LT92?05_\R;2FN%1G>TM.CJJSL\^4`((= M3-C^8F5[@;:)+G2AP5(FD9&C)+UN-#-!NLGI,GH+G805-4CQK[)7BNM:+EDB M\B:I/VGB7PB]R(8KW&,9NQ_&7%6KRRT>\A1(%=-2W,#GC!W5IF(%.$9NDTS6 M4*N:?2,,OK?@N8YSY\,H%1A[0D7B-"%]H# MTJI3GH09S6Z@P"%Y':6JR+Y(6?:F)<5CG#0UO=GXQI#+M+_8P ME=F'PC/*";D)=?Y-?=TXV9CJ?+!L51;.YRFKBP?YH/UQY%B0K=,D9S&3M12$ M>=I5&(6U7'X5K/5%`4N5?S[']BV_4-3.Q^U MDLWF*T]NJ)ECA]A^M5D_6/1>8_^S!`?K2*P[#X3)O-%F<8H/J\;&J"(?KEWN M"A0@&J*YTJ$]V`!+(I97^`2_1<<)K"C-]YDG=A@^=:O8YH>X]S*P"^ZCNQAU M%8F.4()>PVXA^)MIY(F`!9#^)F=&:P\CL0?\M*HJMM`ZD`XL'50$,+&-X4(. MJI/HJ!C*_@57PHBGEN29J;#Y!/TG4B:I21A;E=-5D4DM%K\SB;.3>O79FB2D MLB/YB-4(D)(CQM^_#1S@&S?N)*)2VI(3S[U_RRW!E3(D%3AR`N?2A&F%F@6: M/5MR+=`0/"CK2W/V-=7<1SAY(]"-G(7J:5R8!B;W+I.>&9UM2)THGI^< M.*8FC276FYRUP-?'PJ?>_#\L;S;'5'T_SI'?"OV(LE"2`?;F4/W%)/>2W5C- MQF?KL,I-;G`((."#B[.4P[@@"(8ZY]Y,>3`FPM#8%EDF=._#%O$0C,PDD_I2 M5DOY=M!=H?9DE&',MH7]R.MJFWP=B^=89+BT@!R"PY$8Q;=0D>+@"_E#U(,H M'D*S;@%A<9"3-;L4T"](&9M!H)S0A8AB_X(')!H-6HQFZ-J9O]RSD\#)Y*B[ M!7Z1HX-8Q9(`6IHRR(RGW?^30:0VXABS_L8(3BRO7Z/>&_R)]5-L77LG]$TP M$E'RF$AE6?E[+M>Q%20U046SR;&5@ M*:]O;ET5IU6@(9WS'R/)>PMD%PKX=+K1$N:Q;_1=1(9T&6=:;1$^F,T5==*3 MJNR22=//*LK.3;2232KXCO;&JZ,%G'.LYS8R]ZY[RR>W8U3 M(4$%"@(YCEK_.YG1/`?ZMV0PZPD(^G\,:)1)547_L&3&D'CU/"SF:[[XI6=D2:^73M0]/EJL'F MASS[&__;F21W0"/&+/8S&\^O2^OEL7&=)'I\LCPPISR?/IU^ZWSZK_CTSW?_ M-9_^2=W]+762D>/^?A='8&W7X!2C&([&=848CQ_73#;18GF3]!N?>OK\9-7Z M]=;L"3E,4R>^\\,:?O$GR_S&IOF(3U*4UN-F#W=T&8,[`*-X2#OQB'[_))2: MNZ..L9ML[^((VT-'>^=B3Q?_*(1UIN;72\W-5LON]<_DO)G?9\\;7R4[7P(A M[W5O%RV[53&>_!QZ.E/PJZ/@9J=C#YK]$R/A7;@Y2V`;TW].T\Z0XP@XL\'H M+WF_U"3_Z8;Y>I3M0ZRNM=,WHKNJ`;J:)2Q`>@SMK'9(_\)1#JLZD)SI^PC6 M1]MN-1IG(M\IE0>C\,-!^2SRWJ]&=R*T_9RSJ@@89\(^)&&W&_:@-W@) MA/U,\Z6S`K:JATF:O7+[966F6I12]>CC*9H[,6\V1.GAM"H`B/KP!6)#)G)< ME_6J(WR:ZV1+G%35T;T**7N-Y%2'LJL#R?F.O;H[UFQW[<'>XDO5(>T=0K(' M'7,?-VQ?.N;I7J]#8Z39Z-J=4Q!@NS0QSQ?K?+'V?K'Z7;LWZ+Z$BV68N#]2 MJ9N!1O5CY0:F065?,2Z':R@6?WC+62;#K%-E:%%@6R_E0VV)J; M==F)_XVKLI.R>FP>>TA]6+$\5@31P\JJQD?VSG6-3RYDO#AP(:-8T-KQ83XE'[>6\SM1S$.JY4IUKKK%5U2$C8P=EV&M- ME!-BRLR!S5EYU!3GG7`%:D9Z>LC3N/,+R-]]'@R5-/?9MK>;@Q:VRMK3-3UG MBQ_?T_7BL\4']8M3H]_G"YN%E(]3$S:_<,>_70F4/2)"6>B***%MY5 M"LJ7K@GN+#A=Q8,\&4#/]Z)J]^+(5/^:S:95>14((?YII]2R'/0G]..S^.=" M+NY.9/.J_.[CE)MO7;%0+3`KJ;:OK".PFQ?]/4:'JD)I+\"8/`Q![#,GH8+T M/ZA?'+`IXZF&JP[OKC^>D_ZXKOF*>,[/Q_P*C_F@^OU!%6H9[^`Y>ILHU$=3 MHBNM.I\59E*8^R>G,!]*33XKQR],.>YU*JH*QS1R5L"_/9Z#6YC#K6=5>]9H MKDJ])W"THGQ2]0S+,_*9ZU/ISAVFL]U;'W?[-9[#7R%`&X-&&`@ MAHGO3JR'*`L\GH(\$B+,J0,(`-*O<[J!=_Q88Y$Q11/#<:(U MS62GM<+(RD)C^/'2!&@`)'#D)/DBC49+CL[BW/<2NCHVZ:WBE=::"%`IJFH,/QX,G!H>-)VL`2$B`%U\VF&9^I MAR3O^G3:=>NCXT[\4,3SXJ=L:YS%(<\XQS^,_6\TA=SF'O19&B6TFOY8?C&P M-3WBND:#V>'.^(F>/0_4F<]4SQ(QS@(K`(HG2NHBN34;UEPXP/&L7P5<-Z1Q MRY_"U;X74[JFN*HSC4#,%(;:XS;A1R+XQY;AIV,Q=?P0B3CPQT*^!=^`%4^, MA._]1(ZDMSZ$<)&%=>M\6RXYKL`F6+"*L8ACY"S`7QTX,CQ1H*C`=T9^X*>^ MX!,VN%.!ZV)?4!=/5O$\9P8WA34'PDP/NPSPG$-2>;C M%7L"$40RA%FL@V/E81F!;5E`;@4^7M@[H,@$;_3<"@6P["5,6?[8+F+C079P ML)Q[QP](/(I[W\-MV9:?XN?AI@!A^[^C4`11$`+S3UDF)`@[D`U)%+X`RVLF MH-S!W_&E$9X*$`6<217OR/Y\$2`V@8<0@O@A4=*"]KY:147>IB0)@&<'/YFTVU"]NE[.=UH:J5#UU=AQ4T`'0G9K=3% M-B=ZE$$L$)P4!`;<.KJ)H$8[?(4!1_(:@TSS(P^N2<'+\R$DE,8>W94''Q"W M,=8Z@+6N;942!/V\X_92DOG>:*YQ&0!6H?\H7DB220I:P8!XXJ')(&?I9V3F9F10T`=LI8DB6M:"B4:OQIS4X^'WY>?XZ?YP^ M31^F[UX65=D06N_$=8,3GOWYM-%K?P85R06<( M$FQ=]>?^!=AP!CJV7U_C1B=O6V_@XB?4$^2'T@U^2)*L^'WN($)_E+U=\J\M M[Z^Y>G_-A?TM[FVKI8O'+@V1?R/U&3CB,`6[:91QMS#0Z:X=E,6E&Y:ORA<7 M-]1JMMK-QX^IV>]T!^U.;V$WA>\>"-H-B*IYT>T,6LWV9M!F(]9K4NOJGG3? M?^"]L^CB_=\E`/73_+"^HFO)Y,^/.J>>W*'M6$KQ1=VZ^?KVYNHO7Z\^W5I7 M?X7_O=E2&:FL!T59\(*52>`!24XD@HD$Q:I4GUGRQ"#B$W17D,(\B:/L;L+> M#G]*ML\8!#9[NT!NH#:-B7KT]1)U.$$E`ACU%,"J_87E$7[LYNH2_S+,[F#' MUL4*?T")G%E%M_H>?"&O"%Y/P(XV(+[@=C.6&(;>9Q2%ZJ%\%1)R9=?[15^;O:C.CQY=0?/9Y!RK8G8?V3E-Y*N,C40Z M#=DW6O#_D,%")BO]B*H)&I=L0BVI\[O09HHU<^;$7`@4 M9$&^)QT[XPCAH0^#V1#!RV3@>`+TW2G[<,@=RULQ5D3?.RJP>EF]@Y_R7[FP MN`]GC%:9'XH$4#]S@'^EH.DEV&<5_:Q^0M:+9G7J;5N[&8#=AM$4UO)##_X( M#Z?P>T^ZRURPN^\`1X!.*C&(Q.=[-=6XEMT>B0.N`Y`IO57Y\YO@>R8B` MG8.YGUJ+!?A+PHI3%-_!=_X@Q;>PSKN,M"K$6^B0L2?MSD>HU+5)I0.R.2Z'$TRAS@"T!O4P4F\:^ M=NQ).BZ/'Z;%P(J][LI0M*E=OU!!+XJ)S6(@IQ@`D4P9&(2F>YON?DR&)+[; MJG?UN_3TN_=O.9S9K'>*?QEFW^`.9--7>3):BXFE`HK(:QC((^F5I#II:>=* M%6BG(B0O]UB0Y-6Q.A).3C+13"F/*&:A$JCJ]*SA72S85P4<8(:LCT,O?"F7 M0RS:]^[!SH.(0T[LN<.]NB(F_0%$H'1ZL:KPMP_#][]>_:U>4/=>(^7\QF&- M&!VQ(4H/E#<@+$8.HG24N^X`B<)Q)SHL10K)!`Y+A<8*4MS@IN7ZFN(0)5%R M8"^8Y^6D*[(:-K#?-C*FM"UWBZ(D`_V(_![2,[ALG_%#]`P]\11?2[O=:C<: M?1/2Q<_N'*P-'%:MBU:OV>UM!U;"8+'K\#$O8N%C[,#;!,A%YV"K!_AMK8"1 M/[MG(#?P8+8&W79W0R"_)L2HKZ2"!3=56OG_D/__B&<-WOT\UF^^-K_`)6AV M9$48H1<5!K!SA++]GB39M+P#>54BA,@P9[&8.;&.RZSW>/DDU8&[3E'S)SOP M:_VF;OTR'%XKO9X3B#*F,X#'N:.7F54/6LW^SXG6[Z6(S;'%RCB;&H;=GLC8 M&\7XI)F[#E;ZLLMV'46MPRBE`+2;9A3,0SL=J1C-$H[]*9,]`N`UB!NP_N+% MR/W6?*/)$=?VX)I&?RAHO>H-%=SQM6K5YQ7&S' M(2[ZS=[@!>-BFQMR,>BTNH.7BHOM>.9%K]?H=)^/"WZ0\HMRSVK1O4&QSFCN M!*"6C;(Y&+\/H=K\*$G=G]1B0_V%2_C`M7S_?11_X;??9O-W\.ZC5-!>M)KZ MYLX_?'K_W9]AUT]95F_Y,O!#4K9OR3-PQ0Z!Y#$KA=93[]%KZBU^IZIY`%Q5 MLC>KI1R15;5*/E/M`&9ZN6X,:CI3MJLVD>(FV-&N\S]S6T*ZB>#[][XK#)\? M971+)SWYEM#S-,OB),/4<8K_A6GLN)3E"3;-O1/[498LK"LGW;!EH?^$51-. MC$ZJ8N#G`]LI(=A*%':!U<@B&F%>+J:B/PB]K(JH^3$&`&-*4@.H@*6AJ;4* M'#G]T.>`&I5)A'<1LBW3+PE+SL#P`7L57O'B[`Y@NRV$A"CR)I&'^7+*&\IX M3K+1/\D8BX#;WD6I+R,7(1:-Q=*AKC=BX)(>F3IS:6DAC%F(KF(=\AL'T0-` MH[B!X9K-S\,3>%QXSBKJF62`;">1<8`)AL;41I7GE1-`.%0`CP,M).@(%&$< M!8'&"FPD?PP%3""4?*$\3RKS&,L:%Q/S-J:2)#Y0NA/G`36)UXC0!62G`FR2 MDN&;Q+E\&?1-W8G,P$=/*)X:/"\4GZ-05%QNV$K_ML-V+-T6C/)N1/5@_C(& M[7PMPV].WE:)&(DNEK_.$O$5<]-C!Z.?('O$G1]2+#J;X=T,,03LAQ)D^6IH M^-+SBX'_DDL7?`5("WZ8"7DU7'_&%"AIGKZIKQN=/&'2B3'1FT+C6FU8W`6% M5^E\,`"G<@0T9\$34-Q%09@73(116'/1G\SYYM$(^*&C"HZ*::J4HNZS2H&2 MN9RLZM9G8\%EUTC!4Y'D6:DZJC4Q`Z1.2I>/J81.!C4E#-,O9ZWG'HV-A:B6 MU-=.2K4!$49Z&)=>,3I6$-#\^"4^/>2'W\.S.A3S%/=V@_)3-_CZ@6`N49,7 M8>YUMH8Y5P(Y-H5RD8OGEL(F6*2@`BRE2N#?\0N@?/V&[[]UO'?PMCSG3Q$` M+6,S:_6DZ_;?%_2\S;YZW3\HLE0;>5^[U$)`WLU1$=E%?O0^DAJLIK]1[*7%&K2,##E!24P M4!&G@T4L?K_Y"5?1Z$O"EJ(YR=4%$DZ7@ZFH&0@]%/@QY7E#8J& MU""5$OC(DJBO?N/,.%K>0=7&)W7=M/&YBMI(K^!J5-`S5SH%X`=234@5(_O` MY3P]SI)Q\%.@;D2AU)LJ6\TV7"ZPMG5BENO,J(`)&?SWK7H_QU`A(00K#',: MXJISK.@;+571%E,#",4L;XQOJO*K'_3)O6, MS2SM:.""'.DNP\ML^JDX\$\*KH&!T1Q%ZV,Y>PM9Q+DTT-Z@F6GMF.H*:!(9$"H.;F9DN&+PBJE>EP:SG(4RYT MB3UTJ5)Q2VT:_==-G`/=):.MM6"RZ,]I0'0B*[.Q(?-7%GM<`%J`2SW.%KOQ M,#^[@1W555;SFD\9_@KI,%T7Y9$//C.<4_!6U+I@^'8;!2=+^2('`G=];>FQ MH7W4K;`([<9P%E,SUTK;0A)@M87J?B-@1;QMTS_LQ=;-F?JR68R(C8M1*`-4 M5J_,_R/?KE)!%FX()FS+UZ[YK6'H22>L#CD_(;6YW>CTVEV]ATV6.=9N-G&P M][J-;N=INY&_+R@>!;#E`X83_+DQ@.4O:FC>@E4M+20D*V$6;B#]_^K/X!I9 M]U$`UEOMHP,*$:AU__@H4'4HLE?UJ8_YEUAH`P/GS_R5OK*.U?[/%W3\#+_Y MR?_(]7@U=*Y_E#O:=*VG[A/+!@^Y3UY/[[/YY'WF*B318YPW=U&5L,XHDOG- MVOD#^_4\N%%73D+6]_]K?:)61,,QUGN&P!G5ITH1HO5(]1@U)+HTU\KKB4I) M^7]T;YQ?1'07.[,)!ML(-3?B;O'WO\11-DN,]>@7MP^1Q%_A7G26U=\E_7<# MN)^)X$L,^V*RB<3P58;-^DX#L9^1_#9!;'-P>,3N%EUK2>>)._SW'[^-X@!^ M^/\!4$L#!!0````(`"LZ"4-2KC-(APL``/60```5`!P`8G-T8RTR,#$S,#8S M,%]C86PN>&UL550)``/"SP12PL\$4G5X"P`!!"4.```$.0$``-U=67/CN!%^ M3U7^`Z-]EN4CN\E,C;-ER_:4JSQCE^U)Y2T%D9"%&HI0`%"6]M<'X"&)("Y2 ML@CNRQQDH]''QT:CV82^_+Z:Q\$2$HIP`A@@- M?O_77__RY6_#X5>80`(8C(+).KA!-(PQ30D,7G"<,LZ!!D_/CW?W#[?!^<6C/%B3=#;C`5GGS[]&@R#\].SB^!UAN<4)\$S3!F?.[@*0QBG]"2XBN,@ M(ZXR2GY_%'Q-`8<"E3NCG%467@QECB\^CT?O[^\G[Q0DF M;Z/ST].ST7^^/;R$,S@'0Y10!I(0#@)._YEF%Q]P"%BF\L[PU83$)8.+T68N M+87XW[`D&XI+P[/SX<79R8I&@T)$<=MADI)\5:,O=.+6^S3*[FY(.2-D8+U1 MFULO"'+[$1S#9S@-Q-\_GN\WHR<(TP4,T12%]"3$\Y$@&#UQ3R=LC"FC-Y`! M%%,^=\:'K1?PQY%YO!CM#'.!W779E#$(=IG*GUP/]?F1&N>$2(MG((L?=7 M*IN\G#[&867*6,1[3*I:%C-F87,*Z"2+G7S->P-@P6/HV?D(QHR65X0]SH>G M9T6`_Z6X_-\K2KD<)><83&!\.:A>9(@)#ISSL4N4>1!W7NIE>PRJ7^#MEWG(0IOY@PC=_,Q)(C M=<0^>M9),8NK=3P*W__=']_G8HZ5KE;>J\26L=J1'6-7K8T#I0&U&DV/#UE9 M9`URU9HI8%L0ZM`[EJ#[JS_0S3,Q+BRDSS"$:"F2:,GI1IK"*!H:#QWMHHW9 MQ1H._L6E)P(7`)4[(;XU>F0S2$S1JL&(PE1.(SR$07--S:!PXE=`Y#=_("(V MF5Q8\=?M_U(.Y5CL;Z[8&!"R1LG;OT&(YC/`1*&VW-4''D6(#E MS!^PE+66;=33)@HNI&469"3U$!$-=#,#P$)B@&#$$*5^8 M7Q@.?\YPS*6D8H%F:PD5KN2%L>SD/BBN7L?U!'7E_"ED/,,E3%)HKF&HB:3R MA4S4W7-K\`1V5*KRU-;Y[98O9#X>%EP176`*XJ\$IPN^)<^CC'B_C1.&N.S1 MYAU-\49P1V,9$H?@52)G/U[>`NR`)G+!X7[3^;?$:-]36T-PBY'2SLIII*_` M:Z^^`\P:,?_7AFK-F]-9_W*H-_%NU-"8QN`4GX"DEY_$KGPFTPXOA%(9+C@/N`0EV7 M`=U!W@SRQLI60*^&N0M/_]+EJRA"0BL0/P$4W2=CL$`,R/4."U695^BH?(6! MFUH.OM*@)?/6Q5QL&Y*AZJC<2P\[>Z>5ZB M]:R!8OO6MD[AJV_MZC@X5\G$OWZ,,9[/<:+UK.YV^9:U=MM7GUH4<7!HG4// M$W)KWMDX(5=Q]"\SD4J.UJ9)+9VZ=.M'JV03(+@JVA@/!L:6@MF7D6RQ!_[_ MX[2.V]KNN\+M=\CR3K`'3.6"LO)>X3;I7L>M?T*(.P[1<5Y7Y1N:K8VOX103 MN-/N=KMB!'"HH`20]3WW"A48XB.YT[A\;_<)@P12^#-0%)914G28YE`FXE3YD58MS5'?WJ0Y\NT.RR\4\O@O^KEN>%2-\4)$ MJD*P6N7%@793=#'2=K>0:5V#FRE86;QDIGF9Q MY9*_`9)&^_<>_AFO0-B*?8R],G;9,%8,^H%2"<=R:LL=9K)-K4)']J='GZ.%C@E!O4@>!@EU>1$?L])6\4U%GNTG MLA\DAW]IR4:-8@]VS3>JTUKGC85*_I):IO(6;C:-7*"BX.'A+I8C$E>7*G5Q MQTI7O@K0TW7H;:OP+2.XEK%3_#WU_-64\8"K#ML)9*'X`_@XY8];O;/`1KEM M,M!3=O=H?L3;N./64>T.P&9=I`*JEI]XWB0^_B7;V?D)"B6$O!H,-QE2OA9S M&N(]*EIHW@0L;NPM>9DW@;I^KJ)?IV\\08)PQ"TL^A'A#OV#0B[?IE9P%3*T5'W-UWS@=BUP'MAANQ1_"D.4/2;\ MWS',XE`27B/['JM<\I]R*:)RF5(IUN2IC[&K0PA;UX<9\W;K5QF\Z\' MM?>I5#MP.&=6S5"@3K3^Z8^[Y9!_G[A\%5FO;>S!9%OZ:,6D;T@[B+'V@&3; M^?W[R.5E!@B\YBI$(COEJ:EJ^3,3;4XE4A/U#5M.RNZ!'1U__XZVJZ.\['_> MJ3I;PYAAC#9J*GV):R*T^SM>*L"1,M^-R8]!^1+8QU4)BZS:\J[?JX[$K'J3IO4DWGFCL, MZ3\,K8;XD.VFXOATZ^O^H[Y]:5-DQWM4H*LO91K,7E2:G&?U;RNOD3[O"VA1 M[C<,-)?[E0,[/.T!AQ!&61^5Z%_E@/@&6$H06S].OP'R$S+Q_+S`4%RK6Z?U M^,U)$8W'>Q<-35#`^YO()30J1,A/I6@\M7_=;WS3E+U:?<57(8]3!+K`LLF8 M$HIN8WH'OQ:FV`=R;M,=M/NN_M-TXDH)G#M,BB]/KM/U#7Z7Z[V;P$6F8WD5&D\;XL*9S"9\*+N(1WU,,_YHM M*WFH.#OH<9%]I7&[@B1$=-MWI]I5F.A5NP@U?=^@V-0$>\#-82K_]O-EGBER M#+A(23CCST;6)E\>VZ;9$M@'2/L!TX#>H:JI$?:!E<-##5>*`Z6# M;1:&8W=0:[N"RJ-&;L11R#'M[F>\^_6C"L?,5^>+&*\A?(;9P=16>SC3EWFG MG;[#G[AJX5S#0;M#F1W&U0[^#2RAK[P,9U0LN^ MXM@9R1,/E@G+3CSK.O?P]]GM:PHT8>-^A74O^BR4)5AUF5JI=8,BBZ M+V"JK-M^$ES<$'],^#Z:7_D_4$L#!!0````(`"LZ"4./V;G33@\``!#?```5 M`!P`8G-T8RTR,#$S,#8S,%]D968N>&UL550)``/"SP12PL\$4G5X"P`!!"4. M```$.0$``.U=27/CN!6^IRK_0=&<97E)3])=[4QY[7*5N^V2W5W):0JB((EI MDM``I"W-KP_`1:)(D`1`@(0<7[R0P%N_]_BP$/S\V]KW!B\0$Q<%Y\.3H^/A M``8.FKG!XGP8D1$@CNL.?_O77__R^6^CT1<80`Q".!M,-X-KES@>(A&&@R?D M12&E0`:/DX?;N_N;P>G1Z1&E-KA"JPUV%\MP%XBGZ!@ M,(%12'D/+AP'>A$Y&EQXWB!N3@88$HA?X.QH-&+CU[`CAQ?CT^/AD_.^O]T_.$OI@Y`8D!($#AP/:_A.) M+]XC!X2QRKGNZRGV,@)GXRVORA;LOU'6;,0NC4Y.1V;9PP"`IP8"]BM$4:ZO)4%2LZ"Q\#%8_&4D=37FV948WF4B-9M(W$5\A?8;BD M=-P7N$M]*G)6DM*5I"&!J*&R$6)K4QHT`;F:^1$S'?TNQX0]-YN+D+ MY@C[L8]5I*VGEY<38"<3-?TS+^UV)L\-PO',]<=IFS'P!&!0,7>830FR*"4M`YY8U(C'_I3B'4* MNT]7@Z1+*A1VHBD<;0VA45XN];S4%"1NX+)XNZ?_[C&&:SJFF.W2$!.W57XP MQU:A84X4J2=Q-V*(US<=R=-0/?8E16=XD1_RZ.6O,EC4*X'`R%HW M"@2F&?2RE)R!TX<)X#,HVKYXB,%@"L:!5]CHZ/DDWM/R27O[]"GD>F")65;W`"TS#?Y$\SZG`WQ`%"?]V/D]0 M4\$[6@5L)RMI#^B=#TV0IL4X,[M>TF-YXY?G`-B5W[]%;$#%"D2*2Z[FN[0_P%WM>;CNPR/ND@3W&\.L?(-X0&U,IN M.]T_#72*-PC10$XLA.G-=,.>/C1>`@)I*_@5`K:OC[&BR=Y%,UI;W+LKZJL? MR*,#W0(29;NEUA3O]L80J&@OD^@3%RE%WJDB\O0\A-C6SEGD018NK0T1/]<+ MD#;'('6F"08FPR0WH6PV.(Q;WF08F1`^#;@S%G#AR2>VYQK.SHIV)B%?,T.= MA(!!J")QZ^3QK%^B&-75DK2L0S3A+4%\7KKKO=6:#&]-[3*\5;0/715<:Q`5R,G6],.7_#G M5]0.="4"LJ#+$7@3H*LRB'[0Y3A9D>DFK$CCE-&EZZE%(YWDA]KBMNQ$5"=UWK?;KEN76/6D$')*J3[KPRV\LK/)+[6% M995GK"D=OU)1_H=[+U6R<*^GQRHO/%"]X"7O)*V8?PK=K(B=KV!=[1_> MO]6CI_/XX)Z]_3?GC$^G06_Q4"O>=P'GDW;OSXK*'1(\F`^1[]!2!$MY$*KKG MP[69%XMB(1Y6Y-Y=R5PI<_VZF5BWTFI84[=.U[CD`*2HNSR*Q!GE'Q.'L79T M^(-<0>=+#UWKZ?('I`]C`8P9#O;9NS=$YI6DEV4GI>>_OE.@U+>I5VABD3&&[94B!0D]Q M:0I72(];[C>52^5#6J2!^O=>`S4U!YSQK96^[%T(.KE. MJ:=$.[V]8%`REV%@B\J4@O2#)0NB>BQ1OWIJ@$=IJ54KCT[794T^-#IP@>GG MA1D5TBC\]7#6DG4;XG(S@2N$X\5XWNN,';$S%,AE=I8LJ)L(1`.1WN`N_J*^ M1MU,A'Y9)ROF7O4HMU.-^\J@629:5WW*3'I\3[6KL$(=N6TTKS4]GC,IH;;PRZK M&^H[+'"/R\/\"L.9&S)NU.I?P7\1OHI(B'R(R<64V=\I'F"I3H"GIR"!WHX2 M;/0=TF"1_;/-JEBR"%%A945ROX9SB*FT$_H,"J+B#'K%W=0\I;M6HZ%>%W%7 ME^A8D?:RLYUI3H?N"YO`^@;#JPAC6#KI5J1IML!7V]1J=TMH*>[[>J(MMVDT MG6F<99"".ROO%T\GWMVWVG%-^HA[BT/)B@7ZDM2T_&(7P`(6]\*(-*TJ4_:: M6NUR"2T5'\DEHE8L@D_0!GCAAO_LY=_,QO2%FU:[MU83<8<6R>174.V)9=Y& MA/I&5?';SS'$2O':?#"P5*3N+Y'_XW"6R`NE?GE1N[K!]MVV%XX;?(T$ M=*I%PG:QE4?&BB'2-^##A_F>>-QUDL9V64%6W:Z_=<8:)R)QU?*>+E.,:[)J M2F_#V:45D_[=S5N:4O1W[7J0I,PLV>ZJKF M>$,-BN3]4DDM'M(6J)CY%,KU?'KIHA`ZR[O`X;JEID4VW<1K8;.#FE42]A*7 ME!433Z4'^N7F$@;.T@?X)Z<`$FU>5127FEM>'$GJ*U8J-1.U%!J9D-Q'JFCS M2F@4F_=730E[G8N06K5K$5)@P\=*D;P5=9=FK)3J%&O0PBO&=,*EMD+3`1AK M]LZ4)^/Y]5Y#L\JECIY+#.&\P%WL:"PWFLCSESO,5HGWKL/")%BP3US3**%_ M702S_7D_KH_E.Z86D>EX`#A0MH,L,F08]7VX+O=KN]E9NGU^;K<#&7+?V^W[ M].!;IA:\=U_@["X(0;!PF5$(@=5'1,ET28$LUJ6W9U:U>)6'",MT:32"!<<( M2SD5*>F?SV8B[%A&$V-C1:U#AU*-#?2":9^1'76T MCW"8?B;]85Z4MUA-"S7.:NJ&Q@<"&RF=5>#2Q,"*\U]JE+F-P@C#O!9IB2.? MBX1)-6%2HBR5(-8, M8"%BAP]A>9MI!K&0`%9L&)-3XC\0X.=7U`J]!1I*H-W2>)-8Y5O(/$2W?*W8 M!Z<@.V4O/M85HJ*.SH3*V\4GQTH=(33AG-_*=T`8O451<:JY'1%EA"9$WBQ` M.3;J!I\)XQ2>_SPT>-*V[>&9(Z(.SYC(VX5GV48=P3-FG,+SHRWP3%85V&>= M2J#+#]5H>'H!HM6T)DGW(V\WQL"PA*"':@$!N MJB)P>*A2LXWNG%3%-,-BO\L@G)GUF[7C13,W6'Q!:/;J[MYN2=$GTR6UJ5B7 M`T&8@OXJF!)CDZ&HYT\4;`\QJM&N_G19T8ZEDR:;.W;Z\I<-?%N>)R6 M>=J^FV`G+WLY@;L15[%W,P+YO?O;TJT"IGH,"MA',%$6!6@`(I_Q_Q\82UNE M;84C;\]X-WBLW4UN%I'6[#-/Q^'ZFI"O?L&R+4)B!4KYP@#G@L&!8* MI*W(/8?_K729XDCN:^DBI4_Y>^D]GZT*WK^7GN]B3Y"]?R_]_7OI[]]+5SA= MYOU[Z<+?2^_V':-'C%Y-GH&ZT[>\)G`>(+^$>!P\XQ!0(##2/?^ MND^%7*6)Q.VQYF+-MV>:-S7O+4H?:+D&V`MQ]Q`02":Y4[V3G,*N`*]H`-EN MJ2'$N_45]J*.1Q8[A!G8T7:CZ6D`KK)&YG75+_B,9%U3;(W7;E- M#@`4`KK)`H!/THH:;#?DJDKL["L9N3NU*U,*-$J+5%(T.EVODD&1#IO(PDR1 M9_YMG\-8O!)3CS>U(MVQ_OG/[6C)Y(P*[E`+$_$G.]VDR?GUTU(MW6_- M]-7%?.YZ+I/N)J!Z;OBG`=4VRMY;KFAD0;7,.?M'1*,JA^?.^JD@4X[MJIF5 M]#K[,:7U-;WR/U!+`P04````"``K.@E#,YLAH6)4``!JS00`%0`<`&)S=&,M M,C`Q,S`V,S!?;&%B+GAM;%54"0`#PL\$4L+/!%)U>`L``00E#@``!#D!``#M MO7ESY+:6)_K_BYCO@.>9F"Y'2'9)]>Z=MKMO3F1I\6A&)6DDE;O]*B8Z*"8D M\9I)Y.6BDOSI!P"7Y(*5/$A"*D=T7ZN29P&)W^_@8/_7__Z\CM$33K.()'_[ M[N"']]\AG(1D%24/?_NNR/:#+(RB[_[[XC_]/__Z_^[O_X(3G`8Y7J&[%W0< M96%,LB+%Z(;$14XM9.CJ^O+T[/P$'?YP^`.UAH[(YB6-'AYS=/#33W]!^^CP M_<$'=/M(UAE)T#4N+B&4IQAM,GO/IA?Y]YCZ/D]Y_9 M_]P%&4:TU$GV\W,6_>V[QSS?_/SCCU^_?OWAZX(RO^<\1_/21CD_)5;ZL]W:5P;^/!CXTLJP?ZU7XOMLY_V M#P[W/QS\\)RMOJN*R!X;.*G%GP?RU3O1K_?3C_QI(TH-10K3S6O3KX=0^?U2 M$N-K?(_8?S]?GTFU?_J12?R8X/P\N,,Q=Q+C^[3'%]V([ M<9HV9MC7^8E]G8._LJ_SG[>6?YQ2O`>&Q5N2!S%,.;F]85D';J87^@+JTZJ* M?`'YE2E/\0Z^QX&)?B/^"ZV^E*=BBZ+)C.ZCJE;EES@9/_SS7L"T3\U+U%)_!@2VEYN\OW.^]RG9"VK M!:+Y>-6WX/9^1ATQE!,DT?UQ-Z`[*M*4^:5I7!#_AH.4!J]CRJH>.G1BU3O* MQ2:@4F84"J`:^S*L*M46U5-4/D;L.:("B$G,"V)M51+SS]Z%MDRC1KG:XHX` M?TS"@C&M::H%:%?*5.\LD9F`(UHA6V=@3GDX06]^7?'66905.>R`SDJW>7B,[`>9* MRU!P-W$B@[U>=U&*(":S_SL30K44*L7FY8%911/+^NCR0JE6\\/`]DYY\BN) MBX1V;UY.HYCV,87\D,AT>#&0FG?9')4.T:A$6KT+8:L`*5&K/;1X@] M\P&VD@HC9A]8!-ZN=!>_(DN[39QIBI(&\5FRPL__"XO3`XE,-U7NRTS/D;L6 M@9-CH7%-5BS0:=+A\AGB#Q%]Z@.49?5&##^S,//MBO=27I&MW<*9K-8!Z:`WI.&#SH##3FX(.*2>ZB4 M12UA+[AB@@,RIJ:$+%+H]BBE];+CR:+ME-4I_:4_Q**1ZDT8#:0`IHQZ-J$G MC<3F==-&(JWMQ%%[8I0_]V/J2%:'Q/B#BZ>/>@K]"22AO5E`7DYEZ6$ND!," MO2,'!O6653=@'SHP@WM?;P#X:L+4.\B+ZE,(>LFG5\&^I2(&_L#FCJ%_2\U* MT-Y^U`-X^0@`T\P0-(Q;-G7(;42W8&4_^8'.SO<=@?^-,+ M5N^M$AR)4GUA(7!K[$6$9$/EQS`G6@UVC]1`X`[+Q"PC4PU;0O6H% MW4H)M;3VZL4PWQ*H#^<$]:'G>=9V)_`M?LX_TM+\/B+G4EBQR+^$5G80$@1^ M9\K+Y"69&B]DEA=53^H&72U_6WX\/T'+BV/6O;K^?'*,3O[]ZN3BYN3&_W"A M0J!EZ-#`P3Z*"`S:1A1IF>:CAU6N-[7U5)3!$3,.S%O5]G$*7Y@1Q*WX,0PQ M,VLF9)3N:#/,-/UJE*O\03VR.,:"_6`(]%BDC4_;1C@?GG,P.D^W'\*TMFHV M5.+;L.8HV(U+WHT'0FV,C57//Z$ MUW>#LPUT8M(X7(N!LZ8T[#;^=GS8D:2ENN7']C'Z4@IXDA1)JU5)DF$5Z/A1 M:JBYT;8Z)RU8'G65DGN6\3%=! MM#I+CH)-E`=QGUAJJ9I1,JFI5!+;!>60TH62/`K-Q?8AVM"G^U&"PO+YS#31 MU">Q^O@]8H@5.HQ0V9R1"G\OLIRMFLUN"6T&Z>>+>(9XEH1DC<])1G\_"K)' MRN2G:(57'U\^9Y@6_W+#SHF.DH=EF$=/O+,O&XAVZ*(AH0L7DQD,7RA8^CLK MGSIV.'*[:%EFQ$MKVVR4`47<.ON=_2ND]EDSSAV@CR^(U,91T%C_>>YXY9`W M9'&_=,.OJ;>:+T??W41RQTY#+'93B/K)2J(Z3$J&ID4YH%GY>3N5& M&7+DBHOEQZ/]B]]\Z1&K*Y'8?/(>[83R'>(H+#K#!]QRS>U)6*&P)U>L;9F:;'4K(E#KLD=%(OT-."X\[ M`RA?GJ04^ MR)3:&])4K]^GJ:G'^5BZ9D?2_L$#Q^7]69)3"$5L45*6X;Q_UHF9<,U*C?!4 M-BK-@[+0Q).2?7H#BRL:SY,MQW_S`;]ZX)HB5@Y5V!TD`Y-P(S%"TW9U>U!7KC_[-$;4LZQEMJAH M;UI>58NK:FEA6UCK,6WM$3$"Z\;-:AF%^"$O*.PTJCY@5;7*3_9-%6VHM.T$ MC$=C]QL8)U#FT:BWE8#_YLOI)];5JPQ$)O4[?Q@2QA]AX`'"HJ-08QQCVL'% MGZ`BAYLNC`SQ!1@X'$0,\U#1B1'^5Y(R&(AK:4[Z?PRR*+N\7S:'4?:`('U> MO9[@^43(#2Q"]O=EQE4P%.LL^,^(W*,K^D(TD/,!GGGQ*:\L8OA]NZ`=B+;Q M*[$S&Y+9VL)ELF+_.?E'$3T%,1N07.9'09J^T.+]&L3%X`9V&YWJVQCJ3&2! MD1=(9M@X5+'%W,Z"R?#=/7Q5,-Y*SWR7NQ4HR(0ZZ[+-2+W-0`M_NT*C59:P MJ2_X5N5U5JY!@'F@0"8* MI#D(7'6GC%H84L/U#C]$2<(:;PK:%QS,?(VZ>\A*#A1U!]DY#Q$5%Y*?*/\B M.S+42D>9]0QTG%"WY\5]UB-V:,]6D1U.UCV.1G329FK"%CF2--_/<;I&9\D3 MKK;3^,A7&5BT?%74I0E=>^IZN@K]^<96WK2<)6&*@PP?X_*_9J15JJJY*U%U M0V&A,_!!P!'.1[!:;FY1_XKXYNM7U+W1`$G/:VT%&]%;:,6`Y0KO.\8SV#CI M&,>08&YW@_JMU5Y]XUJ#]W>UZO??%KJM^D?P\)YSZ/B(Q/1M"=N\^X27:4J! MAWG"0E_@@M:0Y/$M_2MCF[U)DIU'"3[+\;H__^3"=-T8@IJ>&EP`"P.:%L.7 M2QF:H-TM.A91VR2/9]3H?B@306V[Z`NSC+CIF=?(."$%<0_&7F0$]-*)G."E MGS&P-C%9>$/Y??GC__@!M M@A0],9%_00?O]]Z_Y_^/LO+R\*#(::<[^@.OT+^@O^[]]?`O>P=__>?Z:91E M[!RR($?_LZ!1X,/[/43K[`./(;09+G=H?SC@OQ[N(:JRP>P4"QR_S!TK)!@A M9O7:YVQ7LLL[D14'D(-+K"7&;=%VT,"MNH^>/]E#9QPTK[/^9>FL)0#F34M[ M]]R7]2$/HB*I82SM2L'ANVT7-H53N3#$^D"S%V"K^/@N2JJ(.7?O3U.K8O3+ MJD#*@;:"A`I#FSX0XBI(+].;G&W^YERE'4M>4#DY=!I#HL@UX$@C\^&(0!IW MAF126ND1J\E9.+=6+'E-,S;E7/+,'YII\2&FG$D%2NDG4Y904>W+!UJ6P6+9 MI**ZMFHH*6NOVI+0;=;6MM-V:^#&JNWJ:?=HULK^_6W#!+6M:L?$U:)IR[9* MRO:L;WM.\FQ2_(B3C':VRA,&+W!^>7\;/$OV]UEH;,FDUYA.*IT/8'(9NM.0 MS,C*XNCRT]7UR?\XN;@Y^_4$G5W0?Y^@=^>7-S??>[/SS`879'3%#>BG4^[1 MT,R7CW0TIZ$Y_5S2#GY.6NMK)->:!FTK4)VVZRVC+)DTBD&&S($:IU+9AQRR MTOF9`**#/HI*$1JI299]OX>H+%L[2*7WT#+/T^BNR.O3BFAR/?N./5C`R8?` M`!`W\\#8H&@DEUXL;BJN"-==<0=<:SMPG2<)?-ER;F!"E2'YQREA[6N():LA M/;G:FCJ&#;W,R#+Z39,\Y=O!KJ/L]W/I&@>=8,,LN>!D3LE,P[))XT7-(Z7R MHO,<,0&OINRU=4QL:Z//')E.ES-JR_ZPY2-.PL=UD/Y^3-9!E.@X(Q&7,6<@ M#LV?G@.G+!+[LN*2R(2(48T<^E)*^L8K&0Y4[%+4E89C/4TETX1>_.';K>`4 M7;60C%NW(*?DBLTZY=&MX2FX"D5A*\0?^T:46]D!M_H/KR'%;?\`6Y5%?PCP M\:5AZ/(YTB9I$G%I@],7!V]PN@[<-CA"7W8-CL"$IL%A*GX.\D14=%EM/.E\DAH'YI/.CX9/:O7% M51HE8;2),3\]JR,_.WOT-4WL:V3`'JE6CST:ZS.R)^/[:JJK@F1':NO$&M;( MQ"8S1FP8EBU*'VJF*%07_"G/UNI[/&8^2EY;F\3NR_=9(=;H,D)EU1LV:%B@ M03\XZATL:!$ZL(%Z"?'R]%7VC./\Q(O[:J35I8"W.:Q5<`9:D3(T"K@,16S< MMNH/VN'M=5>[=+6(7;W/N2[D&-_C-&67`&:#@Z"%SZI7[3V;"-R.-<@66F18 M!=BA_*+^":7D)8CS%W17O.ROR->9\U5QY1"#;]H%:T>LC52!_NPHO<9/.!GL MB98\[2&U>0J$U@PW18@\FL&UKM(!;_NH'7ON5)$"LX,N*,5L)BE#;L0%? MXV"MJL2V964?M&K[^O76MJ0]M:MN'UI3MCB?G_!^'@5W41SE$G# M/<3``ZO&UT1\M0,O6PQ>7V9#'[]%E&D"-`S,O`K@M$SB6[H,)&6!NRT)S:BM M;1?=*+D;*Q[UM%]!C!94KHHYXEK0D&:KI"1,W_;L7*ER+W;.EI(I4CEQ1ZTM M!YO`;RV[X(C,B45*W]-=G)/DH3P9>N5SGTY0L_)\7UP)RL1_JZ+H`O3M^D(/ M=2LB%A(3`[KMZ)IU/YYAWW`(%/T>W3!H*^1?776YA)J847B[2"K$)MWG7Z/RB\4!D1).-I',6$7 MO]'4PP_>:.I=DY/;Y!QB/5UF[EWV00O7ZF%KN[)RV2&G1+)PE!I:=\0HJ2-# M0DGTNWR**Z&93X8UJVDQB]05(B714$W"(9G]&2FT27$8\25X].\8LS^6R6JY M)FD>_<%_'S#)7*4AE(G*9%[IG<#2R]B?FF6&9A9M2;ZP)&B)S,TY"TR0\776 M9Z!>NTM$4V_S\3'*-B0+XE]24FS.DC`N5E'R0'^E'S^/:$*[NMS@!IMJ92>XIW4,X#%$09#";;7U2_-ZUQ5*Y"7[5L(%(;F7L( M&@2AQ`%0>H%FBME.!)I>OME"TTF0LDLVL_ITV>,H+O+!4:X:J>J[2J4F!@J) M7<@0H':A(K=*K+>Q.0%XVLVTU(%A6QCULR,,@8"&5E7/8[I5#MD,_,S.^MNA?E_?7."0/";N`I;P3FN_,.Y><,.S(>H_18-:!^`]4'A?1`K9H)K$% MTN.B-HHJJV42O'_'[**VX3VT-27ADM5LGH+%XZ,2+D-POEG^165)"]P%:Z!@\3N^A MT@_BX=J/$\`=TPH\;JM`[")\]_W!1W'Q&_D=S"](\H0SVA-8?@W25<8/(&H_ M9R]V0?+?<+Y]97[]X>6&KP<8$]NA?-J$^ND^=Q'YIY9RYPT!4($GMPL@Y5A\ M3M)MO`];ZGQ8H1ECH($C((`.KW@-\5L)ZA-+]_'33$8L>M5%;0 M._:/8_IG&.$D?/F^))J\Y]L81UOK?]).`BI?>3?GDH+3($I_#>("?\)!5J0\ M<)?'=*O/D[?6JSZ^A=[$8&3L";(#9NM4%6+L;"V8..+RJ*4PG26T`_L0W<68[^#]G.'[(CZ/[OODL%&I&6ND M,I6L!D[`#^ZS<*KDJ:F9Q4F61VL^'%'P)RBF2G,SU`819'R-]7AIH-VAI+&W M'0$1+%.U<0B!0IIWEJ+[7!9MA*`H@X^1H;UEOKKFX3<<"W.^.F&Y0!-A<8&N9I;]_]9;H1LB:U*(/JGEJB\X-3FO26V7R,6B<%GF1 M8D'9)5NU(4SIPX>!*7LKDKW99@X"3K,( M9`42XS"DM6H8BPQ+-S.'=M$S-RZ(2P(9]-(OV$26N*M^&F5A$)<]]D\!=1?E M+W]23HF& M`.Y>.I-G7YBBOR%#BB:S"*&J9N-XT#=B2'^Q;Q_)O@S#8EWP74:*`]7'&S`8 M'9`9<#@P('9I'`A^*@-!@A_XB28CAP:4A1@[*J`PNF@][&07WD8`';8,QP?T MM6T^-""V93HJH"K)+'#?R7R8VCT\TDWFP?ZD@@P)\W/!T[R8]LKLQ\$$2OHF ML:/D+BZTW.QR%&OH=F0(Z!M:L$N.KRBBDKP^W,C_CK$((&9DEE2?,7];^H:< M'7C<&39WT4X)7,(`TVS$YYL"JWUK,QFMGK0J97S*?DE)IAA9$4D-VXVN%!P9 MVW8=C8X(7!B2;:"YJ'[QAC7"RA/31/:EI;1H*TAX,+3I`^X-9D@O\'-^^Q7' M3_@32?)'BX%'"V.CEBL,C>UTU4+?_7R+%R0E@5O#('3`EC+\?][0>PKX1J]H M4$%@RL*&OMWQZQO$)7PEH8>OMZ2$G;PTJFUD_,X`;F3WBZ2IN7G71;5*`+Q$ MNC;,0LE_>TVA9`"J:U4\>94SM3=QE7-3HE<4*FZ_DNF+*+[-;QY+637\G$E9-U>>9"^XP[ MAUHE<`+U:?N&J)%OG25@FX:@:#+G6-$G<`/E M[PC'2AY;VUM<+6]/+F[1T>7-[8TW$[;CH$,`:K3':1LS'6[;^Y^-XV?\CN]S MDF7LI-0CDN114D3)P^4&ISP;SS[B>Y+B4NXV>,;9R3,M.$E741*D+WS?\`6M M3*K)[A*DJO2=,>5Y/SD;4EO3R/5R%4E0K"(J\[TWG31=C0^HKZP>$6L'"D/&26S.3!;*[VTW3W9E@XEHAS8R M41#NB(W;$LC@AB4#=WHR*=075]>7OY[=G%U>H-/+:W1V<73YZ03=+O_]Y,8' MOFCJ>T`:?;V(F"/6&M)'9=TQK(#S4;6C*8C:9H3\,J!&"'UA8HC+>1&*X:"E MS*6F8VO^;*93-F5&HY24AV?@S$9H&SZ[4;FQI%!OE%D:DSU+9]35K::0:5HC M5-+PQ[?TIIJDJJ[8DC%'+-5G35\*BC%=N^`+_-1^C.@BT.1;/K>CC\V@Y+OJ MKL?O/6&)I&I%#)'7@X0=704A,T0VW>'&+%TM@WQ87 M@GYH;W[$JR]!U8GU<0]]Q:G,L!/TVU]@JE1=7*7D*T_*$"`8W ME)I4@(0.BOM'U5;G)P7.KH)H)6\`VD^'H;]\"A?TF3U'X;YEVC#0-QH+GY#< MJQ)Q,.]_1VD89X*2`+ZU,2=*4QQD^!B7_SU+CO$]3E.V`:0IYQ"[YCI;1)OH M3,>YWHN#4Q=M_&JH86AG43_@65'`ER[.3A\+5)`)E3:@FEZ]1T!3?[N"XY@! MC%N#`3!S[R"H/&"P+&50E*#5MP=1^0"((XR"#(Z8N8(<*C'W"`+,LV:!XVY2/?..D"A!*3FKJ2T=)@;J:DE)_'C&R#AO7 M^`DGA9Z-$GEM7Z.1=]9F5AY1S77+9M;'L6:?FK;\R35;Y12RBH']-& ML%(U:P`[?G:!-LCU6F;>)D/M0)^57;]M"%IW%\9B<.8E7<,FB11)KIP>,U91 MI5\#%1?95\_)3H:7I&ZM4S"1F47]NT_3;>:`T*5?B@HSR+YZVMKD2^AM1SAT MV"C('4)`4-XT--"\_D:@:=Q&PSY:BZKBPPSC*[LQY%-Q%<91'!K,3-D:T MK8G:B#->J]PZ[^Z;EF`<\[6&M\U1-190'BY5C1)4Z^>\&[2S0IU17##%@&F@ M4-DS"QWZ$GD42ZY2O`FB59T=U_=C)JO+_!&GY>D?VEAB8T0:2\R,@,<2$[<[ MR5XM"F(74HP-+RK))GKPD$*8%`H+JIODGLY860%0&59LX:`+*R;VU&'%O$2S M<<-A1FU3!#>TD&?=-5WJ%[J ML].3-K)2/?#8(?'D-BU7.[6+#RI;BZ-':H@VD#0*D%JN:AMY&(BW*=_/OH4! M'7:4S#>H5AW7)2;4]%;ZG9?0["2'(#XBZS5);AX#RI1EGJ?179&S;L`MX;]] MI&^QHCT#?NQ#FC+T\#,S1$P',=@.`1,-0L2&244`#QH0I=%&D^E.%CL;$_`-#Q M/F_O^A%?3Y%Q"4EI_]4%)N?MF0YN[3UY#N-B13/N^EQH38N@4I$T"6(58&:* MG,`FE,;^;)@I-5-=M(M"=K?Z'DKP["=R6N!`04%=/:DI*-)6<5#N;4?PLVH9 M#,Z\-O<*@<*#\LR730N*;QN%ABT!%`QG;@OX&:["#;K#1]O8WGHTG42-,>!8 MW;>K84-7?.'+(T8H/M&"L!YSN7=&>D>#6JR!J$QL M,ES%AIWT/96NU&A6J#;(KL[QFAO@F@HE=A^_#WRQ1I<$*JL.\0+88U0[&0L5 MWC>L'U<[!/>\.1T>!C?2UGX:<.9LU<_9/,K)\R8JC^<^IIG;00^>*I'J0XA% M)M)!9!2RU5?85Y%`JK:XQ>DZ2LIK6,D]XH)H^9!B/K@[+P64E4C,/WH7^2+I M-NKEUN8#_'8*]JA.J&7BTY!H>E/M MMH>OKVO+_Q,J-;RAH1E8F768B5\!,\VZ:`ZCVCV`1EQ M_1"CC]I'=4>P"V*!C=D@^RGX.TF/"MKBK2F-EL]1?S6_7*!Z8Y'`1.P.34+" M5VI=A6")TH+_CIH'Z`M[-/-Z0D65$=./W(7S4+:-:)FE&4']'*V+]2>\OL/I M`,^"9PV4.\\FH[AE#1;`0\-J[/;E%]5/Z$OYX^R`%=4),?B4?9BVQ+H('>C/ M!\XHD8-3]*P&9_?95'"VK8&"4V!8"3YN`,`)5YSW&6]OJA(*1)?$M1I0+ZSH%-HL-"D5U3!`JNHD%`E?@$P/6 MKD<$`)DQOELD9.0OJ!P[-B.J)5O,]Y+X*OCH":^I6".B"VP8$%SJ>:<(!IM9 ML'<+!]]JMQ-OO&H5=/>"WGTNP?P]:A31\AM$LV1Z8A=PGG/*PKQE'9W$CDY> M=YBT[JJADKN&R50E#94H1?62VBKXC,I,(3+2<9FHRX9*XLYU0Z5P"P=??4/5 M*/K>4#E!LUU#!0IG#QLJ09-J-^IB8,"ZA^5ZU$7A<@>C+GKO,%FK>M1%U/?R M<]3%!&&CTM;1HRX*6^.R6+]'7;;G+HZ,$08&U#%":8C2[" MB$"A,SH(%*VS33T/%"8PTP<*PXHW"A0*6P:!0EN269#O.DDV<`\/>WW2W!AH M)N#MZT-7*^S)84+S5K5[\)JK5Q[!#.O7PWZ] M(%*.SM5'Y^@[S%!V-0`M=PV3E/0&H#>M7$24B,].-5L(C4HW(/+N<=G%CO/L MF?)KV+QZ?#[][:!Y\2@@.0+*^:C*"9LR9QP>39DIF\+MQ"9D=J#\!9D9&S463J9D&7K1B,WE57 MYGX_?ZIC6/TFK#)*;=2J1B3S))6Y[!9.,)BOD*B^BU!B(H,$-L%3%KD/%55D M6HMM#]^')$55;<3X.W>1+Q!N8UUJRPT6P-(0A?T10#AH(Z'..]C#F9..:8"0 M)!KC$#%G\CR^-@H9J_="H58/BB,819.)AZ=.( M2R:F%I](DC_&+R@MAV,V:13Z$FU-X2%BG$7525BHL2"DII'7^>B:/@1)]`<_ M8?V()!F)HQ7_QS)975%.L$*R?U[>5R-%07Q#?REO')7T%T!MUD2'L3DU"D"4 M`C1$`!9(&3_`_"PNKW]97IS]_\O;L\L+M+PX1LGZ./GF[.+ MDYL;;Q9#P<*9.$13+VI!F.^$-+CROLYXI[_2V)5YB"CHXK)DZ`+9QD:#VZT< M%=%9M)3>V6P:.%]QM#2\:=;`&^-H:]W/V[-?:P"0C<"\L@@PZ]@/F[XX(NM-BA_94<)/>#LN M=8'SR_O;X+F?,%FHU$F0D[9\+C387/JB_2>S:13AUKD+P1&5819"B_J'[R MY'A3<9T0@T_9A7)'K(U9@?Z,X'P)[F+,;@]8AF%:!+%L3-%`L@&N0G(RC*6V M84&MG_#.)/WQ^O/),3KY]ZN3BYL3?X;? M3&J>6%=1GRQ2I2YU-+;G)!)/"D])>HTW%,&/088O[VG3M"8)OYACR"=#A2VM MM`K3V:5Q84RRGTJ2)?B!1KN5:GC(V*F&0/Z:71[+#3RM!,T@HUMF+N;#L2#'A*O.T@LA\X9\W8#0Z+5+23TTJGUSQH=(`XJ?3BL)$P\6M" M3[V=Q56%)KX#9MV(5>BF*%*=1%)#?SM"I[@K8:11Q!D MMML.^I$K:;051UOYMPY031L"C]!96Q)J"Z26=)%J+&YRRRE^B1J),^??0?_GA+^_1)DC1$Y/>0__M_?N]]^_? MH^PQ8/L@@R)_)>!U[]"]L023.U(L_R(%E%R<*.&UYGRZ;*E$21"0LY,Q0&I4_?O#LF23R9DTIH0,&O+8'0NRBI:#7S+(95TTRD):2=7`J6?S(T[ M&FH\FM-1:4A!RZ;%XZQ89D\SKF:UV-L M+FH9;\?T1R.+`%5VG_J6IKJ!8%0Y_`@++).XW/"3SDZ><1I&F6`4R5!>1'NQ M/"3-11ZEY(^$5>)!1E1==6E(*9(54I$ MN9\YB;?!:?YR17&2TRAQ\H\BVK!H_#G#]T5\'MT/1Y2,-;;DTVM,IY_.!S`! M#=UI*&AD97&2Y=&:#6>P6_3H$Q331ZPAW506]M"&V>"9,ZZMS$Y+8YR0T14Y MH*9.N4=.,U_^T5.V5-A47D=-N&7#.@_61R_I;@`R]3B*F=W5Q%<-_:X:^C6B M_JPB-@:%"0\-5A3K5(TX"'H]CY$7N)4IIMXF0_#@3PS*%J*`@W#>!2B2`EZ1 M.`I?9$"*I8V+G?"S[VT4,[M&=(TGDT95^Z M!M\Q60=1X@/\Y'O-)1]0`,'A/O.![GPPQ#$;-[P*:'"^;5TAHS_.;81F#6,; MS:DP-_?EX'PU>^]*MEA:6UR?G"]O3X[1U?+Z]C=T>[V\N%D>L2/19CX';0QT MR.0Z[3'3W$B'N;:^=XM?L"&J$7X!H7M`L5MJ(*Z"VCI^'NVU6TQ+!K5V`^HY M![HD195UETW%U2T37%=9YP`T%3/S-8*VO4ZRE*H>=9"-@:#GI$'G6*=I0#YO M.L:MXI5IN8)B70$!J6H!0!J5)ET1IV/=E"HMI1XY/.G9R*M,`O_A1Y8#OI25 M0;QMR0M0MQL\R:RYJ;BF?P,V9ZYSL(-6Q.;0+2,3BLZ*-Y.4QC@P2.STT^0Z M39,,SI,CN&3%^_C2?B(:?K56U'!0I.B(C4-7N^"EU.L8ADJ,]1LU'\:*[8%B M0%)U%9K1=6C#A+@RSS-2.,.T'AZ7R>H8/^&8\.D;\=W#1K(-496RD[FIL`Y+ M1[TC-0-U^HM:A$]"KK9"S'LI2EBN$;)A8E?#A(FU MADLFECYVQL2.N]%,;%F1,[&2G7EGD0TD3)DXK#,+)I;*QDQL^YJ1B7D0)7AU M$J1)E#QDRS`LU@7/?8_Q?11&P]$84X6&AWJ%R334N7`RNVSH5,U%(R.+6@[A M2A"]6Y7/9S[XP@(.9&R%]2FHT^TRT,S33A`(.#]LZFXZ^`Y:Z#MIT->21<=O M'HG2"5]X*,X[O?N$DP)?XY`\)!$;"5%O8#"6;YH"K?QD'FH\P*9C9L[4'#2Q ML:C$4$MN;K:95CT963M]JFE4NTPS\C,?S\A+$.SB5+AUS MH-P065828:BP*'^;_;AF28T0D^_80W%'K@-9@07PRK7*/[0[><7V[>KXH*[D M%Y26O[Z^JI8E!Q9U/6>CST^%NPLRO&+7Q=&.:7G/8YJR5=*LN_KQ92M2G0>^ M_!JDJ^Y9&>S`FK,D3Z,DBT)^KN-!#Y?N'545X-+11$ZZ*QKX1GWG155%"L?. M%\N'AY1?KH&B^G%UUBNYKP[0R3HG3?*C.[9&YXU2.V`2V35FN\'3G<]V(';] M9EX'"[#!"/?%G"]2T/R$:^]S==1V@5H^T-T+:LM5?A!WM(X0 M]_=G2`%']MN+*:\R43P-HI2_PC++BG7]FAL2F=1'XSYXOE$TZ#!]PNTS&TGO#2`VA;J128S MAUL7D"?NH=8+J8!>.D$4O/2>,1>NC^R@8+ND+>L'5R;9"%EI=)];15NSJ+2[ MI^(S^L*M(V^VCK\VBLMZMZ^$X[/V8(,89]6TRR^$K+(+W%_>IA*IF032'5)(K7F!;36LU8B&!O,( M'.6AS)7G^-E#A>@>WLE]AUU0X/75C@NK=]OPIB/WN% M;=7.?(-OK82Z:!^^TN;L(W*7]WQ$\6-_T+%]\;;K`W^C;% M(%#/?7P10%D*51J3/OI$)XN;8KT.4GYS&U>IIIM1K>-']QH`K().-0Q>I)?4@?"D&`'B)I6'*5'$0CO2*8&%'Y\I->#'T:A9&C(Q9C.-50W6> MC,]9P$@8*&PJ6!80=#;$Q#?S[`'!EV%(BB3/KH(75JYELJ*_I`5>G4?!713S MJR@-,Y/QI@9!8(PIL+!@[]S9C-^$PIC%CY'F%[4>JA3Y8ME*U9.]XB#`%(:5 M:0"1!1I[J^+0,[9T,_,'?-YM2D%L,WT6;;NS385-N6P:8'D"OX68CQE=!SE:J'Y%L[BO>I\!J5,9O MU2(;&QO7!W#5_EKY==#L6OMW`'2KQ2L>-ZUST$+;D.Z2%WXTF_^&HX?''*^J M]>$7!3M0K1K>,VTX1]@8-)U6-L`"BH57A\VG?2G,XHJMW44IP<+*$5FOV3*W M?Q314Q"S-K74HB$FC(L5C37W)$7Y(T9'01RRUFRZR*1_XV MS'/Q1-LX[YHH?C301R2F7X*D-,(^X=:6GHSVSB]H?4H>MP\`5\]G03L8-.UP M#L`"%U21W,RC`9?.+."!.NT$PX[E]D;SC(\(4N/[H4RD>UN;9U-XX,P1AE$7 M6)6%6"A?XO@+^R8>Q.:3]28F+QC?X/0I"K%X3<0RYF6A?UW>5X>X_8%75WS[ M+1^H8O#N.W*'5@4=U-`-S'=:5G-(KS#(G3B?>T'58XZ MAXFT?>VAK3>FN/6'2H?E0.X>.Y"D=(J85R\NB=D9*X5M@GODRUH(-Y[%[87+ MMWPSK8EG"T$'.PDP_-Q)NRUAQ3MC-IKC2E^S,R9W;>K M[I^/L#%(VZQL@`5C"Z]N^L_V!3`+H;9V.]&Q>YMU6[T:Q>Q<=NU7WW8,%H6A M;"0T9%'*PIPX`EF7QX/@CXQG]#[`@I;UZO,I:K+8B);>)U/B[C M!U:47S!Y2(/-8Q0&\2\I*389FP@OV&GH..,_7";B^[K'&ZCY/<+`5*9;NP3E M_%CO2O:/,[HXHDII$*.3(,MQFJ"3@J$5-3J>7`$^`64$JMY[,<':5BI]1,\GICQA!Q8V*&$`,C8T9C:U3,Z)7$IYAQ3-9!E.A#0U=.'@%J M.7BBEY8=\[GCQ)*V+=U%]7@/M070EU+$/QKV:E?-MF%%:$E5JFBXT[8[[P4_ M@W'&/C^40NV+=01"$)?B#,R"7V@C\Z"]C$:L6,T'EL/]87L^$'LQ'ZBNT/YM M,,K/+[C)92`_N(5%8M$S&K077U=WPWR47.%U2M)['+$3T;.SI!R0[^VCJ2[Y MPE;F\P5KWE->7;/4F9 MHFUCY*P`ILV1@P*X;I#`B[S3)LE5Z2MTKNN&G3 M+CE%NV7+!%X6J[;)T9=XM:W3+U0P;YKA7U*2#39RNO,`U+X(/RR9`YG7!'U0=#][9R'SO;4P`/6#@UJ`,-C(+G$&&7NF[S!M;I<-#TH$; MP"&548,=^FT??=-:SK=&"8YBDM'6$6UXM[`\>#MTH.[4FW2W MQ1UA>1=U6HW#+?$?F#6O;K:(GOW@3:IM6(NR)>0&U3CK(NVI(RO=&+K+`6][ MSU!CW3:>YQ[F-B^K5R/Q M;=_]]38K)\^;*.5*L[0M(]U#-3#6[N=N92P+[%53,Z[L3MN;,45:<*6WVNB, M)21DRS,!Y,#-CV5)0-N@45_A-3=$Y(9I-^C#0OQ/Z0,S$CD$HT+RLJ6N065J[]WP;L9Z=%1?2-NU7 MPFX*BJ/\Q76T5WMT$>]E'GV*^.(R>AOSE<7=6=17E&)1/T-/S<.W%O@U3'(5 M^O50=1C\QQUYL64AN6T;1`VO.-Z MDJRTBZ5V5G:7JR]M2K)H">\AG*S82J_R>[W.,25@_@&NX1P!;MAUG88%@%SK M:?7.KR?XP*[9VUV9/8DZ]6I#P:F\G)B]11F4R8NQ#&WQW+838J^= ME30\U7SM>X-4H`>-S$J400?A@3/8@"MYEU<<6YLFI+S0V=V`0M<^_-!!;7_V MJ-HKD>_#`9U2[B@%;_G4=?'?2*R5T/O/:QI]TM MW?%<1EN9U]X!IV^B?ZN"/6"8U>`, M-L8*G$$&6.F[O-KH:GAHG;M<=X=+EHR]^I,-PR]9NLF#-'@].#2T# M?$MX#]WAARA)V%%5;WOIDBT/=W]NZ.R'A]*/3VETZ^COCC:`S6[P`T'*_U.`(=^M)KM2RS)X'G$';ZIQ/$WO3BR=<1 MOPZ_Q?AU^#8ZY4X6^$CMPW>T/5G@,RB1_YWGG2WQ$?LTZQ"_B8%0.1W'2TO;M'RZ.CR\\7MV<4OZ.KR_.SH[.1F9K[9(89,J<\>)XWT.RRU M\+@SL,+M-+-R"8-3MB=L*XRVTJ@61U^8`N(:_^?M0U4VHN,0J[-NFLJ#G/<3 M+^^/@NSQ-"9?L^5=EJ=!F/>;%@/1ND%1BDYEIL(X:+:E]Z/DH$Y]<43[WQ0/ MJX!-G#?B&;\RDVH@KH+>%4E0K-BB]._1E]K`W$0T@0*QK[(>YQ1:':9IK?M` MK],H"9(P"N(KDD6\>Z6EF59E2#>%"ASMI$X M4M=,&X[%)OX<$=K"M2&WC2TJ6]VV+BJ5?:>^%>;$4<`6"-*`8&)($AO,RS!_ MF/@%DX/D>#T4>=7)_Z0SDHDO/\.N'!0DZ&^6[[415<5&;CZ M7F>%3MO$'KK`.>-*:R_ZM\P4V:CL+%29=[R6%ODLRXINB7EA,_ZP=_WBX!B5 MT0;:3:VE`8C08N42-M$=Z5T;5NR-]BYN]6/U[GA$]0/#Z#H6A`4K6X.H,*(D M\\:$1Q*O:+9X\H\BRE^D0U4ZP3;')8(07!::!N>LRHN6FW+E1?OY/R',)7[V M@(/JFNUS35L'`DX)=0;<45CVB"-:;F@YX8`+UAU$=C:@MH,H_TO^=>XV?MEZ)917T^"!3Z=!";=13@)5UP#1BDO`*U_F2&`;M>JE]V!"DU^WJQU1_ MIN-UU:K@AD'/2Z*A(H8OO:YBLXGYG&40UTOSSI)[DJX#U0HX.ZV&-(9:DSED MY`>64C8NU0PSM[1H"Z-5E(4QR=A$!)N7"-D"U7NJC:*M^MR#():X(9,JM4]2 M(P-=SEKXG(W"MVFP8NMR+O-'G%8+V;-K'.+HB77RA#MPK72J[VBH,Y&\1EX@ MJ6OC4$5<8]HP%!@%R0HM8PHUOKR5H@T=D^(NOR_B M>O/'S!.-=N`A$^JVRV`C]39_+?S-R%X_EV.<>.OSGO^Q]^,LA)]/A7]_O_?7# M8347AX('E@'+63=E,CBSUXO#B2=^S%`F+,[ MWRE1.?&KBIM="5'@K"4@L5W:A$U69.:-L=W2&D3-*D)ZLW!!58Z@1+I/L+"O6/JQQE50B,?GT77!WY=JX%ED`QP-8&RXV;0<&VG;3 M']E02//S'JHZ"5^J_WHS>C\&`I*FW`8#B//1%,B0)9*WZE).M3:361/^0*0=,4534A?"PN&ANWPS)>DT2ONSE*8C9 M7%V5UD1)&!E2Y3@G,FRK86^S%]`H9LX@5@W M_DPTW`Y8(&7T*\!=W@\*_C'(HM`DG.ET5<%+KNLB5,F\.0],&L?684AI;U%U M'PJV/IGVF6C(V!1Y$T_NF&`[FC37!?G3PQJ',UT8,:E^@Z`A,Z,-$6K_O@4$ M64`S"PDZ;750D&N["0LR?SL(#!K7(T*#TJ(F.`B2C=<3'K28TP<($R`8A0B9 M(8,@H2[#B#!!\XZ0D?_#^[]^>,^ISW[YC]K?`!OHBR<2MEJ;&-QW*P)Y"S=SHELRO%O1L^PLH9R M9@[ARM[,C9$58LC(&NWRT42[(:&YJUU`%*95L?$V&9RT_:A%$9=%M;!_LS-. MP2AI'9R@XLD>;8,P[3`JU/ZM9;%+0YAD@HS/Q,02!.)JS;T@@J/K%)1+?C&D"7)&<"@-3%/ MT#L`S!#,G$T`V.$W"#!)4@`&,-!$H!X0^0T'*1O_^+?'*'S\&*R.\5U>)2,7 M)+_&(4E7@^/6QBGW1M=-E2$&&\U\.1M;MW*O'7"TL+:X?8PR1,N%493C-4KQ MAGXN/LJ8=\;<7YA-/K3QE5E%;+4;3^;O@A5:40?U&`>B]A*24TNE&T_&WRV1 MV!^8M,>'>%C2S,Y@5-+&_6[I`#OT;N<7D`B=@?<^U@<0;^/[&X.W9MC=.;Y! M!]W%UX"V#SM4Z&--ENM(4'D"<=@^ M)[=S2C?-2DMM;]:L3@`<@8&`R3V\*F,-]T>7`S['_=]%D++^T/*>_B^/0=6^ M\3.VLYD\)-$?TA372K>7X1KJ0K3H1JZ.> M5B<$T+0U;;1IX\\."ZA'TBI%MN*L5,J"F*U]SQ`)PX(=-.!)EFL'QGX68(T1 M<0Y@9&:0`E@XWRD?8!-<*[=P3.BDM^8T^*9`KAW7,EE= MXPU)\V6*RS-KI'D=@,5>MC?)(D1PF%``9YGA]#)I(\E4%[TL$EK`SR M$:-.R&G6:K(]\2DWBUB/,ZT,>Y(O0H"\'X:`4":.31.,#R+6Y()ZP$G8[!2@ M,*[9V,ED0:CX)Q-UV/*>BD#)\\12.$BI`4KDFI"')H3<^Y.1H`CSGI&@27YW MZX5Z4X21;/7Y-+)30HK2-'@R;>)-&@?TRD8['OH;DF;.<,UP0&RKJTL\I5I# M*0/C3J$&DR,:N1D/,IK753*("B&^-\N[+0O`H)(D6$"HFI@4:>T#ICM&OL9C MZ["#K?WCV;=+`N-(DA8`X,*LCQ#9=Q5#C50XJ-4'4]&2I M@J86Q>@V6'(@5I#@6;UT``@RJWIS4RQ40?*<38F466,2_A>T812R)DVVJA9 M+ZIE'N7,/MHP!VBU]5#NF)B[?S4)F00**#WBCS&WC0OC"S,+68!RDBGNX6G" M,IHV![@RXMJHI8ZXOH<]Q'EI(4N9YN'%U(1KK%_(?&Q*&>#9<6C#CF^:";+4 M]/3FX`X`H.! MWCDN>Y:RP;51RE9]2:#!."M?NTZ(S0?O1IBS2H$]H?A(7-DU M]";#@U:&+)MVR.%$:X<[3VO-AQ]'F/L3XS95/A/&G:S5;AK('BVDSWOKJ%O/ M(59]->:]`NR>HJM-97;3,[?DY*N9R*;9\,DA>VO>$!YWQ$L;7CX0ZS M'QYP@E-V>:@G"X^'==Q?*B6L%O&ZI^U7Z:]BZAD!APOL\MN!:3N@'`B1\BKK M6[/TU+#"@9:%=FPZ6.0YL&]7[9T%F.&KKG;-^D;#:G>Q8.%3D/[^>7.9L!;R M\OX70E;9#8E7)T&:7!9YM=-)O9QAE(GN8@=+$P"SW58>P1=*C/*NFR0?8;29 M0F>ZJ-@@DO#,E#&.&T#,`F(F$+71W#KO3=XZ!8$$"A'"27HK<_TI_#%EF8,4 M\`M$1A4!G!FMQ24_@K)-<;!>XEF_J3<-5'G.UA7135O4)X+3/N(,>L0 M,M2P,TZ"EBK?RE/9Y:M-9NXUFJ*#V%=AEW8:Q89A1@X<@Q`FTS)T-`5^-'^J MI:KQO+8<*@7?',`D:0\@PB8F,P8>`/,60V]3<';8PAE?(K?7#6J;MPDT208! M"#30O.`\"G&21`+O,%M[D_1EC(XM:E.=+I3!J27LSCFH%#3*VZGJ]'`/U;5?'W!?D MA6K\I!3=A>0ZL>82-9G8M*N%Q%;!^RD:1XK[A!1Z?'23WY!,BOP^)E_++D>4 M1#F[H*0Z;:@_WKFA'^,QR/A>O/KLDBBA+3&>?W.=%@S$HN+ZEPV)-5K7#*E, MND(9U+5H:@^C\,6O0BLAY-_%VR!(D5Y\-@$JDR\[DYLV2ZU_*K&2X`?&>FER MK7,T"C*';QXRTJO,)D!FF-J"0>:#37AYPND=4=Z-IW8T"C(?OEN<]1JL-PJ= M#PZ@\P&T5W1_]S$B.0X?SY)0.!2MD*C[/"*)25V. M)#SG8CG8FF]7VSP&-`D/<9'S.Z+K)8RU$"Y[/*T%SP&*@_0!\Y,1>/JV7>WL MRSIG%4*(697V.CI#X6V_1F;(`>"`NM!RX[908QWDTX^H>D0[QJ$G0U$3("#K M[-IC8.HBTNWT51*MC/NW'SH:E M[;)LN[F);+VS7"T[:1.YRC3@?G$3-_*MX7KM!9.A;5^T:D^Z\F//6<;HRVB@ M6:T3Z\KI;>16Z6WW;!M8=PHMJX"IZW\8>1N/L$,-PGY^4[B2Q%<@7('&W-L4 M!UF1OO`K$M7GQIF(5B^L%IW""I5E\+Z+@3,I);2Z1D>WY965\@K1F?L?1@`@ MEA75I8A*JV&(WK1+A,&TZ"9>1F.+MN>U".(R_IUI!HHE23L.`J:)K;C./&"O MQ\35:$@=]B'UAN`C::Y!X`/<6`&%G+BR3%?TE+?"JNMN\?P*" MG5+3@)LI3:.&B0\'C;J%6P5?C*W0S#=-7UC#_A3$!6:+4*M1R+N`&@\QRAXQ MSM$JR'DF0.[BZ"$H[PJ/DO(J8/2.K=-@&4$Y6ADE3R0*<88>@R>,Z+=FHYSQ M"[K#.&FNO/F>+^[8E(5CB'W"R8JP^C8X)L+6QW%;:W-OR&)27YQ3L M*G.V2C:I1DS_*4-W118E."MU-SC-@RCAZ3PI%\AOM3-:"07%-IL#1PG].\5[ M_$'S5B1ARV]Y9EL$L=N!$I6F%VOC$Z>@_6&7[J&;+B>LI^STF6RZ1*?(H MCMB2XA_0YZR<\*=,C3%+W-E*`?8^5)3=6E,M(V8_QU%P5^FA=RM:]U^C_)%^ M##9L(4C]#-LV'`S^Z;A2TAK+KI',4D> M#\0F^JV0;.YN-_$+*F6T\0<0N7@:287KODG6Q!+&B*!40+C2>./0E.:8CK`) MNEYL63S3,%2LA1./XH?5:_8?3B%,UQ9XPRXT+Z6!0/I;GU^4`(%HJZ]+B:Y< M`WV1.BR:8,*LV*X%CFC8K'_T9*K(NF(EPAYMR#KXE<2TZ>H! MR5:M>F5SM2D`-_4"WHA;.I:RP-=JE+GKBRC.W MGM8((A-JM\LX4PL-#^U<[@JZ,&VUK4<0T-)V_:,-5K\!J$J2`Z=8G9A(V+@" M3"]LW8(@]O!/Q$JK=(>(=7.6/!N=36FO]#.;*#HB,7T34IX/LWQ(,2]1#_]C M5/LGT!NI@IP];>`)/!<:X5Q_9+6IK?9AUK5.>YSV,&X2KO;W/J=_T1_KG^C_L'X<_>7_ M`E!+`P04````"``K.@E#&+CZ[?HJ``#NV0(`%0`<`&)S=&,M,C`Q,S`V,S!? M<')E+GAM;%54"0`#PL\$4L+/!%)U>`L``00E#@``!#D!``#M?5ESY+:RYOM$ MS'_0]'WNU7-]3CN.YT9IZU!UD>G21ZG."\).KK#:5E0#OG1 MS>WU^<7EV=&G=Y_>46Y')WBU)LGC4W'T\?/G_SQZ>_3IP\(AR=$1KG>4_ MO>3)SV^>BF+UT_OWW[Y]>_?MAW>8/+[_].'#Q_?_[^OE7?R$EM';),N+*(O1 MFR-*_U->_7B)XZBH5-XI_O)`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`.2C[P`Y*0FS M\7F2T\'U=Q21,QJ&TZ&,PXB.K#&AG"P8I``UM0.+G'F#ET^^XZ56[S>4IO^= MX6_9'8IRG*'Y19Z7B`@=BX:VXV"DM,'`QT3G(0Y'*J$!T@]A`.E7G);4`F1] MGJ2(Y$(`26@ZP.G1!`88M8Y#@-+CW`#D?XO5@$=`)X=*A"Q0P-^E-PP:GN/8MKSW:["M?IM3*X(%>R4-YP`XFF`0`=%QF$O@.+<( M&;JX^J_W/=->TA]&W'P')"D,P^XBRA\JEG"<9K5E"AV&<)XH=>Y,B#0Y@109V8'LCS/*<-H9$7?''UIUS'R=6H5DQ M5&HBH>DHU*.93"^6[T;]!?OK[*\R>8Y26J]\5IQ$A*SI//37*"U[VZ4F9=J] M4UB9R;RSNNVPG=)=]RP44>V;PEA/G94QP`D^85+<([*\R)Y17E39?+S34Y"T M3DY(XB]B`"H!`2+F-'42Q@!GVF3PWZ(84;@_I.@*%8W>O$\%D+:N54GJ+TX, M5`3B1]SLG(W9JL8!1DG3F%%"XR]$($H!L2%A-75BA3TH3IO*4I5J MI:6^!$#9SAU5E/["!*X@$"Q*AE.G6MA#YH:@592TY\5HZ'5=/"'2L0(''8,2 MC85!)?R%DKG"0$B!&$^=@>%HGJB:'ZKFA3X#PP$$Q(UMD5=1].X]FLQB6E-) MU@-$)I/::LLCW+E@.Z1TCB9S`W3WV')W2.Z<2?:JN56UUS4S5S;S`>#J#?V](1]I?W9XI/>E].OK63QW:`DMQ8/*CF9EP&T*QYB MA:[CD4O;7;,'20G>%^T$LUH4@FC[DX0`D6:BJ0FV-'S#GVW>HF>4E4B-'S$1 M!QR>*!#$*'6S@0K/T'YVZ8O'2?(5SJ/T"\'EZB)K)COLH0#,+A*CCG9SNU#? M\?*(1M`RBHOO9X4D@(-\0%K].`5V:\7(NY M:1NEJITHZUA!L4VYZ%-,N(0)Z15ZK?C52U4/$'(+UY7N')`6YJ%+/KK=%'Z4V4S"^RDVB5%!&_,:BA:I(P2F MG0E0I!S#W4Z^9:^29&A^%I&,3OIR.L$KEV7U``"-$)(XX4=.>('&P)`"GB/) M6&<34$&8VT^Q/?%']P1%>4G6TN%)3M"85$3@.6RT.IG`1,3,8J8M?-G-HWA= M&Z=KXW/O8:'5R006(F;V"<'!+L"`YW/V$V:5B'#'?YT%#/,;#/,:`D.9H?9. M%OLD@NPC`B_ZN&G*DF5>C5TR$UR8HY4R'R^!Z#ZU\7HCA,<^^KO+1?LNEWEI MA[PF%5+G5?C/OV@F7/G5%1(N!LL+>1Y96^ENOV0L%Q#N*G)7P_JFS5E9/&&2 M_+T=8818DQ$+,=8G#@I;&EWM,=5G'.YNG$@S^5VZ0&H%FORX1=<>3M"+<\WQ M)+HK-\#)ZLY`T-"C1WP@+=APTU]IRNTP[`@:8%-:[:%HZ_`$H^Z`*;N"# M:VD)(NF0%^!E&3VUJK=XM,#I4LE`TU*%!ABA=H/`TG(,]^J+SG9.K91J1ZQ+ M(=H2:RD\!X=>*^M-L9:;XZ='/%^3]F/GP]5,]W4)VG()>F@#3+L$K7NW>MH[ M]#:UDZPR:J@Z]^@)J*9;1HU2=J]=G?^+9-IIJ-H%5!F5%]JQ:QK8O0T*U7@2 M@5Y;DNF)>5:>7\@KW-7-6[R.4O:$+FYVR=?-;ACWU>>&5ZL";OD>FW!7##DMU4.;>DCS MN^G5JE@Y_%U?'VJ>B2XTZUL.%,9+V`HL>`B']*I[]M@[*?4UI+*W*71DFV4M M&=F$2?`YHEAB[PJ)3`FA*S&Z%I[Q,05SG!7K?:.?7%L"Z9OC`N@G_`&X?9=I+IF%UF! M*!;ZJ]IJLLVRMHQLLNX!;RP,5K/;6[02ZGN#99R#OY%0JC^TVT"[2R@H@BIJ M`2,%:_LQ.93XQM3O@@>MSEZH MUE3C)(O(^H+:*V!_9D8W'E&K=(8U\=- M\>Q>XT^.4886O5LT-%3\TWL\E?]XU:EFB#4!.XO,:*@DX-E0AP4.LFC5`-NP:B/PS/(C\AI+')ZK#[)G& M68_HJEP^('*]Z)WQ$OD4J[*-S0W+^@RR(68`0\]02`/(SP<#R*:KZ4Y\6I96 M@U)>.D!8`DTQ%)AR,>T*T^&DEY_@)17U1*<2R7,S09T^SWSG6$!=I5DV%U14 M?^.)2>G^Y2>PTJ\3IN$G3HS:R6@B92A$/L$*,`FG>AU;H"S3BRIYO;B/7OBM M7X,B[5XPJ$B(*+,PQF#PP62&FWT@4$T"10#E]F2PG#)$X,%5'XPWI2B760T> MA3Q1_G2>XF\>'*C;:;!-K?11C92T'\((2*>,5UAU;@A^3FA+'J]_R='$MOD MT\SB(GFNSWA*LDZL&6PC'V,&K^&=;<*`?6L917CF<@XJR)O-_UW6:37Y/;Y% M,<[B)$4=]>[QL'XWIHC-HPICB)CP'2<*HCBI$$K_G:*JOV7SV1*3(OF[^ITS MLDF1S>M.D"+3O4X^)FRPE<6ZGF.,"M9O24$J%J[+:3>84!5%+'PW+B=U<])R'MED M%L>XI)"A@$')<_20\DGX)D6DEA`5F7)#U;"!A4Y<:X;>OBI,JM@QBZ19A,1^ MY3#VU;PA:!4E\W88:K/JLWFUT%\;2@M0$R92R,*8A`YB"U,YA35,OL4@Y#O0 MV_Y\$ZU99V;3W3@F):WJ]NX^L">&,-'Z9C63T(%N8:I1_+=:?KA7)0DU9OI5 M`V"@=BM*!A.^YH5CA.;5 MD6]VR26=`'V-BI(DQ?IZ\34B?Z*"19UW*&:_]9VO=?G-BU_&Y7USQ1!DX.&6 M`GED15WJ5\2,ZQ#N_CZ=,#6[+K/XKS(A"`)GDS(MA&%E0H6MA46<0!4F=\(E M2%K9F&'OAP\__O"A0A[[I87=.2;-7>O'Y?H4?^,32W1D77`)R,+&DTYOAQ`2 MB!IGY]S+*,&F84BT;=ZOLI\G M`1BH/8J2@1_S)/9PU_6JNA+K[`61.,D%CV@#Z47S(#&];UX5TM+\O`=@"9`S M5XE1GM]'+\U=;E7?$R9G"ZS%(=8)K_;6I&&\`L6Y2PNZZ`(#ZV._K>7+ MWF4!1J-;=!?QZ$NPSNE85DFDU2'&PZ/OCT_>,OY[V8R+0Y+[O M#@+/LLDGOG?E:I56IHC2UA07V0*39=WFDHMPS$JU)\VAI=SM9U8A%CL+4A+: M;+^CB)QC(E$*1+O3F12T$R8IUV\6L+KU\I'[GS:IQ[N?IGN:#]0`6*E*MY\K M.=;)J;N-]L7V.H89^&9MY/6X0 MA0EKQU.%D'$>'_,P=K$;-\UB%[`,^U(O%;RI6NP)%4DR1P*8ZF;OL/9J[)8Y0U M6*+ZG:($LFJ1M9QF2<9RO/)(I?=RFVCKKJF-SN&N%XT[1*EVX!,,M`[Y=G> M?^^&YW2O!`RI_VF2QRG.2X+N*?Z.TWX.U5CL75A?R'XR_^<6G'ATTW?]J9/: M5R\@.*^UVRG^_MWT7;E<1F1]O;A+'C/V+O_O M7'G9OM\X67?G'Y*4='8=F>1I3@\Z.E\E6=_6TDE4]*$':UM'\``IK,O*.(O> M(#V@/BIYLFFR7JIXUT>V!0TOH7]WR8-N+*H=+J2]&4JNT+U+/MU.ID%#2AZ; M4BC.;7#J9F>K*"'8-17H/8G/UYW0NH*E1WE8I2F6!.8!R>\!)3CG=&C7@ M+DK]2L5`+MVYBSF7R?P%I/6Q*_-TW8="=+76;2LR]&AB9T]I,O?Q!>/YMR1- MJ=7Y78:MS24.Q:IL@Q##LE.FNTDJ)W,P!B6VR7'Z$I,Y#KM6QC:&Z+H-(\%- MJIU>8/!.@QWGR=E!0$QVGSN9/"]0ZRX`E'R^H&>NH%V8;G],E MF'(5D9[:49-MCNG(R"8\I=2MDG2K3TM^_VH>1SE27Z]V-:-TT[ZO5%*\-WSO7>=1B;;[`)>X1Y6ZV045=JN MY3M">M+-;I"*U'.L&.AI`ALUVW#O?_R%W4!VEA?)DD:;?`*\^&-C/?ZCY[A0 MZF*"!)Z1_54R7IR(D-Q0HO8E)F74-\B$YETL-#=R,S#^X;[]=1XEI+KSX2N* MV"26Y;G6ZJDA9URN,;Y!.<^A9VL!$_@9R+"_,V9J"-*A/*9ZD5*P?_5C)AWE-F224WH.++B6A@&3G*O]=2]3@Z=Y!8\]X$ZGPOJP&TR_6335 MTGL.)U.-34`%X.WH++Z+L\WWI/*BZ^IJ7S5,(*2-O=2DGH/#0$\37*C9-I#X M1Z`1^CV)YMLWMWL/S=?J]O!D4&8#+%`9[Q%FKKD9U$#\&\S]TP,W=(N2Y4-) M$U'M*I]25IGBU;#.S=,/8`!Z;H8M*`#T+;@DQ-ZSN8##0U`HV:;[M\&>JM'K?4$K0)GJI3_YN.T*2L"\=' M@Q(;[P4HX3N\C+4V\TP`[BW4]KI4+KO2DI*PZZSN21*E[0$'S#0YFO8TK38]@$T8#'/06FI MOPD2X2):^`6X6K_)D%;#34?&9Z&'!B>@?B;PD;-LX3)T?=[73+7[ZIC>:Y[: MR.%._(3F9`2=I55=JKN0F@7^O]&\?BJE6M.0IJJ. M+:<-G<:3X[GSV9>%C<*P\>H4^!VG6\N(3;'[$NJL?AMK77E$?0<;RK#7D^P9 M!M-E'-G,KF_8"W>4TNC)_5(3C_@'?\O4%G&_H>3QJ4#SV3,BT2.Z*I68Z>&U-Q/[C^_G\ILM_"#7I0#]B3VK MGENQ8>7[73@.#65T(=_##B$=Y/.<$,-O%G'J@('LER`53J?EP4SU MT=0RF[.'>B2?=V^!J;J)-,QP+:`7A;@3,%USM-CX@O`CB59/+/]H]I+P9Z"U M=/PC@GVZZ71$CWR-3O$R2C)>1QU=JZ.C4L?KA.D-? M$5O"TBL/9""WBI;!='?C:)L:.S`)=VN.3&85+EC("O?"#K"V]]_P,+3V&)BB M=8?!@:!59I(QT+HCZP#>,)2.?6+S"P5W"]=RW3&5!?-C[O3TOLOU]VCH+AQ'!E]UZBQW_'FO^-C?*?0ZWHO'>]FPLX_Q?4=VN!??.3#(99*AZO%L MSH^-P7ISSY!+UNZ.4K;)09M)T"\9!<9.;6EW>R2HJ@QG+9NBC37,BD[XA-D( M>,"#+-=U$RXK6+TV;U2Q*8(9"8Q9IBREZEQ_5J6(GV-RF:SH'/17G)9+?N7= MM-CV(EY@L8.#KJ7%QH4MO%(N=R4/+C09]B? M[*+#2?V[24'NZAWL`Z&P`Y93YS1\)RW=LBM("U$2R^TNGWI[_&OT;DY,R M+_"2CIB"=5L7BF#YA4R"WPFH/"B&.Z-ND;L\ZS6!.2\PEWCU8RM&#!,\5-:$<-ZHZ#/ M*-QMH)Z>Q^MCE,5/-+;\4S#80\EET4R/W"/%VXH)XP$HN51QGGSR5^VW5^6* MPPH-&?A>`P+]@8TJ1@$`"RMH0YI$Q$!1X-@8<9T:L9:L^LLWM7D/`!C9Z` M0XZ;#$=\:!2E9QORCC:G6V\57194R);;580.K^'=E7*]V+X30]T,%_6*%_'L M&8CT!#+P*)"Z0L5)24A_:QU"*@VH=DG]\8OFY5:S_4O#R$MR_)-5WV^E.%SKFX3F1P^*?8U(G_^LKK.V-UJUPMV M?4U^A],YN_/RNBR:'B5921C"HAMH&+)P/ZG[OV5$V!`\6]`_?WM*XJ=&Z$6^ MO?]:,N$S*LM-!H%EISNG-*2)\3`;<8>>+&JR.Y$$UF"RZ\DT`#V-UG753]@C M]_.(_(XBLM7E)EJWJ96W:(5),2.H7EB1PM8!1P[,@S@&#W%W]G0+_$'U"GR+ MRN@=R2'CF$EP8"=NLM4OC6-B:,K/<0VFXVA^BA[:5PRO<,%<*YE+?9!98<[= M0`M[CKY!MC#!G:F@^V/,EWR(:@E,M3W'Y4"S*M+_=P&__&!5J-X*`A3S' MH)7N)MB#"K!?0',_00(]'2V;&ED5-GKZ>XSI4'./^,YUV_T]4@G!=F>T1S!= M:&?7"AB@)Q>C&0EJ=C][`L:8>WCG:@;U#*,PRU!08WV+1Q_W\>:[>@E&0B1\ MY7T,O]%,(JAS[\KB:JLCV[ZU(2&;>I(HLS,&ZR:S\S8R8S><) MTRM*3Z)\,['4@<*R-#<9`)?V&$+#+`%%EK&4<'/\VHTA420C_,9MI4T>OV@A MH](""@B.QQ33/MDYO-V:[5Y_7U\TH6I1.;6HC474H;2Z5E,K'(BX!I[=8+08 MJ(ZH+);[>@P;:UJ\&NU%.IOS%V65=_2/(&.L=XJGOJG?L3['ZWI;X#+)1!>Z M[DO<2*W5%S=9P[E1:*N.\(3DN$+:%U='$C)=(B7U]G1\>:H>I=FL'S1KYN(; M@^$E-HM^@!+3O;PZ+FZPC<6Z@_`X-:P7D@`U"S?G\`O*$(G8BU6S^3+)DKRH MKV12P=NH3/N"(:S,`4/N+RW0`7O:925W>XWCGH,(V.I%>[) MW'$G*'COX?6XF-H^>3&Z5N$.QVXL!_^6@8].NWKO#\9]?2)05 M:'Y:$K:T4U7PUR@M:[T>>+WXB;$]A\T;>18<`@^?^LC"+DPY1A1UN7L$Q:J* MH3^%++;;]B;7X_66I-E?FGV+R/P\2DAEF%F>E\OJ@=>5./W\7VH%.YFJU/SL#-3YP2A"^I0:;L68SL# ME;PQ7(%8WJLC&-Y,8;D!L4+A9EZ+0YV^<1Y,?.0](DO^BHSQ!>UV^Y$$'6Q_ MWT?#[*>CCZ3)%'GN[LY64.9H+C9QLUXL.%L!+[1SM@)2Z!![D97!1N\1T%J- MD4I]2*NZXZ["[6D1U[D2X>XMP3++]I'-9)*8-E)]FF;\T8/\4;$BU5K==3TL MS^(B>::3;\GQ"GL&RDFCFD%X,_A&E>NRR(LHFU.\W>(T/<>$?70U;0<)&3I7 MUP@YA*:I\__':Y4N?_<-TO*?+CP8%\%#UDR`K<%%"*/H,VBI1*Z'_9[)JAJI M[HJ(%,'NG#1VJ3::\HLF,?\+P7DO+7<\"8YZM%#":Y\>T"*A]&JA)M_AOD=C M#FK9!4J*DK;>A?A@TX@2''5FH837SCR@14+IS$)-`MZ_8#.SBSPONVDUDE]>VH8PUZ M"@F.!CVAA$/NBJ.W2"B#GE`3^TV/T#OSWA>7_OCTNKSDT_)2KSU"Z:F)4*HGF<;HSU+^S@;F'O_7WFS=&J'T98$>]EN1ZKX\.7Y` M.Y!N/;U\LPT"$%6%'3OR3D7#/0?FT"*_H>3QJ4#SV3,BT2-J)Z`W)(D1L]9B M[(U:PPJX#^K`%3CTYIZFC:=I6.^\]E[ZCENO;]"JH\4)0`LX'D;4FG\?V]"Y MT4Z>2[_C7C+4][B4_.I_]MRZ0?@@E]H?\+:YSDR"G<=]>B!+\:[&XE\]TA3M?"`^R=`$K\DB7BY4CYE8\NI\IENJWE^"BL>+U:\I M+55RP!Z]CJ%4]^DOKSYG!)]CUZJ'X''`FK\FWDR=/.%94@Y8B7`W-&X(CA&: MY^<4/I"30F#Z]E5,/7V@G<74$BZP#9`9^"KV@[[C/NC]_$56D"3+D[BZT,S9 M+7Q@04-OX0,("K37[,WVSH:2D2H[QK.$^^ZLTMF'=(+@9PQO!%[;,!D$ML$+ M;5Z``W0SUQ7.GE'.HBO68_)[7$3I[G=V.]<5+GY'Q?;>KET;3_)A8!@^NVD34?OP4NQTEJJ'^6%%>N]W*HK-MTSGRP8%;QQV_N] M?;)S^_NT=18_0=K_LEMO\7N+>ZSYUR1+EN526'?AMZ;VW+?IGFD7V!>KJ\Z] MQ+YEP!PO5S#9=PRJJKF[8;L%PKSGN^T&L+ M,KU,%GP89E!"9X#=$I/U)8/VQ#;:=_N77EJS2:"7\GVY+^-N9^_7(*+"'4SA M,TEL/><"8E[\*(!.4KBXAZVZF$[U3199`+P;\_[3Q<+UO][W3$S[T)_U-^&G MCOG12X&R^78;MM,`#PG.5RA.%DF6-7,,,C&+;KTP?6E#E^%S4,=^#5>E;LVNMP3Z))Y+.6&2S74;/L M?ZQN0I6<@HWACX8C]!=2HGGSGEL^];C=5"QO:Q:EO8"MG13K*=O)L(IRNL<5 M94UQF40/[)5H&D>>E(3(!^T!'-IG%VTXN'NSZYY$U6:%&46BAJ>A#A:&I*9P@$2`TW&1S`YO8 MQRKV,4JX4+4WCROW"1<_(`>;Y?M-?=@+,F\P:Q'0?%0AUK`%7$Q#?5@WOJ'^ M,2NJYX2GGG5^P7C^+4E3:O8+JF'VF+`VR'-$JY;D<8KS4KJ$;%6V@8AA60_2 M!\^3+"G09?*,>C56)Q!""_92"/4%)S.+HFK'ZZ_1OS$Y2:,\%Z096I1L#&-4 MTD?+;.MX%2W1*5Y&20:WCJJTWD+BTM-E@E0>,!=FSPF_;1:T.M\F&TIMVPFK MU>L.G(9"JBW7+O-P%]%MW`0>VG_`YN>KP$QO+#K#]2L-`W\>D#,)$I)U]'(`5+-@B-OM[\.[B M0T5PXCI"[(JRGZ9Y$2/N^K7K!:\IG[X#(FXS=C3$P8#.2&L[L.E$#.CF/H!, M88;SDKTRMJM_DRQL/CT!L]('5`!6/AI34.$K]%+(+#>U!VAKE*X+XY::$QIA_>#'2;V_:!B\CWV@[[U)N\' M597&N'K?CQ8U78TT78MPOD8)J,`8KVAXG[1CD6@R4L;M9>]..U=QU!X;P>[8 M$QYP)*C;&D;RN[?=Z>4&>[_+#<'/"3O_?HY)?2G;??0R_:TNFZIH3],!*+<7 M8'M`Z&JM?MSPK6S65:8I:!9VI5 MEX1%.3I%]=\7V6FCPT[W[:,'7F;WVCA]F0"09:RZ*:F;I&(-.R=KGKN_\@I+GZY"8BQ?J>1%E.U::L M)X]"9/62A")0\O9,EI;<@^/[LDH>KSM?E"?Y+7CT#O4;\9CN:!ZHEJ+SAL8% M-2`2%?3"+,+S^W("@9J3G\*?+1;4][+ZG&6T?FOAL3P9 MU(-O#IW\:#>EO_Q_4$L#!!0````(`"LZ"4/_O4XP_0D``-U7```1`!P`8G-T M8RTR,#$S,#8S,"YX"QX1XYB2Z][9R6D/(&)3!Y/5 M=2_@?G9Q=@OJ8>IP28*!"R;J#9-G(#?@(T MUP6A.`<,<<0>D7/2[ZO:G_D5M]?(@T!`MD)B"CW$?6BCZ]Y:"/]J,%A@RGUD MXR6V^8E-O8&JZO3]A0K)11XBXI8R;X26,'#%=>^/`+I2%CD](-N`\*MGOC7U M]/1T\G1Q0ME*&CD]&WRYGUAAY8GL@@N[3L61M&Q'L?'1SOX2\D5H/2E1*N?] MT[/^Q5FBY&+R+>/0\X*YB4L7`U6\@!QMO<_)QP'(=K\ M*E!20X>2_IZ>@W"Q:[(@[9?L;P"H'@<)H0*JGAV^BE_Z/B9+&K^1[U3;7B4\ M3+0$86M?*2^N>QQ[OJN:,GRW9FAYW5.]IY]TDM]]ADZD?XD(HRXJ@:.*![X: M'"3R;+*K.#$!F9VSDNL-T@CU$1-8]KY=9QJ\6E@V=)N&)57LP#WJJ!RT;!J5 M5,$$'W-0+EPT#4JJ(/>OC4?9FA1R-J!VJ2UXBC$X'%9BP' M*?/"WM0#V+GNE4IL*T^JWV'[="K7@--3N7@E%M*/D#@@,@=2]CX.]HWLVP\X M<@SR*7S>'\^Q=BQ2IKDW9.HK9GMEL5[\-@%Q&)^A3`^HBQV5/MQ`5RTPUAHA MP1\(#!PLU$*L*-60*V4E286L+-F<*(:5M@EBHR"R"MX$B=V?.FC-H4&ST,UR99JEB*^:(8X4Q&(:NI@MX(-^?K6 MI4]U!V^!?"G8MPW!2O,@M-_A?!V<%6MN$^4*T!5K;QW0W2I?C.5-P#%!G$>4:TF6(GV?[&1VAW=]8)AWVG3\'VT^-J9`FX[` M2+>&YG@6?C9NP?Q60_W]YKY59&RQG?3\>UXJ$WG0!L.C8?I?#R]`S-C,AZ. M]0Y@#N`4B2C5F%#.9XA9:SE91;R*BRKP7.3Q3/4Y&$^'QKT.WDP,R_H)S'03 M6+]JIM[QR"^"N713-7^RR!475C!YFVKDWQI/N@CH'^9 M28#=K)8G-I-I&1%#RD7,)OVB@L+[/(69-M?E@C(TK'G7V/G&9O01J^]/;RF+ M)J4Y?$X&Q4N%%1!^+H!@&I_'ELK(;@TSF;+FVI>N_^>1F,B%T59';.8,$@[M M\/`H8O)B:064#WDHICZ18V,D1X@Y_PKFIC:UM*%*FSLH!;GR@J,_`AFF_JBV MC$E6O/>V`L)E4?Y[8^F_/:@I2O\L_W9MWW*?TF:_4F_?\O-A^Q;P)JFF2\]: MLIVKG*P1V5BCE.N'0[E&E714ZVU,TQ#+!"J8-=ND=I#:[XS2P.H*5\!KNTOJ M,-;9+J6!Y5]7H*G8.G4$#CH"'R$!L=O@)#Q1**5V>F!BTH%ME)ED.)9*5&!KFIMTG%HG)QEFM:4K^+5/3SJ2-?*3#+."]Q5T M*C.4#D+#8]XLD'*9"CB-#GT[5,V/?S.LJH0J8#4Z#/Z_@/5QL'#G:@X/I4'1]2:O'SP9Z$B0+;-'8EK9=\.-R9@#%$[!;> MI!6WGP[V!SW;Z\:^;)7"IX-](%!.A\K>61,G=EK18W]GH)T;'-N-G4ATU$,; M!_:O*UU&*P)!*QC^#O8%'S)J+F,9K;ZRTY=(SMX?[H=H[(-H4W^V487/FI-( ME,*GUV"1OEE:IPU"%?6IG^BIEKA0+7&`%V\'3%U7J^E`**VJ?=L__=`_.VT& M('=+MF:MB8*J^%V[2(OOP=:I/ZTYC10/'@'YF[S-/&GO1OE5Z_9)16BKS4R= MGQGB.Y/255OTT;/O0@(%99M;^;G^;)&VHN^,E+19?"L^]/&Z)U$O$#.6FN.$ MZ1]TU>^Y9W`3_KY;;FA,NH&NV-P$FQ%]BJ]4JGNDOS?6C.ZEAM?0KS`1:(78 M6"!/Y9(RWD`:Q2+\?P)WC`;^5E**]`#!KJL.**Y[@@52'$II)D.^[BVA&UZ' M#X5]V5^H,P\K<@(6WP)]*?:AS&?5C]/G#$,W.?`(SQLW<_0L;EQJ?TL%7$\\ MBC*ZJWXEDO=_;Z"I$X/X>.>644\+GK&+`R\58I5@&J%'Y2(%V>:O#"U:`412 MM(@N_5WW;(9DIZONU5\19*HK_GN-[?4-=$9H(6)R4RI,9%/F)/=D,IVZKF*Z M01(.?R_K\-3U!LJMF_K=K'0XE+>$[(1&^$V))"OP(Q8;+:XN%7X;Y703R'>8 MK%ZA`:+/;>)/"/X6R"T^8EQ;RK\A1A,](A*@,5?X5@3_64B^IM[136:)_R.X MB7P?0A<1!S+5E7?!)/.S1AP3J;5*8TC&A?!C86L<9.WX!D=V27IYJJ^0.\8Y M/NMRP=A^2>#(QJ^)L+<(&%=VYVO,HJ.ZD1R#+O6]9'4J0==._QB1#JE<[(B( MQ(SE,%ST3,R_R>%V#_]+V3#@@GIJLLKC;J/\0W:%HJ[>4/'(XDXFWRVA@HDY M59:99I&-/>A^EYRL8B:ZA^S;@V\0U=;&\HY2AUO4=73(B!&(>%%]>9YJJ'YD M"$=HB1A3:93J:)Y<&>-?KVXW]9Y'OO"W?A M--P8CI:+&TP%LM=C8N?Z:&'IL77&Z)0%.Z-`]1F5CTL@10E`N=R1=;\Y0Y`' M;!/N-5_.[LK%CC&)FS/HH)IW*>,0ZRG\*&E1;K3M%QS;0(M;/'>K,G*^ MH/!'(:(.>%Q,Y'*KQE)8$B4;-+5[8I<_C=,T;\ M@3B(#:FJBD;*VHJA4*4HTZZE]IW/@S))>/B+B^@+`_GI?U!+`0(>`Q0````( M`"LZ"4,F)6ZC%80``+7M!``1`!@```````$```"D@0````!B`Q0````(`"LZ M"4-2KC-(APL``/60```5`!@```````$```"D@6"$``!B`L``00E#@``!#D!``!02P$"'@,4````"``K M.@E#C]FYTTX/```0WP``%0`8```````!````I($VD```8G-T8RTR,#$S,#8S M,%]D968N>&UL550%``/"SP12=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M*SH)0S.;(:%B5```:LT$`!4`&````````0```*2!TY\``&)S=&,M,C`Q,S`V M,S!?;&%B+GAM;%54!0`#PL\$4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`"LZ"4,8N/KM^BH``.[9`@`5`!@```````$```"D@83T``!B`L``00E#@``!#D!``!02P$"'@,4```` M"``K.@E#_[U.,/T)``#=5P``$0`8```````!````I('-'P$`8G-T8RTR,#$S M,#8S,"YX`L``00E#@``!#D!``!02P4&``````8`!@`: )`@``%2H!```` ` end XML 20 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

PROVISION FOR INCOME TAXES (Details) (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Jun. 30, 2012

PROVISION FOR INCOME TAXES [Abstract]

Net income tax expense (benefit) $ 542,009 $ 390,651 $ 1,261,459 $ 906,228

Decrease in deferred tax assets 1,060 416,055

Deferred tax assets $ 1,500,000 $ 2,600,000 $ 1,500,000 $ 2,600,000

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 45

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 21 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

PATENT COSTS (Details) (USD $)
3 Months Ended 6 Months Ended 6 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Dec. 31, 2012

Jun. 30, 2013

Patents [Member]

Jun. 30, 2012

Patents [Member]

Dec. 31, 2012

Patents [Member]

Jun. 30, 2013

Patents [Member]

Minimum [Member]

Jun. 30, 2013

Patents [Member]

Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

Estimated useful lives 2 years 14 years

Net Patent Costs [Abstract]

Patents $ 472,375 $ 472,375

Accumulated Amortization (224,215) (192,053)

Net patent costs 248,160 280,322 248,160 280,322

Amortization expense for patents 16,100 29,000 32,000 29,000

Estimated amortization expense [Abstract]

2014 53,000

2015 25,000

2016 20,000

2017 20,000

2018 $ 20,000

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph a(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph a(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the next fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the fifth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the fourth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the third fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense expected to be recognized during the second fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedPatentsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 42, 45

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 22 R19.xml IDEA: NET INCOME (LOSS) PER SHARE (Tables) 2.4.0.8080300 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)truefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_EarningsPerShareAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0NET INCOME (LOSS) PER SHARE [Abstract]2false 2us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The following table summarizes the number of common equivalent shares that were included for the calculation of diluted net income purposes from continuing operations reported in the consolidated statement of operations.</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Six Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;">Stock options</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">622,780</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">628,331</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">614,962</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">644,328</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr></table></div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 false0Number of Common Equivalent Shares Included for the Calculation of Diluted Net IncomefalseNET INCOME (LOSS) PER SHARE (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/NetIncomeLossPerShareTables12 XML 23 R9.xml IDEA: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 2.4.0.8060200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIEStruefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_AccountingPoliciesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]2false 2us-gaap_SignificantAccountingPoliciesTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Basis of Presentation</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The accompanying consolidated financial statements are unaudited, but include all adjustments (consisting only of normal, recurring adjustments) which we consider necessary for a fair presentation of our financial position at such dates and the operating results and cash flows for those periods. Although we believe that the disclosures in our financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) has been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for quarterly reporting.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The information included in this Report should be read in conjunction with our </font>Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and our <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC.</font></div><div><br /></div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Principles of Consolidation</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The audited consolidated financial statements include the accounts of the Company and its subsidiary, Advance Biofactures Corp. (“ABC-NY”).</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Critical Accounting Policies, Estimates and Assumptions</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of management’s estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Cash, Cash Equivalents and Short-term Investments</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cash, cash equivalents and short-term investments are stated at market value. Cash equivalents include only securities having a maturity of three months or less at the time of purchase. The Company limits its credit risk associated with cash, cash equivalents and short-term investments by placing its investments with banks it believes are highly creditworthy and with highly rated money market funds, U.S. government securities, or short-term commercial paper.</div><div><br /></div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value Measurements</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Management believes that the carrying amounts of the Company’s financial instruments, including cash, cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of those instruments.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Concentration of Credit Risk and Major Customers</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company maintains bank account balances, which, at times, may exceed insured limits. The Company has not experienced any losses with these accounts and believes that it is not exposed to any significant credit risk on cash.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company maintains its investment in FDIC insured certificates of deposits with several banks.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">At June 30, 2013, the accounts receivable balance of $3.9 million was primarily from two customers, comprised of $2.5 million (64% of total) from DFB and $1.4 million (36% of total) from Auxilium.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company has been dependent in each year on two customers who generate almost all its revenues. In the quarter ended June 30, 2013, the licensing and royalty revenues from Auxilium were $4.7 million (65% of total) and royalty revenues from DFB were $2.5 million (35% of total).</div><div><br /></div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Revenue Recognition</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We currently recognize revenues resulting from product sales, the licensing and sublicensing of the use of our technology and from services we sometimes perform in connection with the licensed technology under the guidance of Accounting Standards Codification 605, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenue Recognition</font> (“ASC 605”).</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">If we determine that separate elements exist in a revenue arrangement under ASC 605, we recognize revenue for delivered elements only when the fair values of undelivered elements are known, when the associated earnings process is complete, when payment is reasonably assured and, to the extent the milestone amount relates to our performance obligation, when our customer confirms that we have met the requirements under the terms of the agreement.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenues, and their respective treatment for financial reporting purposes, are as follows:</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Product Sales</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We recognize revenue from product sales when there is persuasive evidence that an arrangement exists, title passes, the price is fixed or determinable and collectability is reasonably assured. No right of return exists for our products except in the case of damaged goods. To date, we have not experienced any significant returns of our products.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Net sales include the sales of the collagenase for laboratory use that are recognized at the time the product is shipped to customers for laboratory use.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Royalty/Mark-Up on Cost of Goods Sold / Earn-Out Revenue</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">For those arrangements for which royalty, mark-up on cost of goods sold or earn-out payment information becomes available and collectability is reasonably assured, we recognize revenue during the applicable period earned. For interim quarterly reporting purposes, when collectability is reasonably assured but a reasonable estimate of royalty, mark-up on cost of goods sold or earn-out payment revenues cannot be made, the royalty, mark-up on cost of goods sold or earn-out payment revenues are generally recognized in the quarter that the applicable licensee provides the written report and related information to us.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Under the Auxilium Agreement, we do not participate in the selling, marketing or manufacturing of products for which we receive royalties and a mark-up of the cost of goods sold revenues. The royalty and mark-up on cost of goods sold revenues will generally be recognized in the quarter that Auxilium provides the written reports and related information to us, that is, royalty and mark-up on cost of goods sold revenues are generally recognized one quarter following the quarter in which the underlying sales by Auxilium occurred.<font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </font>The royalties payable by Auxilium to us are subject to set-off for certain patent costs.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Under the DFB Agreement, pursuant to which we sold our topical collagenase business to DFB, we have the right to receive earn-out payments in the future based on sales of certain products.  Generally, under the DFB Agreement we would receive payments and a report within ninety (90) days from the end of each calendar year after DFB has sold the royalty-bearing product.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Licensing Revenue</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We include revenue recognized from upfront licensing, sublicensing and milestone payments in “License Revenues” in our consolidated statements of operations in this Report.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Upfront License and Sublicensing Fees</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We generally recognize revenue from upfront licensing and sublicensing fees when the agreement is signed, we have completed the earnings process and we have no ongoing performance obligation with respect to the arrangement. Nonrefundable upfront technology license for product candidates for which we are providing continuing services related to product development are deferred and recognized as revenue over the development period.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Milestones</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Milestones, in the form of additional license fees, typically represent nonrefundable payments to be received in conjunction with the achievement of a specific event identified in the contract, such as completion of specified development activities and/or regulatory submissions and/or approvals. We believe that a milestone represents the culmination of a distinct earnings process when it is not associated with ongoing research, development or other performance on our part. We recognize such milestones as revenue when they become due and collection is reasonably assured. When a milestone does not represent the culmination of a distinct earnings process, we recognize revenue in a manner similar to that of an upfront license fee.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The timing and amount of revenue that we recognize from licenses of technology, either from upfront fees or milestones where we are providing continuing services related to product development, is primarily dependent upon our estimates of the development period. We define the development period as the point from which research activities commence up to regulatory approval of either our, or our partners’ submission assuming no further research is necessary. As product candidates move through the development process, it is necessary to revise these estimates to consider changes to the product development cycle, such as changes in the clinical development plan, regulatory requirements, or various other factors, many of which may be outside of our control. Should the U.S. Food and Drug Administration or other regulatory agencies require additional data or information, we would adjust our development period estimates accordingly. The impact on revenue of changes in our estimates and the timing thereof is recognized prospectively over the remaining estimated product development period.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Treasury Stock</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company accounts for treasury stock under the cost method and includes treasury stock as a component of stockholders’ equity.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Receivables, Deferred Revenue</font> and Allowance for Doubtful Accounts</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Trade accounts receivable are stated at the amount the Company expects to collect. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. We consider the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms.  Our accounts receivable balance is typically due from our two large pharmaceutical customers.  These companies have historically paid timely and have been financially stable organizations.  Due to the nature of the accounts receivable balance, we believe the risk of doubtful accounts is minimal.  If the financial condition of our customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required.  We provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after we have used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">At June 30, 2013, the accounts receivable balance of $3.9 million was primarily from two customers, comprised of $2.5 million from DFB and $1.4 million from Auxilium.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Deferred revenue of $0.5 million consists of <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">licensing fees related to the cash payments received under the Auxilium Agreement in prior years and amortized over the expected development period of certain indications for XIAFLEX.</font></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We recorded no material bad debt expense in each of the last three years.  The allowance for doubtful accounts balance was approximately $30,000 at June 30, 2013 and 2012.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Reimbursable Third Party Development Costs</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We accrue patent expenses for research and development that are reimbursable by us under the Auxilium Agreement.  We capitalize certain patent costs related to estimated third party development costs that are reimbursable under the Auxilium Agreement. As of <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">June 30, 2013</font> our net reimbursable third party patent costs accrual was approximately $30,000.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Royalty Buy-Down</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On March 31, 2012, we entered into an amendment to our existing agreement with Dr. Martin K. Gelbard, dated August 27, 2008, related to our future royalty obligations for Peyronie’s disease. The amendment enables us to buy down a portion of our future royalty obligations in exchange for an initial cash payment of $1.5 million and five additional cash payments payable upon the occurrence of a milestone event.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">As of June 30, 2013, we have capitalized $2.75 million related to this agreement which will be amortized over approximately five years beginning on the date of the first commercial sale of XIAFLEX for the treatment of Peyronie’s disease, which represents the period estimated to be benefited using the straight-line method. In accordance with Accounting Standards Codification 350,<font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> Intangibles, Goodwill and Other</font>, the Company amortizes intangible assets with finite lives in a manner that reflects the pattern in which the economic benefits of the assets are consumed or otherwise used up. If that pattern cannot be reliably determined, the assets are amortized using the straight-line method.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Research and Development Expenses</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Research and development </font>(“R&D”) <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">expenses </font>include, but are not limited to, internal costs, such as salaries and benefits, costs of materials, lab expense, facility costs and overhead. R&D expenses also consist of third party costs, such as medical professional fees, product costs used in clinical trials, consulting fees and costs associated with clinical study arrangements. We may fund R&D at medical research institutions under agreements that are generally cancelable. All of these costs are charged to R&D as incurred, which may be measured by percentage of completion, contract milestones, patient enrollment, or the passage of time.</div><div><br /></div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Clinical Trial Expenses</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Our cost accruals for clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with various clinical trial centers and clinical research organizations. In the normal course of business we contract with third parties to perform various clinical trial activities in the ongoing development of potential drugs. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, the completion of portions of the clinical trial, or similar conditions. The objective of our accrual policy is to match the recording of expenses in our financial statements to the actual cost of services received and efforts expended. As such, expenses related to each patient enrolled in a clinical trial are recognized ratably beginning upon entry into the trial and over the course of the patient’s continued participation in the trial. In the event of early termination of a clinical trial, we accrue an amount based on our estimate of the remaining non-cancelable obligations associated with the winding down of the clinical trial. Our estimates and assumptions could differ significantly from the amounts that may actually be incurred.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Stock-Based Compensation</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company has two stock-based compensation plans in effect. Accounting Standards Codification 718, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Compensation - Stock Compensation </font>(“ASC 718”), requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based awards including stock options and common stock issued to our employees and directors under our stock plans. It requires companies to estimate the fair value of share-based awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service periods in our consolidated statements of operations.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Under the ASC 718, we estimate the fair value of our employee stock awards at the date of grant using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions. The most significant of these assumptions are our estimates of the expected volatility of the market price of our stock and the expected term of an award. When establishing an estimate of the expected term of an award, we consider the vesting period for the award, our recent historical experience of employee stock option exercises (including forfeitures) and the expected volatility. <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">When there is uncertainty in the factors used to determine the expected term of an award, we use the simplified method. </font>As required under the accounting rules, we review our valuation assumptions at each grant date and, as a result, our valuation assumptions used to value employee stock-based awards granted in future periods may change. We granted to one of our consultants 15,000 stock options, valued at approximately $79,000, during the three month period ended June 30, 2013. We used the Black-Scholes valuation model to estimate the value of options using 37% volatility, a risk free rate of 0.68% and average exercise period of five years.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Further, ASC 718 requires that employee stock-based compensation costs be recognized over the requisite service period, or the vesting period, in a manner similar to all other forms of compensation paid to employees. The allocation of employee stock-based compensation costs to each operating expense line are estimated based on specific employee headcount information at each grant date and estimated stock option forfeiture rates and revised, if necessary, in future periods if actual employee headcount information or forfeitures differ materially from those estimates. As a result, the amount of employee stock-based compensation costs we recognize in each operating expense category in future periods may differ significantly from what we have recorded in the current period.</div><div><br /></div><div>Stock-based compensation expense recognized under ASC 718 was as follows:</div><div> </div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Six Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Research and development</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">79,049</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">122,679</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">92,249</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">144,817</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">General and administrative</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">13,200</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">13,200</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">30,868</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.2pt; font-size: 10pt; font-weight: bold;">Total stock-based compensation expense</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">79,049</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">135,879</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">105,449</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">175,685</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr></table><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stock Option Activity</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">A summary of our stock option activity during the six months ended June 30, 2013 is presented below:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="width: 73.32%; vertical-align: top;"><div> </div></td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Total Number</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" style="white-space: nowrap; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Weighted-Average</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;">Options</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">of Shares</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Exercise Price</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding as of December 31, 2012</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,182,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">8.90</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Granted</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">15,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">15.85</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Forfeited</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Exercised</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expired</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Outstanding as of </font>June 30, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">1,197,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">8.99</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Exercisable as of </font>June 30, 2013</td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">1,177,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">8.64</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"></td></tr></table><div> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">During the six months ended June 30, 2013 and 2012, zero and $78,000, respectively, were received from stock options exercised by option holders.</div><div style="text-align: left;"><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The aggregate intrinsic value of options outstanding and exercisable as of June 30, 2013 was approximately $8.2 million. Aggregate intrinsic value represents the total pre-tax intrinsic value based on the closing price of our common stock of $15.60 on June 28, 2013, which would have been received by the option holders had all option holders exercised their options as of that date. We have no unrecognized compensation cost related to stock options outstanding as of June 30, 2013.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Property, Plant and Equipment</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Property, plant and equipment are stated at cost, less accumulated depreciation. Machinery and equipment, furniture and fixtures, and autos are depreciated on the straight-line basis over their estimated useful lives of 5 to 10 years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the remaining life of the lease.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Provision for Income Taxes</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Deferred tax assets and liabilities are recognized based on the expected future tax consequences, using current tax rates, of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We use the asset and liability method of accounting for income taxes, as set forth in Accounting Standards Codification 740-10-25-2. Under this method, deferred income taxes, when required, are provided on the basis of the difference between the financial reporting and income tax basis of assets and liabilities at the statutory rates enacted for future periods. </font>In accordance with Accounting Standards Codification 740-10-45-25, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Income Statement Classification of Interest and Penalties</font>, we classify interest associated with income taxes under interest expense and tax penalties under other.</div></div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for all significant accounting policies of the reporting entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 22 -Paragraph 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790 false0SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESfalseSUMMARY OF SIGNIFICANT ACCOUNTING POLICIESUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/SummaryOfSignificantAccountingPolicies12 XML 24 R12.xml IDEA: ACCOUNTS PAYABLE AND ACCRUED EXPENSES 2.4.0.8060500 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSEStruefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_PayablesAndAccrualsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]2false 2us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Accounts payable and accrued expenses consisted of the following:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="width: 66%; vertical-align: top;"><div> </div></td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30<font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: top;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Trade accounts payable and accrued expenses</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">365,054</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$ 304,635</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accrued legal and other professional fees</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">129,822</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">61,147</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accrued payroll and related costs</div></td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">165,684</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">147,084</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.2pt; font-size: 10pt; font-weight: bold;">Total</div></td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">660,560</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><strong>$</strong></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><strong>512,866</strong></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr></table></div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a),20,24) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20, 24 -Article 5 false0ACCOUNTS PAYABLE AND ACCRUED EXPENSESfalseACCOUNTS PAYABLE AND ACCRUED EXPENSESUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/AccountsPayableAndAccruedExpenses12 XML 25 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) (USD $)

Jun. 30, 2013

Dec. 31, 2012

Accounts payable and accrued expenses [Abstract]

Trade accounts payable and accrued expenses $ 365,054 $ 304,635

Accrued legal and other professional fees 129,822 61,147

Accrued payroll and related costs 165,684 147,084

Total $ 660,560 $ 512,866

X

- Definition

Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business and pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

No definition available.

+ Details

Name: bstc_TradeAccountsPayableAndAccruedExpenses

Namespace Prefix: bstc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6911-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 8

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 26 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Cash Flows (unaudited) (USD $)
6 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Cash flows from operating activities:

Net income $ 2,381,270 $ 1,409,072

Adjustments to reconcile net income to net cash provided By operating activities:

Depreciation and amortization 32,162 29,019

Stock-based compensation expense 105,449 175,685

Deferred tax assets 1,060 416,055

Changes in operating assets and liabilities:

Accounts receivable 1,178,418 416,072

Prepaid expenses and other current assets (261,387) 72,403

Accounts payable and accrued expenses 147,694 (5,033)

Accrued taxes payable 382,704 102,471

Deferred revenue (89,761) (218,550)

Net cash provided by operating activities 3,877,609 2,397,194

Cash flows from investing activities:

Maturity of marketable investments 4,430,000 2,000,000

Purchases of marketable investments (7,276,964) (2,000,000)

Payment for royalty buy down 0 (1,500,000)

Net cash used in investing activities (2,846,964) (1,500,000)

Cash flows from financing activities:

Proceeds from stock option exercises 0 78,000

Payments for repurchase of common stock (396,851) (485,904)

Excess tax benefits from share-based payment arrangements 0 102,052

Net cash used in financing activities (396,851) (305,852)

Increase in cash and cash equivalents 633,794 591,342

Cash and cash equivalents at beginning of year 3,383,737 3,196,831

Cash and cash equivalents at end of period 4,017,531 3,788,173

Cash paid during the year for:

Interest 0 0

Taxes $ 888,500 $ 92,000

X

- Details

Name: bstc_CashPaidDuringYearForAbstract

Namespace Prefix: bstc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash outflow from initial payment related to the purchase of royalty interests.

+ References

No definition available.

+ Details

Name: bstc_PaymentForRoyaltyBuyDown

Namespace Prefix: bstc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of excess tax benefit (tax deficiency) that arises when compensation cost from non-qualified share-based compensation recognized on the entity's tax return exceeds (is less than) compensation cost from equity-based compensation recognized in financial statements. Excess tax benefit (tax deficiency) increases (decreases) net cash provided by financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11374-113907

+ Details

Name: us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 27

-Subparagraph f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedTaxesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to reacquire common stock during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 27 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

ORGANIZATION AND DESCRIPTION OF BUSINESS
6 Months Ended

Jun. 30, 2013

ORGANIZATION AND DESCRIPTION OF BUSINESS [Abstract]

ORGANIZATION AND DESCRIPTION OF BUSINESS
1. ORGANIZATION AND DESCRIPTION OF BUSINESS

We are a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. We have a development and license agreement with Auxilium Pharmaceuticals, Inc. (“Auxilium”) for injectable collagenase (which Auxilium has named XIAFLEX^® (collagenase clostridium histolyticum)) for clinical indications in Dupuytren’s contracture, Peyronie’s disease, frozen shoulder (adhesive capsulitis) and cellulite (edematous fibrosclerotic panniculopathy) (the “Auxilium Agreement”). Auxilium has an option to acquire additional indications that we may pursue, including human and canine lipoma. Auxilium is currently selling XIAFLEX in the U.S. for the treatment of Dupuytren’s contracture. In addition, Auxilium has an agreement with Asahi Kasei Pharma Corporation (“Asahi”) pursuant to which Asahi has the right to commercialize XIAFLEX for the treatment of Dupuytren’s contracture and Peyronie’s disease in Japan. Auxilium also has an agreement with Actelion Pharmaceuticals Ltd. (“Actelion”) pursuant to which Actelion has the right to commercialize XIAFLEX for the treatment of Dupuytren’s contracture and Peyronie’s disease in Canada, Australia, Brazil and Mexico. Auxilium has been granted a Notice of Compliance (approval) by Health Canada for XIAFLEX for the treatment of Dupuytren’s contracture in adults with a palpable cord in Canada. In July 2013 Auxilium entered into a long-term collaboration with Swedish Orphan Biovitrum AB (“Sobi”) for the development, supply and commercialization of XIAPEX^® (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture. In addition, work is on-going to file for approval of XIAPEX for the treatment of Peyronie's disease in the EU.

Pursuant to a March 2006 agreement (the “DFB Agreement”) between the Company and DFB Biotech, Inc. (“DFB”), we continue to receive earn-out payments based on the sales of Santyl. Our right to receive earn-out payments with respect to the marketed topical product sold to DFB expires in August 2013, and we expect to receive our final earn-out payment for Santyl by the end of the year.

Operational Highlights

On July 23, 2013 we presented a poster titled “Biomechanical Evaluation of Human Uterine Fibroids after Exposure to Purified Clostridial Collagenase” at the Society for the Study of Reproduction 46^th Annual Meeting in Montreal, Quebec, Canada. The poster provided data which showed that highly purified collagenase can reduce the stiffness of human uterine fibroid tissue in laboratory experiments. Increased tissue rigidity has been implicated as a cause of the morbidity associated with uterine fibroids. The results of this ex vivo study show that treatment of fibroids with determined doses of purified collagenase caused a statistically significant decrease in the stiffness of the tissue. This hypothesis was tested in fibroid tissue obtained after hysterectomy or myomectomy surgery from patients. Tissues were injected with collagenase and compared to control-injected tissue.

On July 16, 2013, Auxilium announced that it has entered into a long-term collaboration with Sobi for the development, supply and commercialization of XIAPEX (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture. In addition, Auxilium stated that work is on-going to file for approval of XIAPEX for the treatment of Peyronie's disease in the EU. Under the terms of the collaboration agreement, Sobi will receive exclusive rights to commercialize XIAPEX for Dupuytren’s contracture and Peyronie’s disease, subject to applicable regulatory approvals, in 28 EU member countries, Switzerland, Norway, Iceland, 18 Central Eastern Europe/Commonwealth of Independent countries, including Russia and Turkey, and 22 Middle Eastern & North African countries. Since 2011, XIAPEX has been approved for the treatment of Dupuytren's contracture in 28 EU member countries, Switzerland, and Norway. Sobi, via its Partner Products business unit, will be primarily responsible for the applicable regulatory, clinical and commercialization activities for XIAPEX in Dupuytren's contracture and Peyronie's disease in these countries.

In April 2013, we completed enrollment in our placebo-controlled, randomized Phase II trial, Chien-804, to evaluate the efficacy of XIAFLEX for the treatment of subcutaneous benign lipomas in 32 canines randomized 1:1 XIAFLEX to placebo. The lipoma volume will be measured at baseline, 1 month and 3 months with the primary efficacy endpoint being the relative change in lipoma volume from baseline to 3 months, as determined by CT scan.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R11.xml IDEA: COMPREHENSIVE INCOME (LOSS) 2.4.0.8060400 - Disclosure - COMPREHENSIVE INCOME (LOSS)truefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_ComprehensiveIncomeNetOfTaxAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0COMPREHENSIVE INCOME (LOSS) [Abstract]2false 2us-gaap_ComprehensiveIncomeNoteTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">4. COMPREHENSIVE INCOME (LOSS)</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">For the three and six months ended <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">June 30, 2013 </font>and 2012, we had no components of other comprehensive income or loss other than net income itself.</div></div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 14-26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e681-108580 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e689-108580 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669619-108580 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 17 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e716-108580 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e640-108580 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e709-108580 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Reclassification Adjustments -URI http://asc.fasb.org/extlink&oid=6522872 false0COMPREHENSIVE INCOME (LOSS)falseCOMPREHENSIVE INCOME (LOSS)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/ComprehensiveIncomeLoss12 XML 29 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

COMPREHENSIVE INCOME (LOSS)
6 Months Ended

Jun. 30, 2013

COMPREHENSIVE INCOME (LOSS) [Abstract]

COMPREHENSIVE INCOME (LOSS)
4. COMPREHENSIVE INCOME (LOSS)

For the three and six months ended June 30, 2013 and 2012, we had no components of other comprehensive income or loss other than net income itself.

X

- Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 14-26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e689-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669619-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 17

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e716-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e640-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e709-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Reclassification Adjustments

-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Name: us-gaap_ComprehensiveIncomeNoteTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R14.xml IDEA: PROVISION FOR INCOME TAXES 2.4.0.8060700 - Disclosure - PROVISION FOR INCOME TAXEStruefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_IncomeTaxDisclosureAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0PROVISION FOR INCOME TAXES [Abstract]2false 2us-gaap_IncomeTaxDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">7. PROVISION FOR INCOME TAXES</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In determining our provision for income taxes, we consider all available information, including operating results, ongoing tax planning, and forecasts of future taxable income.<font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </font><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The significant components of the Company's deferred tax assets pursuant to Accounting Standards Codification 740-10-50 consist of</font> stock-based compensation and deferred revenues. For the six month period ended June 30, 2013, the provision for income taxes was $1.3 million.  For the six month period ended June 30, 2013, the valuation allowance with respect to the Company’s net deferred tax assets remained unchanged.  As of June 30, 2013, our remaining deferred tax assets were approximately $1.5 million.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">For the six month period ended June 30, 2012 our provision for income taxes was $0.9 million, primarily a non-cash charge.  For the six month period ended June 30, 2012, the valuation allowance with respect to the company’s net deferred tax assets remained unchanged.  Our remaining deferred tax assets decreased by $0.4 million to approximately $2.6 million, primarily because we used our Orphan Drug Tax Credit to reduce our taxes payable, during six months ended June 30, 2012.</div></div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 136, 172 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 43, 44, 45, 46, 47, 48, 49 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0PROVISION FOR INCOME TAXESfalsePROVISION FOR INCOME TAXESUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/ProvisionForIncomeTaxes12 XML 31 R2.xml IDEA: Consolidated Balance Sheets (unaudited) 2.4.0.8010000 - Statement - Consolidated Balance Sheets (unaudited)truefalsefalse1false USDfalsefalse$c20130630http://www.sec.gov/CIK0000875622instant2013-06-30T00:00:000001-01-01T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$c20121231http://www.sec.gov/CIK0000875622instant2012-12-31T00:00:000001-01-01T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_AssetsCurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Current assets:2false 4us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse40175314017531USD$falsetruefalse2truefalsefalse33837373383737USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Cash and cash equivalents3false 4us-gaap_ShortTermInvestmentsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse79669647966964falsefalsefalse2truefalsefalse51200005120000falsefalsefalsexbrli:monetaryItemTypemonetaryInvestments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.2) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Subparagraph g -Article 7 false2Short-term investments4false 4us-gaap_AccountsReceivableNetCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse39039423903942falsefalsefalse2truefalsefalse50823605082360falsefalsefalsexbrli:monetaryItemTypemonetaryAmount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 false2Accounts receivable, net5false 4us-gaap_IncomeTaxesReceivableus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse5107051070falsefalsefalse2truefalsefalse5107051070falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Section Appendix E -Paragraph 289 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.10) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 10 -Article 9 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3(a)(4)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 5 -Subparagraph c -Article 7 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.5(c)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 false2Income tax receivable6false 4us-gaap_DeferredTaxAssetsNetCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse7948279482falsefalsefalse2truefalsefalse8891088910falsefalsefalsexbrli:monetaryItemTypemonetaryAmount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31917-109318 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31931-109318 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 41, 42, 43 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31928-109318 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31958-109318 false2Deferred tax assets7false 4us-gaap_PrepaidExpenseAndOtherAssetsCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse411110411110falsefalsefalse2truefalsefalse149724149724falsefalsefalsexbrli:monetaryItemTypemonetaryThe total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 8 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 4 -Chapter 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Prepaid expenses and other current assets8false 4us-gaap_AssetsCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse1643009916430099falsefalsefalse2truefalsefalse1387580113875801falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 9 -Article 5 true2Total current assets9false 3us-gaap_DeferredCostsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse27500002750000falsefalsefalse2truefalsefalse27500002750000falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 17 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.10) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 false2Deferred royalty buy-down10false 3us-gaap_DeferredTaxAssetsNetNoncurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse14925091492509falsefalsefalse2truefalsefalse14841411484141falsefalsefalsexbrli:monetaryItemTypemonetaryAmount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31917-109318 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31931-109318 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 41, 42, 43 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31928-109318 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31958-109318 false2Deferred tax assets - long term11false 3us-gaap_IntangibleAssetsNetExcludingGoodwillus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse248160248160falsefalsefalse2truefalsefalse280322280322falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 42, 45 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Patent costs, net12false 3us-gaap_Assetsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse2092076820920768falsefalsefalse2truefalsefalse1839026418390264falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Concepts (CON) -Number 6 -Paragraph 25 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true2Total assets13true 3us-gaap_LiabilitiesCurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Current liabilities:14false 4us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse660560660560falsefalsefalse2truefalsefalse512866512866falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Article 5 false2Accounts payable and accrued expenses15false 4us-gaap_DeferredTaxLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse382704382704falsefalsefalse2truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed within one year or operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31917-109318 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31931-109318 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 41, 42, 43 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31958-109318 false2Deferred tax liability16false 4us-gaap_DeferredRevenueCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse7832878328falsefalsefalse2truefalsefalse133524133524falsefalsefalsexbrli:monetaryItemTypemonetaryThe carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 7, 8 -Chapter 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Deferred revenue17false 4us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse7813878138falsefalsefalse2truefalsefalse7813878138falsefalsefalsexbrli:monetaryItemTypemonetaryFor the disposal group, including a component of the entity (discontinued operation), carrying value of obligations incurred and payable pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include interest, rent, salaries, and utilities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 47 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Accrued liabilities of discontinued operations18false 4us-gaap_LiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse11997301199730falsefalsefalse2truefalsefalse724528724528falsefalsefalsexbrli:monetaryItemTypemonetaryTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 21 -Article 5 true2Total current liabilities19false 3us-gaap_DeferredRevenueNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse172825172825falsefalsefalse2truefalsefalse207390207390falsefalsefalsexbrli:monetaryItemTypemonetaryThe noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 7, 8 -Chapter 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 48 -Paragraph 6 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Long-term deferred revenue20true 3us-gaap_StockholdersEquityAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Stockholders' equity:21false 4us-gaap_PreferredStockValueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse00falsefalsefalse2truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Series A Preferred stock, $.50 par value, 700,000 shares authorized; none outstanding22false 4us-gaap_CommonStockValueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse66256625falsefalsefalse2truefalsefalse66256625falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false2Common stock, $.001 par value; 10,000,000 shares authorized ; 6,625,168 shares issued at June 30, 2013 and December 31, 2012, respectively23false 4us-gaap_AdditionalPaidInCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse2079415420794154falsefalsefalse2truefalsefalse2068870620688706falsefalsefalsexbrli:monetaryItemTypemonetaryExcess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Additional paid-in capital24false 4us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse20704412070441falsefalsefalse2truefalsefalse-310829-310829falsefalsefalsexbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Retained earnings (deficit)25false 4us-gaap_TreasuryStockValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-3323007-3323007falsefalsefalse2truefalsefalse-2926156-2926156falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Technical Bulletin (FTB) -Number 85-6 -Paragraph 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Treasury stock, 285,352 and 260,632 shares at cost at June 30, 2013 and December 31, 2012, respectively26false 4us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse1954821319548213falsefalsefalse2truefalsefalse1745834617458346falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 true2Total stockholders' equity27false 3us-gaap_LiabilitiesAndStockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse2092076820920768USD$falsetruefalse2truefalsefalse1839026418390264USD$falsetruefalsexbrli:monetaryItemTypemonetaryTotal of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.32) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 32 -Article 5 true2Total liabilities and stockholders' equityfalseConsolidated Balance Sheets (unaudited) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/ConsolidatedBalanceSheetsUnaudited227 XML 32 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended

Jun. 30, 2013

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements are unaudited, but include all adjustments (consisting only of normal, recurring adjustments) which we consider necessary for a fair presentation of our financial position at such dates and the operating results and cash flows for those periods. Although we believe that the disclosures in our financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) has been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for quarterly reporting.

The information included in this Report should be read in conjunction with our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC.

Principles of Consolidation

The audited consolidated financial statements include the accounts of the Company and its subsidiary, Advance Biofactures Corp. (“ABC-NY”).

Critical Accounting Policies, Estimates and Assumptions

The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of management’s estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Cash, Cash Equivalents and Short-term Investments

Cash, cash equivalents and short-term investments are stated at market value. Cash equivalents include only securities having a maturity of three months or less at the time of purchase. The Company limits its credit risk associated with cash, cash equivalents and short-term investments by placing its investments with banks it believes are highly creditworthy and with highly rated money market funds, U.S. government securities, or short-term commercial paper.

Fair Value Measurements

Management believes that the carrying amounts of the Company’s financial instruments, including cash, cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of those instruments.

Concentration of Credit Risk and Major Customers

The Company maintains bank account balances, which, at times, may exceed insured limits. The Company has not experienced any losses with these accounts and believes that it is not exposed to any significant credit risk on cash.

The Company maintains its investment in FDIC insured certificates of deposits with several banks.

At June 30, 2013, the accounts receivable balance of $3.9 million was primarily from two customers, comprised of $2.5 million (64% of total) from DFB and $1.4 million (36% of total) from Auxilium.

The Company has been dependent in each year on two customers who generate almost all its revenues. In the quarter ended June 30, 2013, the licensing and royalty revenues from Auxilium were $4.7 million (65% of total) and royalty revenues from DFB were $2.5 million (35% of total).

Revenue Recognition

We currently recognize revenues resulting from product sales, the licensing and sublicensing of the use of our technology and from services we sometimes perform in connection with the licensed technology under the guidance of Accounting Standards Codification 605, Revenue Recognition (“ASC 605”).

If we determine that separate elements exist in a revenue arrangement under ASC 605, we recognize revenue for delivered elements only when the fair values of undelivered elements are known, when the associated earnings process is complete, when payment is reasonably assured and, to the extent the milestone amount relates to our performance obligation, when our customer confirms that we have met the requirements under the terms of the agreement.

Revenues, and their respective treatment for financial reporting purposes, are as follows:

Product Sales

We recognize revenue from product sales when there is persuasive evidence that an arrangement exists, title passes, the price is fixed or determinable and collectability is reasonably assured. No right of return exists for our products except in the case of damaged goods. To date, we have not experienced any significant returns of our products.

Net sales include the sales of the collagenase for laboratory use that are recognized at the time the product is shipped to customers for laboratory use.

Royalty/Mark-Up on Cost of Goods Sold / Earn-Out Revenue

For those arrangements for which royalty, mark-up on cost of goods sold or earn-out payment information becomes available and collectability is reasonably assured, we recognize revenue during the applicable period earned. For interim quarterly reporting purposes, when collectability is reasonably assured but a reasonable estimate of royalty, mark-up on cost of goods sold or earn-out payment revenues cannot be made, the royalty, mark-up on cost of goods sold or earn-out payment revenues are generally recognized in the quarter that the applicable licensee provides the written report and related information to us.

Under the Auxilium Agreement, we do not participate in the selling, marketing or manufacturing of products for which we receive royalties and a mark-up of the cost of goods sold revenues. The royalty and mark-up on cost of goods sold revenues will generally be recognized in the quarter that Auxilium provides the written reports and related information to us, that is, royalty and mark-up on cost of goods sold revenues are generally recognized one quarter following the quarter in which the underlying sales by Auxilium occurred. The royalties payable by Auxilium to us are subject to set-off for certain patent costs.

Under the DFB Agreement, pursuant to which we sold our topical collagenase business to DFB, we have the right to receive earn-out payments in the future based on sales of certain products. Generally, under the DFB Agreement we would receive payments and a report within ninety (90) days from the end of each calendar year after DFB has sold the royalty-bearing product.

Licensing Revenue

We include revenue recognized from upfront licensing, sublicensing and milestone payments in “License Revenues” in our consolidated statements of operations in this Report.

Upfront License and Sublicensing Fees

We generally recognize revenue from upfront licensing and sublicensing fees when the agreement is signed, we have completed the earnings process and we have no ongoing performance obligation with respect to the arrangement. Nonrefundable upfront technology license for product candidates for which we are providing continuing services related to product development are deferred and recognized as revenue over the development period.

Milestones

Milestones, in the form of additional license fees, typically represent nonrefundable payments to be received in conjunction with the achievement of a specific event identified in the contract, such as completion of specified development activities and/or regulatory submissions and/or approvals. We believe that a milestone represents the culmination of a distinct earnings process when it is not associated with ongoing research, development or other performance on our part. We recognize such milestones as revenue when they become due and collection is reasonably assured. When a milestone does not represent the culmination of a distinct earnings process, we recognize revenue in a manner similar to that of an upfront license fee.

The timing and amount of revenue that we recognize from licenses of technology, either from upfront fees or milestones where we are providing continuing services related to product development, is primarily dependent upon our estimates of the development period. We define the development period as the point from which research activities commence up to regulatory approval of either our, or our partners’ submission assuming no further research is necessary. As product candidates move through the development process, it is necessary to revise these estimates to consider changes to the product development cycle, such as changes in the clinical development plan, regulatory requirements, or various other factors, many of which may be outside of our control. Should the U.S. Food and Drug Administration or other regulatory agencies require additional data or information, we would adjust our development period estimates accordingly. The impact on revenue of changes in our estimates and the timing thereof is recognized prospectively over the remaining estimated product development period.

Treasury Stock

The Company accounts for treasury stock under the cost method and includes treasury stock as a component of stockholders’ equity.

Receivables, Deferred Revenue and Allowance for Doubtful Accounts

Trade accounts receivable are stated at the amount the Company expects to collect. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. We consider the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. Our accounts receivable balance is typically due from our two large pharmaceutical customers. These companies have historically paid timely and have been financially stable organizations. Due to the nature of the accounts receivable balance, we believe the risk of doubtful accounts is minimal. If the financial condition of our customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. We provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after we have used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable.

At June 30, 2013, the accounts receivable balance of $3.9 million was primarily from two customers, comprised of $2.5 million from DFB and $1.4 million from Auxilium.

Deferred revenue of $0.5 million consists of licensing fees related to the cash payments received under the Auxilium Agreement in prior years and amortized over the expected development period of certain indications for XIAFLEX.

We recorded no material bad debt expense in each of the last three years. The allowance for doubtful accounts balance was approximately $30,000 at June 30, 2013 and 2012.

Reimbursable Third Party Development Costs

We accrue patent expenses for research and development that are reimbursable by us under the Auxilium Agreement. We capitalize certain patent costs related to estimated third party development costs that are reimbursable under the Auxilium Agreement. As of June 30, 2013 our net reimbursable third party patent costs accrual was approximately $30,000.

Royalty Buy-Down

On March 31, 2012, we entered into an amendment to our existing agreement with Dr. Martin K. Gelbard, dated August 27, 2008, related to our future royalty obligations for Peyronie’s disease. The amendment enables us to buy down a portion of our future royalty obligations in exchange for an initial cash payment of $1.5 million and five additional cash payments payable upon the occurrence of a milestone event.

As of June 30, 2013, we have capitalized $2.75 million related to this agreement which will be amortized over approximately five years beginning on the date of the first commercial sale of XIAFLEX for the treatment of Peyronie’s disease, which represents the period estimated to be benefited using the straight-line method. In accordance with Accounting Standards Codification 350, Intangibles, Goodwill and Other, the Company amortizes intangible assets with finite lives in a manner that reflects the pattern in which the economic benefits of the assets are consumed or otherwise used up. If that pattern cannot be reliably determined, the assets are amortized using the straight-line method.

Research and Development Expenses

Research and development (“R&D”) expenses include, but are not limited to, internal costs, such as salaries and benefits, costs of materials, lab expense, facility costs and overhead. R&D expenses also consist of third party costs, such as medical professional fees, product costs used in clinical trials, consulting fees and costs associated with clinical study arrangements. We may fund R&D at medical research institutions under agreements that are generally cancelable. All of these costs are charged to R&D as incurred, which may be measured by percentage of completion, contract milestones, patient enrollment, or the passage of time.

Clinical Trial Expenses

Our cost accruals for clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with various clinical trial centers and clinical research organizations. In the normal course of business we contract with third parties to perform various clinical trial activities in the ongoing development of potential drugs. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, the completion of portions of the clinical trial, or similar conditions. The objective of our accrual policy is to match the recording of expenses in our financial statements to the actual cost of services received and efforts expended. As such, expenses related to each patient enrolled in a clinical trial are recognized ratably beginning upon entry into the trial and over the course of the patient’s continued participation in the trial. In the event of early termination of a clinical trial, we accrue an amount based on our estimate of the remaining non-cancelable obligations associated with the winding down of the clinical trial. Our estimates and assumptions could differ significantly from the amounts that may actually be incurred.

Stock-Based Compensation

The Company has two stock-based compensation plans in effect. Accounting Standards Codification 718, Compensation - Stock Compensation (“ASC 718”), requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based awards including stock options and common stock issued to our employees and directors under our stock plans. It requires companies to estimate the fair value of share-based awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service periods in our consolidated statements of operations.

Under the ASC 718, we estimate the fair value of our employee stock awards at the date of grant using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions. The most significant of these assumptions are our estimates of the expected volatility of the market price of our stock and the expected term of an award. When establishing an estimate of the expected term of an award, we consider the vesting period for the award, our recent historical experience of employee stock option exercises (including forfeitures) and the expected volatility. When there is uncertainty in the factors used to determine the expected term of an award, we use the simplified method. As required under the accounting rules, we review our valuation assumptions at each grant date and, as a result, our valuation assumptions used to value employee stock-based awards granted in future periods may change. We granted to one of our consultants 15,000 stock options, valued at approximately $79,000, during the three month period ended June 30, 2013. We used the Black-Scholes valuation model to estimate the value of options using 37% volatility, a risk free rate of 0.68% and average exercise period of five years.

Further, ASC 718 requires that employee stock-based compensation costs be recognized over the requisite service period, or the vesting period, in a manner similar to all other forms of compensation paid to employees. The allocation of employee stock-based compensation costs to each operating expense line are estimated based on specific employee headcount information at each grant date and estimated stock option forfeiture rates and revised, if necessary, in future periods if actual employee headcount information or forfeitures differ materially from those estimates. As a result, the amount of employee stock-based compensation costs we recognize in each operating expense category in future periods may differ significantly from what we have recorded in the current period.

Stock-based compensation expense recognized under ASC 718 was as follows:

Three Months Ended
June 30,

Six Months Ended
June 30,

2013

2012

2013

2012

Research and development

$
79,049

$
122,679

$
92,249

$
144,817

General and administrative

-

13,200

13,200

30,868

Total stock-based compensation expense

$
79,049

$
135,879

$
105,449

$
175,685

Stock Option Activity

A summary of our stock option activity during the six months ended June 30, 2013 is presented below:

Total Number

Weighted-Average

Options

of Shares

Exercise Price

Outstanding as of December 31, 2012

1,182,000

$
8.90

Granted

15,000

15.85

Forfeited

-

-

Exercised

-

-

Expired

-

-

Outstanding as of June 30, 2013

1,197,000

$
8.99

Exercisable as of June 30, 2013
1,177,000
$
8.64

During the six months ended June 30, 2013 and 2012, zero and $78,000, respectively, were received from stock options exercised by option holders.

The aggregate intrinsic value of options outstanding and exercisable as of June 30, 2013 was approximately $8.2 million. Aggregate intrinsic value represents the total pre-tax intrinsic value based on the closing price of our common stock of $15.60 on June 28, 2013, which would have been received by the option holders had all option holders exercised their options as of that date. We have no unrecognized compensation cost related to stock options outstanding as of June 30, 2013.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, less accumulated depreciation. Machinery and equipment, furniture and fixtures, and autos are depreciated on the straight-line basis over their estimated useful lives of 5 to 10 years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the remaining life of the lease.

Provision for Income Taxes

Deferred tax assets and liabilities are recognized based on the expected future tax consequences, using current tax rates, of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

We use the asset and liability method of accounting for income taxes, as set forth in Accounting Standards Codification 740-10-25-2. Under this method, deferred income taxes, when required, are provided on the basis of the difference between the financial reporting and income tax basis of assets and liabilities at the statutory rates enacted for future periods. In accordance with Accounting Standards Codification 740-10-45-25, Income Statement Classification of Interest and Penalties, we classify interest associated with income taxes under interest expense and tax penalties under other.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 22

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

RELATED PARTY TRANSACTIONS (Details) (ABC-NY [Member], USD $)
6 Months Ended

Jun. 30, 2013

ABC-NY [Member]

Related Party Transaction [Line Items]

Monthly rental price $ 11,250

Termination of Lease Agreement Mar. 31, 2011

X

- Definition

Date which lease or group of leases is set to expire, in CCYY-MM-DD format.

+ References

No definition available.

+ Details

Name: us-gaap_LeaseExpirationDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 122

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 16

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 25

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=7661868&loc=d3e34039-112682

+ Details

Name: us-gaap_OperatingLeasesRentExpenseMinimumRentals

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R24.xml IDEA: NET INCOME (LOSS) PER SHARE (Details) 2.4.0.8090300 - Disclosure - NET INCOME (LOSS) PER SHARE (Details)truefalsefalse1false falsefalsec20130401to20130630http://www.sec.gov/CIK0000875622duration2013-04-01T00:00:002013-06-30T00:00:00U001Standardhttp://www.xbrl.org/2003/instancesharesxbrli02false falsefalsec20120401to20120630http://www.sec.gov/CIK0000875622duration2012-04-01T00:00:002012-06-30T00:00:00U001Standardhttp://www.xbrl.org/2003/instancesharesxbrli03false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00U001Standardhttp://www.xbrl.org/2003/instancesharesxbrli04false falsefalsec20120101to20120630http://www.sec.gov/CIK0000875622duration2012-01-01T00:00:002012-06-30T00:00:00U001Standardhttp://www.xbrl.org/2003/instancesharesxbrli01true 2us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Number of common equivalent shares included for the calculation of diluted net income [Abstract]2false 3us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangementsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse622780622780falsefalsefalse2truefalsefalse628331628331falsefalsefalse3truefalsefalse614962614962falsefalsefalse4truefalsefalse644328644328falsefalsefalsexbrli:sharesItemTypesharesAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 28A -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1500-109256 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 20 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false1Stock options (in shares)falseNET INCOME (LOSS) PER SHARE (Details)UnKnownNoRoundingUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/NetIncomeLossPerShareDetails42 XML 35 R10.xml IDEA: NET INCOME (LOSS) PER SHARE 2.4.0.8060300 - Disclosure - NET INCOME (LOSS) PER SHAREtruefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_EarningsPerShareAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0NET INCOME (LOSS) PER SHARE [Abstract]2false 2us-gaap_EarningsPerShareTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">3. NET INCOME (LOSS) PER SHARE</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In accordance with Accounting Standards Codification 260,<font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> Earnings Per Share</font>, basic net income (loss) per share amount is computed using the weighted-average number of shares of common stock outstanding during the periods presented, while diluted net income (loss) per share is computed using the sum of the weighted-average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of diluted earnings per share result from the assumed exercise of stock options using the converted method.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The following table summarizes the number of common equivalent shares that were included for the calculation of diluted net income purposes from continuing operations reported in the consolidated statement of operations.</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Six Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;">Stock options</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">622,780</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">628,331</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">614,962</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">644,328</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr></table></div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for earnings per share.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.21) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256 false0NET INCOME (LOSS) PER SHAREfalseNET INCOME (LOSS) PER SHAREUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/NetIncomeLossPerShare12 XML 36 R5.xml IDEA: Consolidated Statements of Comprehensive Income (unaudited) 2.4.0.8030000 - Statement - Consolidated Statements of Comprehensive Income (unaudited)truefalsefalse1false USDfalsefalse$c20130401to20130630http://www.sec.gov/CIK0000875622duration2013-04-01T00:00:002013-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$c20120401to20120630http://www.sec.gov/CIK0000875622duration2012-04-01T00:00:002012-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$c20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$c20120101to20120630http://www.sec.gov/CIK0000875622duration2012-01-01T00:00:002012-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Consolidated Statements of Comprehensive Income (unaudited) [Abstract]2false 2us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse10281861028186USD$falsetruefalse2truefalsefalse666682666682USD$falsetruefalse3truefalsefalse23812702381270USD$falsetruefalse4truefalsefalse14090721409072USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Net income3false 2us-gaap_OtherComprehensiveIncomeLossNetOfTaxus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse00falsefalsefalse2truefalsefalse00falsefalsefalse3truefalsefalse00falsefalsefalse4truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryNet of tax amount of other comprehensive income (loss) attributable to both parent entity and noncontrolling interest.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669619-108580 false2Other comprehensive income (loss)4false 2us-gaap_ComprehensiveIncomeNetOfTaxus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse10281861028186USD$falsetruefalse2truefalsefalse666682666682USD$falsetruefalse3truefalsefalse23812702381270USD$falsetruefalse4truefalsefalse14090721409072USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Comprehensive Income -URI http://asc.fasb.org/extlink&oid=16317811 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e557-108580 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(3) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A5 -Appendix A true2Comprehensive incomefalseConsolidated Statements of Comprehensive Income (unaudited) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited44 EXCEL 37 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\X8C,Q-30V9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y M,&(Q-V4S838B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-O M;3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F M7T-A#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E!!5$5.5%]#3U-44SPO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E!23U9)4TE/3E]&3U)?24Y#3TU% M7U1!6$53/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I7 M;W)K#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-534U!4EE?3T9?4TE' M3DE&24-!3E1?04-#3U5.5#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY%5%])3D-/345?3$]34U]015)?4TA!4D5?1&5T83PO M>#I.86UE/@T*("`@(#QX.E=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E!23U9)4TE/3E]&3U)? M24Y#3TU%7U1!6$537T1E=#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)%3$%4141?4$%25%E?5%)!3E-!0U1)3TY37T1E=#PO>#I. M86UE/@T*("`@(#QX.E=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP M/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7SAB,S$U-#9F7S(P.6%?-#)F9E\X9#%D7V-D,3DP M8C$W93-A-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X8C,Q-30V M9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y,&(Q-V4S838O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^0DE/4U!% M0TE&24-3(%1%0TA.3TQ/1TE%4R!#3U)0/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA2!796QL+6MN;W=N M(%-E87-O;F5D($ES'0^3F\\2!6;VQU;G1A'0^665S/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L'0^2G5N(#,P+`T* M"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\X8C,Q-30V9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y,&(Q-V4S838-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&(S,34T-F9?,C`Y85\T,F9F7SAD M,61?8V0Q.3!B,3=E,V$V+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6%L='D@8G5Y+61O=VX\+W1D/@T*("`@("`@("`\ M=&0@8VQA6%B;&4@86YD(&%C8W)U960@97AP96YS97,\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D.R!N;VYE(&]U='-T86YD:6YG/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\X8C,Q-30V9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y,&(Q-V4S M838-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&(S,34T-F9?,C`Y M85\T,F9F7SAD,61?8V0Q.3!B,3=E,V$V+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6%L=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E#PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X8C,Q-30V9E\R,#EA7S0R9F9? M.&0Q9%]C9#$Y,&(Q-V4S838-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO.&(S,34T-F9?,C`Y85\T,F9F7SAD,61?8V0Q.3!B,3=E,V$V+U=O'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!O<&5R871I;F<@86-T:79I=&EE'!E;G-E&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA2!O<&5R871I;F<@86-T:79I=&EE6UE;G0@9F]R M(')O>6%L='D@8G5Y(&1O=VX\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES97,\+W1D/@T*("`@("`@("`\=&0@8VQA6UE;G1S(&9O"!B96YE9FET6UE M;G0@87)R86YG96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T M:6]N(&5X<&5N3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\X8C,Q-30V9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y,&(Q-V4S M838-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&(S,34T-F9?,C`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`@ M'0M=&]P.R<^)B,Q-S0[/"]S=7`^("AC;VQL M86=E;F%S92!C;&]S=')I9&EU;2!H:7-T;VQY=&EC=6TI(&9O3L@9F]N="UF86UI;'DZ("2!A;F0@1$9"($)I;W1E8V@L($EN8RX@*"8C.#(R,#M$1D(F(S@R,C$[ M*2P@=V4@8V]N=&EN=64@=&\@'!I M6UE;G0@9F]R(%-A;G1Y;"!B>2!T:&4@ M96YD(&]F('1H92!Y96%R+CPO9&EV/CQD:78^/&)R("\^/"]D:78^/&1I=B!S M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+7-T>6QE.B!I=&%L M:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&IU2!E>'!E2!H87,@ M8F5E;B!I;7!L:6-A=&5D(&%S(&$@8V%U2!A M6QE.B!I=&%L:6,[(&9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B7-T97)E8W1O;7D@;W(@ M;7EO;65C=&]M>2!S=7)G97)Y(&9R;VT@<&%T:65N=',N(%1I3L@9F]N="UF86UI M;'DZ("2`Q-BP@,C`Q,RP@075X:6QI=6T@86YN;W5N M8V5D('1H870@:70@:&%S(&5N=&5R960@:6YT;R!A(&QO;FF%T:6]N(&]F(%A)05!%6"`H8V]L;&%G96YA M71I8W5M*2!F;W(@=&AE('1R96%T;65N M="!O9B!$=7!U>71R96XG&EL:75M('-T871E9"!T:&%T('=O2P@26-E;&%N9"P@,3@@0V5N=')A M;"!%87-T97)N($5U7)O;FEE)W,@9&ES96%S92!I M;B!T:&5S92!C;W5N=')I97,N/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\X8C,Q-30V9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y,&(Q-V4S838-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&(S,34T-F9?,C`Y85\T,F9F7SAD M,61?8V0Q.3!B,3=E,V$V+U=O'0O:'1M;#L@8VAA'0^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL M>3H@)U1I;65S($YE=R!2;VUA;B3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,BX@4U5- M34%262!/1B!324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453/"]D:78^ M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+69A;6EL M>3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]D:78^/&1I M=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+69A;6EL>3H@ M)R=4:6UEF4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^0F%S:7,@;V8@4')E6QE/3-$)W1E>'0M M86QI9VXZ(&IU2!R97!O6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O M;G0M9F%M:6QY.B`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`R,#$S+"!T:&4@86-C;W5N=',@6QE/3-$)W1E>'0M86QI9VXZ(&IU6%L='D@2!R979E;G5E6QE/3-$)W1E>'0M86QI9VXZ(&IU2!R96-O9VYI>F4@6QE.B!I=&%L:6,[(&9O;G0M9F%M M:6QY.B`G)U1I;65S($YE=R!2;VUA;B3L@9F]N="UF86UI;'DZ("3H@)R=4:6UEF4Z(#$P<'0[)SY)9B!W92!D971E&ES="!I;B!A(')E=F5N=64@87)R86YG96UE;G0@=6YD97(@ M05-#(#8P-2P@=V4@6UE;G0@:7,@ M2!A6QE M/3-$)W1E>'0M86QI9VXZ(&IU6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY M.B`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`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`G)U1I;65S M($YE=R!2;VUA;B2!S=&]C:R!U;F1E3L@9F]N="UF M86UI;'DZ("3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^/&9O;G0@3H@)R=4:6UE MF4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+69A;6EL>3H@)R=4:6UEF4Z(#$P<'0[)SY4 M2!D=64@9G)O;2!O=7(@='=O(&QA3L@9F]N="UF86UI;'DZ("3H@)R=4:6UEF4Z(#$P<'0[)SY!="!*=6YE(#,P+"`R,#$S+"!T:&4@ M86-C;W5N=',@3H@)R=4:6UEF4Z(#$P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B&EL:75M($%GF5D(&]V97(@=&AE(&5X<&5C=&5D(&1E=F5L;W!M96YT M('!E6QE/3-$)W1E>'0M86QI9VXZ(&IU3L@9F]N="UF86UI;'DZ("6QE/3-$)W1E>'0M86QI9VXZ(&IU3L@9F]N="UF86UI;'DZ("2!$979E;&]P;65N M="!#;W-T3H@)R=4:6UEF4Z(#$P<'0[)SY792!A M8V-R=64@<&%T96YT(&5X<&5NF4@8V5R=&%I M;B!P871E;G0@8V]S=',@6QE M/3-$)V9O;G0M9F%M:6QY.B`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`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`\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UEF4Z(#$P<'0[)SY7 M:&5N('1H97)E(&ES('5N8V5R=&%I;G1Y(&EN('1H92!F86-T;W)S('5S960@ M=&\@9&5T97)M:6YE('1H92!E>'!E8W1E9"!T97)M(&]F(&%N(&%W87)D+"!W M92!U2`D-SDL,#`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`S,"P\+V1I=CX\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E#L@=VED=&@Z(#,R)3L@=F5R=&EC86PM86QI9VXZ(&)O M='1O;3LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W!A9&1I;F"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG M/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q,SPO9&EV/CPO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z M(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F"!S;VQI9#L@=F5R=&EC86PM86QI M9VXZ(&)O='1O;3LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q M,CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R<^,C`Q,SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@ M8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W!A9&1I;F"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@3H@)R=4:6UE MF4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q,CPO9&EV/CPO=&0^/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!V97)T M:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR M<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$)V9O;G0M9F%M M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXQ,C(L-C6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A M8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXY,BPR-#D\+V1I=CX\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C M8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE6QE/3-$)W!A9&1I;F"!S;VQI9#L@=&5X="UA;&EG M;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXM/"]D:78^ M/"]T9#X\=&0@;F]W#L@8F%C:V=R;W5N9"UC M;VQO6QE/3-$ M)V)O'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R M.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA M;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F"!S;VQI9#L@=&5X="UA;&EG M;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXQ,RPR,#`\+V1I=CX\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[ M(&)A8VMG#L@8F%C:V=R;W5N9"UC;VQO M'!E;G-E/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W!A9&1I;F"!D;W5B;&4[('1E>'0M86QI M9VXZ(&QE9G0[(&)A8VMG3H@)R=4 M:6UEF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^-SDL,#0Y/"]D:78^/"]T9#X\=&0@ M;F]W#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@ M)R=4:6UEF4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)#PO9&EV/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P M(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O M;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E M>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W M:61T:#H@.24[('9E6QE/3-$ M)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R M;W5N9"UC;VQO6QE M/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)#PO9&EV/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K M9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B3H@)R=4:6UEF4Z(#$P<'0[)SY3=&]C:R!/<'1I;VX@06-T M:79I='D\+V1I=CX\9&EV/CQB6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ('1O<#LG M/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^/&1I=B!S='EL93TS1"=T M97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ('1O<#LG/B8C M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@ M,24[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[ M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ('1O<#LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^;V8@4VAA"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@ M<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG M;CH@=&]P.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1EF4Z(#$P<'0[)SY/=71S=&%N M9&EN9R!A6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD M+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)V)A M8VMG6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E M6QE/3-$)V9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R M.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K M9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@ M)R=4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@ M.24[('9E6QE/3-$)V9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&)A8VMG"!S;VQI9#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@8F%C:V=R;W5N9"UC;VQO MF4Z M(#$P<'0[)SY%>'!I6QE/3-$)W!A9&1I;F"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F M=#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXM/"]D:78^/"]T9#X\=&0@;F]W M"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@ M<&%D9&EN9RUB;W1T;VTZ(#)P>#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M M86QI9VXZ(&QE9G0[(&)A8VMG"!S;VQI9#L@=&5X="UA;&EG;CH@#L@8F%C M:V=R;W5N9"UC;VQO6QE/3-$)V)A8VMG6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B6QE/3-$)W!A9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E M6QE/3-$)V9O;G0M9F%M:6QY M.B`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`S,"P@,C`Q,R!A;F0@,C`Q M,BP@>F5R;R!A;F0@)#&5R8VES960@8GD@;W!T:6]N(&AO M;&1E3L@9F]N="UF86UI;'DZ("2`D."XR(&UI;&QI;VXN($%G9W)E9V%T92!I;G1R:6YS:6,@=F%L M=64@"!I;G1R:6YS:6,@=F%L M=64@8F%S960@;VX@=&AE(&-L;W-I;F<@<')I8V4@;V8@;W5R(&-O;6UO;B!S M=&]C:R!O9B`D,34N-C`@;VX@2G5N92`R."P@,C`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`G M)U1I;65S($YE=R!2;VUA;B'10 M87)T7SAB,S$U-#9F7S(P.6%?-#)F9E\X9#%D7V-D,3DP8C$W93-A-@T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X8C,Q-30V9E\R,#EA7S0R9F9? M.&0Q9%]C9#$Y,&(Q-V4S838O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)V9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$ M)W1E>'0M86QI9VXZ(&IU3L@ M9F]N="UF86UI;'DZ("F4Z(#$P<'0[)SX@ M16%R;FEN9W,@4&5R(%-H87)E/"]F;VYT/BP@8F%S:6,@;F5T(&EN8V]M92`H M;&]S6QE/3-$)W1E>'0M86QI9VXZ(&IU M6QE M/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^2G5N92`S,"P\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E#L@=VED=&@Z(#,R)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG M/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W!A9&1I;F"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@ M3H@)R=4 M:6UEF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q,SPO9&EV/CPO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!V M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O M='1O;3LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q,CPO9&EV M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@ M=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F"!S;VQI9#L@=F5R=&EC M86PM86QI9VXZ(&)O='1O;3LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^,C`Q,SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A M9&1I;F"!S M;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^,C`Q,CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA M;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)V)A8VMG6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&)A8VMG3H@)R=4:6UE MF4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^-C(R+#6QE/3-$)V)A8VMG6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^-C0T+#,R.#PO9&EV M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X8C,Q-30V9E\R,#EA7S0R9F9?.&0Q M9%]C9#$Y,&(Q-V4S838-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M.&(S,34T-F9?,C`Y85\T,F9F7SAD,61?8V0Q.3!B,3=E,V$V+U=O'0O:'1M;#L@8VAA M'0^/&1I M=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^-"X@0T]-4%)%2$5.4TE612!)3D-/344@*$Q/4U,I M/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&IU"!M;VYT:',@96YD960@/&9O;G0@'1087)T7SAB,S$U-#9F7S(P.6%?-#)F9E\X9#%D7V-D,3DP8C$W93-A-@T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X8C,Q-30V9E\R,#EA7S0R M9F9?.&0Q9%]C9#$Y,&(Q-V4S838O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@ M3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\ M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU6%B;&4@86YD(&%C8W)U960@97AP M96YS97,@8V]N6QE/3-$)W=I9'1H M.B`Y,"4[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L M('-EF4Z(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@-C8E.R!V97)T:6-A;"UA;&EG;CH@=&]P M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M6QE M/3-$)W9E6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1EF4Z M(#$P<'0[)SXL/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC M86PM86QI9VXZ('1O<#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^ M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM M86QI9VXZ('1O<#LG/B8C,38P.SPO=&0^/"]T#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<^)B,Q M-C`[/"]T9#X\=&0@8V]L6QE M/3-$)V)O#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<^ M)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)OF4Z(#$P<'0[)SY46QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD M+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9EF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G M)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A M8VMG6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE MF4Z(#$P<'0[ M)SXD(#,P-"PV,S4\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG M3H@)R=4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F M.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXV,2PQ-#<\+V1I=CX\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T M:#H@.24[('9E6QE/3-$ M)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F#L@8F%C M:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!B86-K9W)O M=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F M.R!W:61T:#H@,24[('9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O M=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&)A8VMG#L@ M8F%C:V=R;W5N9"UC;VQO6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!P861D:6YG+6)O='1O;3H@-'!X.R!B86-K9W)O=6YD M+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E6QE/3-$)V9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)O6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@ M8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O6QE/3-$ M)V)O#L@8F%C:V=R;W5N9"UC;VQO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\X8C,Q-30V9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y,&(Q-V4S838-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&(S,34T-F9?,C`Y85\T,F9F M7SAD,61?8V0Q.3!B,3=E,V$V+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/&1I=B!S='EL93TS1"=F;VYT+69A M;6EL>3H@)U1I;65S($YE=R!2;VUA;B3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^-BX@ M4$%414Y4($-/4U13/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&IU65A M6EN9R!A;6]U;G0@;V8@&EL:75M('5N9&5R('1H92!!=7AI;&EU;2!!9W)E96UE;G0N("8C,38P M.U1H97-E('!A=&5N="!C;W-T6QE/3-$)V9O;G0M9F%M M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE M/3-$)W=I9'1H.B`U-B4[('9E3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M2G5N92`S,#QF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`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`C9F9F9F9F.R!W:61T:#H@.24[ M('9E6QE/3-$)V9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA M;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M86QI9VXZ(')I M9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E M6QE/3-$)V9O;G0M9F%M M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K M9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$ M)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B3H@)R=4:6UEF4Z(#$P<'0[)SXR.#`L,S(R/"]D:78^ M/"]T9#X\=&0@;F]W3L@ M9F]N="UF86UI;'DZ("'!E;G-E(&9O65A2!A6QE/3-$)V)A8VMG6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE M=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4 M:6UEF4Z(#$P M<'0[)SXU,RPP,#`\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG M3H@)R=4:6UEF4Z(#$P<'0[)SXR,#$U/"]D M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[ M('9E6QE/3-$)V9O;G0M9F%M M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXR,"PP,#`\+V1I=CX\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&)A8VMG3H@)R=4 M:6UEF4Z(#$P M<'0[)SXR,#$X/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)V)A8VMG'1087)T7SAB,S$U-#9F7S(P.6%?-#)F9E\X9#%D7V-D,3DP8C$W93-A-@T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X8C,Q-30V9E\R,#EA7S0R M9F9?.&0Q9%]C9#$Y,&(Q-V4S838O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)V9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU3H@)R=4:6UEF4Z(#$P<'0[)SY);B!D971E&%B M;&4@:6YC;VUE+CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B3H@)R=4 M:6UEF4Z(#$P M<'0[)SY4:&4@2=S(&1E9F5R"!A"!M;VYT:"!P97)I;V0@96YD960@2G5N M92`S,"P@,C`Q,RP@=&AE('!R;W9I&5S('=A M&EM871E;'D@)#$N-2!M:6QL:6]N+CPO9&EV M/CQD:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J M=7-T:69Y.R!F;VYT+69A;6EL>3H@)R=4:6UEF4Z(#$P<'0[)SY&;W(@=&AE('-I>"!M;VYT M:"!P97)I;V0@96YD960@2G5N92`S,"P@,C`Q,B!O=7(@<')O=FES:6]N(&9O M"!M;VYT:"!P97)I M;V0@96YD960@2G5N92`S,"P@,C`Q,BP@=&AE('9A;'5A=&EO;B!A;&QO=V%N M8V4@=VET:"!R97-P96-T('1O('1H92!C;VUP86YY)B,X,C$W.W,@;F5T(&1E M9F5R"!A"!A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X8C,Q-30V M9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y,&(Q-V4S838-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO.&(S,34T-F9?,C`Y85\T,F9F7SAD,61?8V0Q.3!B M,3=E,V$V+U=O'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE M=R!2;VUA;B3H@ M)R=4:6UEF4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^."X@4D5,051%1"!005)462!4 M4D%.4T%#5$E/3E,\+V1I=CX\9&EV/CQB3L@9F]N="UF86UI;'DZ("2!R97!O2P@=&AE("8C.#(R,#M496YA;G0F(S@R,C$[*2!A M;F0@5VEL8G5R(%-T+B!#;W)P+B`H=&AE("8C.#(R,#M,86YD;&]R9"8C.#(R M,3LI('=E2`S,"P@,3DY."!A;F0@;6]D:69I960@ M87,@;V8@2G5N92`R-"P@,C`P.2`H=&AE("8C.#(R,#M,96%S92!!9W)E96UE M;G0F(S@R,C$[*2P@<'5R&5S+B`F(S$V,#M&;VQL;W=I;F<@ M=&AE(&5X<&ER871I;VX@;V8@=&AE($QE87-E($%G7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3L@9F]N="UF86UI;'DZ("3L@9F]N="UF M86UI;'DZ("3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\X8C,Q-30V9E\R,#EA7S0R9F9?.&0Q9%]C M9#$Y,&(Q-V4S838-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&(S M,34T-F9?,C`Y85\T,F9F7SAD,61?8V0Q.3!B,3=E,V$V+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3L@9F]N="UF86UI;'DZ("3H@)R=4:6UEF4Z(#$P<'0[)SY4:&4@86-C;VUP86YY:6YG(&-O;G-O;&ED871E9"!F M:6YA;F-I86P@2!O9B!N;W)M86PL M(')E8W5R2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@*"8C.#(R M,#M5+E,N($=!05`F(S@R,C$[*2!H87,@8F5E;B!C;VYD96YS960@;W(@;VUI M='1E9"!P=7)S=6%N="!T;R!T:&4@&-H86YG92!#;VUM:7-S:6]N("AT:&4@ M)B,X,C(P.U-%0R8C.#(R,3LI(&9O3H@)R=4:6UEF4Z(#$P<'0[)SX\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3H@)R=4:6UEF4Z(#$P<'0[)SY4:&4@:6YF;W)M871I;VX@:6YC;'5D M960@:6X@=&AI2!297!O6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B65A6QE/3-$)V9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ M(&IU2!A;F0@:71S('-U8G-I9&EA3L@9F]N="UF86UI M;'DZ("3L@9F]N="UF86UI;'DZ("6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM M97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[ M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU2!A;F0@=VET:"!H:6=H;'D@6QE/3-$ M)W1E>'0M86QI9VXZ(&IU28C.#(Q-SMS(&9I;F%N8VEA;"!I;G-T6%B;&4@86YD(&%C8W)U960@97AP96YS97,@87!P6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM M97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[ M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU3L@9F]N="UF86UI;'DZ("2!H87,@;F]T(&5X M<&5R:65N8V5D(&%N>2!L;W-S97,@=VET:"!T:&5S92!A8V-O=6YT3L@9F]N="UF M86UI;'DZ("3H@)R=4:6UEF4Z(#$P<'0[)SY!="!*=6YE(#,P+"`R,#$S+"!T:&4@86-C;W5N=',@6QE/3-$)W1E>'0M86QI9VXZ(&IU6%L='D@2!R979E;G5E6QE M/3-$)W1E>'0M86QI9VXZ(&IU2!R96-O9VYI>F4@6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G M)U1I;65S($YE=R!2;VUA;B3L@9F]N="UF86UI;'DZ("3H@ M)R=4:6UEF4Z M(#$P<'0[)SY)9B!W92!D971E&ES="!I;B!A(')E=F5N=64@87)R86YG96UE;G0@=6YD97(@05-#(#8P M-2P@=V4@6UE;G0@:7,@2!A6QE/3-$)W1E M>'0M86QI9VXZ(&IU6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&IU&ES=',L('1I=&QE('!A M&5D(&]R(&1E=&5R;6EN86)L92!A;F0@ M8V]L;&5C=&%B:6QI='D@:7,@2!A3L@9F]N="UF86UI;'DZ("2!U6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE M/3-$)W1E>'0M86QI9VXZ(&IU6%L='DL(&UA M6UE M;G0@:6YF;W)M871I;VX@8F5C;VUE2!R97!O2!A2P@;6%R:RUU<"!O;B!C;W-T M(&]F(&=O;V1S('-O;&0@;W(@96%R;BUO=70@<&%Y;65N="!R979E;G5E6%L='DL(&UA6UE;G0@2!R96-O9VYI>F5D(&EN('1H92!Q=6%R=&5R('1H870@=&AE M(&%P<&QI8V%B;&4@;&EC96YS964@<')O=FED97,@=&AE('=R:71T96X@3H@)R=4:6UEF4Z(#$P<'0[)SY5;F1E6%L=&EE2!B92!R96-O9VYI>F5D(&EN('1H92!Q=6%R=&5R('1H870@ M075X:6QI=6T@<')O=FED97,@=&AE('=R:71T96X@2!A;F0@ M;6%R:RUU<"!O;B!C;W-T(&]F(&=O;V1S('-O;&0@2!R96-O9VYI>F5D(&]N92!Q=6%R=&5R(&9O;&QO=VEN9R!T:&4@ M<75A6EN9R!S86QE2!!=7AI M;&EU;2!O8V-U3H@)R=4 M:6UEF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/E1H92!R;WEA M;'1I97,@<&%Y86)L92!B>2!!=7AI;&EU;2!T;R!U3L@9F]N="UF86UI;'DZ("6UE;G1S(&EN('1H92!F=71U6UE;G1S(&%N9"!A(')E<&]R="!W:71H:6X@;FEN971Y("@Y,"D@9&%Y M2UB96%R:6YG('!R;V1U8W0N/"]D:78^ M/&1I=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU M6QE/3-$)W1E>'0M86QI9VXZ(&IU MF5D(&9R;VT@=7!F6UE;G1S(&EN("8C.#(R,#M,:6-E;G-E M(%)E=F5N=65S)B,X,C(Q.R!I;B!O=7(@8V]N3H@)R=4:6UEF4Z(#$P<'0[)SY5<&9R M;VYT($QI8V5N6QE/3-$)W1E>'0M86QI9VXZ(&IU2!R96-O9VYI>F4@ MF4Z(#$P<'0[)SY-:6QE6QE/3-$)W1E>'0M86QI9VXZ(&IU7!I8V%L;'D@F4@2!AF4@6QE M/3-$)W1E>'0M86QI9VXZ(&IU3L@9F]N="UF86UI;'DZ("F4@9G)O;2!L:6-E;G-E2X@5&AE(&EM<&%C="!O;B!R979E;G5E M(&]F(&-H86YG97,@:6X@;W5R(&5S=&EM871E2!O=F5R('1H92!R M96UA:6YI;F<@97-T:6UA=&5D('!R;V1U8W0@9&5V96QO<&UE;G0@<&5R:6]D M+CPO9&EV/CPO9&EV/CQS<&%N/CPO3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]D:78^ M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+69A;6EL M>3H@)R=4:6UEF4Z(#$P<'0[)SY4:&4@0V]M<&%N>2!A8V-O=6YT2!S=&]C:R!A2X\+V1I=CX\+V1I=CX\6QE/3-$ M)V9O;G0M9F%M:6QY.B`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`P,"!A="!*=6YE(#,P+"`R,#$S(&%N9"`R,#$R+CPO9&EV/CPO9&EV M/CQS<&%N/CPO6QE/3-$ M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&IU3L@9F]N="UF86UI;'DZ("'!E;G-E2!U3H@)R=4:6UEF4Z(#$P<'0[)SY*=6YE(#,P+"`R,#$S/"]F;VYT/B!O=7(@ M;F5T(')E:6UB=7)S86)L92!T:&ER9"!P87)T>2!P871E;G0@8V]S=',@86-C M2`D,S`L,#`P+CPO9&EV/CPO9&EV/CQS M<&%N/CPO2!"=7DM1&]W;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA M;B3H@)R=4:6UE MF4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^4F]Y86QT>2!"=7DM1&]W;CPO9&EV/CQD M:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T M:69Y.R!F;VYT+69A;6EL>3H@)R=4:6UEF4Z(#$P<'0[)SY/;B!-87)C:"`S,2P@,C`Q,BP@ M=V4@96YT97)E9"!I;G1O(&%N(&%M96YD;65N="!T;R!O=7(@97AI6UE;G1S('!A>6%B;&4@=7!O M;B!T:&4@;V-C=7)R96YC92!O9B!A(&UI;&5S=&]N92!E=F5N="X\+V1I=CX\ M9&EV/CQB3L@9F]N="UF86UI;'DZ("65A3H@)R=4:6UEF4Z(#$P<'0[)SX@26YT86YG:6)L97,L($=O;V1W:6QL(&%N M9"!/=&AE2!D971E6QE/3-$)V9O;G0M9F%M:6QY.B`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`\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UEF4Z(#$P<'0[)SY7:&5N('1H M97)E(&ES('5N8V5R=&%I;G1Y(&EN('1H92!F86-T;W)S('5S960@=&\@9&5T M97)M:6YE('1H92!E>'!E8W1E9"!T97)M(&]F(&%N(&%W87)D+"!W92!U2`D-SDL,#`P+"!D=7)I;F<@=&AE('1H2P@82!R:7-K M(&9R964@&5R8VES92!P97)I M;V0@;V8@9FEV92!Y96%R3L@9F]N="UF86UI;'DZ("65E M('-T;V-K+6)AF5D M(&]V97(@=&AE(')E<75I65E('-T;V-K+6)A'!E;G-E(&QI;F4@87)E M(&5S=&EM871E9"!B87-E9"!O;B!S<&5C:69I8R!E;7!L;WEE92!H96%D8V]U M;G0@:6YF;W)M871I;VX@870@96%C:"!G2P@:6X@9G5T=7)E('!E65E(&AE861C;W5N="!I;F9O2!F'!E;G-E(&-A=&5G;W)Y(&EN(&9U='5R92!P97)I;V1S(&UA>2!D:69F M97(@2!F'!E;G-E(')E8V]G;FEZ M960@=6YD97(@05-#(#6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^2G5N92`S,"P\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E#L@=VED=&@Z(#,R)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG M/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W!A9&1I;F"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@ M3H@)R=4 M:6UEF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q,SPO9&EV/CPO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!V M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O M='1O;3LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q,CPO9&EV M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@ M=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F"!S;VQI9#L@=F5R=&EC M86PM86QI9VXZ(&)O='1O;3LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^,C`Q,SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A M9&1I;F"!S M;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^,C`Q,CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA M;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)V)A8VMG6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$)V9O;G0M9F%M:6QY.B`G M)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4 M:6UEF4Z(#$P M<'0[)SXQ,C(L-C6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXY,BPR-#D\+V1I=CX\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&)A8VMG3H@)R=4 M:6UEF4Z(#$P M<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F M.R!W:61T:#H@.24[('9E6QE M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE6QE/3-$)W!A9&1I;F"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F M=#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXM/"]D:78^/"]T9#X\ M=&0@;F]W#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F M9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C M:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F M=#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXQ,RPR,#`\+V1I=CX\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`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`C,#`P,#`P(#1P>"!D M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C M8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^)#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI M9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@ M.24[('9E6QE/3-$)V9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC M;VQO6QE/3-$)V)O M3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)#PO9&EV/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P M,#`P(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD M+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B3H@)R=4:6UEF4Z(#$P<'0[)SY3=&]C:R!/<'1I;VX@06-T:79I='D\ M+V1I=CX\9&EV/CQB3L@9F]N="UF86UI;'DZ("6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ('1O<#LG/B8C,38P M.SPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^/&1I=B!S='EL93TS1"=T97AT+6%L M:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ('1O<#LG/B8C,38P.SPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[('9E M6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B"!S M;VQI9#L@=F5R=&EC86PM86QI9VXZ('1O<#LG/CQD:78@"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN M9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@=&]P M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O M6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E MF4Z(#$P<'0[)SY/=71S=&%N9&EN9R!A M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R M.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B6QE M/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E M969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD M+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O M=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE M=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E M6QE/3-$)V9O;G0M9F%M:6QY M.B`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`M-RXR<'0[(&9O;G0M9F%M M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE M=R!2;VUA;B6QE/3-$)W!A9&1I;F"!D M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`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`S,"P@,C`Q,R!A;F0@,C`Q,BP@>F5R M;R!A;F0@)#&5R8VES960@8GD@;W!T:6]N(&AO;&1E3L@9F]N="UF86UI;'DZ("2`D."XR(&UI;&QI;VXN($%G9W)E9V%T92!I;G1R:6YS:6,@=F%L=64@"!I;G1R:6YS:6,@=F%L=64@8F%S M960@;VX@=&AE(&-L;W-I;F<@<')I8V4@;V8@;W5R(&-O;6UO;B!S=&]C:R!O M9B`D,34N-C`@;VX@2G5N92`R."P@,C`Q,RP@=VAI8V@@=V]U;&0@:&%V92!B M965N(')E8V5I=F5D(&)Y('1H92!O<'1I;VX@:&]L9&5R2P@4&QA M;G0@86YD($5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA M;B3H@)R=4:6UE MF4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I M<&UE;G0\+V1I=CX\9&EV/CQB65A M3L@9F]N="UF M86UI;'DZ("6QE/3-$)W1E>'0M86QI9VXZ(&IU"!AF5D(&)A'!E8W1E9"!F=71U2!D:69F97)E;F-E"!A6QE/3-$ M)W1E>'0M86QI9VXZ(&IU6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B2!M971H;V0@;V8@86-C;W5N=&EN9R!F;W(@ M:6YC;VUE('1A>&5S+"!A&5S+"!W:&5N(')E<75I6QE/3-$)V9O;G0M7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA M;BF5D('5N9&5R M($%30R`W,3@@=V%S(&%S(&9O;&QO=W,Z/"]D:78^/&1I=CXF(S$V,#L\+V1I M=CX\=&%B;&4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,"!C96QL<&%D9&EN M9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`X,"4[(&9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,S(E.R!V97)T:6-A M;"UA;&EG;CH@8F]T=&]M.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@#L@ M=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T M9#X\=&0@8V]L6QE/3-$)V)O M6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA M;&EG;CH@=&]P.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O#L@=VED=&@Z(#$E.R!V M97)T:6-A;"UA;&EG;CH@=&]P.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F3H@)R=4:6UE3H@)R=4:6UEF4Z(#$P<'0[)SXD M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T M:#H@.24[('9E6QE/3-$ M)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$)V9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)V)A8VMG6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXQ-#0L.#$W/"]D:78^/"]T9#X\=&0@;F]W#L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SY'96YE'0M86QI9VXZ(&QE9G0[(&)A8VMG M"!S;VQI9#L@=&5X M="UA;&EG;CH@#L@8F%C:V=R;W5N9"UC;VQO M6QE/3-$)W!A M9&1I;F"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R M;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXQ,RPR,#`\+V1I=CX\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[(&)A8VMG M"!S;VQI9#L@=&5X="UA M;&EG;CH@#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M86QI9VXZ(')I M9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E M6QE/3-$)V9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I M;F6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B6QE/3-$)V)O#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M,3,U+#@W.3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@ M)R=4:6UEF4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,3`U+#0T.3PO9&EV/CPO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@8F%C:V=R M;W5N9"UC;VQO6QE M/3-$)W!A9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A M8VMG3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^,3#L@8F%C:V=R;W5N9"UC;VQO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B3H@)R=4:6UEF4Z(#$P<'0[)SY!('-U;6UA M2!D=7)I;F<@=&AE('-I M>"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,R!I6QE/3-$)W=I9'1H M.B`Y,"4[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L M('-EF4Z(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@-S,N,S(E.R!V97)T:6-A;"UA;&EG;CH@ M=&]P.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W9E6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`Q M)3L@=F5R=&EC86PM86QI9VXZ('1O<#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P M86X],T0R('-T>6QE/3-$)W=H:71E+7-P86-E.B!N;W=R87`[('9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ('1O<#LG/B8C,38P.SPO=&0^/"]T M"!S;VQI9#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@ M=VED=&@Z(#F4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^3W!T:6]N"!S M;VQI9#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!V97)T:6-A M;"UA;&EG;CH@=&]P.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^17AE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F3H@)R=4:6UE6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4 M:6UEF4Z(#$P M<'0[)SXX+CDP/"]D:78^/"]T9#X\=&0@;F]WF4Z(#$P<'0[)SY'6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXQ-2XX-3PO9&EV/CPO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA M;B6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE M/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G M)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$)V)A M8VMG6QE/3-$)V)O3H@)R=4:6UE#L@8F%C:V=R;W5N9"UC;VQO M6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F M.R!W:61T:#H@.24[('9E6QE M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)O"!S;VQI9#L@=&5X="UA M;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXM/"]D:78^/"]T M9#X\=&0@;F]WF4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^/&9O;G0@#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O6QE/3-$)V)O#L@8F%C M:V=R;W5N9"UC;VQO6QE/3-$)V)A8VMG6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R M.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R M.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C M8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)V9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W!A M9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)#PO M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@8F%C:V=R;W5N9"UC;VQO3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^."XV-#PO9&EV M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\X8C,Q-30V9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y,&(Q M-V4S838-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&(S,34T-F9? M,C`Y85\T,F9F7SAD,61?8V0Q.3!B,3=E,V$V+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M3L@9F]N="UF86UI;'DZ M("F5S('1H92!N M=6UB97(@;V8@8V]M;6]N(&5Q=6EV86QE;G0@#L@=VED=&@Z(#,R)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD M:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W!A9&1I;F"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@3H@)R=4:6UE MF4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^5&AR964@36]N=&AS($5N9&5D/"]D:78^ M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B#L@=VED M=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F"!S;VQI9#L@=F5R=&EC86PM M86QI9VXZ(&)O='1O;3LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M4VEX($UO;G1H3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^2G5N92`S,"P\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^ M)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG M;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O#L@=VED=&@Z(#$E.R!V M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O#L@ M=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T M9#X\=&0@8V]L6QE/3-$)V)O MF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^4W1O8VL@ M;W!T:6]N6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F M.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^-C(X+#,S,3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O M;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B'10 M87)T7SAB,S$U-#9F7S(P.6%?-#)F9E\X9#%D7V-D,3DP8C$W93-A-@T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X8C,Q-30V9E\R,#EA7S0R9F9? M.&0Q9%]C9#$Y,&(Q-V4S838O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)V9O;G0M9F%M:6QY.B`G M5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P M<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU6%B;&4@86YD(&%C8W)U960@ M97AP96YS97,@8V]N6QE/3-$)W=I M9'1H.B`Y,"4[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM M97,L('-EF4Z(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@-C8E.R!V97)T:6-A;"UA;&EG;CH@ M=&]P.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W9E6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[)SXL/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@=F5R M=&EC86PM86QI9VXZ('1O<#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC M86PM86QI9VXZ('1O<#LG/B8C,38P.SPO=&0^/"]T#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<^ M)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@=&]P M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)OF4Z(#$P<'0[)SY46QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O M=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E3H@)R=4:6UEF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&)A8VMG6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4 M:6UEF4Z(#$P M<'0[)SXD(#,P-"PV,S4\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A M8VMG3H@)R=4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@,24[('9E M6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F M9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG M3H@)R=4:6UEF4Z(#$P<'0[)SXV,2PQ-#<\+V1I M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W M:61T:#H@.24[('9E6QE M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@ M8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!B86-K M9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F M9F9F.R!W:61T:#H@,24[('9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K M9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A M8VMG6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&)A8VMG#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6)O='1O;3H@-'!X.R!B86-K9W)O M=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@,24[('9E6QE/3-$ M)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O6QE M/3-$)V)O#L@8F%C:V=R;W5N9"UC;VQO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\X8C,Q-30V9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y,&(Q-V4S838- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&(S,34T-F9?,C`Y85\T M,F9F7SAD,61?8V0Q.3!B,3=E,V$V+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)W=I9'1H.B`U-B4[('9E3H@)R=4:6UEF4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^2G5N92`S,#QF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.B`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`C M9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F M9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G M)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC M;VQO6QE/3-$)W!A9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE M9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T M:#H@.24[('9E6QE/3-$)V9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B3H@)R=4 M:6UEF4Z(#$P M<'0[)SXR.#`L,S(R/"]D:78^/"]T9#X\=&0@;F]W'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'!E;G-E(&9O65A2!A3H@)R=4:6UEF4Z(#$P<'0[)SXD M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T M:#H@.24[('9E6QE/3-$)V9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G M)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXR-2PP,#`\+V1I=CX\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXR,#$V/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C M9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXR,"PP,#`\+V1I M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X8C,Q-30V M9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y,&(Q-V4S838-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO.&(S,34T-F9?,C`Y85\T,F9F7SAD,61?8V0Q.3!B M,3=E,V$V+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S2!R979E M;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$Y-RPV,#,\ M2`O M($UA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S7,@869T97(@ M8V%L96YD87(@>65A7,\65A'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6%L='D@0G5Y+41O=VX@6T%B'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0@9F]R(')O>6%L='D@8G5Y(&1O=VX\+W1D/@T*("`@("`@("`\ M=&0@8VQA6%L='D@8G5Y(&1O M=VX\+W1D/@T*("`@("`@("`\=&0@8VQA6%L='D@8G5Y+61O=VX\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!V;VQA=&EL M:71Y(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y96%R'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5R8VES960@*&EN('-H87)E&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES960@*&EN(&1O;&QA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'!I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L92P@96YD M(&]F('!E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@<&QA;G0@86YD(&5Q=6EP;65N M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y96%R'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$F5D(%!E'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65E(%-E'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6%L='D@'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S&EL:75M(%M-96UB97)= M('P@3&EC96YS:6YG+"!#;VYS=6QT:6YG($%N9"!2;WEA;'1Y(%)E=F5N=64@ M6TUE;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!R979E;G5E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L-3`P+#`P,#QS<&%N M/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!2979E;G5E(%M-96UB97)= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'1087)T7SAB M,S$U-#9F7S(P.6%?-#)F9E\X9#%D7V-D,3DP8C$W93-A-@T*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B\X8C,Q-30V9E\R,#EA7S0R9F9?.&0Q9%]C M9#$Y,&(Q-V4S838O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA6%B;&4@86YD(&%C8W)U960@97AP96YS97,@6T%B'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$7)O;&P@86YD(')E;&%T960@8V]S=',\+W1D/@T* M("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&EM M=6T@6TUE;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^,30@>65AF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF%T:6]N(&5X<&5NF%T:6]N(&5X<&5N M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\X8C,Q-30V9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y,&(Q-V4S838-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&(S,34T-F9?,C`Y85\T,F9F7SAD M,61?8V0Q.3!B,3=E,V$V+U=O'0O:'1M;#L@8VAA"!A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X M8C,Q-30V9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y,&(Q-V4S838-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&(S,34T-F9?,C`Y85\T,F9F7SAD,61? M8V0Q.3!B,3=E,V$V+U=O'0O:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^36%R(#,Q+`T*"0DR M,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X M8C,Q-30V9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y,&(Q-V4S838-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&(S,34T-F9?,C`Y85\T,F9F7SAD,61? M8V0Q.3!B,3=E,V$V+U=O&UL#0I#;VYT96YT M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT M+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U&UL/@T*+2TM+2TM/5].97AT4&%R=%\X8C,Q-30V A9E\R,#EA7S0R9F9?.&0Q9%]C9#$Y,&(Q-V4S838M+0T* ` end XML 38 R4.xml IDEA: Consolidated Statements of Operations (unaudited) 2.4.0.8020000 - Statement - Consolidated Statements of Operations (unaudited)truefalsefalse1false USDfalsefalse$c20130401to20130630http://www.sec.gov/CIK0000875622duration2013-04-01T00:00:002013-06-30T00:00:00U001Standardhttp://www.xbrl.org/2003/instancesharesxbrli0U003Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$c20120401to20120630http://www.sec.gov/CIK0000875622duration2012-04-01T00:00:002012-06-30T00:00:00U001Standardhttp://www.xbrl.org/2003/instancesharesxbrli0U003Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$c20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00U001Standardhttp://www.xbrl.org/2003/instancesharesxbrli0U003Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$c20120101to20120630http://www.sec.gov/CIK0000875622duration2012-01-01T00:00:002012-06-30T00:00:00U001Standardhttp://www.xbrl.org/2003/instancesharesxbrli0U003Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 2us-gaap_SalesRevenueNetAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Revenues:2false 3us-gaap_SalesRevenueGoodsNetus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse2750027500USD$falsetruefalse2truefalsefalse12461246USD$falsetruefalse3truefalsefalse2974329743USD$falsetruefalse4truefalsefalse87508750USD$falsetruefalsexbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Net sales3false 3us-gaap_RoyaltyRevenueus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse31976033197603falsefalsefalse2truefalsefalse24913132491313falsefalsefalse3truefalsefalse66305036630503falsefalsefalse4truefalsefalse43912824391282falsefalsefalsexbrli:monetaryItemTypemonetaryRevenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Royalties4false 3us-gaap_LicensesRevenueus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse4488044880falsefalsefalse2truefalsefalse109275109275falsefalsefalse3truefalsefalse589761589761falsefalsefalse4truefalsefalse788550788550falsefalsefalsexbrli:monetaryItemTypemonetaryRevenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 false2Licensing revenues5false 3us-gaap_SalesRevenueNetus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse32699833269983falsefalsefalse2truefalsefalse26018342601834falsefalsefalse3truefalsefalse72500077250007falsefalsefalse4truefalsefalse51885825188582falsefalsefalsexbrli:monetaryItemTypemonetaryTotal revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 true2Total Revenues6true 2us-gaap_CostsAndExpensesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Costs and expenses:7false 3us-gaap_ResearchAndDevelopmentExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse470044470044falsefalsefalse2truefalsefalse404346404346falsefalsefalse3truefalsefalse764918764918falsefalsefalse4truefalsefalse653898653898falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph g -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 86 -Paragraph 11, 12 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Research and development8false 3us-gaap_GeneralAndAdministrativeExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse12362541236254falsefalsefalse2truefalsefalse11499261149926falsefalsefalse3truefalsefalse28547362854736falsefalsefalse4truefalsefalse22386482238648falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 false2General and administrative9false 3us-gaap_CostsAndExpensesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse17062981706298falsefalsefalse2truefalsefalse15542721554272falsefalsefalse3truefalsefalse36196543619654falsefalsefalse4truefalsefalse28925462892546falsefalsefalsexbrli:monetaryItemTypemonetaryTotal costs of sales and operating expenses for the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 true2Total Cost and Expenses10false 2us-gaap_OperatingIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse15636851563685falsefalsefalse2truefalsefalse10475621047562falsefalsefalse3truefalsefalse36303533630353falsefalsefalse4truefalsefalse22960362296036falsefalsefalsexbrli:monetaryItemTypemonetaryThe net result for the period of deducting operating expenses from operating revenues.No definition available.true2Operating income11true 2us-gaap_NonoperatingIncomeExpenseAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Other income (expense):12false 3us-gaap_InvestmentIncomeInterestus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse65106510falsefalsefalse2truefalsefalse97719771falsefalsefalse3truefalsefalse1237612376falsefalsefalse4truefalsefalse1926419264falsefalsefalsexbrli:monetaryItemTypemonetaryIncome derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 115 -Paragraph 14 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(b)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 false2Interest income13false 3us-gaap_NonoperatingIncomeExpenseus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse65106510falsefalsefalse2truefalsefalse97719771falsefalsefalse3truefalsefalse1237612376falsefalsefalse4truefalsefalse1926419264falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Article 5 true2Total other income14false 2us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse15701951570195falsefalsefalse2truefalsefalse10573331057333falsefalsefalse3truefalsefalse36427293642729falsefalsefalse4truefalsefalse23153002315300falsefalsefalsexbrli:monetaryItemTypemonetaryThis element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 10 -Article 5 true2Income before expense for income tax15false 2us-gaap_IncomeTaxExpenseBenefitus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-542009-542009falsefalsefalse2truefalsefalse-390651-390651falsefalsefalse3truefalsefalse-1261459-1261459falsefalsefalse4truefalsefalse-906228-906228falsefalsefalsexbrli:monetaryItemTypemonetaryThe sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Income Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6515339 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 45 -Subparagraph a, b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Income tax benefit (expense)16false 2us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse10281861028186USD$falsetruefalse2truefalsefalse666682666682USD$falsetruefalse3truefalsefalse23812702381270USD$falsetruefalse4truefalsefalse14090721409072USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true2Net income17false 2us-gaap_EarningsPerShareBasicus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse0.160.16USD$falsetruefalse2truefalsefalse0.110.11USD$falsetruefalse3truefalsefalse0.370.37USD$falsetruefalse4truefalsefalse0.220.22USD$falsetruefalsenum:perShareItemTypedecimalThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.23) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 36, 37, 38 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 07-4 -Paragraph 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.21) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 false3Basic net income per share (in dollars per share)18false 2us-gaap_EarningsPerShareDilutedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse0.150.15USD$falsetruefalse2truefalsefalse0.100.10USD$falsetruefalse3truefalsefalse0.340.34USD$falsetruefalse4truefalsefalse0.200.20USD$falsetruefalsenum:perShareItemTypedecimalThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 07-4 -Paragraph 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.21) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 11, 12, 36 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 false3Diluted net income per share (in dollars per share)19false 2us-gaap_WeightedAverageNumberOfSharesOutstandingBasicus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse63452776345277falsefalsefalse2truefalsefalse63433566343356falsefalsefalse3truefalsefalse63510836351083falsefalsefalse4truefalsefalse63399306339930falsefalsefalsexbrli:sharesItemTypesharesNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 07-4 -Paragraph 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 171 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Weighted-Average Number of Common Shares Outstanding -URI http://asc.fasb.org/extlink&oid=6528421 false1Shares used in computation of basic net income per share (in shares)20false 2us-gaap_WeightedAverageNumberOfDilutedSharesOutstandingus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse69680576968057falsefalsefalse2truefalsefalse69716876971687falsefalsefalse3truefalsefalse69660456966045falsefalsefalse4truefalsefalse69842586984258falsefalsefalsexbrli:sharesItemTypesharesThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 07-4 -Paragraph 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false1Shares used in computation of diluted net income per share (in shares)falseConsolidated Statements of Operations (unaudited) (USD $)NoRoundingNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://biospecifics.com/role/ConsolidatedStatementsOfOperationsUnaudited420 XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 HtmlAndXml 38 164 1 false 12 0 false 7 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://biospecifics.com/role/DocumentAndEntityInformation Document and Entity Information R1.xml true false R2.htm 010000 - Statement - Consolidated Balance Sheets (unaudited) Sheet http://biospecifics.com/role/ConsolidatedBalanceSheetsUnaudited Consolidated Balance Sheets (unaudited) R2.xml false false R3.htm 010100 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical) Sheet http://biospecifics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical Consolidated Balance Sheets (unaudited) (Parenthetical) R3.xml false false R4.htm 020000 - Statement - Consolidated Statements of Operations (unaudited) Sheet http://biospecifics.com/role/ConsolidatedStatementsOfOperationsUnaudited Consolidated Statements of Operations (unaudited) R4.xml false false R5.htm 030000 - Statement - Consolidated Statements of Comprehensive Income (unaudited) Sheet http://biospecifics.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited Consolidated Statements of Comprehensive Income (unaudited) R5.xml false false R6.htm 040000 - Statement - Consolidated Statements of Cash Flows (unaudited) Sheet http://biospecifics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited Consolidated Statements of Cash Flows (unaudited) R6.xml false false R7.htm 040100 - Statement - Consolidated Statements of Cash Flows (unaudited) (Parenthetical) Sheet http://biospecifics.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical Consolidated Statements of Cash Flows (unaudited) (Parenthetical) R7.xml false false R8.htm 060100 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS Sheet http://biospecifics.com/role/OrganizationAndDescriptionOfBusiness ORGANIZATION AND DESCRIPTION OF BUSINESS R8.xml false false R9.htm 060200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES R9.xml false false R10.htm 060300 - Disclosure - NET INCOME (LOSS) PER SHARE Sheet http://biospecifics.com/role/NetIncomeLossPerShare NET INCOME (LOSS) PER SHARE R10.xml false false R11.htm 060400 - Disclosure - COMPREHENSIVE INCOME (LOSS) Sheet http://biospecifics.com/role/ComprehensiveIncomeLoss COMPREHENSIVE INCOME (LOSS) R11.xml false false R12.htm 060500 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Sheet http://biospecifics.com/role/AccountsPayableAndAccruedExpenses ACCOUNTS PAYABLE AND ACCRUED EXPENSES R12.xml false false R13.htm 060600 - Disclosure - PATENT COSTS Sheet http://biospecifics.com/role/PatentCosts PATENT COSTS R13.xml false false R14.htm 060700 - Disclosure - PROVISION FOR INCOME TAXES Sheet http://biospecifics.com/role/ProvisionForIncomeTaxes PROVISION FOR INCOME TAXES R14.xml false false R15.htm 060800 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://biospecifics.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS R15.xml false false R16.htm 060900 - Disclosure - SUBSEQUENT EVENTS Sheet http://biospecifics.com/role/SubsequentEvents SUBSEQUENT EVENTS R16.xml false false R17.htm 070200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) R17.xml false false R18.htm 080200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) R18.xml false false R19.htm 080300 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables) Sheet http://biospecifics.com/role/NetIncomeLossPerShareTables NET INCOME (LOSS) PER SHARE (Tables) R19.xml false false R20.htm 080500 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Sheet http://biospecifics.com/role/AccountsPayableAndAccruedExpensesTables ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) R20.xml false false R21.htm 080600 - Disclosure - PATENT COSTS (Tables) Sheet http://biospecifics.com/role/PatentCostsTables PATENT COSTS (Tables) R21.xml false false R22.htm 090100 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) Sheet http://biospecifics.com/role/OrganizationAndDescriptionOfBusinessDetails ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) R22.xml false false R23.htm 090200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) R23.xml false false R24.htm 090300 - Disclosure - NET INCOME (LOSS) PER SHARE (Details) Sheet http://biospecifics.com/role/NetIncomeLossPerShareDetails NET INCOME (LOSS) PER SHARE (Details) R24.xml false false R25.htm 090500 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) Sheet http://biospecifics.com/role/AccountsPayableAndAccruedExpensesDetails ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) R25.xml false false R26.htm 090600 - Disclosure - PATENT COSTS (Details) Sheet http://biospecifics.com/role/PatentCostsDetails PATENT COSTS (Details) R26.xml false false R27.htm 090700 - Disclosure - PROVISION FOR INCOME TAXES (Details) Sheet http://biospecifics.com/role/ProvisionForIncomeTaxesDetails PROVISION FOR INCOME TAXES (Details) R27.xml false false R28.htm 090800 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://biospecifics.com/role/RelatedPartyTransactionsDetails RELATED PARTY TRANSACTIONS (Details) R28.xml false false All Reports Book All Reports Element bstc_PaymentForRoyaltyBuyDown had a mix of decimals attribute values: -5 0. Element us-gaap_AccountsReceivableNetCurrent had a mix of decimals attribute values: -5 0. Element us-gaap_RoyaltyRevenue had a mix of decimals attribute values: -5 0. Process Flow-Through: 010000 - Statement - Consolidated Balance Sheets (unaudited) Process Flow-Through: Removing column 'Jun. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 010100 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical) Process Flow-Through: 020000 - Statement - Consolidated Statements of Operations (unaudited) Process Flow-Through: 030000 - Statement - Consolidated Statements of Comprehensive Income (unaudited) Process Flow-Through: 040000 - Statement - Consolidated Statements of Cash Flows (unaudited) Process Flow-Through: 040100 - Statement - Consolidated Statements of Cash Flows (unaudited) (Parenthetical) bstc-20130630.xml bstc-20130630.xsd bstc-20130630_cal.xml bstc-20130630_def.xml bstc-20130630_lab.xml bstc-20130630_pre.xml true true XML 40 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Balance Sheets (unaudited) (Parenthetical) (USD $)

Jun. 30, 2013

Dec. 31, 2012

Stockholders' equity:

Series A Preferred stock, par value (in dollars per share) $ 0.50 $ 0.50

Series A Preferred stock, authorized (in shares) 700,000 700,000

Series A Preferred stock, outstanding (in shares) 0 0

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, authorized (in shares) 10,000,000 10,000,000

Common stock, issued (in shares) 6,625,168 6,625,168

Treasury stock, shares (in shares) 285,352 260,632

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 41 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

PROVISION FOR INCOME TAXES
6 Months Ended

Jun. 30, 2013

PROVISION FOR INCOME TAXES [Abstract]

PROVISION FOR INCOME TAXES
7. PROVISION FOR INCOME TAXES

In determining our provision for income taxes, we consider all available information, including operating results, ongoing tax planning, and forecasts of future taxable income. The significant components of the Company's deferred tax assets pursuant to Accounting Standards Codification 740-10-50 consist of stock-based compensation and deferred revenues. For the six month period ended June 30, 2013, the provision for income taxes was $1.3 million. For the six month period ended June 30, 2013, the valuation allowance with respect to the Company’s net deferred tax assets remained unchanged. As of June 30, 2013, our remaining deferred tax assets were approximately $1.5 million.

For the six month period ended June 30, 2012 our provision for income taxes was $0.9 million, primarily a non-cash charge. For the six month period ended June 30, 2012, the valuation allowance with respect to the company’s net deferred tax assets remained unchanged. Our remaining deferred tax assets decreased by $0.4 million to approximately $2.6 million, primarily because we used our Orphan Drug Tax Credit to reduce our taxes payable, during six months ended June 30, 2012.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R20.xml IDEA: ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) 2.4.0.8080500 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)truefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_PayablesAndAccrualsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]2false 2us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Accounts payable and accrued expenses consisted of the following:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="width: 66%; vertical-align: top;"><div> </div></td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30<font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: top;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Trade accounts payable and accrued expenses</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">365,054</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$ 304,635</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accrued legal and other professional fees</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">129,822</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">61,147</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accrued payroll and related costs</div></td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">165,684</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">147,084</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.2pt; font-size: 10pt; font-weight: bold;">Total</div></td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">660,560</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><strong>$</strong></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><strong>512,866</strong></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr></table></div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.No definition available.false0Accounts Payable and Accrued ExpensesfalseACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/AccountsPayableAndAccruedExpensesTables12 XML 43 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Comprehensive Income (unaudited) (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Jun. 30, 2012

Consolidated Statements of Comprehensive Income (unaudited) [Abstract]

Net income $ 1,028,186 $ 666,682 $ 2,381,270 $ 1,409,072

Other comprehensive income (loss) 0 0 0 0

Comprehensive income $ 1,028,186 $ 666,682 $ 2,381,270 $ 1,409,072

X

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=16317811

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A5

-Appendix A

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net of tax amount of other comprehensive income (loss) attributable to both parent entity and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669619-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Balance Sheets (unaudited) (USD $)

Jun. 30, 2013

Dec. 31, 2012

Current assets:

Cash and cash equivalents $ 4,017,531 $ 3,383,737

Short-term investments 7,966,964 5,120,000

Accounts receivable, net 3,903,942 5,082,360

Income tax receivable 51,070 51,070

Deferred tax assets 79,482 88,910

Prepaid expenses and other current assets 411,110 149,724

Total current assets 16,430,099 13,875,801

Deferred royalty buy-down 2,750,000 2,750,000

Deferred tax assets - long term 1,492,509 1,484,141

Patent costs, net 248,160 280,322

Total assets 20,920,768 18,390,264

Current liabilities:

Accounts payable and accrued expenses 660,560 512,866

Deferred tax liability 382,704 0

Deferred revenue 78,328 133,524

Accrued liabilities of discontinued operations 78,138 78,138

Total current liabilities 1,199,730 724,528

Long-term deferred revenue 172,825 207,390

Stockholders' equity:

Series A Preferred stock, $.50 par value, 700,000 shares authorized; none outstanding 0 0

Common stock, $.001 par value; 10,000,000 shares authorized ; 6,625,168 shares issued at June 30, 2013 and December 31, 2012, respectively 6,625 6,625

Additional paid-in capital 20,794,154 20,688,706

Retained earnings (deficit) 2,070,441 (310,829)

Treasury stock, 285,352 and 260,632 shares at cost at June 30, 2013 and December 31, 2012, respectively (3,323,007) (2,926,156)

Total stockholders' equity 19,548,213 17,458,346

Total liabilities and stockholders' equity $ 20,920,768 $ 18,390,264

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_DeferredCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7, 8

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7, 8

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 48

-Paragraph 6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31931-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 41, 42, 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31928-109318

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxAssetsNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31931-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 41, 42, 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31928-109318

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxAssetsNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31931-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 41, 42, 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

For the disposal group, including a component of the entity (discontinued operation), carrying value of obligations incurred and payable pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include interest, rent, salaries, and utilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 47

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Section Appendix E

-Paragraph 289

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 9

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 5

-Subparagraph c

-Article 7

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.5(c))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_IncomeTaxesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 42, 45

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph g

-Article 7

+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Technical Bulletin (FTB)

-Number 85-6

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 45 R7.xml IDEA: Consolidated Statements of Cash Flows (unaudited) (Parenthetical) 2.4.0.8040100 - Statement - Consolidated Statements of Cash Flows (unaudited) (Parenthetical)truefalsefalse1false USDfalsefalse$c20130401to20130630http://www.sec.gov/CIK0000875622duration2013-04-01T00:00:002013-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$c20120401to20120630http://www.sec.gov/CIK0000875622duration2012-04-01T00:00:002012-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 2us-gaap_NoncashInvestingAndFinancingItemsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Supplemental disclosures of non-cash transactions:2false 3bstc_PatentCostsAccruedFromAuxiliumbstc_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse3000030000USD$falsetruefalse2truefalsefalse6400064000USD$falsetruefalsexbrli:monetaryItemTypemonetaryAccrued patent costs creditable against future royalties during the period.No definition available.false2Patent costs accrued from Auxilium3false 3us-gaap_AmortizationOfIntangibleAssetsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse1610016100USD$falsetruefalse2truefalsefalse2900029000USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 45 -Subparagraph a(2) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Patent amortization expensesfalseConsolidated Statements of Cash Flows (unaudited) (Parenthetical) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical23 XML 46 R17.xml IDEA: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) 2.4.0.8070200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)truefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_AccountingPoliciesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]2false 2us-gaap_BasisOfAccountingus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Basis of Presentation</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The accompanying consolidated financial statements are unaudited, but include all adjustments (consisting only of normal, recurring adjustments) which we consider necessary for a fair presentation of our financial position at such dates and the operating results and cash flows for those periods. Although we believe that the disclosures in our financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) has been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for quarterly reporting.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The information included in this Report should be read in conjunction with our </font>Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and our <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Annual Report on Form 10-K for the year ended December 31, 2012 filed with the SEC.</font></div></div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).No definition available.false0Basis of Presentation3false 2us-gaap_ConsolidationPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Principles of Consolidation</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The audited consolidated financial statements include the accounts of the Company and its subsidiary, Advance Biofactures Corp. (“ABC-NY”).</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 97-2 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 46R -Paragraph 4 -Subparagraph c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph k -Article 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 18 -Paragraph 5, 6, 16-19 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 140 -Paragraph 46 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 46R -Paragraph 4 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02, 03 -Article 3A Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 96-16 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 18 -Paragraph 20 -Subparagraph a(2) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 46R -Paragraph 14, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2197480 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.3A-02) -URI http://asc.fasb.org/extlink&oid=6959686&loc=d3e355033-122828 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 2-6 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 860 -SubTopic 40 -Section 45 -URI http://asc.fasb.org/section&trid=2197723 Reference 17: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2196966 Reference 18: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 325 -SubTopic 20 -URI http://asc.fasb.org/subtopic&trid=2197087 Reference 19: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=16385135&loc=d3e33801-111570 false0Principles of Consolidation4false 2us-gaap_UseOfEstimatesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Critical Accounting Policies, Estimates and Assumptions</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of management’s estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 94-6 -Paragraph 11, 14 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Critical Accounting Policies, Estimates and Assumptions5false 2us-gaap_CashAndCashEquivalentsPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Cash, Cash Equivalents and Short-term Investments</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Cash, cash equivalents and short-term investments are stated at market value. Cash equivalents include only securities having a maturity of three months or less at the time of purchase. The Company limits its credit risk associated with cash, cash equivalents and short-term investments by placing its investments with banks it believes are highly creditworthy and with highly rated money market funds, U.S. government securities, or short-term commercial paper.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 305 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2122427 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Financial Reporting Release (FRR) -Number 203 -Paragraph 02-03 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Technical Practice Aid (TPA) -Number 2110 -Paragraph 6 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 8, 9, 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Cash, Cash Equivalents and Short-term Investments6false 2us-gaap_FairValueMeasurementPolicyPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value Measurements</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Management believes that the carrying amounts of the Company’s financial instruments, including cash, cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of those instruments.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for fair value measurements, which may include, but is not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 35 -Paragraph 18G -URI http://asc.fasb.org/extlink&oid=15229074&loc=SL7494712-110257 false0Fair Value Measurements7false 2us-gaap_ConcentrationRiskCreditRiskus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Concentration of Credit Risk and Major Customers</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company maintains bank account balances, which, at times, may exceed insured limits. The Company has not experienced any losses with these accounts and believes that it is not exposed to any significant credit risk on cash.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company maintains its investment in FDIC insured certificates of deposits with several banks.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">At June 30, 2013, the accounts receivable balance of $3.9 million was primarily from two customers, comprised of $2.5 million (64% of total) from DFB and $1.4 million (36% of total) from Auxilium.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company has been dependent in each year on two customers who generate almost all its revenues. In the quarter ended June 30, 2013, the licensing and royalty revenues from Auxilium were $4.7 million (65% of total) and royalty revenues from DFB were $2.5 million (35% of total).</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for credit risk.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 55 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14537-108613 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number SOP94-6-1 -Paragraph 7, 11 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 107 -Paragraph 15A -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 113 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 825 -Section 55 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6487554&loc=d3e32600-158583 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13531-108611 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61082-112788 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61044-112788 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 01-6 -Paragraph 14 -Subparagraph m -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 55 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613 false0Concentration of Credit Risk and Major Customers8false 2us-gaap_RevenueRecognitionPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Revenue Recognition</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We currently recognize revenues resulting from product sales, the licensing and sublicensing of the use of our technology and from services we sometimes perform in connection with the licensed technology under the guidance of Accounting Standards Codification 605, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenue Recognition</font> (“ASC 605”).</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">If we determine that separate elements exist in a revenue arrangement under ASC 605, we recognize revenue for delivered elements only when the fair values of undelivered elements are known, when the associated earnings process is complete, when payment is reasonably assured and, to the extent the milestone amount relates to our performance obligation, when our customer confirms that we have met the requirements under the terms of the agreement.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenues, and their respective treatment for financial reporting purposes, are as follows:</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Product Sales</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We recognize revenue from product sales when there is persuasive evidence that an arrangement exists, title passes, the price is fixed or determinable and collectability is reasonably assured. No right of return exists for our products except in the case of damaged goods. To date, we have not experienced any significant returns of our products.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Net sales include the sales of the collagenase for laboratory use that are recognized at the time the product is shipped to customers for laboratory use.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Royalty/Mark-Up on Cost of Goods Sold / Earn-Out Revenue</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">For those arrangements for which royalty, mark-up on cost of goods sold or earn-out payment information becomes available and collectability is reasonably assured, we recognize revenue during the applicable period earned. For interim quarterly reporting purposes, when collectability is reasonably assured but a reasonable estimate of royalty, mark-up on cost of goods sold or earn-out payment revenues cannot be made, the royalty, mark-up on cost of goods sold or earn-out payment revenues are generally recognized in the quarter that the applicable licensee provides the written report and related information to us.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Under the Auxilium Agreement, we do not participate in the selling, marketing or manufacturing of products for which we receive royalties and a mark-up of the cost of goods sold revenues. The royalty and mark-up on cost of goods sold revenues will generally be recognized in the quarter that Auxilium provides the written reports and related information to us, that is, royalty and mark-up on cost of goods sold revenues are generally recognized one quarter following the quarter in which the underlying sales by Auxilium occurred.<font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </font>The royalties payable by Auxilium to us are subject to set-off for certain patent costs.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Under the DFB Agreement, pursuant to which we sold our topical collagenase business to DFB, we have the right to receive earn-out payments in the future based on sales of certain products.  Generally, under the DFB Agreement we would receive payments and a report within ninety (90) days from the end of each calendar year after DFB has sold the royalty-bearing product.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Licensing Revenue</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We include revenue recognized from upfront licensing, sublicensing and milestone payments in “License Revenues” in our consolidated statements of operations in this Report.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Upfront License and Sublicensing Fees</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We generally recognize revenue from upfront licensing and sublicensing fees when the agreement is signed, we have completed the earnings process and we have no ongoing performance obligation with respect to the arrangement. Nonrefundable upfront technology license for product candidates for which we are providing continuing services related to product development are deferred and recognized as revenue over the development period.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Milestones</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Milestones, in the form of additional license fees, typically represent nonrefundable payments to be received in conjunction with the achievement of a specific event identified in the contract, such as completion of specified development activities and/or regulatory submissions and/or approvals. We believe that a milestone represents the culmination of a distinct earnings process when it is not associated with ongoing research, development or other performance on our part. We recognize such milestones as revenue when they become due and collection is reasonably assured. When a milestone does not represent the culmination of a distinct earnings process, we recognize revenue in a manner similar to that of an upfront license fee.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The timing and amount of revenue that we recognize from licenses of technology, either from upfront fees or milestones where we are providing continuing services related to product development, is primarily dependent upon our estimates of the development period. We define the development period as the point from which research activities commence up to regulatory approval of either our, or our partners’ submission assuming no further research is necessary. As product candidates move through the development process, it is necessary to revise these estimates to consider changes to the product development cycle, such as changes in the clinical development plan, regulatory requirements, or various other factors, many of which may be outside of our control. Should the U.S. Food and Drug Administration or other regulatory agencies require additional data or information, we would adjust our development period estimates accordingly. The impact on revenue of changes in our estimates and the timing thereof is recognized prospectively over the remaining estimated product development period.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section B -Paragraph Question 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.B.Q1) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 22 -Paragraph 8, 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790 false0Revenue Recognition9false 2bstc_TreasuryStockPolicyTextBlockbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Treasury Stock</div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company accounts for treasury stock under the cost method and includes treasury stock as a component of stockholders’ equity.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for treasury stock.No definition available.false0Treasury Stock10false 2us-gaap_TradeAndOtherAccountsReceivablePolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Receivables, Deferred Revenue</font> and Allowance for Doubtful Accounts</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Trade accounts receivable are stated at the amount the Company expects to collect. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. We consider the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms.  Our accounts receivable balance is typically due from our two large pharmaceutical customers.  These companies have historically paid timely and have been financially stable organizations.  Due to the nature of the accounts receivable balance, we believe the risk of doubtful accounts is minimal.  If the financial condition of our customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required.  We provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after we have used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">At June 30, 2013, the accounts receivable balance of $3.9 million was primarily from two customers, comprised of $2.5 million from DFB and $1.4 million from Auxilium.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Deferred revenue of $0.5 million consists of <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">licensing fees related to the cash payments received under the Auxilium Agreement in prior years and amortized over the expected development period of certain indications for XIAFLEX.</font></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We recorded no material bad debt expense in each of the last three years.  The allowance for doubtful accounts balance was approximately $30,000 at June 30, 2013 and 2012.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3, 4 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 01-6 -Paragraph 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=7512638&loc=d3e5093-111524 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6378556&loc=d3e10133-111534 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 15 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=7512638&loc=d3e5212-111524 false0Receivables, Deferred Revenue and Allowance for Doubtful Accounts11false 2bstc_ReimbursableThirdPartyDevelopmentCostsPolicyTextBlockbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Reimbursable Third Party Development Costs</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We accrue patent expenses for research and development that are reimbursable by us under the Auxilium Agreement.  We capitalize certain patent costs related to estimated third party development costs that are reimbursable under the Auxilium Agreement. As of <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">June 30, 2013</font> our net reimbursable third party patent costs accrual was approximately $30,000.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for reimbursable third party development costs.No definition available.false0Reimbursable Third Party Development Costs12false 2bstc_RoyaltyBuyDownPolicyTextBlockbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Royalty Buy-Down</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On March 31, 2012, we entered into an amendment to our existing agreement with Dr. Martin K. Gelbard, dated August 27, 2008, related to our future royalty obligations for Peyronie’s disease. The amendment enables us to buy down a portion of our future royalty obligations in exchange for an initial cash payment of $1.5 million and five additional cash payments payable upon the occurrence of a milestone event.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">As of June 30, 2013, we have capitalized $2.75 million related to this agreement which will be amortized over approximately five years beginning on the date of the first commercial sale of XIAFLEX for the treatment of Peyronie’s disease, which represents the period estimated to be benefited using the straight-line method. In accordance with Accounting Standards Codification 350,<font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> Intangibles, Goodwill and Other</font>, the Company amortizes intangible assets with finite lives in a manner that reflects the pattern in which the economic benefits of the assets are consumed or otherwise used up. If that pattern cannot be reliably determined, the assets are amortized using the straight-line method.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for royalty buy down.No definition available.false0Royalty Buy-Down13false 2us-gaap_ResearchAndDevelopmentExpensePolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Research and Development Expenses</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Research and development </font>(“R&D”) <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">expenses </font>include, but are not limited to, internal costs, such as salaries and benefits, costs of materials, lab expense, facility costs and overhead. R&D expenses also consist of third party costs, such as medical professional fees, product costs used in clinical trials, consulting fees and costs associated with clinical study arrangements. We may fund R&D at medical research institutions under agreements that are generally cancelable. All of these costs are charged to R&D as incurred, which may be measured by percentage of completion, contract milestones, patient enrollment, or the passage of time.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2127266 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Research and Development -URI http://asc.fasb.org/extlink&oid=6523717 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 8, 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 6 -Paragraph 5, 6, 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 42 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Research and Development Expenses14false 2bstc_ClinicalTrialExpensesPolicyTextBlockbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Clinical Trial Expenses</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Our cost accruals for clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with various clinical trial centers and clinical research organizations. In the normal course of business we contract with third parties to perform various clinical trial activities in the ongoing development of potential drugs. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, the completion of portions of the clinical trial, or similar conditions. The objective of our accrual policy is to match the recording of expenses in our financial statements to the actual cost of services received and efforts expended. As such, expenses related to each patient enrolled in a clinical trial are recognized ratably beginning upon entry into the trial and over the course of the patient’s continued participation in the trial. In the event of early termination of a clinical trial, we accrue an amount based on our estimate of the remaining non-cancelable obligations associated with the winding down of the clinical trial. Our estimates and assumptions could differ significantly from the amounts that may actually be incurred.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for clinical trial expenses.No definition available.false0Clinical Trial Expenses15false 2us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Stock-Based Compensation</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company has two stock-based compensation plans in effect. Accounting Standards Codification 718, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Compensation - Stock Compensation </font>(“ASC 718”), requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based awards including stock options and common stock issued to our employees and directors under our stock plans. It requires companies to estimate the fair value of share-based awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service periods in our consolidated statements of operations.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Under the ASC 718, we estimate the fair value of our employee stock awards at the date of grant using the Black-Scholes option-pricing model, which requires the use of certain subjective assumptions. The most significant of these assumptions are our estimates of the expected volatility of the market price of our stock and the expected term of an award. When establishing an estimate of the expected term of an award, we consider the vesting period for the award, our recent historical experience of employee stock option exercises (including forfeitures) and the expected volatility. <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">When there is uncertainty in the factors used to determine the expected term of an award, we use the simplified method. </font>As required under the accounting rules, we review our valuation assumptions at each grant date and, as a result, our valuation assumptions used to value employee stock-based awards granted in future periods may change. We granted to one of our consultants 15,000 stock options, valued at approximately $79,000, during the three month period ended June 30, 2013. We used the Black-Scholes valuation model to estimate the value of options using 37% volatility, a risk free rate of 0.68% and average exercise period of five years.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Further, ASC 718 requires that employee stock-based compensation costs be recognized over the requisite service period, or the vesting period, in a manner similar to all other forms of compensation paid to employees. The allocation of employee stock-based compensation costs to each operating expense line are estimated based on specific employee headcount information at each grant date and estimated stock option forfeiture rates and revised, if necessary, in future periods if actual employee headcount information or forfeitures differ materially from those estimates. As a result, the amount of employee stock-based compensation costs we recognize in each operating expense category in future periods may differ significantly from what we have recorded in the current period.</div><div><br /></div><div>Stock-based compensation expense recognized under ASC 718 was as follows:</div><div> </div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Six Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Research and development</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">79,049</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">122,679</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">92,249</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">144,817</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">General and administrative</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">13,200</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">13,200</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">30,868</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.2pt; font-size: 10pt; font-weight: bold;">Total stock-based compensation expense</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">79,049</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">135,879</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">105,449</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">175,685</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr></table><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Stock Option Activity</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">A summary of our stock option activity during the six months ended June 30, 2013 is presented below:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="width: 73.32%; vertical-align: top;"><div> </div></td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Total Number</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" style="white-space: nowrap; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Weighted-Average</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;">Options</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">of Shares</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Exercise Price</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding as of December 31, 2012</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,182,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">8.90</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Granted</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">15,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">15.85</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Forfeited</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Exercised</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expired</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Outstanding as of </font>June 30, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">1,197,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">8.99</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Exercisable as of </font>June 30, 2013</td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">1,177,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">8.64</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"></td></tr></table><div> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">During the six months ended June 30, 2013 and 2012, zero and $78,000, respectively, were received from stock options exercised by option holders.</div><div style="text-align: left;"><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The aggregate intrinsic value of options outstanding and exercisable as of June 30, 2013 was approximately $8.2 million. Aggregate intrinsic value represents the total pre-tax intrinsic value based on the closing price of our common stock of $15.60 on June 28, 2013, which would have been received by the option holders had all option holders exercised their options as of that date. We have no unrecognized compensation cost related to stock options outstanding as of June 30, 2013.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b),(f) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2228939 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 06-11 -Paragraph 7 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Stock-Based Compensation16false 2us-gaap_PropertyPlantAndEquipmentPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Property, Plant and Equipment</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Property, plant and equipment are stated at cost, less accumulated depreciation. Machinery and equipment, furniture and fixtures, and autos are depreciated on the straight-line basis over their estimated useful lives of 5 to 10 years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the remaining life of the lease.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for property, plant and equipment which may include the basis of such assets, depreciation methods used and estimated useful lives, the entity's capitalization policy, including its accounting treatment for costs incurred for repairs and maintenance activities, whether such asset balances include capitalized interest and the method by which such is calculated, how disposals of such assets are accounted for and how impairment of such assets is assessed and recognized.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2155824 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 22 -Paragraph 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section C -Paragraph 5 -Chapter 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 5 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 7 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 34 -Paragraph 8, 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Property, Plant and Equipment17false 2us-gaap_IncomeTaxPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Provision for Income Taxes</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Deferred tax assets and liabilities are recognized based on the expected future tax consequences, using current tax rates, of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We use the asset and liability method of accounting for income taxes, as set forth in Accounting Standards Codification 740-10-25-2. Under this method, deferred income taxes, when required, are provided on the basis of the difference between the financial reporting and income tax basis of assets and liabilities at the statutory rates enacted for future periods. </font>In accordance with Accounting Standards Codification 740-10-45-25, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Income Statement Classification of Interest and Penalties</font>, we classify interest associated with income taxes under interest expense and tax penalties under other.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 4 -Paragraph 11 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 48 -Paragraph 20 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32247-109318 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 30 -URI http://asc.fasb.org/subtopic&trid=2144749 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 740 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2144681 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 17 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32280-109318 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 6-34, 43, 47, 49 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Provision for Income TaxesfalseSUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesPolicies117 XML 47 R16.xml IDEA: SUBSEQUENT EVENTS 2.4.0.8060900 - Disclosure - SUBSEQUENT EVENTStruefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_SubsequentEventsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0SUBSEQUENT EVENTS [Abstract]2false 2us-gaap_SubsequentEventsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">9. SUBSEQUENT EVENTS</div><div style="text-align: justify;"><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We have evaluated subsequent events for recognition or disclosure through the time of filing these consolidated financial statements on Form 10-Q with the SEC on August 9, 2013.</div></div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.No definition available.false0SUBSEQUENT EVENTSfalseSUBSEQUENT EVENTSUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/SubsequentEvents12 XML 48 R27.xml IDEA: PROVISION FOR INCOME TAXES (Details) 2.4.0.8090700 - Disclosure - PROVISION FOR INCOME TAXES (Details)truefalsefalse1false USDfalsefalse$c20130401to20130630http://www.sec.gov/CIK0000875622duration2013-04-01T00:00:002013-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$c20120401to20120630http://www.sec.gov/CIK0000875622duration2012-04-01T00:00:002012-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$c20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$c20120101to20120630http://www.sec.gov/CIK0000875622duration2012-01-01T00:00:002012-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1us-gaap_IncomeTaxDisclosureAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0PROVISION FOR INCOME TAXES [Abstract]2false 2us-gaap_IncomeTaxExpenseBenefitus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse542009542009USD$falsetruefalse2truefalsefalse390651390651USD$falsetruefalse3truefalsefalse12614591261459USD$falsetruefalse4truefalsefalse906228906228USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Income Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6515339 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 45 -Subparagraph a, b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Net income tax expense (benefit)3false 2us-gaap_IncreaseDecreaseInDeferredIncomeTaxesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedTerseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse10601060falsefalsefalse4truefalsefalse416055416055falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Decrease in deferred tax assets4false 2us-gaap_DeferredTaxAssetsLiabilitiesNetus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse15000001500000USD$falsetruefalse2truefalsefalse26000002600000USD$falsetruefalse3truefalsefalse15000001500000USD$falsetruefalse4truefalsefalse26000002600000USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319 false2Deferred tax assetsfalsePROVISION FOR INCOME TAXES (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/ProvisionForIncomeTaxesDetails44 XML 49 R18.xml IDEA: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) 2.4.0.8080200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)truefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_AccountingPoliciesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]2false 2us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>Stock-based compensation expense recognized under ASC 718 was as follows:</div><div> </div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Six Months Ended</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 32%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Research and development</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">79,049</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">122,679</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">92,249</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">144,817</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">General and administrative</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">13,200</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">13,200</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">30,868</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.2pt; font-size: 10pt; font-weight: bold;">Total stock-based compensation expense</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">79,049</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">135,879</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">105,449</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">175,685</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr></table></div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 64 -Subparagraph b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph g(1) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Stock-Based Compensation Expense3false 2us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">A summary of our stock option activity during the six months ended June 30, 2013 is presented below:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="width: 73.32%; vertical-align: top;"><div> </div></td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Total Number</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" style="white-space: nowrap; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Weighted-Average</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;">Options</div></td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">of Shares</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Exercise Price</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding as of December 31, 2012</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,182,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">8.90</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Granted</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">15,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">15.85</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Forfeited</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Exercised</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; background-color: #cceeff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expired</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Outstanding as of </font>June 30, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">1,197,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">8.99</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 73.32%; vertical-align: top;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"></td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 73.32%; vertical-align: top; font-weight: bold;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Exercisable as of </font>June 30, 2013</td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">1,177,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"></td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">8.64</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"></td></tr></table></div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Summary of Stock Option ActivityfalseSUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesTables13 XML 50 R3.xml IDEA: Consolidated Balance Sheets (unaudited) (Parenthetical) 2.4.0.8010100 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical)truefalsefalse1false USDfalsefalse$c20130630http://www.sec.gov/CIK0000875622instant2013-06-30T00:00:000001-01-01T00:00:00U001Standardhttp://www.xbrl.org/2003/instancesharesxbrli0U003Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2false USDfalsefalse$c20121231http://www.sec.gov/CIK0000875622instant2012-12-31T00:00:000001-01-01T00:00:00U001Standardhttp://www.xbrl.org/2003/instancesharesxbrli0U003Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$1true 3us-gaap_StockholdersEquityAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Stockholders' equity:2false 4us-gaap_PreferredStockParOrStatedValuePerShareus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse0.500.50USD$falsetruefalse2truefalsefalse0.500.50USD$falsetruefalsenum:perShareItemTypedecimalFace amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false3Series A Preferred stock, par value (in dollars per share)3false 4us-gaap_PreferredStockSharesAuthorizedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse700000700000falsefalsefalse2truefalsefalse700000700000falsefalsefalsexbrli:sharesItemTypesharesThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false1Series A Preferred stock, authorized (in shares)4false 4us-gaap_PreferredStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse00falsefalsefalse2truefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false1Series A Preferred stock, outstanding (in shares)5false 4us-gaap_CommonStockParOrStatedValuePerShareus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse0.0010.001USD$falsetruefalse2truefalsefalse0.0010.001USD$falsetruefalsenum:perShareItemTypedecimalFace amount or stated value of common stock per share; generally not indicative of the fair market value per share.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false3Common stock, par value (in dollars per share)6false 4us-gaap_CommonStockSharesAuthorizedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse1000000010000000falsefalsefalse2truefalsefalse1000000010000000falsefalsefalsexbrli:sharesItemTypesharesThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Common stock, authorized (in shares)7false 4us-gaap_CommonStockSharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse66251686625168falsefalsefalse2truefalsefalse66251686625168falsefalsefalsexbrli:sharesItemTypesharesTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Common stock, issued (in shares)8false 4us-gaap_TreasuryStockSharesus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse285352285352falsefalsefalse2truefalsefalse260632260632falsefalsefalsexbrli:sharesItemTypesharesNumber of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Treasury stock, shares (in shares)falseConsolidated Balance Sheets (unaudited) (Parenthetical) (USD $)UnKnownNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://biospecifics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical28 XML 51 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2013

Customer

Jun. 30, 2012

Mar. 31, 2012

Payment

Jun. 30, 2013

Quarter

Customer

Jun. 30, 2012

Jun. 28, 2013

Dec. 31, 2012

Concentration of Credit Risk and Major Customers [Abstract]

Accounts receivable $ 3,903,942 $ 3,903,942 $ 5,082,360

Number of customers 2 2

Royalty revenue 3,197,603 2,491,313 6,630,503 4,391,282

Royalty / Mark-up on Cost of Goods Sold / Earn-Out Revenue [Abstract]

Number of quarters after which revenue is recognized (in quarters) 1

Number of days after calendar year, after which payments and report are received 90 days

Number of years for which bad debt expense not recorded 3 years

Allowance for doubtful accounts 30,000 30,000 30,000 30,000

Reimbursable Third Party Development Costs [Abstract]

Accrued patent costs 30,000 30,000

Royalty Buy-Down [Abstract]

Initial payment for royalty buy down 1,500,000 0 1,500,000

Number of additional cash payments for royalty buy down 5

Deferred royalty buy-down 2,750,000 2,750,000 2,750,000

Deferred costs, amortization period 5 years

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock granted during period, value of stock options 79,000

Expected volatility rate 37.00%

Risk free interest rate 0.68%

Average exercise period 5 years

Stock-based compensation expense 79,049 135,879 105,449 175,685

Total number of shares

Outstanding, beginning of period (in shares) 1,182,000

Granted (in shares) 15,000

Forfeited (in shares) 0

Exercised (in shares) 0

Expired (in shares) 0

Outstanding, end of period (in shares) 1,197,000 1,197,000

Exercisable, end of period (in shares) 1,177,000 1,177,000

Weighted-Average Exercise Price

Outstanding, beginning of period (in dollars per share) $ 8.90

Granted (in dollars per share) $ 15.85

Forfeited (in dollars per share) $ 0

Exercised (in dollars per share) $ 0

Expired (in dollars per share) $ 0

Outstanding, end of period (in dollars per share) $ 8.99 $ 8.99

Exercisable, end of period (in dollars per share) $ 8.64 $ 8.64

Proceeds from stock option exercises 0 78,000

Aggregate intrinsic value of options outstanding and exercisable 8,200,000 8,200,000

Closing price of Company stock (in dollars per share) $ 15.60

Unrecognized compensation cost related to non-vested stock options outstanding 0 0

Minimum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful life of property, plant and equipment 5 years

Maximum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful life of property, plant and equipment 10 years

Research and Development [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation expense 79,049 122,679 92,249 144,817

General and Administrative [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation expense 0 13,200 13,200 30,868

Auxilium [Member]

Concentration of Credit Risk and Major Customers [Abstract]

Accounts receivable 1,400,000 1,400,000

Royalty revenue 4,700,000

Deferred revenue 500,000 500,000

Auxilium [Member] | Accounts Receivable [Member]

Concentration of Credit Risk and Major Customers [Abstract]

Concentration risk percentage (in hundredths) 36.00%

Auxilium [Member] | Licensing, Consulting And Royalty Revenue [Member]

Concentration of Credit Risk and Major Customers [Abstract]

Concentration risk percentage (in hundredths) 65.00%

DFB Biotech Inc. [Member]

Concentration of Credit Risk and Major Customers [Abstract]

Accounts receivable 2,500,000 2,500,000

Royalty revenue $ 2,500,000

DFB Biotech Inc. [Member] | Accounts Receivable [Member]

Concentration of Credit Risk and Major Customers [Abstract]

Concentration risk percentage (in hundredths) 64.00%

DFB Biotech Inc. [Member] | Licensing, Consulting And Royalty Revenue [Member]

Concentration of Credit Risk and Major Customers [Abstract]

Concentration risk percentage (in hundredths) 35.00%

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for patents. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

No definition available.

+ Details

Name: bstc_AccruedPatentCosts

Namespace Prefix: bstc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: bstc_ConcentrationOfCreditRiskAndMajorCustomersAbstract

Namespace Prefix: bstc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The duration period related to the amortization of deferred cost.

+ References

No definition available.

+ Details

Name: bstc_DeferredCostsAmortizationPeriod

Namespace Prefix: bstc_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of additional cash payments for royalty buy-down.

+ References

No definition available.

+ Details

Name: bstc_NumberOfAdditionalCashPaymentsForRoyaltyBuyDown

Namespace Prefix: bstc_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of Customers from which Company is getting revenue is being generated.

+ References

No definition available.

+ Details

Name: bstc_NumberOfCustomers

Namespace Prefix: bstc_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of days after calendar year after which payments and report are received.

+ References

No definition available.

+ Details

Name: bstc_NumberOfDaysAfterCalendarYearAfterWhichPaymentsAndReportAreReceived

Namespace Prefix: bstc_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of quarters after which revenue is recognized following the quarter in which sales is occurred.

+ References

No definition available.

+ Details

Name: bstc_NumberOfQuartersAfterWhichRevenueIsRecognized

Namespace Prefix: bstc_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

This line item represents the number of years for which material bad debt expense is not recorded.

+ References

No definition available.

+ Details

Name: bstc_NumberOfYearsForWhichBadDebtExpenseNotRecorded

Namespace Prefix: bstc_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash outflow from initial payment related to the purchase of royalty interests.

+ References

No definition available.

+ Details

Name: bstc_PaymentForRoyaltyBuyDown

Namespace Prefix: bstc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: bstc_ReimbursableThirdPartyDevelopmentCostsAbstract

Namespace Prefix: bstc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: bstc_RoyaltyBuyDownAbstract

Namespace Prefix: bstc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: bstc_RoyaltyMarkUpOnCostOfGoodsSoldEarnOutRevenueAbstract

Namespace Prefix: bstc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph g(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=7512638&loc=d3e5074-111524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13531-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_DeferredCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate unrecognized cost of option awards made to employees under a stock option plan or plans, that have yet to vest.

+ References

No definition available.

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

No definition available.

+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(c), d(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(g)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(f)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. This element is not the recognition of equity-based compensation expense in pursuant to FAS 123R. That element is AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue (Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Value).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 30

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6743629&loc=d3e3913-113898

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 30

-Section 35

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418191&loc=d3e15009-113911

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 52 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

PATENT COSTS
6 Months Ended

Jun. 30, 2013

PATENT COSTS [Abstract]

PATENT COSTS
6. PATENT COSTS

We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 2 to 14 years, and review for impairment on a quarterly basis and when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.

As of June 30, 2013, the Company’s capitalized costs related to certain patent costs paid by Auxilium on behalf of the Company, which are reimbursable to Auxilium under the Auxilium Agreement. These patent costs are creditable against future royalty revenues. For each period presented below net patent costs consisted of:

June 30,

December 31,

2013

2012

Patents

$
472,375

$
472,375

Accumulated Amortization

(224,215
)

(192,053
)

$
248,160

$
280,322

The amortization expense for patents for the six months ended June 30, 2013 was approximately $32,000. In the comparable period of 2012, the amortization expense for patents was approximately $29,000. The estimated aggregate amortization expense for each of the next five years is approximately as follows:

2014

$
53,000

2015

25,000

2016

20,000

2017

20,000

2018

20,000

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16373-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16265-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 44, 45, 46

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R21.xml IDEA: PATENT COSTS (Tables) 2.4.0.8080600 - Disclosure - PATENT COSTS (Tables)truefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0PATENT COSTS [Abstract]2false 2us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">For each period presented below net patent costs consisted of:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="width: 56%; vertical-align: top;"><div> </div></td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30<font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 56%; vertical-align: top;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 56%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Patents</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">472,375</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">472,375</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 56%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accumulated Amortization</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(224,215</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(192,053</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 56%; vertical-align: top;"><div> </div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">248,160</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">280,322</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr></table></div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16265-109275 false0Net Patent Costs3false 2us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The estimated aggregate amortization expense for each of the next five years is approximately as follows:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 60%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="background-color: #cceeff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2014</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">53,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2015</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">25,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2016</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">20,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2017</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">20,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2018</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">20,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr></table></div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.No definition available.false0Estimated Aggregate Future Amortization ExpensefalsePATENT COSTS (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/PatentCostsTables13 XML 54 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

SUBSEQUENT EVENTS
6 Months Ended

Jun. 30, 2013

SUBSEQUENT EVENTS [Abstract]

SUBSEQUENT EVENTS
9. SUBSEQUENT EVENTS

We have evaluated subsequent events for recognition or disclosure through the time of filing these consolidated financial statements on Form 10-Q with the SEC on August 9, 2013.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R22.xml IDEA: ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) 2.4.0.8090100 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)truefalsefalse1false falsefalsec20130101to20130630_RangeAxis_MinimumMemberhttp://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]2false 4bstc_NumberOfCountriesUnderCollaborationAgreementbstc_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse2828falsefalsefalsexbrli:integerItemTypeintegerNumber of countries the entity has collaboration agreement for exclusive rights to commercialize.No definition available.false0Number of countries under the collaboration agreement3false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2false truefalsec20130101to20130630_RangeAxis_MinimumMemberhttp://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseMinimum [Member]us-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MinimumMemberus-gaap_RangeAxisexplicitMembernanafalse0Minimum [Member]4true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]5false 4bstc_BaselineMeasurementPeriodForLipomaVolumebstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse001 monthfalsefalsefalsexbrli:durationItemTypenaRefers to baseline measurement period for Lipoma volume.No definition available.false0Baseline measurement period for Lipoma volume6false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse3false truefalsec20130101to20130630_RangeAxis_MaximumMemberhttp://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseMaximum [Member]us-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMembernanafalse0Maximum [Member]7true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]8false 4bstc_BaselineMeasurementPeriodForLipomaVolumebstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse003 monthsfalsefalsefalsexbrli:durationItemTypenaRefers to baseline measurement period for Lipoma volume.No definition available.false0Baseline measurement period for Lipoma volume9false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse4false truefalsec20130630_StatementGeographicalAxis_SegmentGeographicalGroupsOfCountriesGroupOneMemberhttp://www.sec.gov/CIK0000875622instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseCentral Eastern Europe Countries [Member]us-gaap_StatementGeographicalAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_SegmentGeographicalGroupsOfCountriesGroupOneMemberus-gaap_StatementGeographicalAxisexplicitMemberU004Standardhttp://www.xbrl.org/2003/instancepurexbrli0nanafalse0Central Eastern Europe Countries [Member]10true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]11false 4bstc_NumberOfCountriesUnderCollaborationAgreementbstc_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse1818falsefalsefalsexbrli:integerItemTypeintegerNumber of countries the entity has collaboration agreement for exclusive rights to commercialize.No definition available.false0Number of countries under the collaboration agreement12false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse5false truefalsec20130630_StatementGeographicalAxis_SegmentGeographicalGroupsOfCountriesGroupTwoMemberhttp://www.sec.gov/CIK0000875622instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseMiddle Eastern & North African Countries [Member]us-gaap_StatementGeographicalAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_SegmentGeographicalGroupsOfCountriesGroupTwoMemberus-gaap_StatementGeographicalAxisexplicitMemberU004Standardhttp://www.xbrl.org/2003/instancepurexbrli0nanafalse0Middle Eastern & North African Countries [Member]13true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]14false 4bstc_NumberOfCountriesUnderCollaborationAgreementbstc_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse2222falsefalsefalsexbrli:integerItemTypeintegerNumber of countries the entity has collaboration agreement for exclusive rights to commercialize.No definition available.false0Number of countries under the collaboration agreementfalseORGANIZATION AND DESCRIPTION OF BUSINESS (Details)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/OrganizationAndDescriptionOfBusinessDetails114 XML 56 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

ACCOUNTS PAYABLE AND ACCRUED EXPENSES
6 Months Ended

Jun. 30, 2013

ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES
5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consisted of the following:

June 30,

December 31,

2013

2012

Trade accounts payable and accrued expenses

$
365,054

$
$ 304,635

Accrued legal and other professional fees

129,822

61,147

Accrued payroll and related costs

165,684

147,084

Total

$
660,560
$ 512,866

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Cash Flows (unaudited) (Parenthetical) (USD $)
3 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Supplemental disclosures of non-cash transactions:

Patent costs accrued from Auxilium $ 30,000 $ 64,000

Patent amortization expenses $ 16,100 $ 29,000

X

- Definition

Accrued patent costs creditable against future royalties during the period.

+ References

No definition available.

+ Details

Name: bstc_PatentCostsAccruedFromAuxilium

Namespace Prefix: bstc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph a(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 R13.xml IDEA: PATENT COSTS 2.4.0.8060600 - Disclosure - PATENT COSTStruefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0PATENT COSTS [Abstract]2false 2us-gaap_IntangibleAssetsDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">6. PATENT COSTS</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 2 to 14 years, and review for impairment on a quarterly basis and when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">As of June 30, 2013, the Company’s capitalized costs related to certain patent costs paid by Auxilium on behalf of the Company, which are reimbursable to Auxilium under the Auxilium Agreement.  These patent costs are creditable against future royalty revenues.<font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> For each period presented below net patent costs consisted of:</font></div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 80%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="width: 56%; vertical-align: top;"><div> </div></td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">June 30<font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 56%; vertical-align: top;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 56%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Patents</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">472,375</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">472,375</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 56%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accumulated Amortization</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(224,215</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(192,053</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 56%; vertical-align: top;"><div> </div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">248,160</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">280,322</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr></table><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The amortization expense for patents for the six months ended June 30, 2013 was approximately $32,000. </font>In the comparable period of 2012, <font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">the amortization expense for patents was approximately $29,000. The estimated aggregate amortization expense for each of the next five years is approximately as follows:</font></div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 60%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="background-color: #cceeff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2014</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">53,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2015</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">25,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2016</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">20,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2017</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">20,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 48%; vertical-align: top;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2018</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: top;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">20,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: top;"> </td></tr></table></div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for all or part of the information related to intangible assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16373-109275 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16265-109275 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 44, 45, 46 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0PATENT COSTSfalsePATENT COSTSUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/PatentCosts12 XML 60 R23.xml IDEA: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) 2.4.0.8090200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)truefalsefalse1false USDfalsefalse$c20130401to20130630http://www.sec.gov/CIK0000875622duration2013-04-01T00:00:002013-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170U005Standardhttp://biospecifics.com/20130630Customerbstc0U001Standardhttp://www.xbrl.org/2003/instancesharesxbrli0U003Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2false USDfalsefalse$c20120401to20120630http://www.sec.gov/CIK0000875622duration2012-04-01T00:00:002012-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$c20120101to20120331http://www.sec.gov/CIK0000875622duration2012-01-01T00:00:002012-03-31T00:00:00U007Standardhttp://biospecifics.com/20130630Paymentbstc0U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$c20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00U004Standardhttp://www.xbrl.org/2003/instancepurexbrli0U001Standardhttp://www.xbrl.org/2003/instancesharesxbrli0U006Standardhttp://biospecifics.com/20130630Quarterbstc0U003Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170U005Standardhttp://biospecifics.com/20130630Customerbstc0USDUSD$5false USDfalsefalse$c20120101to20120630http://www.sec.gov/CIK0000875622duration2012-01-01T00:00:002012-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false USDfalsefalse$c20130628http://www.sec.gov/CIK0000875622instant2013-06-28T00:00:000001-01-01T00:00:00U003Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$7false USDfalsefalse$c20121231http://www.sec.gov/CIK0000875622instant2012-12-31T00:00:000001-01-01T00:00:00U001Standardhttp://www.xbrl.org/2003/instancesharesxbrli0U003Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 4bstc_ConcentrationOfCreditRiskAndMajorCustomersAbstractbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Concentration of Credit Risk and Major Customers [Abstract]2false 5us-gaap_AccountsReceivableNetCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse39039423903942USD$falsetruefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse39039423903942USD$falsetruefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse50823605082360USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 false2Accounts receivable3false 5bstc_NumberOfCustomersbstc_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse22falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse22falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:decimalItemTypedecimalNumber of Customers from which Company is getting revenue is being generated.No definition available.false256Number of customers4false 5us-gaap_RoyaltyRevenueus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse31976033197603USD$falsefalsefalse2truefalsefalse24913132491313USD$falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse66305036630503USD$falsefalsefalse5truefalsefalse43912824391282USD$falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRevenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Royalty revenue5true 2bstc_RoyaltyMarkUpOnCostOfGoodsSoldEarnOutRevenueAbstractbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Royalty / Mark-up on Cost of Goods Sold / Earn-Out Revenue [Abstract]6false 3bstc_NumberOfQuartersAfterWhichRevenueIsRecognizedbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse11falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerThe number of quarters after which revenue is recognized following the quarter in which sales is occurred.No definition available.false256Number of quarters after which revenue is recognized (in quarters)7false 3bstc_NumberOfDaysAfterCalendarYearAfterWhichPaymentsAndReportAreReceivedbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse0090 daysfalsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaThe number of days after calendar year after which payments and report are received.No definition available.false0Number of days after calendar year, after which payments and report are received8false 2bstc_NumberOfYearsForWhichBadDebtExpenseNotRecordedbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse003 yearsfalsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaThis line item represents the number of years for which material bad debt expense is not recorded.No definition available.false0Number of years for which bad debt expense not recorded9false 2us-gaap_AllowanceForDoubtfulAccountsReceivableus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse3000030000USD$falsefalsefalse2truefalsefalse3000030000USD$falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse3000030000USD$falsefalsefalse5truefalsefalse3000030000USD$falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFor an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=7512638&loc=d3e5074-111524 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.10) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 false2Allowance for doubtful accounts10true 2bstc_ReimbursableThirdPartyDevelopmentCostsAbstractbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Reimbursable Third Party Development Costs [Abstract]11false 3bstc_AccruedPatentCostsbstc_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse3000030000USD$falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse3000030000USD$falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred through that date and payable for patents. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).No definition available.false2Accrued patent costs12true 2bstc_RoyaltyBuyDownAbstractbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Royalty Buy-Down [Abstract]13false 3bstc_PaymentForRoyaltyBuyDownbstc_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse15000001500000USD$falsefalsefalse4truefalsefalse00USD$falsefalsefalse5truefalsefalse15000001500000USD$falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow from initial payment related to the purchase of royalty interests.No definition available.false2Initial payment for royalty buy down14false 3bstc_NumberOfAdditionalCashPaymentsForRoyaltyBuyDownbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse55falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerThe number of additional cash payments for royalty buy-down.No definition available.false256Number of additional cash payments for royalty buy down15false 3us-gaap_DeferredCostsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse27500002750000USD$falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse27500002750000USD$falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse27500002750000USD$falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 17 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.10) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 false2Deferred royalty buy-down16false 3bstc_DeferredCostsAmortizationPeriodbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse005 yearsfalsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaThe duration period related to the amortization of deferred cost.No definition available.false0Deferred costs, amortization period17true 3us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]18false 4us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse7900079000USD$falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. This element is not the recognition of equity-based compensation expense in pursuant to FAS 123R. That element is AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue (Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Value).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 30 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6743629&loc=d3e3913-113898 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 30 -Section 35 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6418191&loc=d3e15009-113911 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Stock granted during period, value of stock options19false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truetruefalse0.370.37falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsenum:percentItemTypepureThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph e(2)(b) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Expected volatility rate20false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truetruefalse0.00680.0068falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsenum:percentItemTypepureThe risk-free interest rate assumption that is used in valuing an option on its own shares.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph e(2)(d) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Risk free interest rate21false 4us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse005 yearsfalsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaExpected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.D.2) -URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section D -Subsection 2 false0Average exercise period22false 4us-gaap_AllocatedShareBasedCompensationExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse7904979049USD$falsefalsefalse2truefalsefalse135879135879USD$falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse105449105449USD$falsefalsefalse5truefalsefalse175685175685USD$falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 64 -Subparagraph b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph g(1) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F false2Stock-based compensation expense23true 3us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForwardus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Total number of shares24false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberus-gaap_truenainstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse11820001182000falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesThe number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph b(1)(a) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph b(1)(b) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false1Outstanding, beginning of period (in shares)25false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse1500015000falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesGross number of share options (or share units) granted during the period.No definition available.false1Granted (in shares)26false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph b(1)(f) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false1Forfeited (in shares)27false 4us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercisedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of share options (or share units) exercised during the current period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Exercised (in shares)28false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(4) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph b(1)(g) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false1Expired (in shares)29false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse11970001197000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse11970001197000falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesThe number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph b(1)(a) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph b(1)(b) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false1Outstanding, end of period (in shares)30false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse11770001177000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse11770001177000falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph b(1)(c), d(2) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false1Exercisable, end of period (in shares)31true 3us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforwardus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Weighted-Average Exercise Price32false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceus-gaap_truenainstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse8.908.90USD$falsetruefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph b(1)(a) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false3Outstanding, beginning of period (in dollars per share)33false 4us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse15.8515.85USD$falsetruefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalWeighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.No definition available.false3Granted (in dollars per share)34false 4us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse00USD$falsetruefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.No definition available.false3Forfeited (in dollars per share)35false 4us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse00USD$falsetruefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalWeighted average price at which option holders acquired shares when converting their stock options into shares.No definition available.false3Exercised (in dollars per share)36false 4us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePriceus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse00USD$falsetruefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.No definition available.false3Expired (in dollars per share)37false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse8.998.99USD$falsetruefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse8.998.99USD$falsetruefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph b(1)(a) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false3Outstanding, end of period (in dollars per share)38false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePriceus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse8.648.64USD$falsetruefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse8.648.64USD$falsetruefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph b(1)(c) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false3Exercisable, end of period (in dollars per share)39false 3us-gaap_ProceedsFromStockOptionsExercisedus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse00USD$falsefalsefalse5truefalsefalse7800078000USD$falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (j) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph i -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Proceeds from stock option exercises40false 3us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1us-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse82000008200000USD$falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse82000008200000USD$falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false2Aggregate intrinsic value of options outstanding and exercisable41false 3us-gaap_SharePriceus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse15.6015.60USD$falsetruefalse7falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalPrice of a single share of a number of saleable stocks of a company.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258 false3Closing price of Company stock (in dollars per share)42false 3us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptionsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse00USD$falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse00USD$falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate unrecognized cost of option awards made to employees under a stock option plan or plans, that have yet to vest.No definition available.false2Unrecognized compensation cost related to non-vested stock options outstanding43false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8false truefalsec20130101to20130630_RangeAxis_MinimumMemberhttp://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseMinimum [Member]us-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MinimumMemberus-gaap_RangeAxisexplicitMembernanafalse0Minimum [Member]44true 4us-gaap_PropertyPlantAndEquipmentLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Property, Plant and Equipment [Line Items]45false 5us-gaap_PropertyPlantAndEquipmentUsefulLifeus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse005 yearsfalsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.No definition available.false0Estimated useful life of property, plant and equipment46false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse9false truefalsec20130101to20130630_RangeAxis_MaximumMemberhttp://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseMaximum [Member]us-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMembernanafalse0Maximum [Member]47true 4us-gaap_PropertyPlantAndEquipmentLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Property, Plant and Equipment [Line Items]48false 5us-gaap_PropertyPlantAndEquipmentUsefulLifeus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse0010 yearsfalsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.No definition available.false0Estimated useful life of property, plant and equipment49false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse10false USDtruefalse$c20130401to20130630_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_ResearchAndDevelopmentExpenseMemberhttp://www.sec.gov/CIK0000875622duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseResearch and Development [Member]us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxisexplicitMemberU002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Research and Development [Member]50true 3us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]51false 4us-gaap_AllocatedShareBasedCompensationExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse7904979049USD$falsefalsefalse2truefalsefalse122679122679USD$falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse9224992249USD$falsefalsefalse5truefalsefalse144817144817USD$falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 64 -Subparagraph b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph g(1) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F false2Stock-based compensation expense52false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse14false USDtruefalse$c20130401to20130630_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_GeneralAndAdministrativeExpenseMemberhttp://www.sec.gov/CIK0000875622duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseGeneral and Administrative [Member]us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_GeneralAndAdministrativeExpenseMemberus-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxisexplicitMemberU002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0General and Administrative [Member]53true 3us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]54false 4us-gaap_AllocatedShareBasedCompensationExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00USD$falsefalsefalse2truefalsefalse1320013200USD$falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse1320013200USD$falsefalsefalse5truefalsefalse3086830868USD$falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 64 -Subparagraph b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph g(1) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F false2Stock-based compensation expense55false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse18false USDtruefalse$c20130401to20130630_MajorCustomersAxis_AuxiliumMemberhttp://www.sec.gov/CIK0000875622duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseAuxilium [Member]us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldibstc_AuxiliumMemberus-gaap_MajorCustomersAxisexplicitMemberU002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Auxilium [Member]56true 4bstc_ConcentrationOfCreditRiskAndMajorCustomersAbstractbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Concentration of Credit Risk and Major Customers [Abstract]57false 5us-gaap_AccountsReceivableNetCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse14000001400000USD$falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse14000001400000USD$falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 false2Accounts receivable58false 5us-gaap_RoyaltyRevenueus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse47000004700000USD$falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRevenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Royalty revenue59false 4us-gaap_DeferredRevenueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse500000500000USD$falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse500000500000USD$falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A false2Deferred revenue60false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse19false truefalsec20130101to20130630_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_MajorCustomersAxis_AuxiliumMemberhttp://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseAuxilium [Member]us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldibstc_AuxiliumMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseAccounts Receivable [Member]us-gaap_ConcentrationRiskByBenchmarkAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AccountsReceivableMemberus-gaap_ConcentrationRiskByBenchmarkAxisexplicitMemberU004Standardhttp://www.xbrl.org/2003/instancepurexbrli0nanafalse0Auxilium [Member] | Accounts Receivable [Member]61true 4bstc_ConcentrationOfCreditRiskAndMajorCustomersAbstractbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Concentration of Credit Risk and Major Customers [Abstract]62false 5us-gaap_ConcentrationRiskPercentage1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truetruefalse0.360.36falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsenum:percentItemTypepureFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13531-108611 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592 false0Concentration risk percentage (in hundredths)63false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse20false truefalsec20130401to20130630_ConcentrationRiskByBenchmarkAxis_LicensingConsultingAndRoyaltyRevenueMember_MajorCustomersAxis_AuxiliumMemberhttp://www.sec.gov/CIK0000875622duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseAuxilium [Member]us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldibstc_AuxiliumMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseLicensing, Consulting And Royalty Revenue [Member]us-gaap_ConcentrationRiskByBenchmarkAxisxbrldihttp://xbrl.org/2006/xbrldibstc_LicensingConsultingAndRoyaltyRevenueMemberus-gaap_ConcentrationRiskByBenchmarkAxisexplicitMemberU004Standardhttp://www.xbrl.org/2003/instancepurexbrli0nanafalse0Auxilium [Member] | Licensing, Consulting And Royalty Revenue [Member]64true 4bstc_ConcentrationOfCreditRiskAndMajorCustomersAbstractbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Concentration of Credit Risk and Major Customers [Abstract]65false 5us-gaap_ConcentrationRiskPercentage1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truetruefalse0.650.65falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsenum:percentItemTypepureFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13531-108611 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592 false0Concentration risk percentage (in hundredths)66false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse21false USDtruefalse$c20130401to20130630_MajorCustomersAxis_DfbBiotechIncMemberhttp://www.sec.gov/CIK0000875622duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseDFB Biotech Inc. [Member]us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldibstc_DfbBiotechIncMemberus-gaap_MajorCustomersAxisexplicitMemberU002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0DFB Biotech Inc. [Member]67true 4bstc_ConcentrationOfCreditRiskAndMajorCustomersAbstractbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Concentration of Credit Risk and Major Customers [Abstract]68false 5us-gaap_AccountsReceivableNetCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse25000002500000USD$falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse25000002500000USD$falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 false2Accounts receivable69false 5us-gaap_RoyaltyRevenueus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse25000002500000USD$falsetruefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRevenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Royalty revenue70false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse22false truefalsec20130101to20130630_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_MajorCustomersAxis_DfbBiotechIncMemberhttp://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseDFB Biotech Inc. [Member]us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldibstc_DfbBiotechIncMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseAccounts Receivable [Member]us-gaap_ConcentrationRiskByBenchmarkAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AccountsReceivableMemberus-gaap_ConcentrationRiskByBenchmarkAxisexplicitMemberU004Standardhttp://www.xbrl.org/2003/instancepurexbrli0nanafalse0DFB Biotech Inc. [Member] | Accounts Receivable [Member]71true 4bstc_ConcentrationOfCreditRiskAndMajorCustomersAbstractbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Concentration of Credit Risk and Major Customers [Abstract]72false 5us-gaap_ConcentrationRiskPercentage1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truetruefalse0.640.64falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsenum:percentItemTypepureFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13531-108611 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592 false0Concentration risk percentage (in hundredths)73false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse23false truefalsec20130401to20130630_ConcentrationRiskByBenchmarkAxis_LicensingConsultingAndRoyaltyRevenueMember_MajorCustomersAxis_DfbBiotechIncMemberhttp://www.sec.gov/CIK0000875622duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseDFB Biotech Inc. [Member]us-gaap_MajorCustomersAxisxbrldihttp://xbrl.org/2006/xbrldibstc_DfbBiotechIncMemberus-gaap_MajorCustomersAxisexplicitMemberfalsefalseLicensing, Consulting And Royalty Revenue [Member]us-gaap_ConcentrationRiskByBenchmarkAxisxbrldihttp://xbrl.org/2006/xbrldibstc_LicensingConsultingAndRoyaltyRevenueMemberus-gaap_ConcentrationRiskByBenchmarkAxisexplicitMemberU004Standardhttp://www.xbrl.org/2003/instancepurexbrli0nanafalse0DFB Biotech Inc. [Member] | Licensing, Consulting And Royalty Revenue [Member]74true 4bstc_ConcentrationOfCreditRiskAndMajorCustomersAbstractbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Concentration of Credit Risk and Major Customers [Abstract]75false 5us-gaap_ConcentrationRiskPercentage1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truetruefalse0.350.35falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsenum:percentItemTypepureFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13531-108611 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592 false0Concentration risk percentage (in hundredths)falseSUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)NoRoundingNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://biospecifics.com/role/SummaryOfSignificantAccountingPoliciesDetails775 XML 61 R26.xml IDEA: PATENT COSTS (Details) 2.4.0.8090600 - Disclosure - PATENT COSTS (Details)truefalsefalse1false USDfalsefalse$c20130401to20130630http://www.sec.gov/CIK0000875622duration2013-04-01T00:00:002013-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$c20120401to20120630http://www.sec.gov/CIK0000875622duration2012-04-01T00:00:002012-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$c20121231http://www.sec.gov/CIK0000875622instant2012-12-31T00:00:000001-01-01T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDtruefalse$c20130101to20130630_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMemberhttp://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00falsefalsePatents [Member]us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PatentsMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberU002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDtruefalse$c20120101to20120630_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMemberhttp://www.sec.gov/CIK0000875622duration2012-01-01T00:00:002012-06-30T00:00:00falsefalsePatents [Member]us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PatentsMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberU002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false USDtruefalse$c20121231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMemberhttp://www.sec.gov/CIK0000875622instant2012-12-31T00:00:000001-01-01T00:00:00falsefalsePatents [Member]us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PatentsMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberU002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false truefalsec20130101to20130630_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember_RangeAxis_MinimumMemberhttp://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00falsefalsePatents [Member]us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PatentsMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberfalsefalseMinimum [Member]us-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MinimumMemberus-gaap_RangeAxisexplicitMember8false truefalsec20130101to20130630_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember_RangeAxis_MaximumMemberhttp://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00falsefalsePatents [Member]us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PatentsMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberfalsefalseMaximum [Member]us-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMember1true 3us-gaap_FiniteLivedIntangibleAssetsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Finite-Lived Intangible Assets [Line Items]2false 4us-gaap_FiniteLivedIntangibleAssetUsefulLifeus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse002 yearsfalsefalsefalse8falsefalsefalse0014 yearsfalsefalsefalsexbrli:durationItemTypenaUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.No definition available.false0Estimated useful lives3true 4us-gaap_FiniteLivedIntangibleAssetsNetAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Net Patent Costs [Abstract]4false 5us-gaap_FiniteLivedPatentsGrossus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse472375472375USD$falsetruefalse5falsefalsefalse00falsefalsefalse6truefalsefalse472375472375USD$falsetruefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryGross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 false2Patents5false 5us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortizationus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse-224215-224215falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse-192053-192053falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 45 -Subparagraph a(1) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Accumulated Amortization6false 5us-gaap_IntangibleAssetsNetExcludingGoodwillus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse248160248160falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse280322280322falsefalsefalse4truefalsefalse248160248160falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse280322280322falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 42, 45 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true2Net patent costs7false 4us-gaap_AmortizationOfIntangibleAssetsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse1610016100falsefalsefalse2truefalsefalse2900029000falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse3200032000falsefalsefalse5truefalsefalse2900029000falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 45 -Subparagraph a(2) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Amortization expense for patents8true 4us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Estimated amortization expense [Abstract]9false 5us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonthsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse5300053000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of amortization expense expected to be recognized during the next fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 false2201410false 5us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwous-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse2500025000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of amortization expense expected to be recognized during the second fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 false2201511false 5us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThreeus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse2000020000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of amortization expense expected to be recognized during the third fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 false2201612false 5us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse2000020000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of amortization expense expected to be recognized during the fourth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 false2201713false 5us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse2000020000USD$falsetruefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of amortization expense expected to be recognized during the fifth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 false22018falsePATENT COSTS (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/PatentCostsDetails813 XML 62 R28.xml IDEA: RELATED PARTY TRANSACTIONS (Details) 2.4.0.8090800 - Disclosure - RELATED PARTY TRANSACTIONS (Details)truefalsefalse1false USDfalsefalse$c20130101to20130630_RelatedPartyTransactionsByRelatedPartyAxis_AffiliatedEntityMemberhttp://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00U002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse1false USDtruefalse$c20130101to20130630_RelatedPartyTransactionsByRelatedPartyAxis_AffiliatedEntityMemberhttp://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseABC-NY [Member]us-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AffiliatedEntityMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberU002Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0ABC-NY [Member]2true 3us-gaap_RelatedPartyTransactionLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Related Party Transaction [Line Items]3false 4us-gaap_OperatingLeasesRentExpenseMinimumRentalsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse1125011250USD$falsetruefalsexbrli:monetaryItemTypemonetaryThis element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 13 -Paragraph 122 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 13 -Paragraph 16 -Subparagraph c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 55 -Paragraph 40 -Subparagraph (Note 3) -URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 25 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=7661868&loc=d3e34039-112682 false2Monthly rental price4false 4us-gaap_LeaseExpirationDate1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse002011-03-31falsefalsetruexbrli:dateItemTypedateDate which lease or group of leases is set to expire, in CCYY-MM-DD format.No definition available.false0Termination of Lease AgreementfalseRELATED PARTY TRANSACTIONS (Details) (ABC-NY [Member], USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/RelatedPartyTransactionsDetails14 XML 63 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

NET INCOME (LOSS) PER SHARE (Tables)
6 Months Ended

Jun. 30, 2013

NET INCOME (LOSS) PER SHARE [Abstract]

Number of Common Equivalent Shares Included for the Calculation of Diluted Net Income
The following table summarizes the number of common equivalent shares that were included for the calculation of diluted net income purposes from continuing operations reported in the consolidated statement of operations.

Three Months Ended
June 30,

Six Months Ended
June 30,

2013

2012

2013

2012

Stock options

622,780

628,331

614,962

644,328

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 64 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

RELATED PARTY TRANSACTIONS
6 Months Ended

Jun. 30, 2013

RELATED PARTY TRANSACTIONS [Abstract]

RELATED PARTY TRANSACTIONS
8. RELATED PARTY TRANSACTIONS

Our corporate headquarters are currently located at 35 Wilbur St., Lynbrook, NY 11563. As previously reported, our previous lease for our headquarters terminated on June 30, 2010. Our subsidiary, ABC-NY (together with the Company, the “Tenant”) and Wilbur St. Corp. (the “Landlord”) were parties to a lease agreement initially dated as of January 30, 1998 and modified as of June 24, 2009 (the “Lease Agreement”), pursuant to which the Landlord leased to the Tenant the premises located at 35 Wilbur Street, Lynbrook, NY 11563 (the “Premises”) until June 30, 2010 and for a monthly rental price of $11,250 plus utilities and real estate taxes. Following the expiration of the Lease Agreement, the Tenant continued to lease the Premises from the Landlord on a month-to-month basis. We notified the Landlord of our termination of the Lease Agreement effective March 31, 2011, but continue to hold over in the Premises.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)
6 Months Ended

Jun. 30, 2013

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Number of countries under the collaboration agreement 28

Minimum [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Baseline measurement period for Lipoma volume 1 month

Maximum [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Baseline measurement period for Lipoma volume 3 months

Central Eastern Europe Countries [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Number of countries under the collaboration agreement 18

Middle Eastern & North African Countries [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Number of countries under the collaboration agreement 22

X

- Definition

Refers to baseline measurement period for Lipoma volume.

+ References

No definition available.

+ Details

Name: bstc_BaselineMeasurementPeriodForLipomaVolume

Namespace Prefix: bstc_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of countries the entity has collaboration agreement for exclusive rights to commercialize.

+ References

No definition available.

+ Details

Name: bstc_NumberOfCountriesUnderCollaborationAgreement

Namespace Prefix: bstc_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 66 R15.xml IDEA: RELATED PARTY TRANSACTIONS 2.4.0.8060800 - Disclosure - RELATED PARTY TRANSACTIONStruefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_RelatedPartyTransactionsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0RELATED PARTY TRANSACTIONS [Abstract]2false 2us-gaap_RelatedPartyTransactionsDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">8. RELATED PARTY TRANSACTIONS</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Our corporate headquarters are currently located at 35 Wilbur St., Lynbrook, NY 11563.  As previously reported, our previous lease for our headquarters terminated on June 30, 2010.  Our subsidiary, ABC-NY (together with the Company, the “Tenant”) and Wilbur St. Corp. (the “Landlord”) were parties to a lease agreement initially dated as of January 30, 1998 and modified as of June 24, 2009 (the “Lease Agreement”), pursuant to which the Landlord leased to the Tenant the premises located at 35 Wilbur Street, Lynbrook, NY 11563 (the “Premises”) until June 30, 2010 and for a monthly rental price of $11,250 plus utilities and real estate taxes.  Following the expiration of the Lease Agreement, the Tenant continued to lease the Premises from the Landlord on a month-to-month basis. We notified the Landlord of our termination of the Lease Agreement effective March 31, 2011, but continue to hold over in the Premises.</div></div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph b -Article 3A Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Article 4 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 1-4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0RELATED PARTY TRANSACTIONSfalseRELATED PARTY TRANSACTIONSUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/RelatedPartyTransactions12 XML 67 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)
6 Months Ended

Jun. 30, 2013

ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]

Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses consisted of the following:

June 30,

December 31,

2013

2012

Trade accounts payable and accrued expenses

$
365,054

$
$ 304,635

Accrued legal and other professional fees

129,822

61,147

Accrued payroll and related costs

165,684

147,084

Total

$
660,560
$ 512,866

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 68 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
6 Months Ended

Jun. 30, 2013

Aug. 07, 2013

Document and Entity Information [Abstract]

Entity Registrant Name BIOSPECIFICS TECHNOLOGIES CORP

Entity Central Index Key 0000875622

Current Fiscal Year End Date --12-31

Entity Well-known Seasoned Issuer No

Entity Voluntary Filers No

Entity Current Reporting Status Yes

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 6,339,815

Document Fiscal Year Focus 2013

Document Fiscal Period Focus Q2

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2013

X

- Details

Name: bstc_DocumentAndEntityInformationAbstract

Namespace Prefix: bstc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

XML 69 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

PATENT COSTS (Tables)
6 Months Ended

Jun. 30, 2013

PATENT COSTS [Abstract]

Net Patent Costs
For each period presented below net patent costs consisted of:

June 30,

December 31,

2013

2012

Patents

$
472,375

$
472,375

Accumulated Amortization

(224,215
)

(192,053
)

$
248,160

$
280,322

Estimated Aggregate Future Amortization Expense
The estimated aggregate amortization expense for each of the next five years is approximately as follows:

2014

$
53,000

2015

25,000

2016

20,000

2017

20,000

2018

20,000

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16265-109275

+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 70 R1.xml IDEA: Document and Entity Information 2.4.0.8000100 - Document - Document and Entity Informationtruefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000875622duration2013-01-01T00:00:002013-06-30T00:00:002false falsefalsec20130807http://www.sec.gov/CIK0000875622instant2013-08-07T00:00:000001-01-01T00:00:00U001Standardhttp://www.xbrl.org/2003/instancesharesxbrli01true 1bstc_DocumentAndEntityInformationAbstractbstc_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Document and Entity Information [Abstract]2false 2dei_EntityRegistrantNamedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00BIOSPECIFICS TECHNOLOGIES CORPfalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:normalizedStringItemTypenormalizedstringThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false0Entity Registrant Name3false 2dei_EntityCentralIndexKeydei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse000000875622falsefalsefalse2falsefalsefalse00falsefalsefalsedei:centralIndexKeyItemTypenaA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false0Entity Central Index Key4false 2dei_CurrentFiscalYearEndDatedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00--12-31falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:gMonthDayItemTypemonthdayEnd date of current fiscal year in the format --MM-DD.No definition available.false0Current Fiscal Year End Date5false 2dei_EntityWellKnownSeasonedIssuerdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00Nofalsefalsefalse2falsefalsefalse00falsefalsefalsedei:yesNoItemTypenaIndicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.No definition available.false0Entity Well-known Seasoned Issuer6false 2dei_EntityVoluntaryFilersdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00Nofalsefalsefalse2falsefalsefalse00falsefalsefalsedei:yesNoItemTypenaIndicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.No definition available.false0Entity Voluntary Filers7false 2dei_EntityCurrentReportingStatusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00Yesfalsefalsefalse2falsefalsefalse00falsefalsefalsedei:yesNoItemTypenaIndicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.No definition available.false0Entity Current Reporting Status8false 2dei_EntityFilerCategorydei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00Accelerated Filerfalsefalsefalse2falsefalsefalse00falsefalsefalsedei:filerCategoryItemTypestringIndicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.No definition available.false0Entity Filer Category9false 2dei_EntityCommonStockSharesOutstandingdei_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2truefalsefalse63398156339815falsefalsefalsexbrli:sharesItemTypesharesIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.No definition available.false1Entity Common Stock, Shares Outstanding10false 2dei_DocumentFiscalYearFocusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse002013falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:gYearItemTypepositiveintegerThis is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.No definition available.false0Document Fiscal Year Focus11false 2dei_DocumentFiscalPeriodFocusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00Q2falsefalsefalse2falsefalsefalse00falsefalsefalsedei:fiscalPeriodItemTypenaThis is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.No definition available.false0Document Fiscal Period Focus12false 2dei_DocumentTypedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse0010-Qfalsefalsefalse2falsefalsefalse00falsefalsefalsedei:submissionTypeItemTypestringThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".No definition available.false0Document Type13false 2dei_AmendmentFlagdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:booleanItemTypenaIf the value is true, then the document is an amendment to previously-filed/accepted document.No definition available.false0Amendment Flag14false 2dei_DocumentPeriodEndDatedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse002013-06-30falsefalsetrue2falsefalsefalse00falsefalsefalsexbrli:dateItemTypedateThe end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.No definition available.false0Document Period End DatefalseDocument and Entity InformationUnKnownNoRoundingUnKnownUnKnowntruefalsefalseSheethttp://biospecifics.com/role/DocumentAndEntityInformation214

PROVISION FOR INCOME TAXES (Details) (USD $)	3 Months Ended		6 Months Ended
PROVISION FOR INCOME TAXES (Details) (USD $)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
PROVISION FOR INCOME TAXES [Abstract]
Net income tax expense (benefit)	$ 542,009	$ 390,651	$ 1,261,459	$ 906,228
Decrease in deferred tax assets			1,060	416,055
Deferred tax assets	$ 1,500,000	$ 2,600,000	$ 1,500,000	$ 2,600,000

PATENT COSTS (Details) (USD $)	3 Months Ended			6 Months Ended			6 Months Ended
PATENT COSTS (Details) (USD $)	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Jun. 30, 2013 Patents [Member]	Jun. 30, 2012 Patents [Member]	Dec. 31, 2012 Patents [Member]	Jun. 30, 2013 Patents [Member] Minimum [Member]	Jun. 30, 2013 Patents [Member] Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives							2 years	14 years
Net Patent Costs [Abstract]
Patents				$ 472,375		$ 472,375
Accumulated Amortization				(224,215)		(192,053)
Net patent costs	248,160		280,322	248,160		280,322
Amortization expense for patents	16,100	29,000		32,000	29,000
Estimated amortization expense [Abstract]
2014	53,000
2015	25,000
2016	20,000
2017	20,000
2018	$ 20,000

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Accounts payable and accrued expenses [Abstract]
Trade accounts payable and accrued expenses	$ 365,054	$ 304,635
Accrued legal and other professional fees	129,822	61,147
Accrued payroll and related costs	165,684	147,084
Total	$ 660,560	$ 512,866

Consolidated Statements of Cash Flows (unaudited) (USD $)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities:
Net income	$ 2,381,270	$ 1,409,072
Adjustments to reconcile net income to net cash provided By operating activities:
Depreciation and amortization	32,162	29,019
Stock-based compensation expense	105,449	175,685
Deferred tax assets	1,060	416,055
Changes in operating assets and liabilities:
Accounts receivable	1,178,418	416,072
Prepaid expenses and other current assets	(261,387)	72,403
Accounts payable and accrued expenses	147,694	(5,033)
Accrued taxes payable	382,704	102,471
Deferred revenue	(89,761)	(218,550)
Net cash provided by operating activities	3,877,609	2,397,194
Cash flows from investing activities:
Maturity of marketable investments	4,430,000	2,000,000
Purchases of marketable investments	(7,276,964)	(2,000,000)
Payment for royalty buy down	0	(1,500,000)
Net cash used in investing activities	(2,846,964)	(1,500,000)
Cash flows from financing activities:
Proceeds from stock option exercises	0	78,000
Payments for repurchase of common stock	(396,851)	(485,904)
Excess tax benefits from share-based payment arrangements	0	102,052
Net cash used in financing activities	(396,851)	(305,852)
Increase in cash and cash equivalents	633,794	591,342
Cash and cash equivalents at beginning of year	3,383,737	3,196,831
Cash and cash equivalents at end of period	4,017,531	3,788,173
Cash paid during the year for:
Interest	0	0
Taxes	$ 888,500	$ 92,000

ORGANIZATION AND DESCRIPTION OF BUSINESS	6 Months Ended
ORGANIZATION AND DESCRIPTION OF BUSINESS	Jun. 30, 2013
ORGANIZATION AND DESCRIPTION OF BUSINESS [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	1. ORGANIZATION AND DESCRIPTION OF BUSINESS We are a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. We have a development and license agreement with Auxilium Pharmaceuticals, Inc. (“Auxilium”) for injectable collagenase (which Auxilium has named XIAFLEX^® (collagenase clostridium histolyticum)) for clinical indications in Dupuytren’s contracture, Peyronie’s disease, frozen shoulder (adhesive capsulitis) and cellulite (edematous fibrosclerotic panniculopathy) (the “Auxilium Agreement”). Auxilium has an option to acquire additional indications that we may pursue, including human and canine lipoma. Auxilium is currently selling XIAFLEX in the U.S. for the treatment of Dupuytren’s contracture. In addition, Auxilium has an agreement with Asahi Kasei Pharma Corporation (“Asahi”) pursuant to which Asahi has the right to commercialize XIAFLEX for the treatment of Dupuytren’s contracture and Peyronie’s disease in Japan. Auxilium also has an agreement with Actelion Pharmaceuticals Ltd. (“Actelion”) pursuant to which Actelion has the right to commercialize XIAFLEX for the treatment of Dupuytren’s contracture and Peyronie’s disease in Canada, Australia, Brazil and Mexico. Auxilium has been granted a Notice of Compliance (approval) by Health Canada for XIAFLEX for the treatment of Dupuytren’s contracture in adults with a palpable cord in Canada. In July 2013 Auxilium entered into a long-term collaboration with Swedish Orphan Biovitrum AB (“Sobi”) for the development, supply and commercialization of XIAPEX^® (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture. In addition, work is on-going to file for approval of XIAPEX for the treatment of Peyronie's disease in the EU. Pursuant to a March 2006 agreement (the “DFB Agreement”) between the Company and DFB Biotech, Inc. (“DFB”), we continue to receive earn-out payments based on the sales of Santyl. Our right to receive earn-out payments with respect to the marketed topical product sold to DFB expires in August 2013, and we expect to receive our final earn-out payment for Santyl by the end of the year. Operational Highlights On July 23, 2013 we presented a poster titled “Biomechanical Evaluation of Human Uterine Fibroids after Exposure to Purified Clostridial Collagenase” at the Society for the Study of Reproduction 46^th Annual Meeting in Montreal, Quebec, Canada. The poster provided data which showed that highly purified collagenase can reduce the stiffness of human uterine fibroid tissue in laboratory experiments. Increased tissue rigidity has been implicated as a cause of the morbidity associated with uterine fibroids. The results of this ex vivo study show that treatment of fibroids with determined doses of purified collagenase caused a statistically significant decrease in the stiffness of the tissue. This hypothesis was tested in fibroid tissue obtained after hysterectomy or myomectomy surgery from patients. Tissues were injected with collagenase and compared to control-injected tissue. On July 16, 2013, Auxilium announced that it has entered into a long-term collaboration with Sobi for the development, supply and commercialization of XIAPEX (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture. In addition, Auxilium stated that work is on-going to file for approval of XIAPEX for the treatment of Peyronie's disease in the EU. Under the terms of the collaboration agreement, Sobi will receive exclusive rights to commercialize XIAPEX for Dupuytren’s contracture and Peyronie’s disease, subject to applicable regulatory approvals, in 28 EU member countries, Switzerland, Norway, Iceland, 18 Central Eastern Europe/Commonwealth of Independent countries, including Russia and Turkey, and 22 Middle Eastern & North African countries. Since 2011, XIAPEX has been approved for the treatment of Dupuytren's contracture in 28 EU member countries, Switzerland, and Norway. Sobi, via its Partner Products business unit, will be primarily responsible for the applicable regulatory, clinical and commercialization activities for XIAPEX in Dupuytren's contracture and Peyronie's disease in these countries. In April 2013, we completed enrollment in our placebo-controlled, randomized Phase II trial, Chien-804, to evaluate the efficacy of XIAFLEX for the treatment of subcutaneous benign lipomas in 32 canines randomized 1:1 XIAFLEX to placebo. The lipoma volume will be measured at baseline, 1 month and 3 months with the primary efficacy endpoint being the relative change in lipoma volume from baseline to 3 months, as determined by CT scan.

COMPREHENSIVE INCOME (LOSS)	6 Months Ended
COMPREHENSIVE INCOME (LOSS)	Jun. 30, 2013
COMPREHENSIVE INCOME (LOSS) [Abstract]
COMPREHENSIVE INCOME (LOSS)	4. COMPREHENSIVE INCOME (LOSS) For the three and six months ended June 30, 2013 and 2012, we had no components of other comprehensive income or loss other than net income itself.

RELATED PARTY TRANSACTIONS (Details) (ABC-NY [Member], USD $)	6 Months Ended
	Jun. 30, 2013
ABC-NY [Member]
Related Party Transaction [Line Items]
Monthly rental price	$ 11,250
Termination of Lease Agreement	Mar. 31, 2011

Consolidated Balance Sheets (unaudited) (Parenthetical) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Stockholders' equity:
Series A Preferred stock, par value (in dollars per share)	$ 0.50	$ 0.50
Series A Preferred stock, authorized (in shares)	700,000	700,000
Series A Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	10,000,000	10,000,000
Common stock, issued (in shares)	6,625,168	6,625,168
Treasury stock, shares (in shares)	285,352	260,632

PROVISION FOR INCOME TAXES	6 Months Ended
PROVISION FOR INCOME TAXES	Jun. 30, 2013
PROVISION FOR INCOME TAXES [Abstract]
PROVISION FOR INCOME TAXES	7. PROVISION FOR INCOME TAXES In determining our provision for income taxes, we consider all available information, including operating results, ongoing tax planning, and forecasts of future taxable income. The significant components of the Company's deferred tax assets pursuant to Accounting Standards Codification 740-10-50 consist of stock-based compensation and deferred revenues. For the six month period ended June 30, 2013, the provision for income taxes was $1.3 million. For the six month period ended June 30, 2013, the valuation allowance with respect to the Company’s net deferred tax assets remained unchanged. As of June 30, 2013, our remaining deferred tax assets were approximately $1.5 million. For the six month period ended June 30, 2012 our provision for income taxes was $0.9 million, primarily a non-cash charge. For the six month period ended June 30, 2012, the valuation allowance with respect to the company’s net deferred tax assets remained unchanged. Our remaining deferred tax assets decreased by $0.4 million to approximately $2.6 million, primarily because we used our Orphan Drug Tax Credit to reduce our taxes payable, during six months ended June 30, 2012.

Consolidated Balance Sheets (unaudited) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 4,017,531	$ 3,383,737
Short-term investments	7,966,964	5,120,000
Accounts receivable, net	3,903,942	5,082,360
Income tax receivable	51,070	51,070
Deferred tax assets	79,482	88,910
Prepaid expenses and other current assets	411,110	149,724
Total current assets	16,430,099	13,875,801
Deferred royalty buy-down	2,750,000	2,750,000
Deferred tax assets - long term	1,492,509	1,484,141
Patent costs, net	248,160	280,322
Total assets	20,920,768	18,390,264
Current liabilities:
Accounts payable and accrued expenses	660,560	512,866
Deferred tax liability	382,704	0
Deferred revenue	78,328	133,524
Accrued liabilities of discontinued operations	78,138	78,138
Total current liabilities	1,199,730	724,528
Long-term deferred revenue	172,825	207,390
Stockholders' equity:
Series A Preferred stock, $.50 par value, 700,000 shares authorized; none outstanding	0	0
Common stock, $.001 par value; 10,000,000 shares authorized ; 6,625,168 shares issued at June 30, 2013 and December 31, 2012, respectively	6,625	6,625
Additional paid-in capital	20,794,154	20,688,706
Retained earnings (deficit)	2,070,441	(310,829)
Treasury stock, 285,352 and 260,632 shares at cost at June 30, 2013 and December 31, 2012, respectively	(3,323,007)	(2,926,156)
Total stockholders' equity	19,548,213	17,458,346
Total liabilities and stockholders' equity	$ 20,920,768	$ 18,390,264

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	3 Months Ended			6 Months Ended
	Jun. 30, 2013 Customer	Jun. 30, 2012	Mar. 31, 2012 Payment	Jun. 30, 2013 Quarter Customer	Jun. 30, 2012	Jun. 28, 2013	Dec. 31, 2012
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable	$ 3,903,942			$ 3,903,942			$ 5,082,360
Number of customers	2			2
Royalty revenue	3,197,603	2,491,313		6,630,503	4,391,282
Royalty / Mark-up on Cost of Goods Sold / Earn-Out Revenue [Abstract]
Number of quarters after which revenue is recognized (in quarters)				1
Number of days after calendar year, after which payments and report are received				90 days
Number of years for which bad debt expense not recorded				3 years
Allowance for doubtful accounts	30,000	30,000		30,000	30,000
Reimbursable Third Party Development Costs [Abstract]
Accrued patent costs	30,000			30,000
Royalty Buy-Down [Abstract]
Initial payment for royalty buy down			1,500,000	0	1,500,000
Number of additional cash payments for royalty buy down			5
Deferred royalty buy-down	2,750,000			2,750,000			2,750,000
Deferred costs, amortization period				5 years
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock granted during period, value of stock options	79,000
Expected volatility rate				37.00%
Risk free interest rate				0.68%
Average exercise period				5 years
Stock-based compensation expense	79,049	135,879		105,449	175,685
Total number of shares
Outstanding, beginning of period (in shares)				1,182,000
Granted (in shares)				15,000
Forfeited (in shares)				0
Exercised (in shares)				0
Expired (in shares)				0
Outstanding, end of period (in shares)	1,197,000			1,197,000
Exercisable, end of period (in shares)	1,177,000			1,177,000
Weighted-Average Exercise Price
Outstanding, beginning of period (in dollars per share)				$ 8.90
Granted (in dollars per share)				$ 15.85
Forfeited (in dollars per share)				$ 0
Exercised (in dollars per share)				$ 0
Expired (in dollars per share)				$ 0
Outstanding, end of period (in dollars per share)	$ 8.99			$ 8.99
Exercisable, end of period (in dollars per share)	$ 8.64			$ 8.64
Proceeds from stock option exercises				0	78,000
Aggregate intrinsic value of options outstanding and exercisable	8,200,000			8,200,000
Closing price of Company stock (in dollars per share)						$ 15.60
Unrecognized compensation cost related to non-vested stock options outstanding	0			0
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of property, plant and equipment				5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of property, plant and equipment				10 years
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	79,049	122,679		92,249	144,817
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	0	13,200		13,200	30,868
Auxilium [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable	1,400,000			1,400,000
Royalty revenue	4,700,000
Deferred revenue	500,000			500,000
Auxilium [Member] \| Accounts Receivable [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)				36.00%
Auxilium [Member] \| Licensing, Consulting And Royalty Revenue [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)	65.00%
DFB Biotech Inc. [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable	2,500,000			2,500,000
Royalty revenue	$ 2,500,000
DFB Biotech Inc. [Member] \| Accounts Receivable [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)				64.00%
DFB Biotech Inc. [Member] \| Licensing, Consulting And Royalty Revenue [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)	35.00%

SUBSEQUENT EVENTS	6 Months Ended
SUBSEQUENT EVENTS	Jun. 30, 2013
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	9. SUBSEQUENT EVENTS We have evaluated subsequent events for recognition or disclosure through the time of filing these consolidated financial statements on Form 10-Q with the SEC on August 9, 2013.

Consolidated Statements of Cash Flows (unaudited) (Parenthetical) (USD $)	3 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Supplemental disclosures of non-cash transactions:
Patent costs accrued from Auxilium	$ 30,000	$ 64,000
Patent amortization expenses	$ 16,100	$ 29,000

RELATED PARTY TRANSACTIONS	6 Months Ended
RELATED PARTY TRANSACTIONS	Jun. 30, 2013
RELATED PARTY TRANSACTIONS [Abstract]
RELATED PARTY TRANSACTIONS	8. RELATED PARTY TRANSACTIONS Our corporate headquarters are currently located at 35 Wilbur St., Lynbrook, NY 11563. As previously reported, our previous lease for our headquarters terminated on June 30, 2010. Our subsidiary, ABC-NY (together with the Company, the “Tenant”) and Wilbur St. Corp. (the “Landlord”) were parties to a lease agreement initially dated as of January 30, 1998 and modified as of June 24, 2009 (the “Lease Agreement”), pursuant to which the Landlord leased to the Tenant the premises located at 35 Wilbur Street, Lynbrook, NY 11563 (the “Premises”) until June 30, 2010 and for a monthly rental price of $11,250 plus utilities and real estate taxes. Following the expiration of the Lease Agreement, the Tenant continued to lease the Premises from the Landlord on a month-to-month basis. We notified the Landlord of our termination of the Lease Agreement effective March 31, 2011, but continue to hold over in the Premises.

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)	6 Months Ended
ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)	Jun. 30, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of countries under the collaboration agreement	28
Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Baseline measurement period for Lipoma volume	1 month
Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Baseline measurement period for Lipoma volume	3 months
Central Eastern Europe Countries [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of countries under the collaboration agreement	18
Middle Eastern & North African Countries [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of countries under the collaboration agreement	22

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2013	Aug. 07, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	BIOSPECIFICS TECHNOLOGIES CORP
Entity Central Index Key	0000875622
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		6,339,815
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2013